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Abstract 
 
P-glycoprotein (P-gp) mediated classical drug resistance is one of the mostly 
investigated mechanism of multidrug resistance (MDR). Despite the development of new 
anticancer drugs, P-gp mediated MDR that protects cells from cytotoxic compounds will 
continue to hinder successful treatment of cancer. Currently available P-gp inhibitor drugs 
are associated with significant drawbacks that limit their use on restoring the 
chemotherapy efficacy. The search for new alternative P-gp inhibitor agents with a 
feasible synthesis and fewer secondary effects is a challenge to medicinal chemists. 
Besides, antitumor agents that are P-gp inhibitors themselves represent a good “first step” 
towards the development of “multi-functional drugs”. The next generation of drugs might 
be compounds that work on more than one target, because this will really accelerate 
progress against disease, reduce the number and concentration of drugs that have to be 
administered and increase patient compliance. Therefore, in this work, the design, 
synthesis and evaluation of xanthones and thioxanthones as P-gp inhibitors with 
concomitant antitumor activity was accomplished.   
Firstly, a set of in-house xanthones, previously described as antitumor agents, 
were assayed for their P-gp inhibitory activity. This study revealed two potential P-gp 
inhibitors: a pyranoxanthonic derivative (11) and a xanthonolignoid (15). The 
pyranoxanthonic derivative (11) was also discovered to be a promising leukemia cell 
growth inhibitor. As xanthonic derivatives were therefore showing potential as dual activity 
agents, a virtual library of xanthones and thioxanthones were prepared and used for the 
screening of potential P-gp inhibitors through a docking study on P-gp models. These 
virtual compounds resulted from the hybridization between a (thio)xanthonic scaffold 
(present in several antitumor compounds described in the literature) and an amine 
(present in several P-gp inhibitors). The best scoring molecules were aminated 
thioxanthones, which, allied with the safety profile of the building block 1-chloro-4-
propoxy-9H-thioxanthen-9-one (43) and synthetically least challenging protocol, turned 
them into promising molecules to be selected for synthesis.  
Therefore, several thioxanthonic derivatives (16-42), were synthesized, and all of 
them are presented for the first time. The new 1-aminated thioxanthones (17-38, 41) were 
obtained by conventional heating and/or microwave assisted nucleophilic aromatic 
substitution. The structure of compounds 16-42 were determined by several spectroscopic 
techniques and elemental analysis. 
Six novel compounds (16, 19, 23, 27, 29, and 41) presented GI50 concentration < 
10 µM, being 1-{[2-(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (23) the 
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xiv  
 
most potent (GI50 = 1.90 µM). Both apoptosis and cell cycle arrest were found to be 
implicated in the growth inhibitory effect of the new xanthonic derivatives in K562 cell line. 
Those thioxanthones (16, 19, 23, 27, 29, and 41) were found to be nontoxic when tested 
in a nontumor fibroblast cell line. Thioxanthones were also tested on additional cell lines 
(A375-C5, MCF-7, and NCI-H460), being compounds 23 and 40 the most potent ones.  
Fiftheen of the investigated compounds (compounds 6, 19, 21, 23, 24, 27-31, 34-
37, and 41), caused an increase in the accumulation ratio of rhodamine-123 (rh123) in a 
leukemia cell line that overexpresses P-gp (K562Dox), an effect compatible with P-gp 
inhibition. Eleven (of the previous fiftheen) compounds were found to be inhibitors of the 
P-gp ATPase activity, i.e., behaved as noncompetitive P-gp inhibitors (compounds 16, 19, 
21, 24, 27, 28, 31, and 34-37). Four other aminated thioxanthones increased the 
hydrolysis of ATP by P-gp, indicating that they are competitive inhibitors of P-gp, possibly 
being themselves transported by the pump (compounds 23, 29, 30, and 41). Finally, a 
study with a combination treatment with thioxanthones (compounds 16, 19, 23, 24, 27, 29, 
31, and 34) and doxorubicin in the P-gp overexpressing cell line (K562Dox) confirmed the 
sensitization effect of some of these compounds to doxorubicin treatment. At a 
concentration of 10 µM, 1-[2-(1H-benzimidazol-2-yl)ethanamine]-4-propoxy-9H-
thioxanthen-9-one (31) caused a 12.5-fold decrease in the GI50 of doxorubicin in K562Dox 
cell line, possibly due to its dual activity as P-gp and tumor cell growth inhibitor, being 2-
fold more potent than verapamil. 
Simultaneously, a pharmacophore-based screening on a drug bank of commercial 
compounds allowed the identification of twenty one commercially available compounds as 
potential P-gp inhibitors. Six compounds were acting as competitive inhibitors (such as 
propafenone) while other six were acting as noncompetitive inhibitors (such as econazole 
or amoxapine). The available data for commercial and newly synthesized thioxanthones 
allowed the construction of two pharmacophores: a pharmacophore for competitive P-gp 
inhibitor and a pharmacophore for noncompetitive P-gp inhibitors. 
Finally, two of the most potent P-gp inhibitors (compounds 29 and 31) were tested 
for selectivity against MRP1, MRP2 and MRP3 and BCRP, and against cytochrome P450 
(CYP3A4). Results showed that these thioxanthones were not selective for P-gp, as they 
interfered with other ABC transporters and with CYP3A4. 
In conclusion, aminated thioxanthones provide an adequate scaffold for the design 
of dual ligands with antitumor and P-gp inhibitory activities. Therefore, the compounds 
developed in the present work may represent models for the design of new antitumor 
agents with concomitant ability of circumventing MDR. 
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Resumo 
 
A resistência a múltiplos fármacos (MDR) mediada pela glicoproteina-P (P-gp) é o 
mecanismo de MDR mais intensamente investigado. Apesar do desenvolvimento de 
novos agentes anticancerígenos, a MDR mediada pela P-gp protege as células dos 
agentes citotóxicos, limitando a eficácia dos tratamentos quimioterápicos. Actualmente, 
os inibidores da P-gp disponíveis estão associados a vários inconvenientes que limitam o 
seu uso no reestabelecimento da eficácia da quimioterapia. A procura de inibidores de P-
gp alternativos, com um processo sintético exequível e efeitos secundários reduzidos, 
continua a ser um desafio para os químicos farmacêuticos. Além disso, os agentes 
antitumorais que são eles próprios inibidores da P-gp representam um ponto de partida 
interessante para o desenvolvimeto de fármacos multifuncionais. A próxima geração de 
fármacos poderá ser formada por substâncias que se ligam a mais do que um alvo 
terapêutico, o que acelerará o progresso contra a doença, reduzirá o número e a 
concentração de fármacos que devem ser administrados e aumentará a adesão à 
terapêutica por parte do paciente. Pelo exposto, nesta tese foi efectuado o design, 
síntese e avaliação de xantonas e tioxantonas como novos inibidores da P-gp com 
concomitante actividade antitumoral. 
Inicialmente, um conjunto de xantonas pertencentes a uma biblioteca do 
CEQUIMED-UP, e previamente descritas como agentes antitumorais, foram testadas 
quanto à sua capacidade de modular a actividade da P-gp. Este estudo revelou dois 
novos potenciais inibidores da P-gp: um derivado piranoxantónico (11) e um 
xantonolignoide (15). O derivado piranoxantónio (11) foi também descoberto como sendo 
um promissor inibidor do crescimento de linhas celulares leucémicas. Pelo facto dos 
derivados xantónicos terem revelado potencial como agentes com dupla actividade, uma 
biblioteca virtual de xantonas e tioxantonas foi desenvolvida e usada no screening de 
potenciais inibidores da P-gp, através de um estudo de docking em modelos da P-gp. O 
design destas moléculas baseou-se na hibridização entre um esqueleto (tio)xantónico 
(presente em vários agentes antitumorais) e uma amina (presente em vários inibidores da 
P-gp). As tioxantonas aminadas revelaram ser as moléculas com melhores valores de 
docking score. Estes resultados in silico, aliado ao perfil de segurança do bloco 
constructor 1-cloro-4-propoxi-9H-tioxanten-9-ona (43) e a um processo sintético 
apropriado, permitiram a selecção dos derivados  tioxantónicos a sintetizar. 
Assim, vários derivados tioxantónicos foram sintetizados (16-42), e todos são 
apresentados nesta tese pela primeira vez. As novas tioxantonas, aminadas na posição 1 
(17-38, 41), foram obtidas por substituição nucleofílica aromática, com aquecimento 
(thio)Xanthone derivatives with dual activity: antitumor and p-glycoprotein inhibition 
 
xvi  
 
convencional e/ou com aquecimento por microondas. A estrutura dos compostos 16-42 
foi determinada por várias técnicas espectroscópicas e por análise elementar. 
Seis novos compostos (16, 19, 23, 27, 29 e 41) apresentaram GI50 < 10µM, sendo 
a 1-{[2-(dietilamino)etil]amino}-4-propoxi-9H-tioxanten-9-ona (23) o derivado tioxantónico 
mais potente (GI50 = 1.90 µM) na linha celular K562. O aumento dos níveis de apoptose e 
o bloqueio do ciclo celular mostraram estar implicados neste efeito. Porém, os mesmos 
compostos (16, 19, 23, 27, 29 e 41) não mostraram toxicidade numa linha celular não-
tumoral fibroblástica. Além disso, as tioxantonas foram testadas noutras linhas celulares 
tumorais (A375-C5, MCF-7, e NCI-H460), sendo os compostos 23 e 40 os mais 
promissores. 
Quinze dos compostos investigados (compostos 6, 19, 21, 23, 24, 27-31, 34-37 e 
41) causaram um aumento da acumulação de rodamina-123 (rh123) numa linha celular 
que sobreexpressa a P-gp (K562Dox), um efeito compatível com a inibição da P-gp. 
Onze compostos (dos quinze anteriormente mencionados) inibiram a actividade ATPase 
da P-gp, i.e, comportaram-se como inibidores não-competitivos (compostos 16, 19, 21, 
24, 27, 28, 31 e 34-37). Os restantes quatro compostos causam um aumento na hidrólise 
do ATP pela P-gp, sugerindo um mecanismo de inibição competitiva, possivelmente 
sendo eles próprios transportados pela bomba (compostos 23, 29, 30 e 41). Finalmente, 
a combinação dos derivados tioxantónicos com a doxorrubicina na linha celular que 
sobreexpressa a P-gp (K562Dox) permitiu confirmar que alguns daqueles compostos 
aumentavam a sensibilidade à doxorrubicina. Numa concentração de 10 µM, a 1-[2-(1H-
benzimidazol-2-il)etanamina]-4-propoxi-9H-tioxanten-9-ona (31) causou uma diminuição 
de 12,5 vezes no GI50 da doxorrubicina na linha celular resistente (K562Dox), 
possivelmente devido à dupla actividade daquele composto como inibidor da P-gp e do 
crescimento celular, mostrando ser 2× mais activo que o próprio verapamil. 
 Simultaneamente, com base num farmacóforo, um screening virtual a uma 
biblioteca de compostos comerciais (DrugBank), permitiu a identicação de vinte e um 
compostos como sendo potenciais inibidores da P-gp. Seis compostos mostraram actuar 
como inibidores competitivos (como por exemplo a propafenona), enquando outros seis 
actuaram como inibidores não-competitivos (como por exemplo o econazol e a 
amoxapina). Os resultados experimentais obtidos para compostos comerciais e derivados 
tioxantónicos sintéticos permitiram a construção de dois farmacóforos: um farmacóforo 
para inibidores competitivos e um farmacóforo para inibidores não competitivos da P-gp. 
Finalmente, dois dos mais potentes inibidores da P-gp (compostos 29 e 31) foram 
testados contra outros alvos como MRP1, MRP2, MRP3, e BCRP, assim como contra o 
citocromo P450 (CYP3A4), de forma a delinear o seu perfil de selectividade. Os 
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resultados mostraram que estas tioxantonas não são selectivas para a P-gp, já que 
interferem com outros transportadores ABC e com a CYP3A4. 
Em conclusão, as tioxantonas aminadas mostraram possuir um esqueleto 
apropriado para o design de ligandos duplos com actividade antitumoral e inibidora da P-
gp. Os compostos desenvolvidos neste estudo podem constituir um modelo para o 
desenho de novos agentes anticancerígenos com concomitante capacidade de reverter a 
MDR. 
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Abbreviation List 
 
ABC  ATP-binding cassette 
ADP Adenosine diphosphate 
AML Acute myelogenous leukemia 
ATP Adenosine triphosphate 
BBB Blood brain barrier 
BCRP Breast cancer resistant protein 
CML Chronic myelogenous leukemia 
CNS Central nervous system  
CYP Cytochrome P450 
DNA Deoxyribonucleic acid 
GI50 Concentration of the compound that causes 50% of cell growth inhibition 
IC50 Concentration of the compound that causes 50% of inhibition 
IUPAC  International Union of Pure and Applied Chemistry 
MDR Multidrug resistance 
MRP Multidrug resistance-associated protein(s) 
NBD Nucleotide binding domain(s) 
Pi Inorganic phosphate 
P-gp P-glycoprotein 
Rh123 Rhodamine-123 
Sav1866 Staphylococcus aureus ABC transporter 
SRB Sulphorhodamine B 
TM Transmembrane (α-helix) 
TMD Transmembrane domain(s) 
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General and specific objectives of the dissertation 
 
The general objectives of this thesis were to design, synthesize and evaluate the P-
gp inhibitory activity of several (thio)xanthones in order to conclude about the features 
important for activity, and to establish their potential as dual activity agents (P-gp and cell 
growth inhibitors) and as a therapeutic alternative to the existing anti-MDR drugs. 
 
The following specific objectives were established: 
 To investigate the cell growth inhibitory activity and potential P-gp inhibitory effect of a 
series of in-house xanthones. 
 To screen in a library of virtual aminated (thio)xanthones for the potential P-gp inhibitors 
(using docking and P-gp homology models). 
 To synthesize a series of new aminated thioxanthones. 
 To access the cell growth inhibitory activity of the synthesized thioxanthones on human 
chronic myelogenous leukemia cell line K562 and additional cell lines (breast 
adenocarcinoma, MCF-7; melanoma, A375-C5; non-small cell lung cancer, NCI-H4460). 
 To investigate the cytotoxicity of thioxanthones on a nontumor cell line (MRC-5). 
 To initiate the understanding of the mechanism underlying the cell growth inhibitory 
activity of those derivatives through the study of the levels of apoptosis and of the cell 
cycle profile. 
 To screen the potential P-gp inhibitory activity of (thio)xanthones using the rh123 
accumulation assay (flow cytometry). 
 To further investigate the P-gp inhibitory mechanism (competitive/noncompetitive) of 
aminated thioxanthones using the P-gp-ATPase assay and the UIC2 assay. 
 To characterize the effect of these dual inhibitors in combination with a known 
chemotherapic drug (doxorubicin) in the K562Dox cell line. 
 To create pharmacophores that reflects the features important for the P-gp competitive 
and noncompetitive inhibition. 
 To explore potential interactions of thioxanthonic P-gp inhibitors on other ABC 
transporters (MRP1, MRP2, MRP3, and BCRP) using specific ATPase assays. 
 To analyse the potential interaction of thioxanthonic compounds with CYP3A4, using a 
luciferine-based luminescence assay. 
 To screen a database of commercial compounds using a pharmacophore model (based 
on known P-gp inhibitors), and evaluate the P-gp modulatory activity of the best fitting 
compounds. 
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outline of the Dissertation 
 
The present thesis is structured in seven main parts: 
 
CHAPTER I- INTRODUCTION (THEORICAL BACKGROUND) 
In the first chapter, a brief introduction of some key concepts about multidrug 
resistance (MDR) is presented in section 1. The ATP-binding cassette transporters (ABC) 
most commonly described as being involved in MDR, namely P-glycoprotein (P-gp), 
multidrug resistance proteins (MRP) and breast cancer protein (BCRP) are described on 
section 2.  
P-gp is more thoroughly explored in regarding its structure, transport cycle, role of the 
lipidic membrane, physiological role, envolvement in MDR, other functions, and 
approaches for overcoming P-gp mediated MDR in sections 2.1.1 to 2.1.8. Also, a 
systematic review on the available generations of P-gp inhibitors is presented on Annex I.  
A brief description of cancer and its cellular alterations is presented on section 3, 
followed by a briefing on the therapeutical activities of xanthones and thioxanthones on 
section 4, and by an introduction to the concept of dual ligands on section 5. Finally, a 
summary of the two virtual screening methods used in this work – docking and 
pharmacophore screening – concludes this chapter (section 6). An overview of the 
computational tools applied in the development of new P-gp inhibitors is presented on 
Annex II. 
 
CHAPTER II- RESULTS AND DISCUSSION (ORIGINAL RESEARCH) 
In the second chapter, results from the original research concerning the design, 
synthesis, and biological activities of xanthones and thioxanthones are described. The 
chapter starts with an outline of the strategies undertaken, followed by the results 
obtained, that are presented as five papers forming an integrated part of this thesis 
(Annexes III-V, VII and VIII) as well as unpublished results (Annex VI). An integrated 
discussion of the results is presented within this chapter. The chapter ends with the main 
achievements of the present work. 
 
CHAPTER III – EXPERIMENTAL 
Chapter three describes the experimental methodologies used in this work. The 
majority of the experimental methods are presented in five papers (Annexes III-V, VII and 
VIII) and unpublished results (Annex VI), which form an integrated part of this thesis. In 
this section, the authors contributions in the experimental procedures are also presented. 
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CHAPTER IV - CONCLUSIONS 
This chapter consists of a general conclusion of the dissertation. 
 
REFERENCES 
The references are presend at the end of this thesis. The references followed the ACS 
American Chemical Society style guide. The main bibliographic research motors were 
PubMed powered by the National Center for Biotechnology Information (NBCI) and Scirus 
powered by Elsevier. 
 
ANNEXES 
This chapter includes two submitted reviews (Annexes I and II), the published 
(Annexes III and VIII) and submitted (Annexes IV, V, and VII) papers, as well as 
unpublished results (Annex VI).  
 
APPENDIX 
This chapter includes a table with the chemical structure and IUPAC name of the 
(thio)xanthones presented throughout this thesis, as well as their numeration according to 
the papers in “Annexes”. 
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i. Introduction 
 
1. Multidrug-resistance (MDR) 
 
Multidrug resistance (MDR) is defined as resistance of tumor cells to the cytostatic or 
cytotoxic actions of multiple, structurally dissimilar and functionally divergent drugs 
commonly used in cancer chemotherapy1. MDR is named 'intrinsic' when the disease is 
refractory to chemotherapy from the outset, or 'acquired' when the disease becomes 
insensitive to treatment upon relapse2.  
As illustrated in Figure 1, different causes for cellular multidrug resistance have been 
described. 
 
 
Figure 1. Cellular factors that cause drug resistance (adapted
3
) 
 
Regarding cancer chemotherapy, several factors have been proposed to be 
responsible for the resistance of tumor cells to anticancer drugs, including: 
1) downregulation of the uptake system or induction of the efflux system (e.g., P-gp)4, 
5,  
2) induction of detoxification enzymes (e.g., glutathione-S-transferase that catalyze 
the conjugation of glutathione and drugs)6, 7, 
3) alterations of the target molecule (e.g., topoisomerase and tubulin)8,  
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4) increased repair of the target DNA4, 5,  
  5) alterations in the apoptotic signal pathway by overexpression of anti-apoptotic 
proteins like Bcl-2 or p53 mutations and ceramide alterations9.  
 
Resistance to drugs, sometimes known as classical MDR, often results from 
expression of ATP-dependent efflux pumps with broad drug specificity3. MDR may involve 
reduced cellular accumulation of drugs due to increased drug efflux out of cells by the 
overexpression of several ATP-dependent efflux pumps or transporters known as the 
ATP-binding cassette (ABC) family10 (Section 2). The most widely studied example of 
these efflux pumps is P-glycoprotein (P-gp) (Section 2.1), encoded by the multidrug 
resistance mdr1 gene. Other members of the ABC superfamily have also been implicated 
in cancer MDR, including multidrug resistance-associated protein-1 (MRP1), its homologs 
MRP2-811 (Section 2.2.1), and the breast cancer resistance protein (BCRP)12 (Section 
2.2.2).  
 
 
2. ABC-binding cassette transporters 
 
The ABC transporters belong to a super-family of more than 100 membrane 
transporters/channels that are involved in a multiplicity of functions, including the extrusion 
of harmful compounds, uptake of nutrients, transport of ions and peptides, and cell 
signalling. They are universally expressed in bacteria, plants and mammals13. In humans, 
48 ABC transporters have been identified, and classified on the basis of phylogenetic 
analysis into 7 subfamilies (A–G)14. P-glycoprotein (P-gp) is a member of the ABCB 
subfamily. 
In mammals, functional ABC proteins consist of at least two transmembrane domains 
(TMD) and two nucleotide binding domains (NBD)15. The two NBD form a common 
binding site where the ATP bind and hydrolise, promoting efflux through a cavity that is 
delineated by the transmembrane helices (TM)16. For P-gp, the secondary structure can 
be divided into two similar halves, each containing one TMD and one NBD (Figure 2A). 
This basic ABC efflux transporter structure is shared by MRP4, MRP5, and MRP8 (Figure 
2A), whereas MRP1-3 and MRP6-7 contain an additional aminoterminal domain 
consisting of 5 TM helices17 (Figure 2B). They encode a single polypeptide that includes 
all domains (full transporters)18. BCRP is considered a half transporter and must dimerize 
to create a functional transporter (Figure 2C)19.  
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Figure 2. Predicted membrane topology for the human ABC transporters P-gp, MRP1-8 and 
BCRP. P-gp, MRP4, MRP5 and MRP8 consist of 12 TM and two NBD (A), whereas MRP1-3 and 
MRP6-7 have an additional aminoterminal domain consisting of 5 TM (B). BCRP is a half-
transporter, and therefore only consists of 6 TM and one NBD (C). The position of the membrane is 
indicated by the yellow boxes, and all transporters are depicted with the same orientation, down 
being towards the inside of the cell (adapted
20, 21
). 
 
 
Within the ABC family there are transporters involved in MDR, because they exclude a 
wide variety of structurally distinct compounds out of the cell. These carriers are 
overexpressed in tumor cells, conferring cross-resistance against several cytotoxic 
compounds14. At the cellular level, P-gp has been found not only in the plasma membrane 
but also in the nuclear envelope, in caveolae, cytoplasmic vesicles, lysosomes, Golgi 
apparatus, endoplasmic reticulum22, and mitochondria23. P-gp is also expressed on 
hematopoietic stem cells24, 25, natural killer (NK) cells26, 27, antigen-presenting cells28, T 
and B lymphocytes29 and developing fetus30. 
P-gp (ABCB1) is extensively distributed and expressed in the intestinal epithelium, 
hepatocytes, renal proximal tubular cells, adrenal gland and capillary endothelial cells 
comprising the blood brain barrier (BBB) and blood-testis barrier31, as it will be further 
explored in Section 2.1.4.  
MRP1 (ABCC1) is expressed in most tissues of the body, and it is present in high 
levels in the lungs, testis, kidney, peripheral blood mononuclear cells and in low levels in 
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the liver. It is usually located in the basolateral cell surface, which in certain tissues results 
in efflux of its substrates into the blood21. MRP1 confers resistance to several hydrophobic 
compounds that are also P-gp substrates. Like other members of the ABCC subfamily, 
MRP1 can export glutathione (GSH), glucoronate or sulfate conjugates of organic anions. 
MRP1 homologues implicated in resistance to anticancer agents include MRP2, MRP332, 
33, MRP434, MRP535, MRP6, MRP736, and MRP837. 
BCRP (ABCG2) is also involved in MDR. ABCG2, which is overexpressed in several 
cell lines selected for anticancer drug resistance, is a high-capacity transporter with wide 
substrate specificity38.  
P-gp and BCRP have a more limited tissue distribution than MRP1, and are located on 
the apical surface of epithelial cells, usually in places that need to be protected from 
xenobiotics, such as the BBB, placenta, liver, intestines and kidneys, since those carriers 
have excellent ability to modulate the absorption, distribution, metabolism and elimination 
of xenobiotics21. 
The mentioned transporters illustrate the multiplicity of ABC transporters and 
redundancy of functions and variety of substrates19. 
However, several MDR cell lines that do not overexpress ABC transporters have been 
described, indicating that additional mechanisms are functioning, namely the presence of 
non-ABC transporters, such as the lung resistance-related protein (LRP)39. 
 
 
 
2.1. P-glycoprotein 
 
2.1.1. P-glycoprotein at a molecular level 
 
P-gp is a plasma membrane glycoprotein with 170KDa encoded by the mdr1 gene 
located at chromosome 740. It has 1280 amino acids arranged in two halves, each 
containing 610 amino acids, which are connected by a flexible linker region of about 60 
amino acids31. Each P-gp halve encompasses a transmembrane domain (TMD) 
composed of six membrane spanning α-helices (TM), and one intracellular nucleotide-
binding domain (NBD), and behaves as a full transporter (Figure 3).  P-gp has TM1–TM6  
in the former repeat (TMD1) and TM7–TM12  in the later repeat (TMD2)41. So, P-gp is 
comprised of four domains: two transmembrane domains (TMD), which contain the drug 
binding sites and define the translocation pathway across the membrane; and two 
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cytoplasmic nucleotide binding domains (NBD), which couple the energy associated with 
ATP binding and hydrolysis to drug transport42, 43. 
 
 
Figure 3. Schematic representation of P-gp structure with TMD 1 (TM1 to TM6) and TMD 2 (TM7 
to TM12), and with the two ATP-binding sites (NBD1 and NBD2) (adapted
44
). 
 
Although P-gp is glycosylated in the first extracellular loop (N91, N94, and N99), the 
role of glycosylation is not well known45. It appears to be required for the proper trafficking 
of P-gp to the cell surface and P-gp stability in the membrane, but it is not required for its 
transport functions45. P-gp is also a potent substrate for phosphorylation by protein kinase 
A (PKA) and protein kinase C (PKC) at four serine residues in the linker region (S661, 
S667, S671, and S683)44, 46. However, the functional role of phosphorylation of P-gp is still 
unclear, but the lack of phosphorylation sites in P-gp may affect the stimulation of P-gp 
ATPase activity by some substrates47. Stability of P-gp is also regulated by ubiquitination6.  
 
Transmembrane domais (TMD) 
 
The TMD contain the drug-binding site and form the translocation pathway. This 
domains shares low sequence identity within the ABC transporters superfamily48. 
Important clues that the TMD may be important for drug binding were obtained from 
photoaffinity labelling, cystein-scanning mutagenesis, and thiol-reactive substrate 
labelling49-52. The number and location of the drug binding sites remains unclear. A large 
common binding site had been initially proposed53, but subsequently, several distinct or 
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overlapping binding sites were proposed to explain the complex behavior of P-gp when 
cooperative, competitive, and noncompetitive interactions with MDR modulators are 
observed44, 54-58. Drug binding involves an induced fit mechanism59 and only binding in 
some orientations can allow for conformational changes to induce ATP hydrolysis60. There 
is also the possibility for different binding locations and orientations of the same ligand61. 
Drug substrates bind at distinct regions in a common drug-binding pocket that is 
formed by the interface between the TMD of both halves of P-gp.  In the initial models of 
P-gp, it was predicted that the last three TM segments of each TMD (TM 4-6 and 10-12, 
respectively) formed the drug binding pocket49-52, 62. Later, it was demonstrated that TM1 
also lines the drug-binding pocket (residue L65)63, as well as TM7 (residue F728)64. The 
substrates undergo partition in the plasma membrane and enter the binding pocket of P-
gp through "gates" formed by TM4 and 6 on one side of the carrier and TM 10 and 12 on 
the opposite side61, 65 (Figure 4), that open and close with the conformational changes 
associated with pumping and resulting in open and closed conformation of P-gp65. On the 
other hand, ligand interaction with allosteric residues L339 (TM6)66 or F983 (TM12)67, 68 
prevent the conformational changes required for drug transportation.  
      
 
Figure 4. Binding cavity in the inward-facing conformation of an homology model of human P-gp: 
(A) general view (face); (B) closer view (from inside). The protein backbone is colored by the 
secondary structure; TM4 and TM10 are coloured in blue, and TM6 and TM12 are coloured in 
purple (adapted
61
). 
 
 
A      B 
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 Nucleotide binding domains (NBD)  
 
The NBD, which share a high degree of sequence identity with the equivalent domains 
of all ABC transporters, couple the energy of ATP binding and hydrolysis to drug 
transport48. The two NBD of P-gp share 30-40% amino acid sequence identity with each 
other. NBD bind and hydrolyze ATP, generating the energy necessary for substrate 
translocation across the membrane40. Although the catalytic cycle of P-gp is still under 
controversy, it is known that both NBD of P-gp are required for the transport of substrates 
out of the cells69. Each NBD is made of several conserved sequences, involved in ATP 
binding, namely the Walker A (427–434 and 1070–1077), ABC signature (LSGGQ) (531–
542 and 1176–1187), the Walker B (543–555 and 1188–1200)31, and A, D, Q, and H 
loops70 (Figure 5). 
The functional NBD appears to be a “nucleotide-sandwich dimer”71 with ATP flanked by 
the Walker A and B motifs of one NBD and the signature motif and D-loop of the other 
NBD72. Thus, since ATP binding and hydrolysis within NBD are crucial for maintaining P-
gp-mediated drug translocation, disruption of these processes is potentially a powerful 
means of inhibiting the P-gp transportation cycle. 
 
Figure 5. Scheme showing residues in conserved subdomains of NBD1 and NBD2 of human P-gp 
interacting with ATP. ATP is sandwiched between the Walker A and B, and A, Q, and H loops of 
the NBD1 and the ABC signature region and D-loop of the NBD2 (adapted
73
). 
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Three dimensional structure of P-gp 
 
In 1997, direct structure data on P-gp was obtained at low resolution by electron 
microscopy74-76 and suggested that the TMD form a cup-shaped chamber in the 
membrane, with the two NBD in opposition at the cytoplasmatic face52, 62, 77. Recently, the 
description of the three dimentional structure of mouse P-gp65 was a major step in the 
understanding of P-gp function. The structure of P-gp (Figure 6A) represents a nucleotide-
free inward-facing conformation arranged as two “halves” with pseudo molecular 
symmetry spanning ~136 Å perpendicular to and ~70 Å in the plane of the bilayer. The 
NBD are separated by ~30 Å65. Substrate suffers partition into the membrane bilayer from 
outside of the cell to the inner leaflet, and enters the internal drug binding pocket through 
an open portal of the inward-facing structure of P-gp (Figure 6A). It was hypothesized that 
the inward-facing conformation was a pre-transport state (high affinity for substrates). 
During the catalytic cycle, binding of ATP, stimulated by the substrate, likely causes a 
dimerization in the NBD, which produces large structural changes that originate a 
outward-facing conformation (low affinity for substrates) (Figure 6B) similar to the 
nucleotide-bound structures of MsbA or Sav186665. Substrates can either be released as 
a consequence of decreased binding affinity caused by changes in specific residue 
contacts between the P-gp and ligand going from the inward to outward facing 
conformation or, alternatively, facilitated by ATP hydrolysis. In either case, ATP hydrolysis 
likely disrupts NBD dimerization and resets the system back to inward facing and 
reinitiates the transport cycle (Figure 6)78. 
 
Figure 6. A) Inward facing and B) outward facing P-gp models (adapted
65
). Pink = substrate; 
yellow = ATP. 
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2.1.2. Transport cycle of P-gp  
 
Various models have been proposed to explain how P-gp extrudes compounds across 
the membrane. "Flippase" and "hydrophobic vacuum cleaner” models are in agreement 
with data on the tertiary structure of P-gp which indicate that the access of the substrate to 
P-gp is through a gate inside the membrane48, 79. However, this is still a controversial 
topic. 
Two molecules of ATP are hydrolysed per transport cycle80, being both NBD 
catalytically active81. However, the role of ATP binding and/or its hydrolysis to transport 
substrates of P-gp is still controversial48, 82. Generally, ATP-dependent transport by P-gp 
involves three major steps: 1) substrate recognition, 2) substrate translocation, and 3) 
substrate dissociation83. 
Two potential models have been proposed to explain the sequence of events that 
occur during the efflux: the ATP hydrolysis model (Figure 7A) and the ATP switch model 
(Figure 7B).  
 
A 
 
B 
 
Figure 7. ATP hydrolysis model (A) and ATP switch model (B). Light purple areas represent the 
TMD, and dark purple areas represent the NBD (adapted
72, 84
). 
 
The ATP hydrolysis model (Figure 7A), proposed by Ambudkar et al., hypothesized 
that the binding of a substrate and ATP hydrolysis initiates the transport cycle72. Two ATP 
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hydrolysis events are required, but one powers the efflux of the drug and the other resets 
the protein to its ground state58. On the other hand, in the ATP switch model (Figure 7B), 
proposed by Higgins et al., the interaction of the substrate with the high-affinity P-gp 
binding site enhances the binding of ATP and initiates dimerization of the NBD84. The 
dimerization of the NBD in turn induces a conformational change of the TMD, resulting in 
exposure of the substrate binding sites to the extracellular medium, a reduction in its 
affinity for the binding and subsequent release of the substrate85. Finally, the ATP is 
hydrolyzed sequentially to give energy to break the dimer of NBD. The inorganic 
phosphate (Pi) is released followed by ADP, allowing the P-gp back to original 
conformation84. Thus, according to this model, ATP binding rather than ATP hydrolysis 
induces a conformational change in the tertiary structure of P-gp that brings NBD1 and 
NBD2 into close proximity, leading to substrate translocation79, 86. 
 
2.1.3. Role of the lipidic membrane in P-gp function 
 
The function of P-gp is associated to the lipid bilayer in which it is embedded, and from 
which obtains its substrates87. The bilayer plays a major role in the interaction of drugs 
with P-gp. P-gp may have a relatively low intrinsic affinity for its substrates; the role of the 
membrane is to concentrate the drug for presentation to the protein88. Transported drugs 
are concentrated near the surface zone of the inner leaflet of the plasma membrane89. 
Here, the drugs can easily diffuse laterally into the drug-binding site of P-glycoprotein 
through an open cleft and are extruded to the exterior by a solvation exchange 
mechanism (Figure 8)90. Moreover, the fluidity of the membrane also affects P-gp 
mediated drug transport91. 
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Figure 8. Solvation exchange mechanism of drug transport by P-glycoprotein. (A) A substrate is in 
equilibrium between the aqueous phase and the lipid bilayer. Due to hydrophobicity, the substrate 
partitions to the inner leaflet of the plasma membrane. It maintains contact with water and with lipid 
headgroups through polar interactions. (B) The substrate can laterally diffuse to the inside of the 
drug-binding chamber and bind to the drug-binding site. Polar groups establish interactions with 
polar residues in the TMD. The hydrophobic part of the drug is adsorbed by hydrophobic residues 
in the chamber (light purple areas) through van der Waals interactions. (C) ATP binding/hydrolysis 
closes the entry cleft, rotates TMD helices (dotted curved arrow), destroyes electrostatic 
interactions (for example, ionic interactions and hydrogen bonds) between the polar part of the 
drug and P-gp and opens an exit through which water access is available. Loss of polar 
interactions with the polar part of the substrate initiates the efflux of drug (solid curved arrows). 
Hydrophilic residues scattered inside of the putative drug binding chamber, and water molecules, 
may form transient polar interactions with the substrate aiding in the efflux process. The substrate 
is thus forcibly rehydrated and partitioned to the water phase allowing diffusion to the extracellular 
aqueous space (adapted
90
). 
 
 
2.1.4. Physiological role of P-gp 
 
The human P-gp was first identified due to its overexpression in tumor cells associated 
with cross resistance to multiple cytotoxic anticancer agents, which provided an 
explanation for the phenomenon of MDR92. However, after the initial characterization of P-
gp, it was found that the transporter was also expressed in many normal tissues, leading 
to supposition about its physiological funtions20.  
Due to its very broad and strategic location in the human body, inhibition of P-gp, 
especially in some tissues such as the blood-brain barrier (BBB) (Figure 9A), placenta 
(Figure 9B), blood-testis barrier (Figure 9C), enterocytes and hepatocytes (Figure 9D) 
may influence the pharmacokinetics and biodistribution of administered compounds, 
leading to an increased toxicity. This is therefore a major factor to be considered when 
attempting to inhibit P-gp93. The most significant physiological effect seems to be in the 
luminal membrane of capillary endothelial cells of BBB, where the P-gp prevents the 
passage of drugs and toxins through the capillary membrane to the brain  (Figure 9A)21. 
P-gp is also located in the syncytiotrophoblast and pumps xenobiotics from the fetus back 
to the maternal blood (Figure 9B)20. P-gp is expressed in somatic testicular cells, namely 
in the peritubular cells, allowing germ cells protection (Figure 9C)21. The P-gp is also 
located on the apical surface of bronchial and bronchial epithelium, and alveolar 
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macrophage plasma membrane and is thought to participate in the removal of 
environment compounds into the lumen of the lungs21.  
After oral exposure to anticancer agents such as paclitaxel, the low systemic exposure 
observed is due, at least in part, to the drug efflux carried by P-gp located in the apical 
domain of enterocytes in the gastrointestinal tract (duodenum, jejunum, ilium, and colon) 
(Figure 9D), which limits the absorption by mediating their excretion back to the lumen of 
the intestine19. Similarly, the presence of P-gp in hepatocytes and brush border of 
proximal renal tubules is consistent with its role in biliary (Figure 9D) and urinary excretion 
of xenobiotics and endogenous substrates15. 
Therefore, a compound that interacts with P-gp may inhibit the transport of another co-
administered compound that is a P-gp substrate, in a competitive or noncompetitive way, 
resulting in increased bioavailability and decreased clearance15. 
 
         
 
  
 
 
Figure 9. Expression of P-gp in epithelial cells of the BBB (A), placenta (B), testis (C), enterocytes 
and hepatocytes (D) (adapted
21, 23
). TJ=tight junctions; CYP3A4= cytochrome P450 3A4. 
 
A       B 
C       D 
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P-gp and cytochrome P450 CYP3A4 isoform, important in the metabolism of many 
drugs, have many substrates in common94. Both P-gp and CYP3A4 are expressed in the 
intestine and liver (Figure 9D) and work together in the elimination of xenobiotics, e.g., P-
gp pumps the drug out of the cell while CYP3A4 metabolizes the drug in the cell95. A P-gp 
inhibitor that also interferes with CYP3A4 may cause pharmacokinetic interactions that 
can compel the reduction of the dose of a co-administered chemotherapy drug (if this one 
requires CYP3A4 for metabolization) to avoid increased toxicity94.  
 
2.1.5. P-gp and multidrug resistance 
 
P-glycoprotein (P-gp) is a MDR efflux pump, being over-expressed in cancer cells96. P-
gp confers cells the ability to resist lethal doses of certain cytotoxic agents, pumping them 
out of the cells and thereby reducing their toxicity. Structural characteristics of MDR 
neoplastic cells expressing P-gp are typical of cells engaged in a metabolically demanding 
process of protein synthesis and transport (increased cell size and internal organelles)6. 
Many anticancer agents undergo P-gp-mediated transport (Table 1), despite their 
structural diversity and mechanisms of action. The P-gp confers resistance to 
anthracyclines, vinca alkaloids, taxanes and epidofillotoxines, as well as other very 
diverse compounds19, 69. As a result, there is a positive correlation between the expression 
of P-gp and the failure of chemotherapy treatment in leukemias, lymphomas, osteogenic 
sarcoma, small cell lung cancer, breast cancer, and pediatric solid tumors97. In particular, 
there are uniform correlations between P-gp gene expression and drug resistance in 
acute myelogenous leukaemia (AML). P-gp overexpression has been reported in one-third 
of patients with AML at the time of diagnosis, and more than 50% of patients at relapse98. 
Moreover, P-gp expression is correlated with a decrease in the level of response to 
chemotherapy and increased resistance99, a reduced complete remission rate and a 
higher chance of refractory disease100.  
 
Table 1. Anticancer drugs pumped by P-gp (adapted
19, 101
) 
 
Anthracyclines Vinca 
alkaloids 
Taxanes Epidophyllotoxins Camtothecins Kinase 
inhibitors 
Others 
Doxorubicin 
Epirubicin 
Idarubicin 
Vincristine 
Vimblastine 
Vinodesine 
Vindesine 
Paclitaxel 
Docetaxel 
Etoposide 
Teniposide 
Irinotecan 
Topotecan 
Imatinib 
 
Bisantrene 
Methotrexate 
Mitoxantrone 
Dactinomycin 
Actinomycin D 
Mitomycin C 
Amsacrine 
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The importance of P-gp or any transport mechanism (e.g., MRP or BCRP) that confers 
resistance to drugs depends on the level of expression of the transporter by tumor cells 
and the therapeutic regimen. An anticancer agent that is expelled by the expressed pump 
should not be employed in the chemotherapeutic regimen, or an inhibitor of the efflux 
should be administered together with the antitumor drug19. Indeed, the modulators of P-gp 
function can restore the sensitivity of MDR cells to anticancer drugs. Therefore, the 
development of effective MDR-reversing agents is important. Nevertheless, although there 
have been several potential P-gp inhibitors under investigation, clinical trials have not yet 
shown convincing results of full reversal of MDR99. 
 
2.1.6. Other functions of P-gp 
 
P-gp has been reported as being implicated in cellular differentiation, cell cycle 
progression, and apoptosis. All of these processes are important in tumorigenesis102-104. In 
fact, P-gp is downregulated during differentiation of pluripotent stem cells24. Additionally, 
P-gp positively regulates cell cycle105, by increasing the intracellular levels of ceramide. In 
addition, P-gp also confers resistance to caspase-mediated apoptosis106; the mechanism 
is though to be related to the increased intracellular pH that follows P-gp overexpression 
or to the increased intracellular levels of ceramide107.  
 
 
2.1.7. Approaches for overcoming P-gp-mediated MDR 
 
The efforts to understand MDR in cancer has resulted in the identification of a limited 
number of distinct, clinically proven mechanisms. There are several strategies to 
overcome P-gp-mediated MDR (Figure 10)101. 
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Figure 10. Strategies to  circumvent P-gp-mediated MDR: the co-administration of P-gp inhibitors 
and cytotoxic agents (“engage”), the use of cytotoxic agents that are not P-gp substrates (“evade”), 
and the downregulation of P-gp expression (“downregulate”) (adapted
101
). 
 
The most classical pharmacological strategy for P-gp mediated MDR reversal is the 
administration of agents capable of inhibiting P-gp function (Figure 10, “engage”). 
Strategies such as the decrease in mdr1 gene expression by antisense108, ribozymes109, 
small interfering ribonucleic acid (siRNA)110, or transcriptional regulators111 (Figure 10, 
“downregulate”), or the use of drugs that are not substrates of drug transporters (e.g. 
epothilones)93 (Figure 10, “evade”) have also been intensively described in the literature. 
Other approaches include the encapsulation of anticancer drugs in liposomes or 
nanoparticles (e.g. liposomal anthracyclines), the use of P-gp targeting antibodies (e.g. 
UIC2, MRK16) or post-translational modifications5, 6. 
 
2.1.8. Compounds directly targeting P-gp (Annex I) 
 
As there has been a crescent interest in the topic of P-gp inhibitors, a systematic 
review on P-gp inhibitors is presented on Annex I. 
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2.2. Other MDR ABC transporters 
 
P-gp was the first MDR related transporter that was identified. Following that discovery, 
other transporters such as MRP and BCRP were discovered112. The primary structures of 
the TMD differ significantly among ABC transporters and have been recognized as being 
the main determinants of substrate specificity113. The ATP-binding domains on NBD, on 
the other hand, share an overall sequence identity of approximately 20-30%. They contain 
three main core consensus motifs, known as Walker A, Walker B, and ABC signature114, 
which are essential for ATP binding (Figure 5, section 2.1.1). The high conservation of the 
NBD in ABC transporters suggests that these proteins may use similar energy-dependent 
transport mechanisms115.  
Although these proteins share few similarities in the amino acid sequences, they show 
both distinct and overlapping substrate specificity116. MDR cells may overexpress one 
ABC transporter alone117, or several in simultaneous118. 
 
 
2.2.1. Multidrug resistance proteins (MRP) 
 
Multidrug resistance-associated protein (MRP) belongs to the C subfamily of the ATP-
binding cassette (ABC) protein family. This C sub-family contains 13 members, of which 
eight are MDR-related: MRP1 through MRP8 (ABCC1–6, and ABCC10–11, 
respectively)119. The substrates of these transporters are diverse and include lipophilic 
anions16.  
The amino acid sequence of MRP1 resembles P-gp only in 15%. MRP1 is composed 
of a large “core” segment similar to P-gp, but has in addition an N-terminal region 
composed of a third membrane spanning domain with five TM, an intracellular loop, and 
an extracellular N-terminus120. MRP1 was the first identified member of its family; MRP2, 
MRP3, MRP6, and MRP7 resemble MRP1, whereas MRP4, MRP5, MRP8 and MRP9 
lack the extra five TM domain segment121 (Figure 2, section 2). 
In contrast to P-gp, which extrudes xenobiotics into bile, intestine, or renal tubules for 
terminal elimination from the body, MRP1 is a basolateral transporter whose operation 
results in the movement of compounds away from luminal surfaces and into tissues that 
lie beneath the basement membrane (Figure 11A)122. 
MRP1 overexpression enhances resistance to several cytotoxic drugs such as 
doxorubicin, vincristine, and etoposide. ATP-dependent transport of these anticancer 
drugs can be enhanced by the presence of glutathione (GSH), suggesting that MRP1 co-
Introduction 
 
 19 
 
transports anticancer drugs and GSH. Supporting this idea, it has been reported that 
depletion of intracellular GSH resulted in a complete reversal of drug resistance in MRP1 
overexpressing cells123. Based on these results, three different modes could be proposed 
for MRP1-mediated transport of drugs and endobiotics (Figure 11B). These are (i) 
transport of GSH conjugates; (ii) co-transport of drugs and GSH; (iii) transport of 
multivalent organic anions. These transport modes explain the wide substrate specificity 
of MRP1124. MRP1 has been highly expressed in leukemias, oesophageal carcinomas, 
and non-small cell lung cancers125. 
A           B 
 
Figure 11. A) Subcellular localization of MRP in polarized epithelial cells. The localization of MRP 
in epithelial cells surrounding a hypothetical lumen is shown. MRP1, MRP3, MRP5, and MRP6 are 
localized in basolateral membranes. MRP2 is localized in apical membranes. MRP4 may be 
localized in both basolateral and in apical membranes. The localizations of MRP7, MRP8, and 
MRP9 have not yet been determined. P-gp and ABCG2 are apical efflux pumps (adapted
122
). B) 
Three different modes for MRP1-mediated transport of xeno- and endobiotics. (I) transport of 
glutathione conjugates; (II) co-transport of drugs with GSH; (III) transport of multivalent organic 
anions (adapted
124
). 
 
2.2.2. BCRP 
 
The human breast cancer resistance protein (BCRP) is a member of the G subfamily of 
the ATP-binding cassette (ABC) efflux transporter superfamily, also called ABCG2. It is a 
655 amino acid protein that contains an ATP-binding domain and six TM, and it is a half 
transporter member of the ABCG subfamily126 (Figure 2, Section 2). As a half transporter, 
BCRP functions as a homodimeric efflux pump, in a similar way to other ABC 
transporters127. 
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There is low protein sequence identity in NBD (20-30%) and no significative protein 
sequence identity in TMD between BCRP and P-gp or MRP1. Moreover, BCRP is widely 
expressed in normal cells including the capillary endothelial cells, the hematopoietic stem 
cells128, the placenta and the BBB129. 
BCRP uses the energy from ATP hydrolysis to transport a large number of 
structurally unrelated compounds. This protein can efflux large, hydrophobic molecules 
(both positively or negatively charged)130. Cells overexpressing BCRP are resistant to a 
variety of chemotherapeutic agents such as mitoxantrone, methotrexate and topotecan131. 
It has been suggested that BCRP underlies the drug resistance observed in clinical 
samples of different cancers such as acute myelogenous leukemia (AML) and acute 
lymphocytic leukemia (ALL)38. Although BCRP was originally cloned from a human breast 
cancer cell line, expression can also be found in gastric carcinoma, hepatocellular 
carcinoma, endometrial carcinoma, colon cancer, small cell lung cancer, and melanoma12. 
More studies to assess BCRP expression are required to properly delineate the 
involvement of BCRP expression in the drug resistance of cancer patients129.  
 
3. Cancer and chemotherapy 
 
Cancer is a leading cause of death in industrialized countries, accounting for 13% of 
total death rates according to the WHO report 2008*. About 12.7 million cancer cases and 
7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the 
cases and 64% of the deaths occurred in the economically developing world132. Cancer 
begins from a single cell that multiplies uncontrollable and progressively. The 
development of a cancer occurs in three stages: initiation (mutation of a single cell), 
promotion (proliferation of the cell, giving rise to a large number of daughter cells 
containing the mutation created by the initiator), and progression (additional mutations 
that result in malignancy). A malignant tumor spreads into distal organs in the body 
through the lymphatic system or blood vessels133.   
Many years of research have revealed that cancer results from the genetic alterations 
in cancer cells which confer cellular advantages, such as capacity of unlimited division 
and evasion of cell death134. Surgical excision, radiation, and chemotherapy are the main 
approaches to treat cancer. The use of anticancer drugs as part of the treatment strategy 
for cancer has greatly improved the overall prognosis of cancer patients135, 136. 
 
__________________________________________ 
*http://www.who.int/mediacentre/factsheets/fs297/en/, accessed on the 11
th
 July 2011 
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Leukemia (from the Greek leukos - white, and haima - blood) is a cancer of the blood 
or bone marrow characterized by an abnormal increase in white blood cells137. Based on 
rates from 2005-2007, 1.30% of men and women born nowadays will be diagnosed with 
leukemia at some time during their lifetime. This means that 1 in 77 men and women will 
be diagnosed with leukemia during their lifetime*. 
There are two major types of leukemia, myelogenous or lymphocytic, whether 
cancerous changes take place in a type of marrow cell that normally goes on to form 
granulocytes and red blood cells, or lymphocytes, respectively.   Myelogenous and 
lymphocytic leukemias include both acute and chronic forms**. Chronic leukemia takes 
years to progress and is characterized by a large number of relatively mature, but still 
abnormal, white blood cells. Acute leukemia occurs due to an overabundance of immature 
blood cells, called blast cells, or "blasts”, which divide quickly. Without treatment, acute 
leukemia is often fatal within months137. 
It is important to highlight the fact that P-gp has been detected in a high percentage of 
patients with chronic myelogenous leukemia (CML) in blast crisis and it has been 
suggested as a possible cause of the refractoriness of this disease to treatment138. 
Besides, P-gp expression is correlated with the resistance to agents used in the treatment 
of CML, such as imatinib139. Also, in acute myelogenous leukemia (AML), the remission 
rate is significantly lower in P-gp positive patients than in P-gp negative patients. P-gp 
positive AML patients have a shorter survival and relapse-free survival when compared 
with P-gp negative patients140. P-gp overexpression must therefore be considered as an 
important clinical mechanism in the diversity of existing known mechanisms of resistance 
to treatment. 
 
3.1. Cellular alterations following chemotherapy treatment 
 
In normal cells, the balance between apoptosis and survival signals allow controlled 
homeostasis of the tissue141. Deregulated apoptotic and proliferation pathways disrupt this 
balance, resulting in diseases with either premature cell loss or alternatively unrelenting 
cell survival142. 
In cancer cells, survival signals triggered by oncogenic transformation favour 
uncontrolled proliferation. Anticancer therapy aims to increase levels of apoptosis and 
decrease proliferation (Figure 12)143, 144. 
  
__________________________________________ 
*http://seer.cancer.gov/statfacts/html/leuks.html, accessed on the 11
th
 July 2011 
**http://www.cancer.gov/cancertopics/wyntk/leukemia/, accessed on the 11
th
 July 2011 
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Figure 12. Balance between proliferation and apoptosis signals in normal and cancer cells and 
following therapy of cancer cells (adapted
145
). 
 
 
3.1.1. Proliferation 
 
At the center of cellular proliferation is the cell division cycle, the process by which a 
cell replicates its DNA and then divides to give two daughter cells. This process is divided 
into four sequential phases (Figure 13): G1, S, G2, M. The G1 phase is marked by the 
synthesis of various enzymes that are required for the S phase, mainly those needed for 
DNA replication. The S phase is charactherized by the DNA synthesis; the amount of DNA 
in the cell doubles146. During the G2 phase biosynthesis occurs, mainly the production of 
microtubules, which are required for the process of mitosis. The relatively brief M phase 
consists of nuclear division (karyokinesis), followed immediately by cytokinesis. Finally, 
there is a fifth state, G0 (also known as quiescence) into which the cell may reversibly exit 
from G1, if it is deprived of the appropriate growth-promoting signals146. 
Regulation of the cell cycle includes the detection and repair of genetic damage as well 
as the prevention of uncontrolled cell division. Two key classes of regulatory molecules, 
cyclins and cyclin-dependent kinases (CDK), determine the cell progress through the cell 
cycle (Figure 13). Two families of genes, the cip/kip family (such as p21 or p27) and the 
INK4a/ARF (inhibitor of kinase 4/alternative readingframe; such as p16) prevent the 
progression of the cell cycle, and so they are accepted as tumor suppressors147.  
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Figure 13. Cell cycle and its regulation (adapted
148
). The purple circle represents phases G1, S, 
G2, and M phases of the cell cycle. The cyclin-cyclin dependent kinases (CDK) complexes present 
on each phase are represented around the circle. Stop signs represent the cell cycle checkpoints. 
 
Checkpoints throughout the cell cycle prevent progression of proliferation to ensure 
that damaged or incomplete DNA is not passed on to daughter cells149. Checkpoint 
signaling may also result in activation of pathways leading to programmed cell death if 
cellular damage cannot be properly repaired150. 
DNA damage may cause a G1 arrest so that it can be repaired before the cell enters S 
phase. Arrest at the G1 checkpoint is mediated by the action of a protein known as p53, 
which is rapidly induced in response to damaged DNA148. p53 is the gatekeeper of the 
genome151, because following cellular stresses, p53 binds to DNA and transcriptionally 
regulates genes that are involved in key cellular processes, such as DNA repair, cell-cycle 
arrest, and apoptosis152. Interestingly, the gene encoding p53 is frequently mutated in 
human cancers153.  Finally, a checkpoint at the end of G2 phase prevents the initiation 
of mitosis until DNA replication is completed or if DNA damage is detected. At the end 
of mitosis  another checkpoint checks the integrity of the genome and the alignment 
of chromosomes on the mitotic spindle, thus ensuring that each daughter cell will receive 
a complete set of chromosomes148.  
Several anticancer drugs bind directly to DNA (for example, intercalating agents), 
interfere with DNA synthesis (for example, antimetabolites) or with microtubule 
polymerization/depolymerisation (vinka alkaloids and taxol, respectively), interfering with 
the cell division, thus blocking cell growth154. 
. 
(thio)Xanthone derivatives with dual activity: antitumor and p-glycoprotein inhibition 
 
24  
 
3.1.2. Cell death 
 
Cell death is a critical process in development and homeostasis of normal organisms. It 
had been believed that the mechanism of cell death induced by chemotherapy is confined 
solely to apoptosis. However, accumulating evidence suggested that tumor cellular 
response to chemotherapy includes other modes of cell death157. Indeed, there are four 
described modes of cell death that can be induced by chemotherapy: apoptosis, necrosis, 
mitotic catastrophe, and autophagy158. Senescence, a form of permanent growth arrest, is 
not a cell death mechanism but is considered of significant importance as a response of 
cancer cells to chemotherapy159. These five kinds of cellular responses are classified 
based on biochemical and morphological features that are present in dying cells158. 
 
Apoptosis 
 
The mechanism responsible for the naturally occurring turnover of cells in the body is 
commonly refered as apoptosis, one of the known mechanisms of “programmed cell 
death”. All cells are “equipped” with a genetic program for self-destruction that plays 
important roles in balancing cell proliferation with cell death160. This cell death process, 
known as apoptosis, has an essential role in maintaining tissue homeostasis and is 
important in certain pathological conditions, including cancer161. 
The pattern of cellular morphological and biochemical changes associated with normal 
programming of cell death include cell shrinkage, condensation and marginalization of 
nuclear chromatin, DNA fragmentation, formation of cytoplasmic vacuoles, mitochondrial 
membrane depolarization, and changes in asymmetry of phospholipids in the plasma 
membrane. As a consequence, the cell is fragmented into compact membranous 
structures (apoptotic bodies) which are subsequently engulfed by macrophages and 
removed from the tissue without generating an inflammatory response160. 
The activation of an apoptosis pathway is a mechanism by which various cytotoxic 
effectively drugs kill tumor cells162. Indeed, despite the diversity of physicochemical 
properties and mechanism of action, several chemotherapeutic drugs kill cancer cells by 
activating cellular machinery regulated by mitochondria to induce cell death163. Defects in 
apoptosis signaling contribute to tumor drug resistance. Activation of apoptosis signaling 
following treatment with cytotoxic drugs can lead to the activation of the mitochondrial 
pathway or intrinsic pathway (Figure 14A) or the death receptors pathway or extrinsic 
pathway (Figure 14B)164. Both pathways will converge in the activation of caspases, 
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cysteine proteases that are synthesized as inactive zymogens and activated by proteolytic 
breakdown165.  
Current evidence suggests that there are several different routes for the activation 
of caspases, depending on the stimulus that triggers the death machinery (Figure 14). 
 
 
Figure 14. Apoptosis pathways. Current conventional treatments such as radio and chemotherapy 
exert their effect by indirectly promoting apoptosis. These regimens induce apoptosis by causing 
DNA damage (intrinsic pathway) (A). The extrinsic pathway is triggered through the Fas death 
receptor or TNF receptor (B). Both pathways converge to a final common pathway involving the 
activation of caspases that cleave regulatory and structural molecules and culminate in the death of 
the cell (adapted
166
). 
 
The extrinsic pathway of apoptosis, initiated via death receptors, such as through Fas 
and tumor necrosis factor (TNF) receptors, requires pro-caspase-8/-10 and -2, 
respectively (Figure 14B). Adapter molecules such as for example Fas-associated death 
domain (FADD), are recruited, thereby forming the so-called death inducing signalling 
complex (DISC). The local concentration of several procaspase-8 molecules at the DISC 
leads to their autocatalytic activation and release of active caspase-8. Active caspase-8 
then processes downstream effector caspases which subsequently cleave specific 
substrates resulting in cell death167. The link between this caspase signalling cascade and 
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the mitochondria is provided by a Bcl-2 family member, Bid. Bid is cleaved by caspase-8 
and when it is in its truncated form (tBid) translocates to the mitochondria where it binds to 
the pro-apoptotic Bcl-2 family members Bax and Bak to induce the release of cytochrome 
c and other mitochondrial proapoptotic factors into the cytosol168. 
The mitochondrial pathway of apoptosis is frequently activated in response to DNA 
damage, involving the activation of a pro-apoptotic member of the Bcl-2 family, such as 
Bax, Bak, Noxa or PUMA (Figure 14A)169. Proapoptotic Bax and Bak can assume an 
active conformation (after interaction with tBid from the extrinsic apoptosis pathway, or 
with Bim detached from microtubules) that results in their insertion into the outer 
mitochondrial membrane, where they facilitate release of cytochrome c and other 
proteins170. Antiapoptotic Bcl-2 family members (Bcl-2, Bcl-XL, Mcl-1) bind the active 
conformations of Bax and Bak171, 172, preventing the formation of pores in the 
mitochondrial membrane, consequently inhibiting the liberation of cytochrome c into the 
cytosol173. Therefore, the balance between pro- and anti-apoptotic members of Bcl-2 
family regulate the release of cytochrome c from the inner mitochondrial membrane174. 
Cytochrome c then associates with Apaf-1, ATP and pro-caspase-9 to create the 
apoptosome. The active caspase-9, as well as caspases-2, -8, and -10, can then cleave 
and activate the subsequent effector caspases (-3, -6, -7)175, 176, culminating in the 
cleavage of substrates such as Poly(ADP-ribose)polymerase (PARP), inhibitor of caspase 
activated DNase/caspase activated DNase (ICAD/CAD), and cytoskeletal proteins, 
ultimately leading to the morphologic manifestations of apoptosis, such as DNA 
fragmentation, and membrane blebbing177. 
Targeting cell cycle154 and apoptosis155 pathways remain attractive approaches for 
the treatment of cancer. However, several challenges remain, including finding ways of 
targeting these agents specifically to tumor cells and avoiding MDR156. 
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4. Xanthones and thioxanthones 
 
Xanthone designates the chemical compound dibenzo-γ-pyrone178. The oxygen 
replacement with sulfur in the xanthone core originates an isoster, the thioxanthone or 
dibenzo-γ-thiopyrone179.  The IUPAC numeration of the xanthone (1) and thioxanthone (2) 
nucleus is represented in Figure 15.  
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Figure 15. Xanthone (1) and thioxanthone (2) nucleus and numbering. 
 
A number of xanthone derivatives are secondary plant metabolites and have been 
isolated from several natural sources, such as fungi, lichens, higher plants, and fruits180. 
Therefore, extracts of these type of natural sources have been used in folk medicines, 
being justified for the presence of such xanthonic derivatives178, 181, 182. Examples are the 
aqueous extracts of Mangifera indica (Vimang®) and Garcinia mangostana (Xango®) that 
contain xanthonic derivatives among their complex composition and are commercialized 
for their various properties, such as antioxidant, antitumoral, antiallergic, anti-
inflammatory, antibacterial, and antiviral (reviewed in180). Naturally occurring xanthone 
derivatives can be subdivided into: simple oxygenated xanthones, glycosylated 
xanthones, prenylated xanthones and their derivatives, xanthone dimers, 
xanthonolignoids, and miscellaneous, depending on the nature of the substituents in the 
dibenzo-γ-pirone scaffold180. Synthetic pathways allowed the preparation of xanthones 
with different substitution patterns180, 183. 
Among the diversity of biological activities described for natural and synthetic 
xanthones, the in vitro growth inhibitory activity on tumor cell lines appeared to be quite 
remarkable182, 184, since they exert their effect on a wide range of different tumor cell 
lines180, 183-187. 
Among natural occurring xanthones some remarkable examples of compounds 
involved in cancer therapy are psorospermin (3), α-mangostin (4), and gambogic acid (5). 
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Figure 16. Natural occurring antitumor xanthones, psorospermin (3), α-mangostin (4) and 
gambogic acid (5). 
 
Psorospermin (3) is a dihydrofuranoxanthone isolated from the roots and bark of a 
tropical African plant Psorospermum febrifugum188, 189. The tetracyclic basic core of 
psorospermine is closely related to that of the pyranoacridone alkaloid acronycine190. 
Psorospermin (3) has been demonstrated to intercalate into DNA and alkylate N7 of 
guanine. It also interacts with topoisomerase II–DNA complexes191. 
Garcinia mangostana belongs to the family of Guttiferae and is named “the queen of 
fruits”. It is cultivated in the tropical rainforest of some Southeast Asian countries like 
Thailand. The pericarp of G. mangostana has been used in traditional medicine for the 
treatment of abdominal pain, diarrhea, dysentery, infected wound, suppuration, and 
chronic ulcer192. Prenylated xanthones isolated from G. mangostana have been 
extensively studied, namely α-mangostin (4)193. This prenylated xanthone induces 
apotosis through caspases 9 and 3 activation, loss of mitochondrial membrane potential, 
and release of reactive oxygen species (ROS) and cytochrome c194. Cell-cycle arrest was 
related with the affected expression of cyclin dependent kinase 1 (CDK1) and p27195. α-
Mangostin (4) was found to induce apoptosis through the activation of the intrinsic 
pathway following down-regulation of signaling cascades involving MAP kinases and the 
serine/threonine kinase Akt193. The exact cellular target(s) of α-mangostin (4) is (are) still 
unknown. 
Gambogic acid (5) is one of the most active components isolated from gamboge, a 
resin extracted from the Garcinia hanburyi tree grown in Southeast Asia196. It has been 
shown that gambogic acid inhibited the growth of different types of cancer cell lines. 
Additionally, it induces apoptosis by involvement of caspase 2, caspase 9, caspase 10, 
bax and p53197. Besides, gambogic acid (5) enhances p53 protein level through inhibition 
of mdm2 expression and thereby hampers p53 harboring tumor growth198. Additionaly, 
gambogic acid (5) has been reported to inhibit heat shock protein 90 (Hsp90), and to 
decrease levels of TNF-α, Nuclear factor-κB (NF-κB), X-linked inhibitor of apoptosis 
protein (XIAP), and the ratio of Bcl-2/Bax, which in turn induces apoptosis199. 
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However, several other mechanisms of antitumor activity have been described for 
xanthonic derivatives (reviewed in180). Not only the planar tricyclic system is determinant 
for their growth inhibitory effect, but also this effect strongly depends on the nature and/or 
position of the different substituents200. Structure-activity relationship (SAR) experiments 
lead to the conclusion that the presence of substituents, in the xanthonic nucleus, as 
amines, dialkylamines, epoxide, prenyl, furano, pyrano, and glycosil, in some way, 
influence the antitumor mechanism of action. Particularly, aminated or dialkylaminated 
xanthones showed a direct DNA interaction and/or DNA synthesis suppression201, 202. 
 Numerous biological experiments have demonstrated that DNA is the primary 
intracellular target of anticancer drugs due to the interaction between small molecules and 
DNA, which cause DNA damage in cancer cells, inhibiting the division of cancer cells and 
resulting in cell death203. In agreement with this, some xanthonic derivatives have been 
shown to intercalate between DNA base pairs and to cause DNA damage in cancer cells, 
thus inhibiting the division of cancer cells185. 
Furthermore, prenyl204 and hydroxyl205 xanthones have also already been described as 
P-gp inhibitors. 
This data has highlighted the potential of the xanthonic scaffold as a promising building 
motif for the development of not only new anticancer drugs but also new P-gp inhibitors. 
Accordingly, xanthones have been isolated or synthesized for the development of 
prospective new drug candidates179, 183, 185-187.  
The thioxanthone scaffold (Figure 15, 2) has also revealed derivatives with interesting 
biological activities, such as antitumor activity202, 206. The biological interest in 
thioxanthones started with the use of lucanthone (6) and hycanthone (7) (Figure 17) as 
antischistosomal agents207, but they were soon discovered to cause mutagenic activity as 
side effect leading to their withdraw from clinical use208. It was proposed that this 
mutagenic activity occurred by alkylation of nucleophilic groups on the DNA bases by a 
strongly eletrophilic carbonium ion formed on C-4. Besides, the intercalation between 
DNA base pairs was also hypothesized to enhance its mutagenic ability due to distortion 
in the helical structure which causes high frequency of frameshift mutations208-210. 
Therefore, due to the capacity of these compounds to bind to DNA, the antitumor activity 
of lucanthone (6) and hycanthone (7) was also investigated. 
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Figure 17. Lucanthone (6) and hycanthone (7) structures. 
 
Lucanthone (6) and hycanthone (7) intercalate preferentially at A-T sequences in 
DNA211 (Figure 18). The similarities of these compounds with other intercalating agents, 
like daunomycin, mitoxantrone, ansacrine or actinomycin D lay on the tricyclic moiety 
(chromophore) and on the aminated side chain. The side chain is positively charged at 
physiological pH and that is involved in the stabilization of drug-DNA complexes212, 
probably by establishing electrostatic interactions with the phosphate groups of DNA. The 
three-ring thioxanthone chromophore stablishes stacking interactions with adjacent A-T 
base pairs213. The methyl group at the 4-position cannot penetrate far into the minor 
groove, having no interference in the intercalation process212. It was also hypothetized that 
the structural elements responsible for the A-T preference of the thioxanthones 6 and 7 
probably reside in the tricycle chromophore and in the C-1 substituent213.  
 
Figure 18. Hycanthone (7) intercalated into A-T sequence. A= adenine; T= thymine (adapted
214
). 
Polar contact established between the amine group and the phosphate group is shown as yellow 
broken line. 
 
A T 
A T 
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Despite lucanthone (6) and hycanthone (7) exhibited significant antitumor properties206, 
their mutagenicity215, which was associated with the presence of the methylene moiety 
directly linked to C-4216, proscribed their use in cancer chemotherapy211. Nevertheless, 
there are still efforts being made to improve the antitumor activity/toxicity relationship of 
these derivatives. Indeed, a series of 4-aminomethylthioxanthone derivatives was 
reported, related to the known antitumor agent hycanthone (7), exhibiting antitumor 
antitumor activity in several cell lines217. One member of this series, SR 233377 (8, Figure 
19) entered phase I clinical trials217, but this compound was found to cause prolongation in 
the QT interval* of cardiac function, which was potentially life-threatening, and the trial 
was therefore discontinued218.  
Another thioxantone derivative, SSR271425 (9, Figure 19), entered clinical trials218-220 
based on an acceptable toxicity profile, highly active antitumor activity and lower hepatic 
toxicity221. The exact mechanism of action of compound 9 is unknown, but it seems to act 
as a non-alkylating DNA binder218. In spite of these evidences, the clinical trials were 
closed due to prolongation of the QT interval and torsade de pointes**, prompting the 
closure of the clinical studies220.  
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Figure 19. Two thioxanthonic derivatives that entered in clinical trials: SR 233377 (8) and 
SSR271425 (9) 
 
Noteworthy, thioxanthone analogues, benzothiopyrano[4,3,2-cd]isoindole 
aminoderivatives, were described as exerting the same cytotoxic activity in both a 
sensitive and a doxorubicin-resistant cell line overexpressing P-gp222. Moreover, simple 
structural changes in the thioxanthone analogue thioxanthilyum originated compounds 
with high affinity for P-gp, being capable of inhibiting (thioamide in the C-9 substituent) or 
stimulating (tertiary amide in the C-9 substituent) its ATPase activity223. 
  
 
______________________________________ 
* QT interval is the measure of time between the onset of ventricular depolarization and completion of 
ventricular repolarization 
** rare variety of ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram  
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5. Dual ligands 
 
Recently, there has been an increased interest in the design of ligands that act on 
multiple targets with the aim of enhancing the efficacy and reducing the side effect profile 
when compared to the action of a single ligand. These multiple ligands are of particular 
relevance to highly complex diseases, such as the central nervous system (CNS) 
disorders and cancer, where the single-target approaches have not been successful to 
treat the pathology224. 
The efficacy of “drug cocktails” is often compromised by poor patient compliance, 
particularly when treating asymptomatic diseases such as hypertension. Multiple activity 
agents are an alternative strategy that, although challenging due to increased complexity 
in the design and optimization of such ligands, might provide a balanced activity at each 
target of interest while simultaneously achieving a wider selectivity and a suitable 
pharmacokinetic profile225. 
The knowledge-based approach for the design of dual ligands is based on a 
combination of scaffolds and/or pharmacophores of two active compounds, each 
associated with a different target of interest, into a single molecule that will combine both 
activities. The resulting dual ligands are termed linked, fused, or merged, depending upon 
the extent to which scaffolds of the selective ligands have been integrated (Figure 20). 
The linked dual ligand has two molecular scaffolds that are connected through a distinct 
linker, which may be stable or metabolically cleavable. The fused dual ligand contains two 
directly connected scaffolds226. However, the maximization of the degree of scaffold 
overlap is desirable in order to produce compounds with more favourable pharmacokinetic 
profile. Thus, merged dual ligand is the most desirable strategy, where the scaffolds are 
integrated by taking advantage of common groups in the structures of the initial 
scaffolds227.  
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Figure 20. Knowledge-based strategies for the design of dual ligands (adapted
224
). 
 
One of the main advantages of the scaffold combination approach is the rapid access 
to the initial scaffolds. However, the screening of focused libraries of compound (that are 
already known to be active against one of the targets of interest) against another targets is 
also a valuable strategy. If a compound is found to have some of the biological activity 
screened, it would need an optimization in order to achieve the desired dual activity 
profile224. 
The virtual design of dual ligands represent an useful strategy, as those molecules may 
then be used in a virtual screening protocol, in order to distinguish which ones will have 
more probability of exerting the desired activities, and are therefore worth of synthesis. 
This approach will reduce drastically the necessary resources and the number of 
molecules to be synthetized and tested. 
 
 
6. Virtual screening 
 
The need for a rapid search for small molecules that may bind to targets of biological 
interest is of crucial importance in the drug discovery process228. Virtual screening is a 
computational technique used in drug discovery research. It involves the rapid 
assessment of large libraries of chemical structures in order to identify those structures 
which are most likely to bind to a drug target229. Virtual screening, sometime also called in 
silico screening, is a new strategy on Medicinal Chemistry that represents a fast and 
effective tool for computationally screening databases in search for novel drug leads230 
(Figure 21). 
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Figure 21. Virtual screening strategies: structure-based design using tridimensional (3D) target 
structure (A) or an homology model (B), and ligand-based design using information about known 
ligands (C). 
 
Most commonly, the structure of the receptor has been determined by experimental 
techniques such as X-ray crystallography. In this case, the prediction of the binding affinity 
of a library of commercial, newly synthesized, virtual potential ligands (docking), or of a 
library of virtual molecules built from a database of fragments (de novo design), to a 
specific binding pocket in the target, are the selected strategies (Figure 21A). If the 
structure of the target is not available, techniques of protein structure prediction, such as 
homology modeling and fold recognition may be applied to build a model of the target of 
interest. The next step would be a regular structure-based design (Figure 21B). When the 
structure of the target is unknown, but there are known active ligands, they can be used to 
build a pharmacophore or a (3D) quantitative structure actitivity relationship (QSAR) study 
(Figure 21C). The virtual screening of large libraries of compounds against a target in 
search of novel scaffolds suitable for further lead refinement is an useful strategy in the 
beginning of a rational drug design protocol. In fact, the high cost of experimental 
screening prompts the use of virtual screening techniques as a preliminary filter to reduce 
the size of the library prior to the much more expensive experimental screening phase231. 
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6.1. Structure-based methods – docking 
 
Computational methods, in particular ligand-protein docking programs, have become 
essential in any drug discovery program. Docking studies are used to place the small 
molecules into a target structure in a variety of poses, trying to find which molecule has 
more probability of binding that target232.  
A protein-ligand docking program consists of two essential components, a search 
algorithm and a scoring function.  
The search algorithm refers to the generation of putative ligand binding conformations 
in a binding site of a protein. Search algorithms can be divided in stochastic / random or 
systematic. Examples of stochastic algorithms are simulated annealing (e.g. AutoDock2, 
Dockvision, MCDOCK), genetic algorithms (GOLD, AutoDock4, Autodock Vina, 
DockVision), and Tabu Search (ProLeads). These methods use a random probing 
technique and do not guarantee a systematic coverage of the search space233, 234. 
Systematic search methods are an alternative to these random trial and error approaches, 
and include the exhaustive search (Glide, FRED), fragment-based incremental 
construction (e.g. FlexX, Hammerhead, DOCK4), and multiple conformers rigid body 
docking (e.g. FLOG, MS-DOCK). Even though these methods are systematic, 
unfortunately, they still do not provide an exhaustive search of the conformational space. 
Simulation methods such as molecular dynamics and quantum mechanics do exist, but 
these methods tend to be too computationally demanding to be applied to virtual ligand 
screening234. 
Estimating binding affinities of ligands within a receptor, i.e. scoring function, is a 
challenging task that is crucial to virtual ligand screening. In order to identify the 
energetically most favorable pose, each pose is scored based on its complementarity to 
the target in terms of shape and properties. A highly negative score for a given molecule 
indicates that it is potential binder. This process is repeated for all molecules in the library, 
which are subsequently rank-ordered by their scores235. The top ranked pose, i.e., with the 
lowest energy score, is predicted as the binding mode. 
Scoring functions in docking programs make assumptions and simplifications in the 
effort to reach a balance between computational time and accuracy of the results. There 
are several types of scoring functions, such as force field, empirical, knowledge-based 
and consensus scoring functions236. 
As an example of docking software package, the eHiTS (electronic high throughput 
screening) is worth mentioning as it is the first truly exhaustive systematic search 
algorithm231 (Figure 22). 
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Figure 22. Overview of the eHiTS docking algorithm (adapted
237
). 
 
eHiTS applies a systematic docking algorithm, that uses a “place and join” approach to 
the docking problem. First, the ligand is divided into rigid fragments and flexible 
connecting chains. The rigid fragments are each docked independently in the receptor 
active site, and then a fast graph matching algorithm finds poses of each fragment that 
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can be reconnected to form the input ligand. A pre-defined number of poses are kept, 
reconnected with the appropriate flexible connecting chain and further optimized (using a 
local energy minimization algorithm) to give the final ligand pose. These poses are then 
scored to give the final ranking237.  
Besides, eHiTS systematic and automatically evaluates all possible protonation states 
for the receptor and ligands for every receptor-ligand pair. Also, eHiTS deals with receptor 
flexibility by providing a soft representation of the receptor, allowing some lateral chains to 
rotate231. In a study to evaluate the reliability of several commonly used docking softwares, 
one of the most successful programs in terms of pose prediction was eHiTS, for which 
nearly 60% of the ligand-protein complexes have their top score conformations below 2 Å 
threshold238. 
 
 
6.2. Ligand-based virtual screening – pharmacophore 
 
Ligand-based pharmacophores are generally used when crystallographic or modeled 
structure of protein are not available. When a set of active compounds is known and it is 
hypothesized that all the compounds bind in a similar way to the protein, then a common 
pharmacophore can be built239. The pharmacophore requires input molecules (active 
and/or inactive molecules), a conformational search and feature extraction for each 
molecule, structure representation, pharmacophoric pattern identification, and scoring of 
the resulting pharmacophores240. The generated pharmacophore can be used as a query 
to screen a library of compounds and it should be able to identify the compounds that bind 
to the same active site of the protein as the known compounds. A 3D pharmacophore 
performs considerably well in predicting new ligands, and it is a viable alternative to 
docking when the structure of the target is not available241. 
The chemical features of the pharmacophore can be hydrogen bonds acceptors, 
hydrogen bond donors, hydrophobic areas, aromatic rings, positive or negative ionizable 
groups. The shape or volume may also be considered. Several pharmacophore packages 
are available, such as Catalyst, PharmaGist, Phase, MOE, and LigandScout242. 
One of the most widely used packages for pharmacophore elucidation is Catalyst243. It 
creates 3D models called hypothesis  from a collection of molecules possessing a range 
of diversity in both structures and activities240. Catalyst specifies hypothesis  in terms of 
chemical features that are likely to be important for binding to the active site244. The list of 
functions includes hydrophobes, charged/ ionizable groups, and hydrogen bond 
donors/acceptors. Each chemical function is graphically represented by colored spheres 
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and/or vectors245. Once Catalyst has identified a hypothesis, it uses this hypothesis as a 
query to search databases. Pharmacophores can be automatically generated from a 
known set of compounds with a diverse range of chemical and structural features, and 
biological activities245. Catalyst has two main components for pharmacophore 
construction: HipHop and Hypogen. HipHop provides feature-based alignment of a 
collection of compounds without considering activity, using an exhaustive search method, 
whereas Hypogen algorithm generates an activity-based pharmacophore model using a 
constructive, subtractive and optimization protocol. The pharmacophoric model can also 
be improved by setting up exclusion volumes to account for steric constraints with inactive 
molecules or with a specific biological active site246. 
After possessing a pharmacophoric model, Catalyst will carry out rapid database 
searches using a pre-defined or customized pharmacophore query, and it fits the 
compounds from the database onto the hypothesis to determine which ones best reflect 
the requirements of the pharmacophore244. 
Concluding, virtual screening has become an integral part of contemporary drug 
research. A variety of computational tools are being developed and refined to effectively 
employ fast screening methods to yield potent compounds directed to specific targets. 
 
 
6.3. CADD for P-gp inhibitors (Annex II) 
 
Concerning the topic of computer-assisted drug design (CADD) for P-gp inhibitors, a 
review on computational methods (homology modeling and docking, QSAR, 3DQSAR and 
pharmacophore) used to predict P-gp structure, screen for new P-gp inhibitors or find 
important features in already known P-gp modulators, is presented in Annex II. 
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ii. Results and Discussion 
 
1. Working plan 
 
The working plan of this thesis is schematized in Figure 23 and is the following:  
 
 
1)   screening for potential tumor cell growth inhibitors (section II.2 and Annex III) and P-
gp modulators (section II.3 and Annex IV) amongst an in-house library of xanthonic 
compounds; 
 
2)   structure-based design, synthesis, and investigation of  thioxanthonic derivatives with 
dual activity: cell growth an P-gp inhibition (section II.4 and Annexes V and VI); 
 
3)    charactherization of the selectivity profile of thioxanthonic derivatives (interaction with 
other ABC transporters and with cytochrome p450 3A4) (section II.5 and Annex VII); 
 
4)   screening for potential P-gp inhibitors on a commercial database of compounds 
(section II.6 and Annex VIII). 
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Figure 23. Schematic representation of the research work presented in this thesis. 
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2. A new pyranoxanthone stimulates apoptosis and causes an S-phase cell cycle 
arrest 
 
 
Some anticancer drugs decrease cell growth by interfering with the processes of cell 
cycle247-249 and/or apoptosis250, 251. Since xanthones have long been described as potential 
antitumor agents (section I.4), the aim of this work was to screen for potential leukemia 
cell growth inhibitors amongst a library of in-house compounds (Figure 1, Annex III), 
namely xanthones 10-13 and 15 that were previously synthesized in CEQUIMED-UP (see 
Table of compounds in appendix for numeric correspondence). 3,4-dihydroxy-9H-xanthen-
9-one (10) had been previously described to be a PKC inhibitor252 having limited growth 
inhibitory effects on human tumor cell lines253. Based on the considerations that prenyl 
groups, namely in the form of a pyran ring, have been associated with potent growth 
inhibition effect186, two prenyl derivatives of 3,4-dihydroxy-9H-xanthen-9-one (10) were 
selected for screening (11, 12). Although these compounds (11-12) have previously 
revealed revealed high cell growth inhibitory effect against an estrogen-positive cell line 
(MCF-7), this effect seemed to involve an estrogen receptor(ER)-independent cellular 
mechanisms254. Bromoalkoxy derivatives had also previously been described as tumor 
cell growth inhibitors, which justified the selection of compound 13, a bromoalkoxy 
derivative, for further analysis187. Compound 15 was selected since previous work had 
shown that it decreased cell growth in breast, renal and melanoma cell lines255 and 
inhibited several isoforms of protein kinase C255.  
First, a screening of the potential antileukemia compounds was performed using the 
trypan blue exclusion assay to access cell viability on the K562 cell line, a human chronic 
myeloid leukemia cell line (Figure 3, Annex III). 3,4-Dihydro-12-hydroxy-2,2-dimethyl-
2H,6H-pyrano[3,2-b]xanthen-6-one (11) was the most potent derivative, with an IC50 of 20 
μM in this cell line. Additonal testing of effect on cellular viability was performed on two 
other leukemia cell lines, HL-60 and BV-173, a human acute promyeloid leukemia, and a 
chronic myeloid leukemia cell line, respectively (Figure 4, Annex III). Additionally, effect on 
the viable cell number of a nontumor fibroblastic cell line, MRC-5, was also investigated. 
In this work, the potential of pyranoxanthone 11 as a leukemia cell growth inhibitor, by 
induction of apoptosis and inhibition of cellular proliferation, was revealed. A BrdU staining 
(Figure 5, Annex III) and cell cycle analysis by propidium iodide staining (Figure 6, Annex 
III), confirmed the antiproliferative effect and the cell cycle arrest (on the S-phase) which 
elucidates the antileukemic activity of compoung 11. The TUNEL assay showed that 
compound 5 also increased the level of cellular apoptosis (Figure 7, Annex III). To better 
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understand which proteins from the apoptotic pathway were being affected, a Western 
blot analysis identified an increase in the levels of cleaved PARP, a decrease in the levels 
of antiapoptotic Bcl-XL, and an increase in the levels of apoptotic Bid (Figure 8, Annex III). 
The anti-apoptotic proteins of the Bcl-2 family (Bcl-2, Bcl-XL, Mcl-1) are attractive 
targets for drug design256, 257. Compounds such as ABT-737 that bind to anti-apoptotic 
proteins and mimic their natural antagonists, such as Bad and Bim, trigger cells to 
apoptosis258, 259. In order to explore in silico the possibility of interaction of compound 11 
with Bcl-XL, a docking study was performed (Figure 9 and 10, Annex III).  Compound 11 
perfectly filled the cavity on Bcl-XL, in the same place as the crystalographic ligand ABT-
737 binds (Figure 9, Annex III). The interaction between Bcl-XL and the pro-apoptotic 
proteins occurs in this same cavity (Figure 10, Annex III). Although a decrease in the 
levels of Bcl-XL was suggested by our study, the direct target of compound 11 is still not 
known. Nevertheless, the docking studies show the direction to further research 
concerning the mechanism of action of compound 11.  
 
 
3. Two xanthonic derivatives as potential inhibitors of P-glycoprotein 
 
In addition to the potential antitumor activity of xanthonic derivatives, these type of 
compounds had also been described as potential P-gp inhibitors204. Therefore, the aim of 
this work was also to test some of the compounds described on Annex III for P-gp 
inhibitory activity (compounds 10, 11, 14, and 15) (see Table of compounds in appendix 
for numeric correspondence).  
A rh123 accumulation assay by flow cytometry (using a P-gp overexpressing cell line, 
K562Dox) allowed the identification of compounds 11 and 15 as potential P-gp inhibitors 
(Figure 2, Annex IV). In order to identify the mechanism of P-gp inhibition, an ATPase 
assay using recombinant human P-gp membranes was performed. Both compounds 11 
and 15 decreased P-gp ATPase activity, suggesting a noncompetitive mechanism of 
action (Figure 3, Annex IV). 
 The Caco-2 cell model provides a physical and biochemical barrier to the passage of 
small molecules, being extensively used as an in vitro model of the human small intestinal 
mucosa to predict the absorption of orally administered drugs260. P-glycoprotein, along 
with other intestinal transporters, is expressed in the apical surface of Caco-2 cells261. 
Using this model, compounds 11 and 15 presented adequate apparent permeability 
coefficients, which are suggestive of potential intestinal absortion. 
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4. Thioxanthones as dual agents: P-gp and cell growth inhibitors 
 
As xanthones have proven to inhibit the growth of leukemia cell lines (Annex III) and 
inhibit P-gp activity (Annex IV), the next aim was the design, synthesis, and evaluation of 
new (thio)xanthonic derivatives as dual inhibitors of P-gp and tumor cell growth (Annex V). 
A virtual library of approximately 1000 aminated (thio)xanthones was prepared using 
previous derivatives as models such as a 3,4-dihydro-12-hydroxy-2,2-dimethyl-2H,6H-
pyrano[3,2-b]xanthen-6-one (11) and (±)-trans-2,3-dihydro-3-(4-hydroxy-3-
methoxyphenyl)-2-(hydroxymethyl)-7H-1,4-dioxino-[2,3-c]xanthen-7-one (15). As 1-
aminated thioxanthonic derivatives had previously been described as antitumor agents219-
221, 262, and a 1-chloro thioxanthonic derivative (1-chloro-4-propoxy-9H-thioxanthen-9-one, 
43) was shown to be an interesting model with a safe profile, a library of 1-aminated 
thioxanthones was also built. For both xanthones and thioxanthones, the followed 
reasoning was: the merging between a xanthone or thioxanthone scaffold (described as 
potential cell growth inhibitor) and some pharmacophoric features of P-gp inhibitors (such 
as an amine group), leading to dual agents (Figure 2.I, Annex V).  
When this work was initiated (2008) there was no known atomic resolution 
cristalographic structure of P-gp42, 76, 263. Therefore, P-gp homology models based on 
Sav1866 structure were built (Supplementary data A, Annex V) and validated 
(Supplementary data B, Annex V). Those models were then used to dock hundreds of 
virtually designed (thio)xanthones, in order to collect the best scoring molecules (Table 1, 
Annex V), which were then selected to be synthesized. Interestingly, following the docking 
studies on P-gp models (Table 1A, Annex V), the best scoring compounds were the 1-
aminated thioxanthones (Table 1B and 1C, Annex V). Since the aminated thioxanthones 
presented highly negative scores, accessibility of the building blocks and one of the least 
challenging procedures for synthesis, they were selected to be synthesized and further 
tested for P-gp modulatory activity. 
 The 1-amino thioxanthonic derivatives (17-38, 41) were synthesized by nucleophilic 
aromatic substitution using conventional and microwave-assisted heating protocols 
(Scheme 1, Annex V). One 1-methoxy (16) and three 4-hydroxy thioxanthonic derivatives 
(39, 41, and 42), as well as one acetate derivative (40) were also synthetized (Scheme 1 
and 2, Annex V). In total, twenty seven new thioxanthonic derivatives were obtained by 
simple and straightforward synthetic protocols (see appendix for compound numberic 
correspondence). 
In order to assess the tumor cell growth inhibitory potential of the newly synthesized 
thioxanthonic derivatives, a SRB assay was performed both on the sensitive and resistant 
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cell lines, K562 and K562Dox respectively (Table 2, Annex V). Six compounds revealed 
GI50 inferior to 10 μM (compounds 16, 19, 23, 27, 29, and 41) in the K562 cell line, and six 
compounds had GI50 inferior to 20 μM (compound 16, 19, 23, 41, 27, and 31) in the 
K562Dox cell line (see appendix for compound numeric correspondence). The 
mechanism of cell growth inhibition on the K562 cell line is more detailed in Annex VI; it is 
mainly caused by a G1-phase cell cycle arrest (Figure 1, Annex VI) and induction of 
apoptosis (Table 3, Annex VI). Besides, these compounds also cause cell growth 
inhibition of other human tumor cell lines (Table 2, Annex VI). In addition, compounds 16, 
19, 23, 27, 29, and 41 had no significant effect on the cell growth of a nontumor cell line, 
MRC-5, in a concentration equal to the GI50 on the K562 cells (results not shown). 
To screen the potential of thioxanthonic derivatives as P-gp inhibitors, a rh123 
accumulation assay by flow cytometry was performed on a P-gp overexpressing cell line, 
K562Dox (compounds 16-43) (Figure 3, Annex V). Fifteen thioxanthones caused a 
significant increase in the accumulation of rh123 (compounds 16, 19, 21, 23, 24, 27-31, 
34-37, and 41), a behaviour that is consistant with P-gp inhibition. To further analyse the 
mechanism of P-gp inhibition, an ATPase assay was performed on these fifteen 
compounds (Figure 4, Annex V). Eleven of them decreased P-gp-ATPase activity 
(compounds 16, 19, 21, 24, 27, 28, 31, and 34-37), and therefore they are probably 
noncompetitive P-gp inhibitors. In contrast, four compounds increased the P-gp ATPase 
activity (compounds 23, 29, 30, and 41), being themselves transported by the pump, 
hence, behaving as competitive P-gp inhibitors. These results were confirmed by a UIC2 
assay (Figure 2, Annex VII). 
To assess the effective MDR-reversal capacity of these compounds on the resistant 
cell line K562Dox, eight of the most active compounds (16, 19, 23, 24, 27, 29, 31, and 34) 
were incubated with doxorubicin for 48 h (Table 3, Annex V). At 10 μM, a 12-, 9-, and 7-
fold decrease in the doxorubicin GI50 value was observed for compounds 31, 24, and 34 
respectively. Compound 31 was 2-fold more potent than verapamil, and compounds 24 
and 34 were approximately 1.5-fold more potent than verapamil. At the same 
concentration, 10 μM, these compounds were also capable of decreasing the doxorubicin 
GI50 value on the sensitive K562 cell line. Therefore, the MDR reversal effect on the 
resistant K562Dox cell line is probably due to a dual activity of these thioxanthonic 
derivatives, as both P-gp and cell growth inhibitors. 
From this study, thioxanthones emerged as a new class of P-gp inhibitors, showing 
potential as dual inhibitors of tumor cell growth and of P-gp function. 
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5. Thioxanthonic inhibitors of P-gp interact with other targets (MRP1-3, BCRP; 
CYP3A4) 
 
This particular study aimed to determine the role of drug transport systems and drug 
metabolism at an early stage of development o these molecules, in order to better predict 
possible problems of pharmacokinetic interaction or toxicity.  
Two of the most potent P-gp inhibitors from each class of competitive and 
noncompetitive inhibitors (compound 29 and 31, respectively) were tested for their effect 
on other ABC transporters involved in MDR (Annex VII) in order to assess if those 
compounds could be either transported or inhibit the activity of other efflux pumps. To that 
purpose, ATPase colorimetric assays were performed (Figures 3 and 4, Annex VII). It was 
verified that both compounds 29 and 31 interfered with the transport of known substrates 
of those pumps, presenting a IC50 as low as 2 μM (compound 29, BCRP) or 4 μM 
(compound 29, MRP1) (Table 1, Annex VII).  
A CYP3A4 inhibition assay based on luciferin luminescence was also performed 
(Figure 5, Annex VII). Both compounds presented CYP3A4 IC50 values close to 1-2 μM 
(Figure 6, Annex VII), similar to that of a known CYP3A4 inhibitor, ketoconazole. 
Moreovere, according to an in silico study, thioxanthonic derivatives 29 and 31 bind in the 
same  CYP3A4 heme-containing binding pocket as ketoconazole (Figure 8 and Table 2, 
Annex VII). Therefore, if these molecules were to be further developed into clinical use, 
precautions and follow-up would be required if these thioxanthonic derivatives (29, 31) 
were to be administered in combination with other drugs that are mebatolized by CYP3A4. 
 
 
 
6. Discovery of P-gp inhibitors in databases of commercially available compounds 
by pharmacophore-based screening 
 
The synthesis of new compounds is not the only available strategy to discover new P-
gp inhibitors. Indeed, P-gp inhibitors may be found amongst drugs that are 
commercialized for other therapeutic activities. The rationale behind the search for active 
compounds in databases of commercial compounds is that, in addition to their main 
activity, almost all drugs used in human therapy show one or several pharmacological 
side effects264. The “selective optimization of side activities” approach represents an 
alternative to high thoroughput screening, generating drug-like hits265. Indeed, several P-
gp inhibitors reported in the literature have other main activity; for example, verapamil is a 
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calcium channel blocker, and cyclosporine A is an immunossupressive drug266, 267. Thus, a 
pharmacophoric-based strategy for the screening of “old drugs” with P-gp inhibitory 
activity as a “side activity” was proposed (Figure 1, Annex VIII). The search of potential 
new P-gp inhibitors was carried out starting with the creation of a pharmacophore, by 
superimposion of flavonoids known to bind the ATP-binding domain on P-gp (Figure 2, 
Annex VIII), that was used as a query to search the drugbank of commercial compounds. 
Compounds with a better fitting to the pharmacophore (Table 1, Annex VIII) were tested 
by the rh123 accumulation assay, the P-gp ATPase assay and by the verification of 
sensitization of cancer cells to the effect of doxorubicin using the SRB assay. 
From the 21 compounds tested in the rh123 accumulation assay, twelve were able to 
increase rh123 accumulation inside the drug resistant (P-gp overexpressing) K562Dox 
cells (Figure 4, Annex VIII). From these twelve compounds, six were acting as competitive 
P-gp inhibitors (propafenone, hycanthone, cyclic pifytrin α, diltiazem, azelastine, and 
prazosin) and six were acting as noncompetitive P-gp inhibitors (tioconazole, zomepirac, 
bicalutamide, loxapine, amoxapine, and econazole) (Figure 5, Annex VIII). Finally, in order 
to verify if these compounds were able to reverse the MDR phenotype of K562Dox cells, 
they were incubated at 10 μM with several concentrations of doxorubicin. Seven 
compounds were able to significantly decrease the doxorubicin GI50 value, being 
econazole, amoxapine, and loxapine the most potent compounds, causing a 4-fold 
decrease in the doxorubicin GI50 value (Table 2, Annex VIII). None of the compounds 
tested with the SRB assay showed cytotoxicity when incubated alone in the K562Dox cell 
line at the tested concentration (Table 2, Annex VIII), indicating that they are not cytotoxic 
at the tested concentrations. However, none of the tested compounds were as potent as 
verapamil in reverting the K562Dox cells resistance to doxorubicin. Finnally, a PCA 
analysis revealed a segregation between inhibitors and activators, being the logP and 
number of hydrogen bond donors and acceptors the features most involved in this 
clustering (Figure 6 and Table 3, Annex VIII). 
 
Overal, several compounds, commercial and newly synthetized, were described for 
the first time as P-gp inhibitors. In a P-gp functional assay, the rh123 accumulation assay, 
compounds 24, 31, and 34, as well as amoxapine, azelastine, loxapine, propafenone, and 
the positive controls verapamil, quinidine, and mibefradil, were able to increase the 
intracellular fluorescence of rh123 on the P-gp overexpressing K562Dox cell line (Figure 
24A). An ATPase assay further allowed the identification of compounds that stimulate 
ATPase activity, acting as competitive inhibitors, being themselves transported by the 
pump (24, 27, 31, 34, amoxapine, econazole, bicalutamide, and loxapine), or as 
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noncompetitive P-gp inhibitors, blocking the ATP binding and/or hydrolysis (29, 30, 
hycanthone, propafenone, and the positive controls verapamil and quinidine) (Figure 
24B). Interestingly, in the sensitization assay (combination of 10 µM of the test drug with 
various concentrations of doxorubicin on the K562Dox cell line), the three best 
compounds, which caused a decrease in the GI50 value of doxorubicin higher than that 
caused by the controls verapamil and quinidine, were all thioxanthonic derivatives (24, 31, 
and 34) (Figure 24C). Therefore, in spite of the promising results obtained for the 
analyzed commercial compounds in the rh123 accumulation assay and in the ATPase 
assay, when it comes to increasing the sensitivity of a resistant cell line to the effect of 
doxorubicin, they were not as potent as verapamil. On the other hand, thioxanthones 24, 
31, and 34 efficiently reversed MDR, probably due to its dual activity as P-gp and tumor 
cell growth inhibitors. Thus, the merged dual ligand strategy used in this work was a 
valuable strategy to overcome MDR in vitro.  
 
Figure 24. Overall results concerning P-gp inhibition. A) Compounds with higher rh123 
accumulation ratio (>1). B) Best noncompetitive (%RLU>10) and competitive (%RLU<-8) according 
to an ATPase assay. C) Best MDR reversal agent - combination of 10 µM of the test compounds 
with various concentrations of doxorubicin on K562Dox cell line (doxorubicin GI50 value fold 
decrease>5). The compounds are ordered starting by the most active on each assay, as 
represented by the gradient triangles. 
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Finally, the biological data obtained from the ATPase assays (Figure 4, Annex V; and 
Figure 5, Annex VIII) were used to build a pharmacophore for P-gp competitive and 
noncompetitive P-gp inhibitors (Figure 1 and 2, Annex II). Therefore, this study also 
allowed to distinghish between competitive and noncompetitive P-gp inhibitors based on 
the pharmacophoric features. The best P-gp inhibitors found in this study, 1-[2-(1H-
benzimidazol-2-yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one (31) (competitive) and 1-
{[2-(4-nitrophenyl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (34) (noncompetitive), 
were visualized in their P-gp binding conformation, as predicted by the docking studies 
(Supplementary data E, Annex V).  
  
 
7. Main achievements of the work developed in the framework of this thesis 
 
 Two in-house xanthones, 3,4-dihydro-12-hydroxy-2,2-dimethyl-2H,6H-pyrano[3,2-
b]xanthen-6-one (11) and (±)-trans-kielcorin C (15), were able to increase rh123 
accumulation and were found to decrease P-gp-ATPase activity. 
 Two P-gp models based on the Sav1866 structure were built and validated. 
 Twenty seven thioxanthonic derivatives were synthesized for the first time, including 
twenty three aminated thioxanthones. 
 Six thioxanthonic derivatives presented GI50 < 10 μM in K562 cell line, and six 
thioxanthonic derivatives presented GI50 < 20 μM in K562Dox cell line, being 1-{[2-
(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (23) the most potent one 
(GI50(K562) = 1.9 μM; GI50(K562Dox) = 1.95 μM). Increased levels of apoptosis and 
cell cycle arrest seem to be related to the K562 cell growth inhibitory effect caused by 
these (thio)xanthonic derivatives. 
 Fifteen newly synthesized thioxanthonic derivatives increased the cellular 
accumulation of rh123 on a P-gp overexpressing cell line; of these, eleven were 
acting by a noncompetitive mechanism of P-gp inhibition, whereas the remaining 
were acting as competitive inhibitors.  
 Six compounds partially reverted P-gp mediated MDR on K562Dox cell line, being 1-
[2-(1H-benzimidazol-2-yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one (31)  the most 
potent at 10 μM, causing a 12-fold decrease in the doxorubicin GI50 value, therefore 
being 2-fold more active than the known P-gp inhibitor verapamil. 
 Twelve commercialized compounds increased the cellular accumulation of rh123 on a 
P-gp overexpressing cell line, half acting as noncompetitive inhibitors and the other 
half as competitive P-gp inhibitors. Seven commercial compounds were able to 
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partially revert P-gp mediated MDR on the K562Dox cell line, being econazole the 
most potent one at 10 µM, causing a 4-fold decrease in the doxorubicin GI50 value. 
 Two pharmacophores, for P-gp noncompetitive and competitive P-gp inhibitors, were 
built. 
 Thioxanthonic derivatives were assayed against other targets and were shown to 
interact with BCRP, MRP1, MRP2, MRP3, and CYP3A4. 
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iii. Experimental 
 
 
1. Computer-assisted drug design 
 
Model construction, validation and docking studies were performed in the Molecular 
Modeling Laboratory, University of Madeira, under the supervision of Prof. Dr. Miguel 
Xavier Fernandes (as described in the experimental part and supplementary data of 
Annex V). Pharmacophore construction using PharmaGist was performed by Freddy 
Rodrigues at Molecular Modeling Laboratory, University of Madeira, under the supervision 
of Prof. Dr. Miguel Xavier Fernandes (as described in the experimental part of Annex VIII). 
PCA analysis (experimental part of Annex VIII), pharmacophore construction using 
Catalyst (experimental part of Annex II), and metabolism prediction using MetaSite 
(experimental part of Annex VII) were performed at CEQUIMED-UP under supervision of 
Prof. Dr. Miguel Xavier Fernandes. 
 
 
2. Synthesis 
All the synthesis and evaluation of HPLC purity were performed in the Laboratory of 
Organic and Pharmaceutical Chemistry, Chemistry department, Phaculty of Pharmacy, 
University of Porto. 
2.1. Synthesis of xanthonic derivatives: Synthesis of xanthonic derivatives (10-13, 
and 15) derived of 3,4-dihydroxy-9H-xanthen-9-one is described in Annex III, and 
were previously obtained by other members of CEQUIMED-UP. Synthesis of 
compound 14 was previously reported183. 
2.2. Synthesis of thioxanthonic derivatives: Synthesis of 1-aminated thioxanthones 
(16-42) is described in Annex V. Compounds 17, 20, and 23 were synthesized by 
the MSc. student Ana Mafalda Paiva. Synthesis with microwave (MW) heating was 
performed with the thecnical support of Sara Cravo. 
2.3. HPLC purity: The purity of each compound was determined by HPLC-DAD 
analysis (details in Annex V), and were performed by MSc. student Ana Mafalda 
Paiva. 
 
3. Permeability assay 
The permeability assays using Caco-2 cells (experimental part of Annex IV) were 
performed by undergraduated student Ana Sara Cordeiro, at the Laboratory of 
Pharmaceutical Technology in the Faculty of Pharmacy, University of Porto, under the 
supervision of Prof. Dr. Domingos Ferreira and Dr. Bruno Sarmento. 
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4. Trypan blue exclusion assay, TUNEL assay, and BrdU assay 
The Trypan blue exclusion assays were performed on a suspension cell line, K562 (as 
described in the experimental part of Annex III), and on an adherent cell line, MRC-5 (as 
described in the experimental part of Annexes III and V), at IPATIMUP (Cancer Drug 
Resistance Group), with technical support of Dr. Raquel Lima and PhD student Hugo 
Seca. 
 
5. Western Blot 
Western blots were performed at IPATIMUP (Cancer Drug Resistance Group), with the 
technical support of Dr. Raquel Lima and PhD student Hugo Seca (as described in the 
experimental part of Annex III). 
 
6. Flow Cytometry 
Rh123 accumulation assays, cell cycle analysis and apoptosis profile were performed 
by flow cytometry, at IPATIMUP (Cancer Drug Resistance Group), with the technical 
support of Dr. Gabriela Almeida, Dr. Raquel Lima, and PhD student Hugo Seca (as 
described in the experimental part of Annexes III-VI and VIII). 
 
7. Sulphorhodamine B assay 
The sulphorhodamine B (SRB) assay on the suspension cell lines (K562 and K562Dox) 
was performed at IPATIMUP (Cancer Drug Resistance Group), with the technical support 
of PhD student Hugo Seca (as described in the experimental part of Annex V). SRB 
assays on adherent cell lines MCF-7, A375-C5, and NCI-H460 were performed by the 
PhD student Kantima Choosang, at the Laboratory of Microbiology of the Faculty of 
Pharmacy, University of Porto, under the technical supervision of Prof. Dr. Panee 
Pakkong (as described in the experimental part of Annex VI). 
 
8. ATPase assays, UIC2 assay, and CYP3A4 assay 
ATPase assays (P-gp-Glo, Predeasy MDR1, Predeasy MRP1, Predeasy MRP2, 
Predeasy MRP3, Predeasy BCRP, Predeasy controls), UIC2 assay (MDR1 shift assay) 
and CY3A4 assay (CYP3A4 P450-Glo) were performed in Cancer Drug Resistance Group 
at IPATIMUP (Cancer Drug Resistance Group) (as described in the experimental part of 
Annex IV, V, VII, and VIII). 
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iv.   Conclusion 
 
From a series of in-house xanthones, 3,4-dihydro-12-hydroxy-2,2-dimethyl-2H,6H-
pyrano[3,2-b]xanthen-6-one (11) exhibited antiproliferative and apoptotic effects in 
leukemia cell lines. From the same library, compound 11 and (±)-trans-kielcorin C (15) 
emerged as P-gp inhibitors. Facing the potential of compounds with a dibenzo--
(thio)pyrone scaffold as inhibitors of tumor cell growth and also of P-gp activity, a rational 
design of dual ligands was performed. Two P-gp homology models based on the Sav1866 
structure were built, validated, and used for docking of virtual aminated (thio)xanthones 
that resulted from a rational merged ligand approach of a scaffold associated to antitumor 
activity (xanthone or thioxanthone) and a P-gp pharmacophore (presence of an amine). 
The best scoring molecules, with straightforward synthesis and easily available building 
blocks (1-aminated derivatives of thioxanthones) were selected to be synthesized. The 
successful identification of novel P-gp inhibitors and the confirmation of their activities 
indicate that computational tools are a valuable approach to discover novel bioactive 
compounds. Homology modelling followed by docking were successful strategies, 
allowing the discovery of a new class of P-gp inhibitors. 1-[2-(1H-Benzimidazol-2-
yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one (34)  was the most potent reverser of P-
gp-mediated resistance to doxorubicin in our model (K562Dox cell line). Besides, some of 
those thioxanthonic derivatives inhibited cell growth by increasing the % of apoptotic cell 
death and blocking the cell cycle progression, being 1-{[2-(diethylamino)ethyl]amino}-4-
propoxy-9H-thioxanthen-9-one (23) the most potent one. Finally, thioxanthones 29 and 31 
also target other ABC transporters and interfere with CYP3A4. 
Therefore, the design of dual ligands, aminated thioxanthones, by the merging strategy 
was successful and was proven to furnish compounds effective in reversing MDR, by 
increasing the sensitivity of a drug resistant (P-gp overexpressing) cell line to doxorubicin. 
Indeed, compounds 24, 31, and 34 had a better sensitizing activity to the effect of 
doxorubicin than the known P-gp inhibitor verapamil, due to their dual action as tumor cell 
growth and P-gp inhibitors. 
Other computational tools were used to screen for P-gp inhibitors. A pharmacophore 
model allowed the identification of P-gp inhibitors amongst a large dataset of commercial 
compounds, belonging to other therapeutical groups (not MDR reversers). P-gp inhibitors 
with a dibenzoxazepine scaffold were retrieved from this study. 
Finally, the combination of the in vitro results from the newly synthesized thioxanthones 
and from the commercial compounds allowed the construction of a pharmacophore for 
competitive P-gp inhibitors and for noncompetitive P-gp inhibitors. 
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In conclusion, this work allowed the identification of thioxanthones that will serve as 
a model for the design of dual P-gp and tumor cell growth inhibitors. However, it is worth 
noticing that the virtual screening was performed only for P-gp inhibition and not for other 
target of tumor cells. Actually, the molecular target of thioxanthonic derivatives that is 
being responsible for the verified tumor cell growth inhibition is still not known. That study 
will be the object of future work. Accordingly, a library of apoptosis and cell cycle 
molecular targets, whose 3D structure have been elucidated, could be built and used in a 
virtual screening protocol.  
Concerning the P-gp inhibitory activity, new 1-aminated thioxanthonic derivatives 
could be hypothesized, namely using longer nucleophiles, seeking for compounds that will 
be more selective for P-gp but will have low affinity for off-targets. Using the recently 
discovered mouse P-gp as a target, and based on the low negative (or positive) docking 
score on MRP and BCRP models and on the ADMET profile, new and more effective 
thioxanthone derivatives as P-gp inhibitors could be synthesized. 
 Interestingly, not only P-gp inhibitors were discovered, but also potent antitumor 
compounds, such as compound 23, which could serve as a model for the synthesis of 
new thioxanthone derivatives as cell growth inhibitors. Besides, as the mutagenicity and 
cardiotoxicity has been reporter as being causes for the withdrawn of thioxanthones such 
as hycanthone (7) from clinical use, assays to assess toxicity must be performed. 
The virtual screening approach used can be illustrated with the metaphor of finding 
a diamond (the idea that will ultimately become a successful compound) in a pile of coal. 
First a filter based on the Lipinski rule of five can be applied, followed by a filter based on 
docking scores, taking forward those compounds that meet the predefined criteria and 
discarding the remaining ones. Several filters may be used with the hope that at the end 
of the process a “diamond” will emerge. Of course, in practice, this rarely occurs. 
However, if these computational tools are carefully applied and decisions are made based 
on previous experience or previously published data, a “rough” diamond may be found 
and lapidated in the future. What this metaphor means is that this work allowed the 
identification of thioxanthones as a scaffold “full of potential”, not only for the design of P-
gp inhibitors but also antitumor agents. 
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Abstract 
Many tumour cells become resistant to commonly used cytotoxic drugs due to the overexpression of 
ATP-binding cassette (ABC) transporters, namely P-glycoprotein (P-gp). The discovery of the reversal of 
multidrug resistance (MDR) by verapamil occured 30 years ago and 13 years before MDR chinese 
hamster cell lines had been isolated for the first time. Since then, P-gp inhibitors have been intensively 
studied as potential MDR reversers. Initially, MDR drugs were not specifically developed for inhibiting 
P-gp; in fact, they had other pharmacological properties as well as a relatively low affinity for MDR 
transporters. An example of this first generation P-gp inhibitor is verapamil. The second generation 
included more specific with less side-effect inhibitors such as dexverapamil or dexniguldipine. A third 
generation of P-gp inhibitors comprised compounds such as tariquidar, with high affinity to P-gp at 
nanomolar concentrations. These generations of inhibitors of P-gp have been examined in preclinical and 
clinical studies; however, these trials have largely failed to demonstrate the improvement in therapeutic 
efficacy. Therefore, new and innovative strategies, such as the fallback to natural products, the design of 
peptidomimetics and dual activity ligands emerged as a fourth generation of P-gp inhibitors. The 
chemistry of P-gp inhibitors, as well as their in vitro, in vivo and clinical trials are discussed, and the most 
recent advances concerning P-gp modulators are reviewed. 
 
Keywords: P-glycoprotein, P-glycoprotein inhibitors, ABC tranporters, Multidrug resistance 
 
1. INTRODUCTION 
 
Drug resistance is the major cause of failure of chemotherapy [1]. In the industrialized countries, cancer 
is one of the leading causes of death. Although enormous progress has been made in the field of cancer 
therapy, only approximately 50% of all cancers are susceptible to chemotherapy and of these, more than 
50% rapidly develop drug resistance [2].  
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Multidrug resistance (MDR) may be defined as a phenomenum whereby cancer cells that have been 
exposed to just one type of drug develop cross resistance to other drugs that are structurally and 
functionally very dissimilar [3]. MDR is termed 'intrinsic' when the disease is refractory to chemotherapy 
from the outset, or 'acquired' when the disease becomes insensitive to treatment upon relapse [4]. 
Several mechanisms may be responsible for the complex phenomenon of MDR such as: induction of 
the efflux systems (e.g., MDR1/P-gp) [5, 6]; altered expression or function of target proteins (e.g., 
topoisomerase and tubulin) [7]; induction of detoxication pathways (e.g., glutathione-S-transferase that 
catalyze the conjugation of glutathione and drugs) [8]; enhanced DNA repair [3]; and alterations in the 
apoptotic signal pathway (e.g., p53 mutation and bcl-2 overexpression) [9, 10]. Some of these 
mechanisms may coexist, rendering the cell refractory to treatment with drugs acting on a single target. 
P-glycoprotein (P-gp) is the best characterized efflux pump that mediates MDR and it belongs to the 
ATP-binding cassette (ABC) protein superfamily [11]. Other members of the ABC superfamily have also 
been implicated in cancer MDR, including multidrug resistance-associated protein-1 (MRP1), its 
homologs MRP2-8 which transport glutathione, glucuronate and sulfate-conjugated drugs, and the breast 
cancer resistance protein (BCRP) [12]. Multidrug transporters are present in almost every cell and protect 
the cell from xenobiotics through active excretion [13].  
One of the best studied mechanisms of MDR reversal is the direct inhibition of the P-gp efflux pump.  
The three main mechanisms (Fig. 1A) of P-gp inhibition are: (i) direct interaction with one or more of the 
drug-binding sites on P-gp, thus blocking transport by acting as a competitive inhibitor; (ii) inhibition of 
the binding of ATP to the ATP-binding site on P-gp, blocking ATP binding and hydrolysis, thus acting as 
a noncompetitive inhibitor [14, 15]; and (iii) interaction with an allosteric residue relevant for P-gp 
activity and translocation, thus also acting as a noncompetitive inhibitor [16]. An interaction with the lipid 
membrane of the cell perturbing the membrane environment or modifying the drug-membrane interaction 
was also described as a possible mechanism of inhibition of P-gp [17]. 
P-gp uses ATP to get energy to pump a wide variety of compounds out of the cell [18]. It is comprised 
of 1280 amino acids and it has two homologous halves, each one containing a transmembrane domain 
(TMD1 and TMD2) which spans the membrane with six α-helices (TM1-6 on TMD1, and TM7-12 on 
TMD2), and a hydrophilic nucleotide binding domain (NBD1 or NBD2) located at the cytoplasmatic face 
of the membrane (Fig. 1B) [19, 20]. P-gp is glycosylated at the first extracellular loop, important for the 
integration of the protein in the membrane [21], and it is phosphorylated by protein kinase C (PKC), 
which modulates its transport function [22]. 
There is still no human P-gp structure of atomic resolution [23]. Even when a sufficient quantity and 
quality of the protein is available, producing crystals is not straightforward due to the amphiphilic nature 
of this protein. Thus, crystallization of prokaryotic membrane proteins has been helping in the structure-
based drug design of P-gp [24]. Recently, the crystallographic structure of mouse P-gp has been described 
[25]. 
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A      B 
 
 
Fig. (1). (A) Three-dimensional representation of the open conformation P-gp, and the possible binding 
sites for P-gp inhibitors (I, II). (B) Schematic representation of P-gp structure (adapted from [20]). TMD= 
transmembrane domains; TM= transmembrane α-helice; NBD= nucleotide binding domains; ATP= 
adenosine triphosphate. 
 
A potential strategy to circumvent drug resistance is to administer a transport inhibitor when 
chemotherapy is initiated. Since P-gp keeps a drug out of a cell, the compounds interfering with P-gp 
reverse drug resistance by allowing anticancer drugs to accumulate in cells [26]. A highly effective P-gp 
modulator candidate should be a lipophilic cation,  possess a LogP value of 2.92 or higher, an 18 atom 
long or longer molecular axis, high Ehomo values and at least one tertiary basic nitrogen atom [27]. 
The reversal of MDR through direct interaction with P-gp has been most widely investigated and the 
development of P-gp inhibitors or modulators has been carried out since the demonstration that verapamil 
could reverse MDR in 1981, indicating the possibility of clinically useful reversing agents for MDR [28]. 
Thirteen years before, in 1968, MDR chinese hamster cell lines had been isolated for the first time [29]. 
Since then, a variety of compounds have been shown to reverse P-gp-mediated MDR and some MDR 
modulators have undergone clinical trials. Since the first P-gp inhibitor, verapamil, was discovered 
already thirty years ago, the aim of this review is to summarise the history of P-gp inhibitors, focusing on 
the three classic generations of compounds and the more recent forth generation. In the first section, a 
brief introduction of the main methods used in the evaluation of P-gp inhibitory activity is presented. 
Thereafter, P-gp inhibitors are organized into four generations. The first generation (Table 1) includes not 
only the classic P-gp inhibitors such as verapamil or cyclosporine A but all compounds that had 
previously been described as having other main therapeutic applications other than P-gp inhibition, 
irrespective of the date of discovery. The second generation (Table 2) comprises derivatives that were 
developed from compounds with another recognized activity, but which were subjected to structural 
modifications in order to decrease their “main” therapeutic activity and increase P-gp inhibitory activity. 
The third generation of compounds (Table 3) is composed of the most selective and potent P-gp inhibitors 
nowadays and were obtained by design. Many of these derivatives entered clinical trials and the results 
are highlighted in Table 4. Finally, the forth generation includes P-gp inhibitors obtained by diverse 
strategies: compounds extracted from natural origins and their derivatives; surfatants and lipids; peptides 
and dual activity agents. Each generation also includes the derivatives obtained from qualitative classical 
SAR as well as QSAR studies which permitted a better understanding of the important substitutents for P-
gp inhibitory activity. 
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2. ASSAYS FOR P-GP MODULATION AND  LIGAND-P-GP INTERACTIONS 
 
Several screening assays have been suggested which can help to identify P-gp inhibitors. Interactions of 
compounds with P-gp are complex and methods of evaluation remain controversial. However, some 
methods have been used over the years, giving credible results. 
A popular method is the cytometry assay. This method is based on the increased accumulation and/or 
decreased efflux of a fluorescent P-gp substract, such as rhodamine-123 (rh123) [30], doxorubicin [85], 
daunorubicin [273], calcein-AM [274], or a radioactive analog of an anticancer drugs ([
3
H]daunorubicin 
or  [
3
H]vimblastine, for example) [275], that are transported by the pump. The increased intracellular 
accumulation of the fluorescent compounds when co-administered with P-gp modulators is considered to 
be mainly due to inhibition of the efflux pumps located in the cellular membrane, such as P-gp. 
Transport assays using adherent cell lines are also common. Generally, using the Caco-2 cell 
monolayer, these studies measure the permeability in the apical to basolateral and in the basolateral to 
apical directions [276]. The ratio of these measurements provides clues about P-gp involvement in 
absortion mechanisms. 
Growth inhibition assays that provide values of GI50 (the concentrarion that inhibits the growth of the 
MDR expressing cells by 50 %) are also used frequently to evaluate effective MDR phenotype reversal. 
GI50 is determined from for several concentrations of a cytotoxic drug, for example doxorucibin, in the 
presence and absence of a non-toxic concentration of a P-gp inhibitor, in a resistant P-gp-overexpressing 
cell line [30]. 
Certain imaging agents can be used to detect MDR tumors [277] and monitor the effectiveness of novel 
P-gp inhibitors in cancer patients [278], human tumor xenograft models and cell cultures [279]. Analysis 
of changes in the cellular and tissue distribution of 
99m
Technetium-sestamibi (
99m
Tc-sestamibi, trade name 
cardiolite), a synthetic gamma-emitting organotechnetium complex, a cardiac imaging agent and a P-gp 
substrate, permit the investigation of the effect of a potential P-gp inhibitor in vitro and in vivo in human 
tumor xenograft models [280]. 
To elucidate the mechanism of action of the P-gp inhibitors, ATPase or UIC2 assays are often applied. 
The P-gp-ATPase activity may be quantified by the detection of the levels of remain ATP by a light-
generating reaction catalyzed by luciferase [30] or by colorimetric detection of levels of Pi liberated 
[281]. On the ATPase assay, the increase in ATP consumption suggests a competitive mechanism of 
action (when a P-gp inhibitor is also a substrate), whereas the decrease in ATP consumption is related to a 
noncompetitive mechanism of action [282]. As far as the UIC2 assay is concerned, since it uses a 
monoclonal antibody that binds specifically to an external epitope of P-gp in its active conformation (in 
the process of transporting a substrate) it allows differentiation between substrates and competitive 
inhibitors from noncompetitive inhibitors [283]. 
For the characterization of the drug binding domain on P-gp, several different approaches have been 
used. One of these is P-gp photoaffinity labelling with a photoactive analogue of a drug substrate (e.g., 
[
3
H]azidopine [65], [
125
I]iodoarylazidoprazosin [116], or [
125
I]N-(p-aminophenethyl)spiroperidol [105]) 
and then peptides are generated from the labelled protein by chemical or proteolytic cleavage. The 
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labelled peptides are then identified using immunological methods [284]. Labelling of the different TM 
with various substrate analogues helps to identify the P-gp binding site of the test molecule [285]. 
To identify specific residues that form the drug binding pocket, cysteine scanning mutagenesis and 
thiol-reactive probes may be used. Several single cysteine mutants of human P-gp are reacted with a thiol-
reactive substrate, such as dibromobimane [286, 287], or a thiol-reactive analogue of a P-gp substrate, 
such as methanethiosulfonate (MTS)-verapamil [288, 289], or MTS-rhodamine [289, 290]. If a residue in 
the drug-binding pocket is modified by the thiolreactive analogue, then the presence of the test drug in the 
drug-binding pocket should protect the residue from being labelled. 
These methods have been used alone or in combination to charactherize the four generations of P-gp 
inhibitors listed in the following sections. 
 
3. FIRST GENERATION P-GP INHIBITORS 
 
First generation P-gp inhibitors (Table 1, 1-89) are defined as drugs already in clinical use or 
compounds under investigation for other therapeutic indications and which were shown to have an 
important side effect: inhibition of ABC transporters such as P-gp. Three representatives of the first 
generation P-gp inhibitors are verapamil (1), quinidine (19) and cyclosporine A (23).  
First generation P-gp inhibitors are listed in Table 1 and include drugs such as cardiac (1-22), 
immunossupressant (23-25), antibiotics (26-33), antifungal (34-38), antimalarial (39), antiprotozoal (40-
42), antiviral (43-44), CNS stimulators (45-51), CNS depressants (52-58), anesthetics (59-62), anti-
histaminics (63-65), anticancer (66-73), steroid hormones (74-82), anti-inflamatory (83-88), and drugs for 
erectile disfunction (89). 
Therefore, the first chemosensitizers identified were themselves substrates for P-gp and thus acted by 
competing with the cytotoxic compounds for efflux by the P-gp pump. However, many of these 
chemosensitizers are substrates for other transporters and enzyme systems, resulting in unpredictable 
pharmacokinetic interactions in the presence of chemotherapy agents [291]. Additionaly, these 
modulators have low affinity for P-gp, requiring the use of high doses and resulting in unacceptable 
toxicity [292].  
 
 
3.1.Verapamil (1) 
 
In 1981, Tsuruo et al made the first description of verapamil (1) as a potential MDR reversing agent, 
indicating the possibility of clinically useful reversing agents of MDR [28]. The calcium channel blocker 
verapamil was the first compound ever found which was able to enhance the intracellular accumulation of 
many anticancer drugs such as vincristine, vinblastine, doxorubicin and daunorubicin [293, 294]. Indeed, 
it was demonstrated that verapamil (1) inhibited the efflux of anticancer drugs from tumor cells that over-
expressed P-gp, causing an increase in the intracellular concentration of the chemotherapeutic drug. Some 
authors suggest that verapamil (1) inhibits P-gp activity by direct competition with P-gp substrates [295]. 
Several assays confirming verapamil sensitization of tumor cell lines to cytotoxic agents have been 
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published throughout the years [294-297]. Verapamil (1), administered at a dose corresponding to a 
typical cardiovascular posology in humans, significantly increased doxorubicin cytotoxicity [298]. 
Clinical experience of verapamil (1) in combination with chemotherapy is highlighted in Table 4 and has 
shown that verapamil (1) levels in blood are associated with hypotension, heart block, neurotoxicity and 
hematotoxicity [211, 299].  
As far as the verapamil (1) binding pocket is concerned, a thiol-reactive analog of verapamil (MTS-
verapamil) was used with cysteine-scanning mutagenesis to identify the reactive residues within the drug-
binding domain of P-gp [288]. Four mutants, S222C (TM4), L339C (TM6), A342C (TM6), and G984C 
(TM12) were significantly protected from inhibition by MTS-verapamil by pretreatment with verapamil. 
Less protection was observed in mutants I868C (TM10), F942C (TM11) and T945C (TM11).  Also, 
reacting the mutant I306C (TM5) with  thiol-reactive compounds reduced its affinity for verapamil, 
suggesting that this residue is close to the verapamil-binding site [300]. These results indicated that 
residues in TM 4, 5, 6, 10, 11, and 12 (Fig. 2A) must contribute to the binding of verapamil [288] and are 
described as providing several groups for hydrophobic and hydrogen bond interactions [301]. 
Structure-activity relationships of verapamil (1) analogs can be summarized in Fig. 2B and showed that 
a decrease in the number of methoxyl groups (replacement by H atoms) on the phenyl rings results in a 
considerable decrease in MDR reversal activities. No significant effect in MDR reversal potency was 
caused by the replacement of the phenyl ring at the position closer to the terciary amine, with long 
aliphatic chains, or the replacement of the methoxyl groups in the phenyl rings with Cl atoms. Finally, a 
drastic decrease in potency was observed by replacing the –CN group with –CH2NH2 or by replacing the 
of -CH(CH3)2 with the -(CH2)11CH3 group [302]. N-Methyl derivatives are generally less potent as MDR 
reverters than the N-desmethyl counterparts [156]. Other structural modifications, such as iodination, 
originates verapamil derivatives that restored daunorubicin activity and when used alone did not induce 
cell death, cell cycle perturbation and modification of calcium channel activity in comparison with 
verapamil [303]. 
 
 
3.2. Tetrandrine (12) 
 
Tetrandrine (12) was charactherized by several in vitro assays (Table 1) demonstrating that it  possesses 
potent and specific activity in reversing P-gp-mediated drug resistance [43]. Besides, the P-gp protein 
expression can be down-regulated (by 77%) as well as the mdr1 mRNA [42]. Fe3O4-Magnetic 
nanoparticles loaded with adriamicyn and tetrandrine (12) can enhance the effective accumulation of the 
drugs in K562/A02 [304]. In a clinical trial, tetrandrine was well tolerated in patients with low risk AML 
[214] (Table 4). 
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Fig. (2). A) Arrangement of TM cylindrical helix and verapamil (stick diagram) in the drug-binding 
pocket (adapted from  [305]). B) Structure-activity relationship of verapamil (1). ▼= ↓ P-gp inhibition; 
▲= ↑ P-gp inhibition; ■= ≈ P-gp inhibition. 
 
Bromotetrandrine derivatives (Fig. 3) have shown significant MDR reversal activity in vitro and in vivo 
[306]. The substitution with this bulky group, resulting in 5,14-dibromotetrandrine showed the strongest 
MDR-reversing effect, increasing intracellular vimblastin accumulation in P388/ADR (resistant) cells to a 
much greater extent than verapamil (1), as well as increasing vimblastin cytotoxic effect [307]. A methyl 
group in the piperidine nitrogen moiety may also be substituted by an H. In fact, a novel derivative of 
tetrandrine (12) with this substitution together with a bromo group, was effective in reversing P-gp-
mediated MDR by inhibiting the transport function of P-gp and inhibiting its ATPase activity. This 
reversal of MDR may also be related with an increase in the ubiquitination of P-gp and the blockage of 
the MEK-ERK pathway [308]. 
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Fig. (3). Structure-activity relationship of tetrandrine (12). ▲= ↑ P-gp inhibition. 
 
3.3. Propafenone (22) 
 
Propafenone (22) and its analogues are inhibitors of a large number of drug efflux pumps including P-
gp and BCRP as well as the microbial pumps. A series of closely related structural homologues of 
propafenone have shown a highly significant correlation between lipophilicity and their P-gp modulation 
effect, and the distance between the carbonyl group and nitrogen atom was hypothised to be important 
[63]. Their activity is determined by the hydrogen bond donor –OH and the hydrogen bond acceptor in 
the amine and carbonyl groups. The alkyl or aryl chains connected to the amine seem to be involved in 
hydrophobic or π- π interactions, respectively [309, 310]. The merging between a pyrazole-based drug 
and the MDR modulator propafenone is a recent strategy for the design of hybrid molecules that 
interacted more effectively with P-gp, helping to decrease the P-gp mediated drug efflux [311]. 
 
3.4. Cyclosporine A (23) 
 
In 1986, Slater et al. demonstrated that an immunosuppressive drug, cyclosporine A (23), also had the 
capacity to reverse resistance to anticancer drugs in vitro [312]. 
Cyclosporine A (23) was reported to interfere with the P-gp mediated effect (Table 1). In fact, it has 
been demonstrated that cyclosporine A competed with the substrates of P-gp to bind to the drug-binding 
site of P-gp [313]. These results in vitro originated a series of clinical trials on the combination of 
anticancer drugs that were MDR substrates and cyclosporine A (23) (Table 4). However, contraditory 
results were observed concerning cyclosporine A (23) effects from both in vitro tests and from clinical 
trials.  
At the beginning of the 90s, the first clinical trial with cyclosporin A (23) and anticancer drugs were 
started in patients with multiple myeloma and acute leukemia [220, 222, 314]. Subsequently, several 
other clinical trials were performed (Table 4). Indeed, cyclosporine A (23) showed no selectivity towards 
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P-gp. In fact, it increased cellular drug uptake in cells overexpressing P-gp, MRP-1 or BCRP and nuclear 
drug uptake in cells overexpressing LRP, at the clinically achievable concentration of 2.5 µM [66, 67]. 
In order to inhibit P-gp, cyclosporine A (23) requires a suitable lipophilicity to cross the cell membrane 
and conformational plasticity to gain access to P-gp binding sites. By use of photoaffinity-labeled 
cyclosporins and membranes from P-gp-expressing cells, it was shown that in vitro, P-gp could bind a 
large cyclosporin domain involving residues 4-9 as well as the side chain of residue 1 of cyclosporine A 
(23) [315]. P-gp inhibition was favored by larger hydrophobic side chains on cyclosporin residues 1, 4, 6, 
and 8, although with no effect on the residue 5 side chain (Fig. 4A); moreover, larger hydrophobic side 
chains on other residues, namely 2, 3, 10, and 11, also favor the eventual inhibition of P-gp function.  The 
N-demethylation of any of the seven N-methylated amides leads to a decreased P-gp inhibitory activity, 
up to its extinction if it occurs at residues 4 and 9 [316] (Fig. 4A). 
Mutagenesis studies have shown that S939 plays an important role in the cyclosporine A (23) 
specificity for the P-gp. This serine was also shown to be an important determinant in the recognition of 
cyclosporine A (23). Photolabelling P-gp with a non-radioactive cyclosporine A derivative, followed by 
enzymatic proteolysis and chemical cleavage of P-gp, was performed to localize the binding site of 
cyclosporine A (23) (Fig. 4B). It has been described that the major binding site of cyclosporine A (23) 
occurs between the end of TM11 and the end of TM12 and amino acid residues 953-1007 are involved in 
binding [315, 317] (Fig. 4B). 
 
Fig. (4). A) Structure-activity relatioship of cyclosporine A (23). ▼= ↓ P-gp inhibition; ▲= ↑ P-gp 
inhibition. B) Proposed model of the cyclosporine A binding site on P-gp (adapted from  [286]). 
 
3.5. Aureobasidin A (AbA) (38) 
 
The antifungal antibiotic aureobasidin A (AbA) (38) was found to be a more active P-gp inhibitor than 
cyclosporine A (23), also a cyclic compound. The replacement of the  [Phe(3)-MePhe(4)-Pro(5)] 
tripeptide moiety by an 8-aminocaprylic acid or the N(7)-demethylation of MeVal(7) led to a 3.3-fold 
decreased capacity to inhibit P-gp function (Fig. 5). The  [2,3-dehydro-MeVal(9)] AbA derivative was the 
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most potent P-gp inhibitory aureobasidin, described as being 13-fold more potent than AbA (38) and 19-
fold more potent than cyclosporine A (23) [318].  
 
Fig. (5). Structure-activity relationship for aureobasidin A (38). ▼= ↓ P-gp inhibition; ▲= ↑ P-gp 
inhibition. 
 
3.6. Caffeine (45) 
 
Various xanthines are naturally occurring compounds present in black coffee, black tea, green tea, and 
which have several biological activities. A xanthine derivative, caffeine (45), was described as a P-gp 
inhibitor [94-96]. Pentoxifylline (46), also a xanthine derivative, was found to reduce P-gp mediated 
MDR in the mouse leukemic cells. Long chain substituted xanthines may in fact act as P-gp modulators, 
although the mechanism of molecular action has not been clarified yet. One of the possible molecular 
mechanisms of action was hypothesized to be by direct competition with P-gp transport [97].  
Structure-activity relationships allowed the discovery of more potent xanthinic P-gp inhibitors (Fig. 6). 
For example, 1-methyl-3-propyl-7-butylxanthine showed great inhibitory activity of the doxorubicin 
efflux. In addition, it enhanced the antitumor activity of idarubicin, with a reduction in the bone marrow 
suppression (secondary effect) induced by idarubicin [319]. It has been described that 1-substituted 
xanthines with longer chains facilitated the doxorubicin efflux from P388 resistant cells. In contrast, 
among 7-substituted xanthines, the N,N-dimethylethanamine and propanol substituted xanthines 
significantly inhibited the doxorubicin efflux from P388 resistant cells, possibly through their interaction 
with P-gp [320]. 
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Fig. (6). Structure-activity relationship of caffeine (45). ▼= ↓ P-gp inhibition; ▲= ↑ P-gp inhibition; * = 
when together in the same molecule. 
 
 
3.7. Others 
 
Not only is direct interaction with P-gp, but also with its surrounding environment (the lipidic bilayer), 
important for P-gp modulation. For example, amiodarone (17) established strong interactions with 
phosphatidylserines. Its MDR-reversing ability could be mediated through their interaction with the 
membrane phospholipids, changing membrane permeability and fluidity, or by changes in the 
conformation and functioning of the membrane-integrated proteins via changes in the structure 
organization of the surrounding membrane bilayer. Another possible mechanism of action of amiodarone 
(17) is the inhibition of P-gp phosphorylation via inhibition of the phosphatidylserine-dependent PKC 
[321]. Cefoperazone (26) and ceftriaxone (27) are effective modulators of P-gp and their ability to reverse 
P-gp is associated with lipid solubility, high protein binding, a polycyclic planar geometry, and the 
presence of the piperazine group in cefoperazone [72]. The anesthetics chloroform (59), benzyl alcohol 
(60), diethyl ether (61) and propofol (62) were described as modulators of P-gp-mediated MDR by 
acceleration of transbilayer movement of drugs by passive difusion. At higher concentrations than those 
required for modulation, the anesthetics accelerated the passive permeation to such an extent that it was 
not possible to estimate their P-gp activity [115].  Moreover, interaction with the phospholipid bilayer 
may justify the chiral selectivity observed with trans-flupentixol (52) [321]. Recent drug-membrane 
interaction and QSAR studies of thioxanthenes pointed to the importance of the stereoisomery for their 
MDR reversing activity. A molecular modeling study of trans- and cis-flupentixol showed that the 
electrostatic fields of the drugs have lipophilic and hydrophilic regions clearly separated in trans- when 
compared to cis-flupentixol. This result led to the hypothesis of a better fitting for trans- derivatives to the 
membrane due to the stronger interaction with phospholipids [322].  
Other cellular mechanism may be involved in MDR reversal. Curcumin (86) was hypothised to 
contribute to the reversal of the MDR phenotype due to the suppression of P-gp expression via inhibition 
of the PI3K/Akt/NF-КB signaling pathway [323]. Trifluoperazine (56) also induced the downregulation 
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of P-gp protein and mdr1b mRNA in rats in a dose- and time-dependent manner in L1210/Adr resistant 
cells [324]. 
Not only the original drug, but also some of its metabolits, may inhibit P-gp. The major metabolite of 
curcumine (86), tetrahydrocurcumin, also inhibited P-gp [325]. 
Most of the first generation P-gp inhibitors lack selectivity (Table 1, MRP and BCRP columns). 
Lapatinib (70) and erlotinib (71) reversed the drug efflux function of P-gp, BCRP [129] and also MRP-7 
transporters [131]. Lonafarnib (72) was shown to inhibit the function of MRP-1 and MRP-2 with a 
potency similar to that of cyclosporin A (23) [133]. 
Besides improving cancer treatment, many of these P-gp inhibitors have applications to other diseases. 
For example, the inclusion of ritonavir (44) in combination regimens may greatly facilitate brain uptake 
of HIV protease inhibitors, which is especially important in patients suffering from AIDS dementia 
complex [91]. P-gp inhibitors may also potentiate the activity of antibiotics by inhibiting bacterial efflux 
(second generation timcodar, 102). 
One of the main issues of the first-generation P-gp inhibitors is the predominance of the original 
therapeutic activity of the drug. This happens not only with the well-known verapamil (1), whose calcium 
channel blocker properties potentiate the cardiotoxicity, but also, to a greater or lesser extent, with all the 
members of this generation. In fact, mifepristone (78) induces a much higher chemosensitization than the 
well-known verapamil (1), but its hormonal properties (progesterone receptor antagonist used as an 
abortifacient) limit its potential for clinical trials [141]. 
The impossibility of applying the majority of these compounds as P-gp inhibitors has been reflected 
from the results of phase I clinical trials (Table 4): these drugs were eighter too toxic in their own right or 
not active enough and were therefore not further investigated. The only first generation P-gp inhibitors 
that today remain a “hope” amongst this class of compounds are tetrandrine (12) and tesmilifene (65), 
having proved in clinical trials to offer a major advantage in the treatment of poor risk AML and 
metastatic breast cancer, respectively. Tesmilifene (65) is a small molecule chemopotentiator under 
development by YM BioSciences and is described as a novel potentiator of chemotherapy which, when 
added to doxorubicin, achieved an unexpected and very large survival advantage. Tesmilifene (65) was 
proposed to allow chemotherapeutical drugs (e.g. anthracycline or taxane) to kill a small but critical 
population (clone) of aggressive, P-gp overexpressing, cells [326]. However, it is not selective for P-gp.  
On the other hand, from the physiological perspective, P-gp is widely expressed in the epithelial cells 
of the intestine, liver and kidney, and in the endothelial cells of the brain and placenta. Despite the lack of 
success from this generation of P-gp inhibitors, since P-gp is widely expressed, having an important 
physiological role,  the inhibition of this membrane transporter could have other implications related to 
drug absorption, distribution, metabolism, and excretion (ADME) [327]. Therefore, there remains a great 
need to identify not only whether an already existing drug has affinity for P-gp but also to understand the 
effects of P-gp on drug pharmacokinetics and pharmacodynamics, as well as efficacy and safety. In this 
context, our group has recently developed a pharmacophore-based screening strategy that allowed the 
identification of “old drugs”, namely with an oxapine scaffold, that are able to inhibit P-gp function [30]. 
Considering the problems related to the first-generation MDR modulators, second-generation MDR 
modulators have been developed. 
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4. SECOND GENERATION P-GP INHIBITORS 
 
On the basis of the experience with the first-generation compounds, the approach then followed was to 
identify analogues that were devoid of the pharmacological properties of the original molecule but could 
specifically inhibit P-gp, with less toxicity and greater potency [328]. Thus, the second generation of P-gp 
inhibitors includes derivatives of cardiovascular (90-99), imunossupressant (100-102), anticancer (103-
105) and other drugs (106-109), and are represented on Table 2.  
Many of the second generation P-gp inhibitors resulted from the study of chiral drugs, through the 
resolution of racemic mixtures. Dexverapamil (90) is the R-enantiomer of verapamil (1). Dexverapamil 
(90) discovery was based on the toxicity profile and experimental potency of verapamil (1) [329].  
The R- enantiomers of compounds with phenylalkylamine structures such as dexverapamil (90), and 
with dihydropyridine structures such as dexniguldipine (94), are widely described as P-gp modulators 
with less cardiac effects [33]. Although R- and S- enantiomers of these drugs differ markedly in their 
potency as calcium channel blockers, they were almost equally effective in reverting P-gp mediated drug 
resistance [33].  
Dexniguldipine (94) is the R-enantiomer of niguldipine (6). Dexniguldipine (94) displays a 45-fold 
lower affinity for calcium channel binding sites than levoniguldipine, but is equally potent in inhibiting 
drug transport by P-gp and reversing drug resistance [33]. Studies with dexniguldipine (94) described that 
P-gp has at least two allosterically coupled drug acceptor sites: receptor site 1 which binds vinblastine, 
doxorubucin, etoposide and cyclosporin A (23), and receptor site 2 which binds dexniguldipine (94) and 
other 1,4-dihydropyridines [330]. Other study suggests that dexniguldipine (94) binds P-gp between 
residues 468-527, flanked by the Walker motifs A and B of the N-terminal ATP-binding cassette, 
suggesting that the mechanism of chemosensitization may be the direct interaction of dexniguldipine (94) 
with the NBD (Fig. 1A and B) [331]. Furthermore, the dexniguldipine (94) structure-activity relationship 
(Fig. 7) allowed the analysis of their Ca
2+
 channel and P-gp blocking activities and revealed a clear 
relationship with the moieties in C-4 and in C-3/5 positions. A  1-methyl-5-nitro-2-imidazole group in C-
4, and a pyridine-2-yl-methyl directly bound to the acetate group in C-3 or in C-5 give rise to a compound 
with the strongest MDR reversing effect while its Ca
2+
 channel blocking activity was among the lowest 
and was only considered a side effect [332]. 
Other structural modifications on the first generation inhibitors are worth emphasizing in the 
development of second generation modulators. For example, MM36 (91) is a verapamil (1) analog with 
an anthracene group [155, 156]. KR-30031 (92) is a rigid analogue of verapamil (1) with a 2,3-dihydro-
1H-indene group and an active modulator of MDR with potentially minimal cardiovascular toxicity [333]. 
RO44-5912 (93) is a phenethylamine and a tiapamil derivative structurally similar to verapamil (1) but 
with a 1,3-dithiane group. PAK-104P (95) is a niguldipine (6) analogue with a phosphate group and with 
more potent resistance-reversing ability than other calcium channel blockers, but it has lower calcium 
channel-blocking activity [160]. 
                                               Annex 1 
 139 
 
 
Fig. (7). Structure-activity relationship of dexniguldipine (90). ▲= ↑ P-gp inhibition;  = ↓ Ca+ 
channel blocking. 
 
 
Dimerization was another strategy used to develop second generation modulators such as the  quinine 
homodimer Q2 (98). Several homodimeric polyenes based on stipiamide (107) linked with polyethylene 
glycol ethers were also found to effectively inhibit P-gp function [334]. 
Molecular modifications by simplification were also used in the discovery of new members of this 
generation of P-gp inhibitors. SB-RA-31012 (104) is a taxane derivative reported to be active at 0.1 µM 
[335]. In contrast to the taxanes paclitaxel and docetaxel, which were shown to be substrates of P-gp that 
limited their efficacy, the synthetic taxane SB-RA-31012 (104) modulates P-gp without being cytotoxic 
due to the removal of the tubulin-binding side chain at the C-13 position of the taxane backbone. 
Biricodar (101) has been developed by Vertex Pharmaceuticals Inc (Cambridge, MA, U.S.A.) [336] and 
is a simplified analog of the immunosuppressive macrolactone tacrolimus (24) without 
immunosuppressive effects.  
Valspodar or PSC-833 (100) was developed by Novartis and derives from cyclosporine A (23) due to a 
reduction in a lateral chain of an amino acid and an oxidation of an alcohol to a carbonyl. It is a 
nonimmunosuppressive cyclosporin analog which is a potent MDR modifier, 5- to 20-fold more potent 
than cyclosporine A (23) [337, 338]. The main problem associated with this compound is the interaction 
with the pharmacokinetics of the associate chemotherapeutic drugs, which resulted in an increase in the 
chemotherapeutic drug toxicity which in turn requires a reduction of its dose [339]. 
Some of the compounds from the second generation lack P-gp selectivity as the compounds from the 
first generation. S9788 (109) is 1.5 to 30 times more active than verapamil (1) and 1.2 to 120 times more 
active than cyclosporine A (23) but was found to also inhibit BCRP [187, 188].  
Several clinical trials have been performed since 1996 using valspodar (100) as a potential MDR 
reversing agent (Table 4). However, it was found that valspodar (100) exerted a deleterious effect on the 
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pharmacokinetics of co-administered anticancer drugs, including etoposide, doxorubicin, mitoxantrone or 
paclitaxel, which obliged a dose reduction of the anticancer drug of 30-50% [241, 339-350]. Despite the 
promising initial pre-clinical results provided by valspodar (100), the more recent clinical trials results 
(Table 4) have confronted investigators and industry with the fact that new agents need to be explored and 
novel trials are required.  
 
In conclusion, the second-generation of P-gp modulators have a better pharmacologic profile than the 
first-generation, but they also retain some characteristics that limit their use as P-gp modulators. In 
particular, these compounds significantly inhibit the metabolism and excretion of cytotoxic agents, thus 
leading to unacceptable toxicity which requires chemotherapy dose reductions. Several of the second-
generation P-gp modulators, including valspodar (100) and biricodar (101), are substrates for cytochrome 
P450. Therefore, the competition between chemotherapeutic agents and these P-gp modulators for 
cytochrome P450 activity has given rise to unpredictable pharmacokinetic interactions [351].  Moreover, 
since the pharmacokinetic interactions between P-gp inhibitors and cytotoxic agents are unpredictable and 
cannot be determined in advance, reducing the dose of a cytotoxic agent may result in underdosing, thus 
limiting the use of these second-generation modulators in the treatment of MDR cancers [352]. Many 
second-generation modulators may also inhibit other transporters, particularly those of the ABC 
transporter family. This can lead to a decreased capacity of normal cells to extrude toxic compounds or 
xenobiotics in the liver, kidney, or gastrointestinal tract [353, 354]. The endothelial distribution of P-gp 
and other ABC transporters indicates that they are involved in physiological roles such as the regulation 
of the entry of certain molecules into the CNS and other anatomic compartments, such as the testis and 
placenta [355]. Therefore, the inhibition of transporters other than P-gp, for example, the ABC transporter 
BCRP, a functional regulator of hematopoietic stem cells, may lead to serious adverse effects including 
neutropenia and other myelotoxic effects [356]. In an effort to alleviate these problems, investigators and 
industry have started to focus on a new generation of P-gp inhibitors, the third generation. 
 
 
5. THIRD GENERATION P-GP INHIBITORS 
 
To overcome the limitations of the second generation P-gp modulators, a third-generation of P-gp 
inhibitors which specifically and potently inhibit P-gp has been developed by using quantitative structure-
activity relationships (QSAR) and combinatorial chemistry [328]. This allowed the design of molecules 
with specific characteristics such as lipophilicity, positive charge at neutral pH and with aromatic rings 
[245]. The most studied third generation P-gp inhibitors are zosuquidar (110), elacridar (111), tariquidar 
(112), laniquidar (113), ontogen (114), DP7 (115), PGP-4008 (116) and CBT-1(117). Their described in 
vitro/ in vivo assays and clinical trials are summarized in Tables 3 and 4, respectively. 
Tariquidar (XR9576) (112) is an anthranilamide derivative and an example of a third generation P-gp 
inhibitor [357]. Tariquidar (112) has long been described as a specific P-gp inhibitor. It is now accepted 
that tariquidar [204] (112) and elacridar [201] (111) also bind the BCRP transporter. Tariquidar (112) 
binds P-gp with a noncompetitive mechanism and with an affinity that greatly exceeds that of the 
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transported substrates [358]. Tariquidar (112) inhibits the ATPase activity of P-gp; however, it is not clear 
whether the binding of tariquidar on P-gp is directed to the ATP binding site or to an allosteric location, 
thus indirectly blocking the P-gp catalytic cycle [202]. Tariquidar (112) is assumed to bind to the same 
binding site of P-gp as the P-gp substrate Hoechst 33342 [202, 359], located within the inner leaflet of the 
membrane [360, 361], and that combines both transport and regulatory functions [362]. The inhibitory 
effects of tariquidar (112) on P-gp greatly exceed those of first- and second-generation P-gp modulators 
with respect to potency and duration of action. In fact, in an in vitro study, the P-gp pump transport 
remained blocked for more than 22 hours after tariquidar had been removed from the culture medium; in 
the same assay, the clearance time for cyclosporine A (23) was only 1 hour  [203]. It has been recently 
described that nanoparticles or liposomes delivering a combination of this P-gp modulator and an 
anticancer drug (paclitaxel) are a very promising approach to overcome tumor drug resistance [363, 364], 
which could be correlated with an increased accumulation of paclitaxel in tumor cells.  
Several structure-activity studies of anthranilic derivatives have taken place in recent years in an effort 
to understand important features for P-gp versus BCRP inhibition, with tariquidar (112) being an example 
(Fig. 8). The most significant groups responsible for the pharmacological activity are described to be: i) 
the nitrogen atom (as an H bond acceptor group) in the condensed heteroaromatic quinoline ring system; 
ii) a hydrogen bond acceptor group such as a nitro or dimethylamine group or an electronegative atom 
like fluorine in the anthranilamide moiety, and iii) a hydrogen bond acceptor group in the 
tetrahydroisoquinoline moiety such as a methoxy group [365, 366]. The active tetrahydroisoquinoline 
substruture appears as either unsubstituted (weak P-gp inhibitors) or 6,7-dimethoxysubstituted (more 
active P-gp inhibitors) and this substruture plays a role in the P-gp inhibitory effect [365]. Small structural 
changes at the benzamide core resulted in large shifts in activity and selectivity from P-gp towards BCRP 
[367]. By changing the amide-attached quinoline on tariquidar (112) from ortho to the meta position, 
generating a meta-benzamide core, the inhibitory activity against P-gp was greatly diminished, while it 
maintained its BCRP inhibitory activity [365]. Also, different aromatic substituents, such as 2-
quinoxalinyl, 2-pyrazinyl, and 3-pyridyl and particularly 2-quinolinyl in position 2 of the benzamide ring, 
greatly increased selectivity against BCRP [365]. These results suggested that although sharing some 
general similarity, the structural requirements for binding of tariquidar (112) analogs to P-gp and BCRP 
differ, and this is probably related to differences in the topology and physicochemical properties of the 
protein binding sites [365]. 
Other third generation agents, such as zosuquidar (110) and laniquidar (113), are more specific for P-gp 
rather than for other ABC pumps, avoiding the risk of blockage of other transporters, which might result 
in altered bioavailability or excretion of the chemotherapeutic agents [203, 368]. Zosuquidar (110) was 
developed by Eli Lilly and Company (Indianapolis, IN, U.S.A.) and is among the most potent modulators 
of P-gp known to date. In fact, it inhibits P-gp at nanomolar concentrations in vitro and in vivo [369, 370] 
and there is evidence that it is not an inhibitor of MRP or BCRP [193, 368]. The mechanism of action of 
zosuquidar (110) is still unclear but a noncompetitive inhibitory mechanism has been suggested since it is 
not a substrate and cannot be transported by P-gp [368]. 
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Fig. (8). Structure-activity relationship of tariquidar (112). ▼= ↓ P-gp inhibition; ■= ≈ P-gp inhibition; 
= ↑ BCRP inhibitory activity. 
 
The third generation P-gp inhibitors do not affect cytochrome P450 3A4 at relevant concentrations 
[371, 372]. Therefore, they generally do not alter the plasma pharmacokinetics of the simultaneously 
given antitumor agent, at least not to the extent verified with the previous generations, and consequently 
they do not need a chemotherapy dose reduction [203, 373]. Ontogen (114) was discovered via a high 
throughput, cell-based screen for inhibitors, being developed from the optimization of a lead identified in 
a library of imidazole derivatives [374, 375] and reported to be a potent inhibitor of P-gp as well as being 
non toxic, causing little interference with the pharmacokinetic of other drugs as it is not a CYP3A4 
substrate [376]. DP7 (115) also displayed weak inhibition of human CYP3A4 enzyme activity, suggesting 
that DP7 should not give rise to important, unpredictable pharmacokinetic interactions [377]. PGP-4008 
(116) was identified by screening a library of synthetic compounds and has shown good systemic 
absorption and lack of interaction with the concomitantly administered chemotherapeutic agent [209]. 
In spite of all the progress that has been made in the field of multidrug resistance, namely with the 
discovery of the third generation MDR modulators (suggested to be more potent and more specific than 
their precursors) they are still far from being considered perfect MDR modulators capable of effectively 
and safely overcoming resistance in cancer cells. 
The “wheel of Aquiles” of the third generation P-gp inhibitors was the unexpected toxic effects shown 
in clinical trials. For example, tariquidar (112) was tested on phase III clinical trials on non-small-cell 
lung cancer patients but had to be stopped due to high toxicity (Table 4). Disapointing results were also 
obtained for zosuquidar (110), elacridar (111), laniquidar (112) and ontogen (114). However, clinical 
trials are still ongoing for verapamil, mibefradil and cyclosporine A from the first generation; valspodar, 
biricodar, timcodar and dofequidar from the second generation; and tariquidar, laniquidar and CBT-1 
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from the third generation (Table 4, right column).  Finally, CBT-1 (117) is an orally administered, 
bisbenzylisoquinoline alkyloid currently being developed as a P-gp inhibitor by CBA Research Inc and 
clinical results are promising although still preliminar. 
 
 
6. NEW PERSPECTIVE: FORTH GENERATION? 
 
Random and focused screening, systematic chemical modifications and combinatorial chemistry 
performed over the last three decades have given rise to the first three generations of P-gp inhibitors. 
However, most of those compounds did not reach the aim for which they were developed, due to several 
side effects and pharmacokinetic interations that limited their clinical use. Even the computational studies 
(namely based on docking studies, pharmacophore-based or QSAR-based screening) still have not led to 
any lead compound with in vitro and in vivo results that make them promising drug candidates. Therefore, 
new strategies to find P-gp inhibitors have been used by investigators, such as the “return” to natural 
products (NP) and NP mimics, peptidomimetics, surfactants and lipids, and dual ligands. 
 
6.1. Natural products (NP) and NP mimics 
 
As a result of the poor success of the three generations of P-gp inhibitors, many investigators have 
focused their attention on screening products of natural origin in order to find new potential P-gp 
inhibitors. The compounds obtained for the first time from natural sources and specifically tested for P-gp 
inhibition, are classified by some authors as belonging to the forth generation of P-gp inhibitors [371]. In 
fact, food components such as orange, grapefruit, and strawberry can interfere with the oral 
bioavailability of many drugs and these drug-food interactions may involve P-gp. The active components 
of food and plant extracts already identified were also exploited as lead compounds for chemical 
modifications to generate novel, selective, and high affinity P-gp inhibitors [378]. 
 
6.1.1. Flavonoids 
 
Flavonoids are constituents of fruits and vegetables and have long been associated with a variety of 
biochemical and pharmacological properties, including antioxidative, antiviral, anticarcinogenic, and anti-
inflammatory activities [379]. Several flavonoids are described as being able to interact with P-gp [379-
384], stimulating the P-gp-mediated efflux in tumor cells or inhibiting P-gp-mediated transport [385].  
4',5,6,7,8-Pentamethoxyflavone (tangeretin, 118), 3',4',5,6,7,8-hexamethoxyflavone (nobiletin, 119), 
and 3,3',4',5,6,7,8-heptamethoxyflavone (HMF, 120) (Fig. 9) are methoxyflavones contained in orange 
juice and all have been shown to increase the steady-state accumulation of  [
3
H]vinblastine by Caco-2 
cells in a concentration-dependent manner. Besides, none of these methoxyflavones inhibited CYP3A4. 
Methoxyflavones (118-120) enhanced vinblastine accumulation by specifically inhibiting drug efflux via 
P-gp as they increased steady-state  [
3
H]vinblastine accumulation by LLC-GA5-COL300 cells (a cell line 
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transfected with human MDR1 cDNA) [386]. In another study, tangeretin (118) and nobiletin (119) were 
shown to inhibit P-gp function [387]. 
 
Fig. (9). Flavonoids as P-gp modulators (118-125). 
 
3',4',5,6,7-Pentamethoxyflavone (sinensetin, 121) is a flavonoid extracted from citrus fruits. It reversed 
the resistance of P-gp-overexpressing AML-2/D100 to vincristine in a concentration-dependent manner. 
Chemosensitizing effect of sinensetin (121) was 10 and 18 fold higher than those of 3',4',5,7-
tetramethoxyflavone and 3',4'-dimethoxy-3,7-dihydroxyflavone, respectively. This result suggested that 
the methoxylated pattern of substitution is more important than the hydoxylated counterpart. Sinensetin 
(121) showed high efficacy and low cytotoxicity [388]. 
A study using 3',4',7-trimethoxyflavone (TMF, 122) combined with paclitaxel showed that apical 
transport loading of TMF increased the paclitaxel sensitivity of paclitaxel-resistant SK-MES-1/PT4000 
cells overexpressing P-gp on the basolateral side, sugesting that TMF, a low toxicity flavones, can be 
used as an enhancer of bioavailability of oral paclitaxel and as a P-gp inhibitor [389]. 
2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC, 123) isolated from the buds of Cleistocalyx 
operculatus potentiated the cytotoxicity of the chemotherapeutic agent doxorubicin to drug-resistant KB-
A1 cells. At 5 µM, DMC decreased the doxorubicin IC50 on KB-A1 cells by 4-fold [390].  
Baicalein (124), a flavone isolated from Scutellariae baicalensis Georgi, a skullcap native to North 
America was also shown to enhance the bioavailability of oral doxorubicin which could be due to the 
inhibition of both P-gp and the CYP3A subfamily in the intestine and/or liver [391] although other factors 
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such as the induction of gene expression and activity of CYP3A4 and mdr1 might also take part in the 
MDR reversal effect [392].  
Quercetin (125), a flavonol, is a plant-derived flavonoid found in fruits, vegetables, leaves and grains. 
Quercetin inhibits CYP3A4 enzyme activity in a concentration-dependent manner with a IC50 of 1.97 μM. 
In addition, quercetin significantly enhances the intracellular accumulation of rh123 in MCF-7/ADR cells 
overexpressing P-gp. Quercetin increases the bioavailability of oral doxorubicin, which can be attributed 
to enhanced doxorubicin absorption in the gastrointestinal tract via quercetin-induced inhibition of P-gp 
[393]. 
Structure-activity relationship for P-gp inhibition (Fig. 10A) pointed to a specific role for the hydroxy 
substitution pattern on the benzyl group. Structural units of B-ring-3‟/5‟-OH group, B-ring-4‟-OH group, 
C3-ring (or isoflavones) negatively contributed to the modulation effect of flavonoids on P-gp activity, 
while the A-ring-7-OH group tended to enhance their inhibitory effects. Among them, the most 
unfavorable factor for regulating the inhibitory effect of flavonoids on P-gp function is the presence of a 
isoflavone scaffold [394]. From both doxorubicin sensitization assays and JC-1 accumulation 
experiments, these compounds can be suggested to act, at least in part, by inhibiting P-gp transport 
activity [395]. Lipophilic compounds containing several ring systems and a tertiary amine are good 
candidates for MDR modulation [396]. Hydrophobicity of both A/C and B rings plays an important role 
in the binding to flavonoid- and steroid-interacting binding pocket of P-gp [397]. The planar moiety of 
flavonoids seems to be important for their interaction with P-gp. Flavanones, which lack the double bond 
between the 2- and 3-position in the C ring, have a lower P-gp inhibitory activity than flavones. The 
double bond confers different torsion angles and a largely planar structure on flavone molecules so that 
they may more readily intercalate between the hydrophobic amino acid residues of P-gp [398]. Flavonoid 
chemosensitizers were found to bind to the ATP-binding site because of their structural similarity to the 
adenine moiety of ATP as demonstrated by crystallographic studies [399]. In addition, flavonoids display 
bifunctional interactions at the ATP-binding site and a vicinal steroid-interacting hydrophobic sequence 
[400] (Fig. 10B).  
 
Fig. (10). A) Structure-activity relationship of flavones. ▼= ↓ P-gp inhibition; ▲= ↑ P-gp inhibition. B) 
Proposed schematic model of NBD showing the relative positions of different binding sides: i) ATP 
binding, ii) Steroid binding, iii) Flavonoid binding sites (adapted from  [401]). 
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6.1.2. Alkaloids 
 
Pervilleine F (126) (Fig. 11), a new tropane alkaloid aromatic ester obtained from a chloroform extract 
of the roots of Erythroxylum pervillei, was found to restore the vinblastine sensitivity of cultured 
multidrug-resistant KB-V1 cells, with an IC50 value of 0.40 µM. Pervilleine F was also able to partially 
reverse the cross-resistance of KB-V1 cells to anticancer agents such as actinomycin D (45.1-fold), 
mithramycin A (42-fold), paclitaxel (32-fold) and vincristine (74-fold) [402]. 
Ellipticine (127), an anticancer alkaloid isolated from Ochrosia sp, and its analogs were also found to 
be P-gp inhibitors [403]. 
 
6.1.3. Coumarins 
 
Cnidiadin (128) (Fig. 11) is a geranylated furocoumarin isolated from Tetradium daniellii. This is a 
cytotoxic agent capable of competitively inhibiting in vitro the binding and efflux of drugs by P-gp and 
enhancing the cell toxicity of vinca alkaloids in two cell lines (MDCK-MDR1 and mutant human 
carcinoma KB/VCR) overexpressing P-gp. It significantly accumulated rh123 and [
3
H]-vimblastine and 
inhibited P-gp photolabelling in MDCK-MDR1 cells. However, due to its cell toxicity, clinical interest in 
cnidiadin (128) as a chemosensitizer appears to be limited [404]. 
Conferone (129) is a coumarin from Ferula conocaula. At 10 µM, it efficiently competes with a 
photoactivatable cyclosporin A analogue for binding to P-gp and accumulates [
3
H]-vimblastine to a 
higher extent than cyclosporin A (23), supporting the hypothesis that conferone (129) sensitizes MDCK-
MDR1 cells to vimblastine by competitively inhibiting drug efflux. Considering its high affinity for P-gp, 
conferone (129) may have an additional usefulness as a tool for the design or (hemi) synthesis of agents 
probing P-gp [405]. 
Praeruptorin A (130) is a naturally existing pyranocumarin isolated from the dried root of Peucedanum 
praeruptorum Dunn and it is know to reverse P-gp-mediated MDR [406]. A praeruptorin A (130) 
derivative, (+/-)-3',4'-O-dicynnamoyl-cis-khellactone (DCK, 131), was more potent than praeruptorin A 
(130) or verapamil (1) in reversing the P-gp-MDR effect. DCK (131) increased cellular accumulation of 
doxorubicin without affecting the expression level of P-gp in P-gp-MDR cells. It inhibited P-gp-ATPase 
and decreased the reactivity of the P-gp-specific antibody UIC2, suggesting a noncompetitive mode of 
inhibition [406]. Another praeruptorin A derivative, (+/-)-3',4'-bis(3,4-dimethoxycinnamoyl)-cis-
khellactone (DMDCK, 132) was able to totally inhibit P-gp ATPase activity using Pgp-enriched 
membrane vesicles. In fact, the co-existence of 3- and 4-methoxyl groups on cinnamoyl remarkably 
enhanced the P-gp-inhibitory activity. These additional methoxyl groups may allow DMDCK (132) to 
interact more efficiently with P-gp [407]. 
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Fig. (11). Examples of P-gp modulators: alkaloids (126 and 127) and coumarins (128-133). 
 
Furanocoumarins extracted from plants from Umbelliferae family strongly inhibit P-gp and CYP3A4. 
Kampo, a tradicional japonese medicinal extract, contains herbal compounds belonging to the 
Umbelliferae family, and will consequently posess furanocoumarins such as rivulobirin A (133) that may 
cause a drug-drug interaction with P-gp or CYP3A4 substrates [408] . 
 
6.1.4. Canabidiois 
 
Cannabinoids are used therapeutically for the palliation of the adverse side effects associated with 
cancer chemotherapy. However, cannabinoids also inhibit both the activity and expression of P-gp in 
vitro. Cannabidiol (134) (Fig. 12), one of the major marijuana constituents, significantly inhibits P-gp-
mediated drug transport by a noncompetitive mechananism, suggesting that cannabidiol could potentially 
influence the absorption and disposition of other coadministered compounds that are P-gp substrates 
[409]. Cannabinoids also reverse MDR in CEM/VLB cells by decreasing P-gp expression [409]. 
Cannabinoid inhibition of MRP1 was confirmed using insect cell membrane MRP1 ATPase assays with a 
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rank order of potency: cannabidiol>cannabinol>δ9-tetrahydrocannabinol [410]. Cannabinoids are also 
BCRP inhibitors, reversing the BCRP-mediated multidrug-resistant phenotype in vitro [411]. Therefore, 
these compounds lack selectivity as they seem to be targeting several ABC transporters [411]. 
 
6.1.5. Taccalonolides 
 
The taccalonolides are a class of microtubule-stabilizing agents isolated from Tacca chantrieri, 
structurally distinct from taxanes. Taccalonolides A (135) (Fig. 12), E, B, and N were effective in vitro 
against cell lines that overexpress P-gp and MRP7. In addition, taccalonolides A and E were highly active 
against a doxorubicin- and paclitaxel-resistant P-gp-expressing tumor, Mam17/ADR [414, 415]. 
 
6.1.6. Diterpenes 
 
The taxanes are diterpenes produced by plants of the genus Taxus. Taxanes have been used to produce 
various chemotherapeutic drugs. The principal mechanism of action of the taxane class of drugs is the 
disruption of microtubule function [412]. It has long been reported that natural taxane diterpenes isolated 
from the japanese yew tree, Taxus cuspidata, could increase the cellular accumulation of vincristine  in 
MDR tumor cells to the same extent as verapamil (1) [413]. 
 
Fig. (12). Examples of P-gp modulators: canabidiol (134) and taccalonolide A (135). 
 
The tetracyclic diterpene moiety of taxol, 10-deacetylbaccatin III (10-DAB, 136), is readily available 
from the renewable leaves of Taxus baccata. 10-DAB (136) (Fig. 13) can be extracted from the leaves of 
this tree in high yields. Based on the 10-DAB skeleton, positions C-7 and C-13 were modified. Hydroxyl 
or acetyl groups at C-13 originate non-cytotoxic compounds (not able to block microtubule 
depolymerization) with P-gp inhibitory activity. Several taxane derivatives were shown to have high level 
of MDR reversing activity (superior to 90%). In fact, the modification of C-7 position makes it suitable 
for strong MDR reversal activity (Fig. 13). The type of substituent on C-7, namely aromaticity and length, 
was the determining factor for the MDR reversal activity [416]. The new noncytotoxic synthetic taxane 
derivatives that modulate efflux and cytotoxicity of substrate drugs in multidrug resistant cell lines 
overexpressing P-gp, MRP-1, and BCRP  were discovered by these structure-activity studies [417].  
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Fig. (13). Structure-activity relationship of 10-DAB (136). ▼= ↓ P-gp inhibition; ▲= ↑ P-gp inhibition; 
■= ≈ P-gp inhibition. 
 
Another series of taxane derivatives based on baccatin III (137) (Fig. 14) were studied for their MDR 
reversal and cytotoxic potential. Baccatin III derivatives with either a C-13-hydroxyl group or C-13-
acetyl group showed potent MDR reversing activities but the compound with a cetone group in C13 was 
shown to be more cytotoxic [418].  
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Fig. (14). Structure-activity relationship of baccatin III (137) (top) and taxuyunnanine-C (138) (bottom). 
▼= ↓ P-gp inhibition; ▲= ↑ P-gp inhibition; ■= ≈ P-gp inhibition. 
 
Taxuyunnanine-C (138) derivatives with 14-acyloxy substituents are a group of taxane-based MDR 
reversal agents isolated from callus cultures of Taxus species. The most effective compound has a 
cinnamoyloxy group at C-14. It was efficient at increasing the cellular accumulation of vincristine in 
MDR 2780AD cells, and it enchanced the intracellular concentration of taxol, adriamycin, and vincristine 
to the same extent as verapamil (1) in MDR 2780AD cells. However, these compounds were also 
cytotoxic. Other substitutions, such as an hydroxyl at C10 and an acetyl group at C5 and C14, or acetyl at 
C10 and C14 and hydroxyl at C5, led to MDR modulators lacking cytotoxic activity [419]. 
A novel class of potent P-gp inhibitors is the lathyrane-type diterpenoids from Euphorbia lagascae, for 
example jolkinol B (139) (Fig. 15), which exhibited an efficacy higher than that of verapamil (1). These 
are MDR modulators as well as anti-cancer agents with apoptosis inducing properties [420].  
                                               Annex 1 
 151 
 
The discovery of macrocyclic jatrophane diterpenes, characteristic of the Euphorbia species as potent 
inhibitors of P-gp has led to an increasing interest in researching this new class of compounds [421]. 
Some examples of these compounds are euphoportlandols A (140) and B (141) [422]. 
 
Fig. (15). Examples of P-gp modulators: diterpenes (139-144). 
 
Euphodendroidin D (142) is a jatrophane polyester isolated from the Mediterranean sponge Euphorbia 
dendroides L. showing relevant P-gp inhibitory activity, outperforming cyclosporin A (23) by a factor of 
2 to inhibit P-gp-mediated daunomycin transport. A SAR study revealed that lipophilicity and substitution 
pattern at positions 2, 3, and 5 are important for activity [423]. Pepluanin A (143) is a jatrophane isolated 
from Euphorbia peplus L., amongst others from the same class, with a P-gp inhibitory activity superior to 
that of cyclosporine A (23). Substitutions on the medium-sized ring (C 8, 9, 14, and 15) are important for 
activity. Activity is blocked by the presence of a free hydroxyl at C-8, and increased by a carbonyl at C-
14, an acetoxyl at C-9, and a free hydroxyl at C-15 [424]. Also, diterpenoid terracinolides from 
Euphorbia dendroides L. and euphocharacins from the mediterranean sponge Euphorbia characias L. 
[425] were discovered as being P-gp inhibitors [426]. 
A new abietane quinoid diterpene 16-hydroxy-abieta-8,12-diene-11,14-dione, named portlanquinol 
(144) isolated from Euphorbia portlandica was found to be both cytotoxic and an inhibitor of P-gp [427]. 
 
6.1.7. Sesquiterpenes 
 
Sesquiterpenes from the Celastraceae family are natural compounds shown to reverse MDR in several 
human cancer cell lines. Moreover, they specifically inhibited drug transport activity of P-gp in a 
saturable, concentration-dependent manner but not that of MRP1, MRP2, and BCRP transporters [428]. 
There are at least two different sesquiterpene binding sites within the transmembrane domains (TMD) of 
P-gp: a high- and a low-affinity binding site, related in a complex allosteric manner with other drug-
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binding sites of the P-gp multidrug-binding pocket, which may explain the differing potential for P-gp 
inhibition of the different sesquiterpenes [428]. In general, the important trends of agarofuran 
sesquiterpenes for high P-gp inhibitory activity are the overall esterification level of the compounds, the 
presence of at least two aromatic-ester moieties (such as benzoate-nicotinate or benzoate-benzoate), and 
the size of the molecule. Sesquiterpenes tetra- or penta-substituted showed the highest potency, whereas 
additional esters in the molecule led to inactive compounds (Fig. 16A). The presence of a basic tertiary 
nitrogen atom was shown to be non-essential for P-gp inhibition [429]. The non-substituted compounds at 
C-8 are less active than those with an ester group in such a position. In addition, the presence of a 
hydroxyl group at C-2 produced a decrease in activity [430] (Fig. 16A). A new series of dihydro-β-
agarofuran sesquiterpenes based on the celorbicol skeleton was isolated from leaves of Celastrus 
vulcanicola. The isolated compounds exhibited in vitro activity as inhibitors of P-gp.  The most active 
compounds have the polyhydroxylated skeleton of dihydroxycelorbicol (145) and hydroxycelorbicol 
(146) (Fig. 16B).  
Sesquiterpenes did not seem to be inactivated by intracellular metabolism as they have a long 
intracellular half-life, and therefore they may be implied in the inhibition of P-gp for a long time both at 
the plasma membrane and in intracellular compartments. This may be important since P-gp is involved in 
other phenomenus other than MDR, such as apoptosis [431-433]. 
 
Fig. (16). A) Agarofuran sesquiterpene structure-activity relationship. B) Example of sesquiterpene that 
inhibit P-gp (145 and 146). ▼= ↓ P-gp inhibition; ▲= ↑ P-gp inhibition; ■= ≈ P-gp inhibition. 
 
6.1.8. Triterpenes 
 
Cycloartanes (9,19-cyclopropyltriterpenes), a class of tetracyclic triterpenes, from Euphorbia species 
were discovered as potential MDR reversing agents. However, some of the compounds were cytotoxic 
due to moderate induction of apoptosis [434]. 
Alisol B 23-acetate (ABA, 147) (Fig. 17) from Alismatis orientale, a triterpene compound with a 
steroid-like structure, restored the activity of vinblastine, a P-gp substrate. It stimulated ATPase activity 
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of P-gp in a concentration-dependent manner, suggesting that ABA (147) could be a substrate for P-gp 
[435]. 
 
Fig. (17). Examples of P-gp modulators: triterpenes (147-152). 
 
Several triterpenes extracted from Betula platyphylla were shown to increase rh123 accumulation in 
KB-C2 cells, and inhibited efflux of rh123 out of cells. The mechanism of action was shown to be 
diverse, weither by a noncompetitive or competitive inhibition of the pump [436]. 
Triterpenoids possessing different skeletons were isolated from the red sea sponge Siphonochalina 
siphonella. One of these, sipholenol A (148) (Fig. 17), was found to be the most potent in reversing P-gp 
mediated MDR, increasing the sensitivity of resistant KB-C2 cells by a factor of 16 towards colchicines, 
and being itself non-toxic [437], inhibiting P-gp by a competitive mechanism of action [438]. 
Also, new sipholane triterpenoids from the red sea sponge Callyspongia (=Siphonochalina) siphonella, 
namely Sipholenone E (149) (Fig. 17), were able to reverse P-gp-mediated multidrug resistance in human 
epidermoid cancer cells [439]. 
Several triterpenes such as β-amyrin (150), uvaol (151), and oleanolic acid (152) (Fig. 17) were 
extracted from Carpobrotus edulis, a creeping, mat-forming succulent species, and were found to reverse 
MDR in the mouse lymphoma cell line, with uvaol (151) being the most effective compound [440]. 
Derivatives of these triterpenic compounds, namely papyriferic acid (153) (Fig. 18), were obtained 
from Betula dahurica („Maurice Foster') and reversed P-gp-mediated MDR on KB-C2 cells. Among the 
alkyl papyriferate derivatives, methyl papyriferate (with a 3-O-methylmalonylgroup) showed high 
capacity to enhance the cytotoxicity of colchicines. The enhancement of the cytotoxicity was decreased 
according to the chain length of the alkyl group. Removal of the 12-acetoxy group of the alkyl 
papyriferate derivatives reduced their MDR reversal effect. The amide derivatives of papyriferic acid, 
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especially 3-(morpholino-β-oxopropanoyl) derivative, demonstrated more potent activity, increasing the 
sensitivity of colchicine against KB-C2 cells 185-fold, and thus the cytotoxicity of colchicine was 
recovered to almost that of sensitive cells [441]. 
 
Fig. (18). Structure-activity relationship of papyriferic acid (153). ▼= ↓ P-gp inhibition; ▲= ↑ P-gp 
inhibition; ▲▲= ↑↑ P-gp inhibition. NRR‟ represents an amine, such as N(CH3)2, NHCH3, NHC2H5, or 
morfoline group. 
 
Four taraxastane-type triterpenes, 21-α-hydroxytaraxasterol, 21-α-hydroxytaraxasterol acetate, 3α,30-
dihydroxy-20(21)-taraxastene and 3β-hydroxy-20-taraxasten-30-al, isolated from Euphorbia lagascae and 
Euphorbia tuckeyana exhibited a significant P-gp modulation activity [442]. 
Novel cucurbitane-type triterpenes, balsaminagenin A (154) and balsaminoside B (155), as well as the 
known cucurbitacin karavelagenin C (156) (Fig. 19), isolated from the aerial parts of Momordica 
balsamina L. (balsam apple), reversed MDR activity on mouse lymphoma cells transfected with human 
mdr1 gene in a similar way to verapamil (1) [443]. 
Dietary phytochemicals, such as glycyrrhetinic acid (157) (Fig. 19), found in the root of Glycyrrhiza 
glabra, have dual inhibitory effects on P-gp and MRP1, with noncompetitive and competitive 
mechanisms of action having been suggested for those transporters, respectively [444]. 
 
Fig. (19). Examples of P-gp modulators: triterpenes (154-157). 
 
6.1.9. Ginsenosides 
 
Ginsenosides are among the active ingredients of ginseng, the root of which has been used in traditional 
herbal remedies in Eastern Asia for more than 2000 years and which has recently attracted attention 
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worldwide. 20S-Ginsenoside (Rh2, 158) (Fig. 20) could synergistically enhance the anticancer effects of 
conventional chemotherapeutic agents at a nontoxic dose. Unlike P-gp substrates, Rh2 (158) inhibited 
both basal and verapamil-stimulated P-gp ATPase activities.  Rh2 (158) was shown to be a potent 
noncompetitive P-gp inhibitor, which indicates a potential herb-drug interaction when Rh2 (158) is 
coadministered with P-gp substrate drugs [445]. However, Rh2 (158) lacks selectivity, as it is also 
described as a BCRP inhibitor [446]. Nonetheless, ginsenoside Rh2 (158) exhibited potent cytotoxicities 
against several cancer cells [447].  
 
Fig. (20). Examples of P-gp modulators: gingenosides (158 and 159), polyenes (160) and lignans (161-
166). 
 
Recently, ginsenosides Rg1, Re, Rc, and Rd were found to have a moderate inhibitory effect on P-gp in 
MDR mouse lymphoma, and increased rh123 accumulation. Of several ginseng components, 20S-
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ginsenoside Rg3 (159) (Fig. 20), so far found only in red ginseng, was shown to have the most potent 
MDR inhibitory activity on resistant human fibroblast carcinoma cells, KBV20C [448]. 
 
6.1.10. Polyenes 
 
Polyenes are poly-unsaturated organic compounds that contain one or more sequences of alternating 
double and single carbon-carbon bonds [449]. Polyenes and polyacetylenes isolated from Echinacea 
pallida roots were found to be capable of reducing P-gp activity. Pentadeca-(8,13)-dien-11-yn-2-one 
(160) (Fig. 20) was found to be the most efficient compound [450]. 
 
6.1.11. Lignans 
 
Schizandins are derivatives of the dibenzo-(a, c)-cyclooctene lignan and may be extracted from 
Schisandra fruits (Schisandraceae chinensis). Schisandrin A (161) (Fig. 20) reversed drug resistance in 
KBv200 cells, MCF-7/Dox cells and Bel7402 cells by factors of 309, 38, and 84, respectively, being the 
most potent derivative of this species [451]. Schisandra sphenanthera extract, which contain 
Schisantherin A, enhanced apical-to-basal drug-transport and decreased basal-to-apical drug-transport in 
the Caco-2 cell line, suggesting they could potentially increase the absorption of drugs that can act as a P-
gp substrate [452]. Also, schisandrin B (162) (Fig. 20), another compound from the same fruit, is also a 
strong inhibitor of P-gp, fully restoring the intracellular drug accumulation on four MDR cell lines with 
P-gp overexpression [453]. However, dibenzocyclooctadiene lignans (schisandrin A, schisandrin B, 
schisantherin A, schisandrol A, and schisandrol B) are not selective for P-gp, as they were also described 
as MRP1 inhibitors [454], and therefore proving to be dual inhibitors [455]. 
Lignans isolated from Phyllantus amarus were also identified as potential MDR modulating agents. 
Nirtetralin (163) and niranthin (164) (Fig. 20) were found as the most potent derivatives. Concomitant 
incubation with the anticancer agent daunorubicin led to a reduction in cell viability of about 60% [456].  
Silibinin (165) (Fig. 20), also known as silybin, is the major active constituent of silymarin, the mixture 
of flavonolignans extracted from Silybum marianum. Silibinin is an inhibitor of P-gp-mediated efflux 
transporters and its oxidative metabolism is catalyzed by CYP3A4 [457].  
Xanthonolignoids trans-(+/-)-kielcorin C (166) (Fig. 20), previously described as a protein kinase C 
inhibitor [458], was found to be also a competitive P-gp inhibitor [459]. 
 
6.2. Peptidomimetics 
 
Among the known P-gp inhibitors, peptides are scarce but represent some good candidates of the forth 
generation of P-gp inhibitors. Valspodar (100), a cyclosporine A (23) derivative, is the best representative 
of compounds that have ultimately reached phase III clinical trials but were stopped because of 
pharmacokinetic interactions with anticancer drugs and lack of specificity [460]. 
Short peptide P-gp inhibitors called reversins are di- and tripeptide derivatives sharing common 
physicochemical and structural features such as bulky aromatic and/or alkyl groups. Among them, 
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reversin 121 (167) (Fig. 21) is an aspartyllysine (Asp-Lys) dipeptide derivative displaying good affinity 
and specificity for P-gp [461]. Beneficial effects of high-affinity peptide reverin 121 (167) on reversing 
chemotherapy-induced MDR were demonstrated in pancreatic cancer in a mouse model. The addition of 
reversin 121 (167) to chemotherapeutic regimens significantly reduced the proportions of tumor cells 
[462]. 
Peptide 15 (168) (Fig. 21) is a compound with high affinity and specificity for P-gp, having limited or 
no activity on MRP and BCRP. Besides, it has no cytotoxicity up to 10-fold its P-gp inhibitory activity 
IC50. It equally inhibited the Hoechst 33342 and daunorubicin effluxes through a typical noncompetitive 
inhibition mechanism, suggesting it binds to a site different from the H and R drug-transport sites [463].  
XR9051 (169) (Fig. 21) is a diketopiperazine (lactam ring formed by peptide bonds stablished between 
two amino acids) which was identified as a potent modulator of P-gp-MDR following a synthetic 
chemistry programme based on a Streptomyces product lead compound. It was found to be more potent 
than cyclosporin A (23) and verapamil (1) in inhibiting P-gp (EC50 = 1.4 nM) [464]. It inhibited the efflux 
of  [
3
H]daunorubicin from preloaded cells and, unlike cyclosporine A (23) and verapamil (1), remained 
active for several hours after removal of the resistance-modifying agent [464]. XR9051 (169) is rapidly 
distributed and accumulates in tumours and other tissues. Besides, the compound is well-absorbed after 
oral administration [465]. 
The discovery of peptide inhibitors of P-gp based on the structure of the transmembrane domains of the 
transporter has been a new nontoxic approach for the design of P-gp inhibitors. These peptides are 
thought to exert their inhibitory action by disrupting the proper assembly of P-gp. A 25-residue long 
retroinverse D-analogue of transmembrane domain 5 inhibited the efflux of the fluorescent P-gp substrate 
with an IC50 of 500 nM. Transmembrane peptides effectively sensitized resistant cancer cells to 
doxorubicin in vitro without demonstrating any cell toxicity of their own [466].   
 
6.3. Surfactants and lipids 
 
Among the several established inhibitors of P-gp, there are a variety of surface-active agents potentially 
capable of accelerating drug transmembranar movement. In fact, surfatants such as Pluronic P85, Tween-
20, Triton X-100 and Cremophor EL can modulate MDR by inhibition of the P-gp-mediated efflux, with 
no appreciable effect on transbilayer movement of drugs. Therefore, surfactants demonstrate a 
transporter-specific interaction rather than unspecific membrane permeabilization [115]. The drug 
sensitivity of K562/MDR cells to vincristine can be completely restored by Cremophor EL [467]. 
Poly(ethylene glycol)-300 (PEG-300) causes almost complete inhibition of P-gp activity in both Caco-2 
and MDR1-MDCK cell monolayers, whereas Cremophor EL and Tween 80 only partially inhibit P-gp 
activity in Caco-2 cells. PEG-induced changes in P-gp activity are probably related to changes in the 
fluidity of the polar head group regions of cell membranes [468]. P-gp-mediated rh123 transport was 
inhibited by five nonionic surfactants in a concentration-dependent manner and in the order α-tocopheryl 
poly(ethylene glycol) 1000 succinate (TPGS) > Pluronic PE8100 > Cremophor EL > Pluronic PE6100 ~ 
Tween 80. In contrast, none of the surfactants showed a significant inhibition of MRP2-mediated efflux in 
Madin-Darby canine kidney/MRP2 cells [469]. Grafting PEG to polyethylenimine (PEI) followed by 
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thiolation with γ-thiobutyrolatone has originated the novel thiolated PEG-g-PEI (170) (Fig. 21) co-
polymer which exhibited promising properties as a novel P-gp inhibitor. The thiolated co-polymer 
increased the accumulation of rh123 up to 3.3-fold in comparison to rh123 without any inhibitor. When 
applied at a concentration of 0.1 %, 0.25 % and 0. 5 % (w/v) not only did it enhance the absorption but it 
also decreased the secretory transport of Rh123 [470].  
 
Fig. (21). Examples of P-gp modulators: peptidomimetics (167-169) and surfactants (170).  PEG = 
poly(ethylene glycol); PEI = polyethylenimine. 
 
α-Tocopheryl poly(ethylene glycol) 1000 succinate (TPGS), added to nanoparticles, decreases the P-gp 
activity, increases the intracellular accumulation doxorubicin, and increases the MDR reversal of the 
nanoparticles [471]. 
Recently, the liposomal shell was discovered to be capable of directly inhibiting P-gp by two 
mechanisms: the liposome shell modifies the composition of rafts in resistant cells and decreases the lipid 
raft-associated amount of P-gp, and the doxorubicin-loaded liposomes directly impaires transport of 
known P-gp substrates, blocking ATPase activity. Glycine-185 is involved in the inhibition of P-gp by 
Lipo-Dox [472]. 
 
6.4. Dual ligands 
 
Recently there has been a paradigm shift in drug design moving towards developing multifunctional 
drugs, meaning compounds that target multiple targets related to a specific pathological condition [473, 
474]. This strategy has already been used for the design of multifunctional agents for HIV [62], several 
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neurodegenerative diseases [475, 476] and MDR cancer [477]. Indeed, a multiple target mechanism as 
MDR modulator and antitumor agent has already been mentioned for ellipticine (127), and lathyrane-type 
diterpenoids jolkinol B (139) [420]. This allows one to take advantage of both tumor-directed cytotoxicity 
and MDR reversal activities into one single molecule. Based on these considerations, we have 
investigated aminated thioxanthones as dual inhibitors of cell growth and P-gp [478]. These derivatives 
were designed by merging a thioxanthonic scaffold (for antitumor activity [479, 480]) with a P-gp 
inhibitor pharmacophore which contains a protonable group (amine) [396]. Our results showed that the 
most potente P-gp inhibitor, 1- [2-(1H-benzimidazol-2-yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one, 
caused an accumulation rate of rh123 similar to verapamil in a P-gp overexpressing cell line (K562Dox) 
and at 10 μM caused a 12.5-fold decrease in the GI50 of doxorubicin in the same cell line. 
Another recently described pharmacological strategy to revert MDR was the design of dual ligands 
which inhibit MDR and stimulate nitric oxide synthase (iNOS) [481]. The resistance to doxorubicin can 
be reversed when HT29-dx resistant cells are incubated with inducers of nitric oxide (NO) synthesis. It 
has been postulated than nitric oxide reduces the number of functionally active P-gp, perhaps by altering 
the proper conformation of the transporter [482]. Folloring this principle, several P-gp inhibitors were 
shown also to stimulate NO via iNOS in U937, Caco-2 and MCF7-Adr cell lines [481]. 
Other kinds of dual activity agents are the inhibitors of more than one transporter from the ABC 
superfamily. In fact, several P-gp inhibitors from the four generations, even elacridar (111) and tariquidar 
(112), two of the most potent P-gp inhibitors found to date, interact with other ABC transporter rather 
than P-gp. Is this really a disadvantage? Much effort has been directed to the exploitation of 
“promiscuous activity” as a novel approach to treat complex disorders, such as cancer, depression and 
cardiovascular disease [483]. The simultaneous modulation of multiple targets is often required to alter a 
clinical cancer phenotype because alternative pathways may be present [484]. Attempts to develop more 
effective MDR reversers by discovering P-gp selective compounds (the so called “magic bullets”) have, 
unsurprisingly, been unsuccessful. Thus, an alternative “magic-shotgun” targeting multiple efflux pumps, 
in some instances, may possess a higher therapeutic efficacy than a specific “magic bullet” drug [485]. A 
selective P-gp inhibitor would be effective if the tumour to be treated was resistant to chemotherapy 
through P-gp overexpression only. However, if the tumor overexpresses both P-gp and MRP1, for 
example, it would be of great advantage if a “promiscuous” dual activity drug targeting both transporters 
was available. Besides, other advantages of this lack of selectivity may be highlighted, such as the use as 
radiotracers to assess the distribution of ABC transporters in tissues [486]. For example, elacridar (111) is 
active against P-gp and BCRP proteins [200, 201]. To evaluate the functions of P-gp and BCRP in 
tumors, a positron emission tomography (PET) study combining the administration of [
11
C]elacridar with 
unlabeled elacridar (111) has recently proved to be a useful tool [487, 488]. 1-[
18
F]fluoroelacridar has 
also been described as a PET tracer for P-gp and BCRP, although its low radiochemical yields and 
defluorination may limit its applicability in vivo [489]. Also, a PET tracer based tariquidar,  
[
11
C]tariquidar (112), was developed and proved to interact specifically with P-gp and BCRP in the 
blood-brain barrier (BBB) [204], being therefore a promising approach for evaluating deficiency of the 
function of drug efflux transporters [490]. For a P-gp focused detection, the radiosynthetic  
[
11
C]laniquidar (113) tracer is also available [491]. 
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In fact, is it logical to design selective compounds for a target that is “promiscuous” itself? Indeed, in 
P-gp large substrate-binding cavities, binding more than one substrate/inhibitor, binding substrates in 
alternative orientations and locations within the binding pockets and substrate-induced conformational 
changes are common features. These are therefore important parameters to be considered when dealing 
with drug design [492]. Thus, from our point of view, the major issue is the discovery of P-gp inhibitors 
without toxic effects in normal tissues and an adequate choice of the MDR reversal agent, according to 
the cancer phenotype. 
 
 
7. CONCLUSION 
 
Despite the development of new anticancer drugs, P-gp mediated MDR which protects cells from 
cytotoxic compounds will continue to hinder successful treatment of cancer. Various types of compounds 
and techniques for the reversal of P-gp-mediated MDR have been developed, and the strategy has been 
mainly to inhibit the function of the pump. 
It has been 30 years since the discovery of the first P-gp inhibitor and 43 years since the isolation of the 
first MDR cells. However, some pessimism still remains on the possibility of finding a “perfect” P-gp 
inhibitor that can efficiently modulate the pump and restore the efficacy of chemotherapy. Resources and 
time have been spent on the development of the third-generation P-gp inhibitors. Despite the initial 
enthusiasm that followed the preliminary results of tariquidar, clinical trials revealed a tragic reality. 
Fortunately, the story of multidrug resistant reversal is a story of convergence of different research 
approaches and concepts. Nowadays, by using computational techniques such as pharmacophore 
construction or QSAR studies, derivatives of known P-gp inhibitors have been synthetised according to 
the features that seem to be implied in P-gp inhibition. However, regarding the plasticity of the P-gp 
binding site(s), this line of thought may become complex. In addition, new compounds extracted from 
natural sources are being tested for P-gp modulations. 
Efforts of several investigators and laboratories spread all over the world, together with the adoption of 
new strategies, have led to an increasing number of new P-gp inhibitors, but further clinical investigations 
need to be done in order to accomplish the clinical reversal of P-gp-mediated MDR. 
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Abstract: Computer-assisted drug design (CADD) is a valuable approach for the discovery of new 
chemical entities in the field of cancer therapy. There is a pressing need to design and develop new, 
selective and safe drugs for the treatment of multidrug resistance (MDR) cancer forms, specifically active 
against P-glycoprotein (P-gp). Recently, a crystallographic structure for mouse P-gp was obtained. 
However, for decades the design of new P-gp inhibitors employed mainly ligand-based approaches (SAR, 
QSAR, 3D-QSAR and pharmacophore studies), and structure-based studies used P-gp homology models. 
However, some of those results are still the pillars used as a starting point for the design of potential P-gp 
inhibitors.  Here, pharmacophore mapping, (Q)SAR, 3D-QSAR and homology modeling, for the 
discovery of P-gp inhibitors are reviewed. This methodical analysis was brought about from the recent 
delimitation of pharmacophores for P-gp competitive and noncompetitive inhibitors based on 
thioxanthonic derivatives. The importance of these methods for understanding mechanisms of drug 
resistance at a molecular level, and design P-gp inhibitors drug candidates are discussed. The examples 
mentioned in the review could provide insights into the wide range of possibilities of using CADD 
methodologies for the discovery of efficient P-gp inhibitors. 
 
Keywords: Computer-assisted drug design, homology modeling, P-glycoprotein inhibitors, 
pharmacophore, quantitative structure-activity relationships, structure-based drug design  
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INTRODUCTION 
Since the discovery that verapamil could reverse multidrug resistance (MDR) in 1981 [1], a 
number of studies over recent decades define generic features that are common to compounds which 
interact with P-gp, through empirical structure-activity relationships (SAR), quantitative structure-activity 
relationships (QSAR), 3-dimensional quantitative structure-activity relationships (3D-QSAR), or 
pharmacophore studies. Several homology models of P-gp constructed using prokaryotic ATP-binding 
cassette (ABC) transporters as templates were also created in order to accomplish the difficult task of 
understanding P-gp‟s structure, identifying possible binding sites and screening potential inhibitors. 
These studies highlight the bottleneck associated with these data sets, such as the unclear distinction of 
substrates and inhibitors, lack of structural diversity, assay complexities and data inconsistencies.  
One of the major mechanisms of MDR is the enhanced ability of tumour cells to actively efflux 
drugs, leading to a decrease in cellular drug accumulation below effective levels. Active drug efflux is 
mediated by several members of the ABC super-family of membrane transporters, which are now 
subdivided into seven families designated from A through G [2]. ABC transporters are present in all 
organisms and participate in diverse physiological processes. This super-family is composed of more than 
100 membrane transporters/channels that are involved in a multiplicity of functions, including the 
extrusion of harmful compounds, uptake of nutrients, transport of ions and peptides, and cell signalling 
[3].  
P-gp is perhaps the best characterized human ATP binding cassette transporter. P-gp prevents 
foreign substances from accumulating in cells by transporting a wide variety of structurally and 
functionally unrelated compounds from the cell interior into the extracellular space. Energy required for 
efflux is supplied by ATP hydrolysis [4].  
This review provides an opportunity to organize all the scattered information concerning P-gp 
modulation, collecting data related to inhibition only. This information, along with recently published 
structural data for mice P-gp [5], may provide a useful tool for the design of new, more potent and 
selective P-gp inhibitors. 
 
1. STRUCTURE-BASED DRUG DESIGN  
Structure-based approaches to P-gp inhibitors design are based upon an understanding of the 
molecular recognition between active site groups and interacting molecules. However, a 3D structure of 
the target is necessary. Until 2009, when an atomic resolution crystal structure of mouse P-gp was 
described [5], only low to medium resolution P-gp 3D structures had been obtained using cryo-electron 
microscopy of 2D crystals [6-8]. Then, a maximum resolution of 8 Å [6, 9] was obtained for a P-gp 
nucleotide bound form and a resolution of 20 Å for the nucleotide free state [7]. A 8 Å resolution is 
sufficient to provide a glimpse of the general backbone fold, but tracing the protein main and side chain is 
not possible, unless through computational interpretations [8]. 
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1.1. P-gp STRUCTURE AND POTENTIAL BINDING SITES FOR P-gp MODULATION 
Human P-gp is a 170 kDa polypeptide consisting of 1280 amino acids [10] organised in two 
homologous halves, each encompassing a transmembrane domain (TMD), which contain the drug binding 
sites and define the translocation pathway across the membrane, and one cytoplasmic nucleotide binding 
domain (NBD), which couple the energy associated with ATP binding and hydrolysis to drug transport  
[6, 11]. The TMD are homologous with only a small subfamily of ABC transporters, contain the drug-
binding sites and form the translocation pathway, while the NBD share a high degree of sequence identity 
with the equivalent domains of all ABC transporters [12]. Some ABC genes encode proteins that are 
„half-transporters‟ (meaning that two subunits must dimerize to create a functional transporter), whereas 
others are „full-transporters‟. The ABC transporter subfamilies D and G and 7 members of the B 
subfamily encode these 4 domains as 2 separate polypeptides (half-transporters). The remaining 
subfamilies, including P-gp, encode the full transporter as a single multi-domain polypeptide [13].  
P-gp inhibitors binding sites are described as the drug binding/efflux site at the TMD, the ATP-
binding site at the NBD interface, and the allosteric residues involved in communication pathways [14]. 
The drug-binding sites are the classic targets for inhibitor design, providing an efficient way to block 
substrate drugs from being transported (competitive inhibition) [15, 16]. Several P-gp modulators 
compete as substrates with the cytotoxic agent, for example, verapamil and quinidine for transport by the 
pump [17]. This diminishes the efflux of the cytotoxic agent, thereby increasing its intracellular 
concentration. However, the precise pharmacophore features of P-gp inhibitors have yet to be fully 
characterized due to the plasticity of P-gp drug-binding sites. On the other hand, the NBD may also be an 
interesting target for the inactivation of P-gp due to the blocking of P-gp‟s catalytic cycle (noncompetitive 
inhibition), as described for several flavonoid inhibitors [18]. The distinct motifs contained within the 
NBD are of great value in de novo ligand design [14]. Another promising avenue for the design of 
inhibitory compounds is presented by those residues identified as being involved in the allosteric 
communication of drug occupancy [19]. Covalent modification of those residues results in a loss of drug-
stimulated ATPase activity [20-22].  
The X-ray structure of apo P-gp at a resolution of 3.8 Å was recently obtained [5] (Table 1, entry 
I). It revealed distinct drug-binding sites in the internal cavity capable of stereoselectivity which is based 
on hydrophobic and aromatic interactions. Apo P-gp structures have an inverted “V” shape, inward-facing 
conformation, for drug entry, whereas the outward-facing conformation releases the substrate to the 
extracellular medium [5]. ATP binds to the NBD, causing a conformational change (outward facing) 
which allows extrusion of the substrate [23]. 
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1.2. HOMOLOGY MODELING 
ABC proteins are widespread across all taxonomic groups [52]. Homology modeling is a useful 
strategy for structure-based drug design when no 3D structural information of P-gp at sufficient resolution 
is available. A major advance in our understanding of the structure and function of ABC transporters has 
come from the crystallization and determination of the structures of bacterial transporters [43]. The 
common feature of all ABC transporters, eukaryotic or prokaryotic, are the TMD, consisting of α-helices 
embedded in the membrane bilayer, and the NBD, located in the cytoplasm [53]. The structural 
architecture of ABC transporters consists, minimally, of  2 TMD and 2 NBD [54]. The TMD recognizes a 
variety of substrates and undergoes conformational changes to transport the substrate across the 
membrane and its sequence and architecture is variable. Structural studies of ABC transporters suggest 
that they possess similar large binding sites which may explain their broad substrate specificity and their 
unusual evolutionary relationships [55]. Since TMD are structurally diverse, some prokaryotic ABC 
transporters have varying number of helices (Table 1). The sequence of the NBD is more preserved 
among different species [55].  
Structures of prokaryotic ABC transporters have already provided valuable information on ABC 
pump structures and on the discovery of new P-gp hit compounds with inhibitory activity through 
structure-based drug design (Table 1). Sequence alignments between the prokaryotic template and P-gp 
target allowed the construction of atomic-resolution homology models, which permitted the design of P-
gp inhibitors [41]. They provided molecular detail on how these proteins recognize multiple substrates, 
and helped identify new MDR modulators. Moreover, photoaffinity labeling, cysteine scanning 
mutagenesis and the use of thiol probes have allowed the identification of the residues involved in the 
drug binding site located in TMD, which also helped in the validation of some of those models [34].  
E. coli‟s MsbA (Table 1, entry II), a lipid transporter from E. coli, catalyses the transfer of lipids 
across the cytoplasmic membrane. MsbA crystal structure revealed it as a homodimer adopting a cone 
shape. It exhibits a 30% homology with human P-gp [56] and is a suitable template for P-gp modeling, as 
it has a tertiary organization reflecting the accepted consensus NBD dimer interface and consistent with 
biochemical cross-linking data [34]. 
Eventually, the withdrawal of MsbA crystal structures proved a major setback to the field, 
requiring a reinterpretation of many key pieces of experimental data [57]. The corrected crystal structures 
of MsbA isolated from several different bacterial species [57] reveal the following three distinct 
conformations: an inward-facing nucleotide-free conformation, an outward-facing nucleotide-free and a 
nucleotide-bound form similar to the Sav1866 structure [58]. In the inward-facing form, the NBD are well 
separated and TMD are in contact only near the periplasmic surface of the membrane, creating a V-
shaped molecule. The large variations between the three structures suggest that substantial conformational 
changes may take place during the catalytic cycle of an ABC transporter [54]. The newly described 
structure of MsbA allowed its convenient use as a template for P-gp homology modeling in the following 
years [29, 30]. 
The crystal structure of the prokaryotic homologue Sav1866 (Table 1, entry III) provided a new 
opportunity for the construction of new P-gp models [58]. The two TMD form a chamber in the 
membrane which is open extracellularly (in the ATP bound state). The two NBD have an ATP-
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sandwiched dimer conformation [59]. The organization and pseudo-symmetrical arrangement of TMD on 
P-gp [6] correlates with the TMD arrangement of Sav1866, and the overall dimensions of the two 
transporters also correspond. Besides, P-gp possesses the same domain inter-linking motif as Sav1866, 
where P-gp intracellular loop 4 (ICL4) interacts with residues in NBD1 [60], strengthening the argument 
for Sav1866 use as a suitable template structure on which to model P-gp.  
BtuCD (Table 1, entry IV) is an ABC transporter for the uptake of vitamin B12 in E. coli [43] and 
is composed of two subunits. BtuCD has better resolved NBD but non-homologous TMD (20 TM 
segments compared to P-gp's 12) in its structure. In contrast to MsbA, the tertiary structure of BtuCD 
contains a parallel TMD:TMD interface [61]. Although biochemical evidence and structural data clearly 
show P-gp to be an asymmetric molecule, homology models of P-gp built using the crystallographic 
structures of  BtuCD as templates show a symmetric structure [6]. 
Maltose transporter MalFGK2 was also used as a template for homology modeling of the ATP-
binding site of P-gp [41]. Three-dimensional models of human P-gp NBD were also built by homology 
modeling using high-resolution ABC transporters TAP1 [47, 48], HisP [49], Mj0796 [34], HlyB [50] or 
Rad50 [34] (Table 1, entries VI-X) structures as templates, allowing interactions between NBD and 
ligands to be investigated using in silico docking studies, or using MD simulations to identify 
conformational changes in P-gp. 
The factors that determine the quality of a homology modeling study are the percentage of identity 
between the protein of interest and the template (which should be greater than 25-30 %), and the quality 
of the crystal structure used as the template. There are several ways for improving the accuracy of the 
sequence alignment, such as alignment with multiple templates. However, for the majority of 
transmembrane proteins the choice of template structures is a critical limitation. Unfortunately, templates 
differ from P-gp in structural organization. It must be noted that a homology model is an approximation 
of the structure and the exact positioning of the various domains may differ from the target. Comparison 
with experimental data may provide more reliable models. 
 
2. LIGAND-BASED DRUG DESIGN 
P-gp ligand-based drug design relies on knowledge of compounds that are known to inhibit that 
transporter and represents an useful CADD strategy when the structure of the target is not available [62]. 
Structure activity relationship (SAR) [63], quantitative structure-activity relationship (QSAR) [64], and 3-
dimensional quantitative structure activity relationship (3D-QSAR) [65], may be used to predict the 
activity of new analogs. A pharmacophore model [66] defines the minimal structural features a molecule 
must possess in order to bind to P-gp. These are the ligand-based strategies most frequently used. 
 
2.1. (Q)SAR STUDIES OF P-GP INHIBITORS 
The amount of literature involving the SAR of P-gp is huge, complex and dates back several 
decades. Since the discovery of verapamil as a MDR reversing agent in vincristine resistant P388 
leukaemia in vivo and in vitro [1], several SAR and QSAR studies (Table 2) were published by several 
workgroups. One of the first structure-activity relationship studies concerning MDR modulation was 
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performed in 1988 using a series of vinca alkaloids with diverse structures and properties. The authors 
concluded that lipidic solubility at pH 7.4 and the presence of the molecule in a protonated form were 
important features for MDR reversal activity [67] (Table 2, entry 1).  
 
Table 2. SAR and QSAR studies concerning P-gp-mediated MDR reversal 
Entry Compounds Method Conclusion 
1 
Several vinca alkaloids P-
gp modulators 
SAR 
Lipidic solubility at pH 7.4 and presence of a 
protonable group favour MDR reversal activity  
[67] 
2 
24 Structurally diverse 
substances and verapamil 
SAR 
Physicochemical properties, namely lipid 
solubility at physiological pH, cationic charge and 
molar refractivity, are important for anti-MDR 
activity of the studied modulators  [68] 
3 
Reserpine, yohimbine and 
nine derivatives 
SAR 
Benzoyl and especially a 3,4,5-trimethoxybenzoyl 
substituent, increased MDR modulating activity; 
two planar aromatic domains and a distant basic 
nitrogen also hypothesised as important for MDR 
reversing activity; lack of a correlation with logP  
[69] 
4 Series of dihydropyridines SAR 
Lipophilicity of the molecules was the main 
determinant for their MDR reversing activity  
[70] 
5 
Hundred MDR reversing 
compounds 
SAR 
Several parameters simultaneously account for 
anti-MDR activity, making it difficult to establish 
a direct relation of the obtained results to MDR 
activity  [71] 
6 
Series of phenothiazines 
and structurally similar 
drugs 
SAR 
A lipophilic electronegative group (Cl, CF3) in 
position 2 of the tricyclic ring system enhances 
anti-MDR activity, while a hydroxyl group 
decreases it; the tertiary amines are more potent 
than primary or secondary amines and the 
derivatives with a piperazine moiety are the most 
potent ones; N-methyl substituted piperazines are 
better than N-hydroxyethyl; activity increases 
with increasing chain length between the nitrogen 
and the tricyclic ring system  [72] 
7 
Phenothiazines and related 
drugs 
SAR 
Aromatic rings in P-gp are oriented by the α-helix 
conformation in such way as to overlap the π 
orbitals of the aromatic groups in the 
phenothiazines and thioxanthenes. The 
hydrophilic acidic residues in P-gp interact with 
the positively charged amino side of the drugs  
[72] 
8 
Drugs belonging to a wide 
variety of pharmacological 
classes as calcium channel 
blockers, neuroleptics, 
antiarythmics, 
antimalarials, 
antiestrogenes, 
antineoplastics and others 
SAR 
The active MDR reversing agents were both 
hydro- and lipophilic, protonable, and all had an 
aromatic structure and a basic amino alkyl group  
[73] 
  
9 
Eight compounds with 
different tricyclic ring 
systems without a basic 
side chain 
 
SAR 
Electronegativity of the heteroatom bound to the 
tricyclic ring system and the presence of a NH-
group  [74] 
                                               Annex 1i 
 199 
 
10 
232 Phenothiazines and 
related drugs 
SAR 
Among the potent reversers, many contained a 
carbonyl group, a feature not described by other 
authors. Other features were the lack of amino 
group, the presence of a carboxyl group, the 
presence of a single ring structure or the situation 
in which one or both rings are of the pyridine type  
[75, 76]  
11 
311 Structurally diverse 
compounds possessing two 
or more phenyl rings 
SAR 
Permanent charge as in quaternary amines 
abolished activity while high anti-MDR activity 
required the presence of two or three phenyl 
rings. The rings could be spatially close and 
connected by one alkyl bridge with a secondary or 
tertiary amine group or distant and connected by 
two alkyl chains (as in verapamil). The presence 
of a carbonyl group was found to increase anti-
MDR activity and/or a dimethoxyphenyl function 
was beneficial  [76] 
12 70 Derivatives of almitrine SAR 
The length of the spacer between the triazine ring 
and the lipophilic moiety was the most important 
for the reversal effect; a hydrophobic aromatic 
domain and two amine groups, one of which 
protonated at physiological pH were also 
important  [77] 
13 14 Verapamil analogs SAR 
No difference in MDR reversal activity when the 
methoxyl groups in the phenyl rings were 
replaced by chlorine, or when one phenyl ring 
was replaced by an alkyl chain. Replacement of 
the methoxyl groups by hydrogens slightly 
reduced activity  [78] 
14 Series of pesticides SAR 
Both inhibitors and substrates: at least one 6-
membered cyclic structure 
MW of the substrates > 399 and of the inhibitors 
> 247 
Log P of substrates < 2 
H-donor potential of substrates > 0.25 
Dipole moment of inhibitors > 3.3  [79] 
15 
24 Quinoline type 
compounds 
SAR 
In the hydrophobic moiety the aromatic rings 
were essential; the most active compounds 
possessed two aryl rings with a nonplanar 
arrangement (related to the possibility of π-
hydrogen-π interactions if hydrogen bond donors 
of P-gp were set between two deviated aromatic 
rings). Compounds with phenyl ring not 
substituted with chlorine or fluorine were more 
potent  [80] 
16 
Series included 
guanidinum and pyridinum 
derivatives 
SAR 
At least one aromatic moiety and certain degree 
of lipophilicity (log P > -1) were necessary for 
MDR activity  [81] 
17 
609 Compounds of diverse 
structures 
SAR 
Importance of a dialkyl-substituted amine; 
quaternary amines did not necessarily enhance 
activity; the arrangement of the alkyl groups 
appeared to affect the activity; molecules 
possessing a cis arrangement and a nitrogen in the 
ring were less often active than when at least one 
of the alkyl chains was acyclic  [82] 
18 22 Diverse drugs QSAR 
An inverse relationship was established between 
surface area and P-gp ATPase activity. The 
number of hydrogen bond acceptors and 
estimated strength of these were also found 
significant  [83] 
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19 
21 2-Chloro-10-substituted 
phenoxazines 
SAR 
Chlorine atom at position 2 and introduction of an 
alkyl side chain containing a tertiary amino group 
at a distance of at least three to four carbon atoms 
from the N10 are favourable for MDR activity  
[84] 
20 
Series of halogenated 
chalcones 
SAR 
Flavone-type compounds are assumed to interact 
with the ATP binding site and therefore are not 
transported by Pgp. Lipophilicity of the ring 
substituents was related with MDR reversal 
activity  [85] 
21 
59 
Tetrahydroisoquinolines 
and isoindolines 
SAR 
Electron donating alkoxy substituents on the two 
aromatic rings positively correlated with MDR 
reversal. Length of the linker connecting the two 
aromatic rings or the replacement of the cyano 
group by hydrogen did not affect MDR 
modulation  [86] 
22 
28 Flavonoid derivatives 
containing a N-
benzylpiperazine chain 
SAR 
Very hydrophilic compounds were inactive; 
position of hydroxyl groups affected MDR 
reversal [87] 
23 
100 Substrates/inhibitors 
obtained from the literature 
SAR 
Specific arrangements of hydrogen bonding 
moieties  [63] 
24 
Substrates and modulators 
as well as clinically 
promising MDR reversing 
agents 
QSAR 
MDR-reversal activity was correlated with the 
lipophilicity (LogP) and molecular weight (MW)  
[88] 
25 Diverse set of 22 drugs QSAR 
Activity related to molecular size and polarity  
[64] 
26 157 Phenothiazines QSAR 
Good correlation was obtained with descriptors 
that model molecular size and polarizability. 
Hydrogen bonding or hydrophobicity did not play 
a role in MDR reversal activity [64] 
27 
Diverse set of P-gp 
modulators 
QSAR 
A highly effective P-gp modulator candidate 
should possess a log P value of 2.92 or higher, 18-
atom-long or longer molecular axis, and a high 
Ehomo value, as well as at least one tertiary basic 
nitrogen atom  [89] 
28 Jatrophane polyesters SAR 
P-gp inhibitory activity increases with 
lipophilicity. The substitution patterns affects 
MDR reversal activity  [90] 
29 
5,7,3',4',5'-
Pentamethoxyflavone 
(PMF) and derivatives 
SAR 
Methoxyl derivatives and numbers or positions 
are more important than their hydroxylated 
counterparts in chemosensitization  [91] 
30 
78 Inhibitors from the 
literature 
QSAR 
Mean values of number of hydrogen bond 
acceptors and donors of 1.7 and 6.7, respectively, 
were found for inhibitors. Substrates tend to have 
a higher number of H-bonds than inhibitors [92] 
31 
Series of N-acyloxy-1,4-
dihydropyridines  
SAR 
Methoxyl groups within the phenyl moiety lead to 
highest activity; regiospecific effects on the 
observed activities indicated a conserved 
interaction between P-gp inhibitor function and P-
gp binding region  [93] 
32 
 
3,9-Diazatetraasteranes 
with varied aromatic 
substitution patterns  
 
SAR 
Increased lipophilicity was found favourable. 
Highest activities were found for meta substituted 
compounds (regiosensitivity of the potential P-gp 
binding site)  [94] 
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33 New pyranocoumarins SAR 
The co-existence of 3- and 4-methoxyl groups 
remarkably enhanced the Pgp-inhibitory activity; 
the lone existence of the 4-methoxyl group 
reduced the activity  [95] 
34 
Dataset of the Prestwick 
Chemical (library retrieved 
from PubMed) 
QSAR Lipophilicity influences P-gp modulation  [96] 
35 
Library of flavonoid 
homodimers and 
heterodimers  
SAR 
Flavonoid dimers with nonpolar and hydrophobic 
substituents (methyl and ethyl groups) were more 
potent MDR reversers than dimers with polar and 
hydrophilic substituents (hydroxy groups). 
Bulkier substituents lead to lower reversing 
activity  [97] 
36 22 Flavonoids  SAR 
Structural units of B-ring-3‟-OH group, B-ring-
4‟-OH group, C3-ring (or structural skeleton of 
isoflavones), and logD negatively contributed to 
the modulation effect of flavonoids on P-gp 
activity, while the A-ring-7-OH group tended to 
enhance their inhibitory effects  [98] 
37 772 Diverse compounds QSAR 
Hydrophobic surface area, LogP, and descriptors 
of size (such as molecular surface), flexibility, 
hydrophilic volume, distance between two 
hydrophobic atoms and one hydrogen bond 
acceptor atom were important for P-gp inhibitory 
activity  [99] 
 
SAR studies examine empirically how structural alterations of individual molecules (with 
concomitant alteration of physicochemical features) influence their ability to inhibit P-gp. On the other 
hand, QSAR studies quantify the observed relationship between molecular descriptors and activity. 
QSAR relates numerical properties of the molecular structure to its activity via a mathematical model 
[100]. A structure-activity relationship study can help to establish which features are implied in the 
activity and help to orient the synthesis towards the structural modifications which would enhance the 
activity. The major achievements concerning P-gp inhibition (Q)SAR studies from 1988 until now are 
presented in Table 2.  
MDR modulation is a complex process and many different pathways can contribute to it. Besides, 
until now, there has not been a complete understanding of the molecular mechanisms involved in P-gp 
inhibition. These facts raise some problems on QSAR studies of P-gp modulators [101]. For more than 
two decades QSAR studies have been one of the rational approaches to understand the binding affinities 
of several classes of compounds towards P-gp. Multiple linear regression, principal component 
regression, and partial-least square regression are frequently used statistical methods [102]. 
Several critical assumptions can influence the validity and correctness of any QSAR study. For 
example, the molecules under study must act through the same mechanism, must share the same binding 
mode to P-gp and biological results must efficiently correlate the biological activity with the binding 
affinities [103]. Meeting these assumptions ensures that proper and reliable relationships are obtained. 
Besides, most QSAR studies deal with a limited number of molecules (Table 2, entries 1, 2-7, 9, 13, 16, 
20, 28, 31-33), and few published studies give activities for sets of compounds with sufficient molecular 
diversity [104]. Therefore, although useful in the process of compound development, QSAR studies are 
not always applicable to other structural series. 
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In some cases simple molecular descriptors such as partitioning coefficients or molecular weight 
and simple models such as multiple linear regressions can establish a QSAR. However, in other 
situations, complex molecular descriptors and methods like artificial neural networks and genetic 
algorithms are needed to establish a relationship between structure and P-gp inhibitory activity [105]. 
Although many studies provide data (Table 2) that could be used to develop (Q)SAR, this data is 
often not directly comparable. Literature is replete with examples of several types of biological activity 
data, such as: cell growth; efflux assays; direct effects on membrane properties; effects on rates of 
transport; levels of ATPase activity; and many others. Important issues that need to be considered 
include: the underlying mechanism probed by the assay; binding site; cell line; approach used to induce 
expression of P-gp; membrane partition coefficients; and permeation rates of the individual compounds 
[106]. The measured compound‟s effect on P-gp activity does not necessarily correlate with its “binding” 
affinity to P-gp, and it has not been established that binding must confer activity, which makes data 
analysis even more complex [89]. Moreover, assays might target different mechanisms of action 
(competition with a substrate, inhibition of the ATPase function, or blockage of the transporter). Even if 
the same mechanism is targeted by an assay, results could differ.  Nonetheless, MDR reversal effects of 
the same compounds in different cell lines, or in similar cell lines from different species, and the use of 
different cytotoxic agents can lead to different results [107]. Biological results should be carefully 
assessed before being used in an SAR study. 
Let us focus on the descriptors that are frequently used in (Q)SAR studies (Table 2). LogP of the 
compound or lipophilicity of substituents appears in several SAR (Table 2, entry 1, 2, 4, 6, 12, 14-16, 20, 
22, 24, 27, 28, 32, 34-37). However, different approaches and programs were used to calculate these 
values. Molecular weight (Table 2, entry 14, 24-27), number of H-bond donors and acceptors (Table 2, 
entry 14, 18, 21, 23, 30, 37), number or aromatic rings (Table 2, entry 7, 10, 15, 21), cationic charge 
(Table 2, entry 1, 2, 8), such as a protonable amine (Table 2, entry 3, 6, 8, 9, 12, 17, 2), and type and 
position of substituents (Table 2, entry 6, 10, 11, 17, 19, 21, 29, 31-33, 36) are described as being implied 
in P-gp inhibition. 
 
2.2. 3D-QSAR 
3D-QSAR refers to the application of molecular field calculations requiring 3D structures. It 
examines the steric fields (shape of the molecule) and the electrostatic fields based upon an energy 
function, correlating them to P-gp inhibitory activity of the compounds [65, 108]. A comparative 
molecular field analysis (CoMFA) and a comparative molecular similarity index analysis (CoMSIA) are 
the most frequent 3D-QSAR algorithms [109]. Examples of 3D-QSAR are listed in Table 3. In 1997, the 
first 3D-QSAR analysis using structurally related thioxanthenes, was performed [110] (Table 3, entry 1). 
Results show that the 3D location of electrostatic and steric fields, as well as lipophilic and hydrophilic 
regions, in both enantiomers coincides with the presence of certain groups already described in section 
2.1. such as tertiary nitrogen atoms, aromatic rings, H-bond donors and acceptors which influence the P-
gp inhibition activity.   
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Table 3. 3D-QSAR studies concerning P-gp-mediated MDR reversal 
Entry 
Molecules 3D-QSAR 
method 
Result 
1 
Thioxanthene 
analogs 
CoMFA 
Electrostatic, hydrophobic and lipophilic fields of enantiomers are 
differently positioned in the 3D space, which justifies the different P-
gp modulatory activity  [110]. 
2 
Phenothiazines 
and related drugs 
CoMFA 
Best models either with hydrophobic fields alone or in combination 
with steric and electrostatic fields pointing to hydrophobicity as a 
property of primary importance  [111]. 
3 46 Imidazoles  
CoMFA 
and 
CoMSIA 
A large substituent on the imidazole ring is not favoured for 
improving MDR modulating potency  [65]. 
 
4 
Dihydro-β-
agarofuran 
sesquiterpene 
derivatives 
CoMSIA 
Provided information on hydrogen bond donor and acceptor 
requirements of sesquiterepenes; substituents at the C-2 position act 
as hydrogen bond acceptor; the oxygen of the furan ring seems to 
form a hydrogen bond with the receptor  [112]. 
 
5 
32 Natural and 
synthetic 
coumarins  
CoMFA 
Favorable electrostatic and steric volumes, like the α-
(hydroxyisopropyl)dihydrofuran moiety, beside C(5)-C(6) or C(7)-
C(8) positions. An important hydrophobic, neutral charge group, like 
phenyl, in position C(4) on the coumarinic ring  [113]. 
6 
76 Dihydro-β-
agarofuran 
sesquiterpenes 
CoMSIA 
The most important features are the substituents at the C-2, C-3, and 
C-8 positions, which seem to be critical for determining the overall 
effectiveness of sesquiterpenes as P-gp inhibitors  [114]. 
7 
24 Structurally 
related 
derivatives of 
tariquidar  
CoMFA 
and 
CoMSIA 
3D-QSAR with an internal predictive squared correlation coefficient 
higher than 0.8; included electrostatic, steric, hydrogen bond 
acceptor, and hydrophobic fields.  
The best single field model was the electrostatic one, followed by the 
steric and hydrophobic. The combination of the electrostatic with the 
steric, hydrophobic, and acceptor indices yields the models with best 
statistical characteristics [115]. 
8 
Third generation 
MDR modulators 
CoMFA 
Presence of tertiary nitrogen, a central phenyl ring and an aromatic 
dimethoxy group contributed to the inhibitory effect  [116]. 
9 41 flavones 
CoMFA 
and 
CoMSIA 
Hydrophobic and steric parameters are important for P-gp inhibitory 
activity  [117]. 
 
 
2.3. PHARMACOPHORE MODELING 
Pharmacophore is an abstract description of molecular features which are necessary for molecular 
recognition of a ligand by a biological macromolecule. The first attempt to characterize important 
pharmacophore features for P-gp modulation was performed by Seelig in 1998. Seelig suggested a 
pharmacophore based on specific arrangements of electron-donor groups [118] (Table 4, entry 1).  
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Considering that the P-gp protein accommodates a variety of compounds with different structures, 
and their binding sites and modes are not well known, it is not surprising that a consensus set of features 
may not exist. Several pharmacophore models (Table 4) have been described in the literature to retrieve 
P-gp inhibitors with considerable accuracy [66, 121, 127]. However, as for the (Q)SAR studies, most of 
the pharmacophore models are limited to a small number of compounds and do not directly define the P-
gp binding site for which they are directed [106]. 
Regarding pharmacophore features, the presence of one or two hydrophobic centres, including one 
or two aromatic rings, one to three H-bond acceptors (oxygen in an amide, hydroxyl or carbonyl group), 
and/or one H-bond donor (H in an amine or hydroxyl group) are hypothesized as being the most relevant 
for P-gp inhibition (Table 4). Features may vary due to the different compound training sets, biological 
assays and software used.  
A distinction between competitive and noncompetitive P-gp inhibitors has been achieved by our 
group, using in vitro ATPase results obtained for thioxanthonic derivatives [42] and several commercially 
available drugs [124] obtained using the same protocol and the same conditions (see Experimental 
Section for details). The compounds used in the modelling included two groups: twenty two compounds 
found to be noncompetitive inhibitors by the P-gp ATPase assay, and nineteen compounds found to be 
competitive inhibitors by the P-gp ATPase assay  [42, 124]. The generated Catalyst HypoGen models 
were evaluated in terms of cost functions and statistical parameters, which were calculated by HypoGen 
module during hypothesis generation. The best pharmacophore models for each activity are represented 
on Fig. 1 and Fig. 2. 
The chosen pharmacophore for P-gp noncompetitive inhibition (Pharmacophore I, Fig. 1A) is 
characterized by the lowest total cost value (88.12), the lowest RMSD (0.551), and the best correlation 
coefficient (0.686), contains four features, namely, two hydrophobic (H) regions, one aromatic ring (Ar) 
and one positive ionizable group (PI) which were intercalated with each other. The fixed cost and null 
cost are 75.65 and 116.85 bits, respectively. Using the centre of the positive ion interaction site (PI) as the 
origin, the distances to the centre the hydrophobic region sites are ~7.3Å (H1) and ~8.4 Å (H2), and the 
distances to the centre the aromatic ring feature is ~5.4Å (AR). Using the same approach, the distance 
between the two hydrophobic regions is ~7.9 Å. Region AR can be viewed as lying in between the two 
hydrophobic regions, and the positive interaction site (PI) locates in a farther place. Amoxapine, a 
previously described P-gp noncompetitive inhibitor [124], was able to superimpose the four-feature 
pharmacophore model (Fig. 1B). 
The chosen pharmacophore for P-gp competitive inhibition (pharmacophore II, Fig. 2A) is 
characterized by the lowest total cost value (77.19), the lowest RMSD (0.604), and the best correlation 
coefficient (0.742), contains three features, namely, two hydrophobic (H) regions and one hydrogen 
acceptor group which is intercalated with the other two features. The fixed cost and null cost are 69.74 
and 112.93 bits, respectively. Using the centre of the hydrogen acceptor group as the origin, the distances 
to the centre the hydrophobic region sites are ~7.2 Å (H‟1) and ~3.4 Å (H‟2) and, the distance between 
the two hydrophobic regions is ~8.2 Å. A thioxanthonic P-gp competitive inhibitor 1-(5-amino-3,4-
dihydroisoquinolin-2(1H)-yl)-4-propoxy-9H-thioxanthen-9-one [42], is fit on the pharmacophore as 
example (Fig. 2B).  
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There is an almost perfect superimposition between the H1 and H2 from the pharmacophore I, and 
H‟1 and H‟2 from the pharmacophore II. The major discrepancy occurred in the remaining features, PI and 
Ar from pharmacophore I and HAc from pharmacophore II that cannot be aligned. 
 
 
Fig. (1). A) The pharmacophore model for P-gp noncompetitive inhibitors (Pharmacophore I) 
generated by Hypogen in which the red sphere represents a positive ion interaction site (PI), the blue 
spheres represent hydrophobic interaction sites (H1 and H2) and the orange sphere represent an aromatic 
ring (Ar). B) Amoxapine fit to pharmacophore [124].  
 
 
Fig. (2).  A) The pharmacophore model for P-gp competitive inhibitors (Pharmacophore II) generated 
by Hypogen in which the blue spheres represent hydrophobic interaction sites (H‟1 and H‟2) and the green 
sphere represent an hydrogen acceptor site (HAc). B) Thioxanthonic derivative fit to pharmacophore [42].  
 
Despite all the progress that has been made in the field of pharmacophore construction, the 
establishment of a consensus pharmacophore for P-gp inhibition has not been achieved so far. These 
studies have helped to unveil the pharmacophore features responsible for biological activity. However, as 
data continues to increase, a more detailed understanding of the P-gp structure allows a better 
understanding of the causes for the variability in the biological results available nowadays.  
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3. IMPORTANT P-GP INHIBITORS DESCRIPTORS / FEATURES 
Summarizing the results of the above reviewed studies, one can postulate several structural 
requirements for compounds involved in P-gp associated MDR reversal. The molecular descriptors that 
have been used to describe the properties of P-gp modulators can range from simple constitutional 
descriptors like number of atoms, bonds or rings, functional group descriptors such as number of H-bond 
acceptors and donors and amine groups, molecular property descriptors such as logP, to 3D features or 
more complex quantum chemical descriptors that describe the electrostatic and electronic properties of 
the molecule. 
No general, valid common structural pattern can be formulated. The MDR modulators are so 
structurally diverse that it is difficult to identify the common structural elements they share. It should be 
noted that many of the descriptors used are correlated to each other. For example, molecular weight, 
surface area and volume are all related. For drug molecules, lipophilicity tends to increase with size. 
Lipophilicity and the number of H-bond donors and acceptors would be expected to correlate inversely. 
In general, substrates have a lower logP than the inhibitors, some of them relatively hydrophilic 
too. Many studies have found that the H-bond acceptor groups are important elements of P-gp substrate 
recognition [89]. P-gp inhibitors act predominantly as H-bond donors rather than H-bond acceptors [79]. 
Substrate binding and P-gp activation increase with the number of H-bond acceptor units [63]. 
Steric or shape complementarity between the ligand and receptor has always been thought as an 
important factor for effective drug-receptor interactions. The most elemental characterization of the 
molecular size, the molecular weight, MW, shows that small molecules (MW < 250 g.mol
-1
) have less 
probability of being P-gp substrates and inhibitors. The range of appropriate MW varies from about 250 
to 2000 g.mol
-1
 [128], and it can be further reduced to 250 - 500 g.mol
-1
  when considering Lipinski‟s 
rules [129]. 
P-gp modulators display lipid solubility at physiological pH, planar appearance, and cationic 
charge usually in a nitrogen-containing cyclic ring [68]. These features were described more than two 
decades ago and are still used in drug development. A more recent set of criteria was described for P-gp 
modulators (Fig. 3):  
(i) the molecule should have a logP value of at least 2.92 or higher, to permit hydrophobic/van der 
Waals interactions [14, 89];  
(ii) the molecule should have a long chain (18 atoms or higher) to cover more than one P-gp unit, 
and strengthen the binding [14, 89];  
(iii) the molecule should establish hydrogen bonds with P-gp [14, 89];  
(iv) a promising P-gp modulator should have at least one tertiary nitrogen atom [14, 89], so as to 
form a cation at physiological pH value, and to strengthen the binding through ionic/ H-bonds with P-gp. 
Although some compounds without a tertiary nitrogen atom also exhibit P-gp inhibitory activity, it is 
indispensable for highly efficient P-gp modulators to have this important structural feature [89].  
(v) P-gp inhibitors would have high EHOMO (highest occupied molecular orbital energy) [130]. 
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Fig. (3). Example of a third generation P-gp inhibitor (tariquidar) and the features described as being 
important for P-gp modulation: (i) Log P of at least 2.92, (ii) chain of more than 18 atoms, (iii) sites for 
the establishment of hydrogen bonds, (iv) a tertiary nitrogen atom. 
 
In spite of all the molecular modeling studies performed, it would be important that each new 
pharmacophore or QSAR study could be compared to those previously described, so that identical or 
similar features or descriptors could be identified. Many types of descriptors have been applied in these 
studies but a general correlation is elusive. It is disappointing that to date there has been no success in 
establishing the conclusive structure activity relationships for inhibitory activities of P-gp interacting 
substances. 
 
CONCLUSION 
Although P-gp inhibitors have been known to exist for 30 years [1], the understanding of the 
molecular basis of interaction between those compounds and the efflux pump is still scarce, which is 
mainly due to the lack of structural information available. However, over the past decade X-ray structures 
of several bacterial homologues as well as the very recent structure of mice P-gp have become available 
[5, 131]. Emerging homology models have allowed researchers to envisage how P-gp may interact with 
its inhibitors. In general, the results from the combined pharmacophore, docking and 3D QSAR modeling 
studies correspond and complement each other in revealing important structural features and could be 
helpful for the development of highly selective and potent P-gp inhibitors [123]. The combination of 
these structure and ligand-based studies with experimental data will play a crucial role in the near future. 
Many of the experimental techniques like photoaffinity studies and cysteine scanning mutagenesis [132] 
provide important results that complement the computational results, providing useful insights into the 
different inhibition-binding sites of P-gp.  
 
 
 
                                               Annex 1i 
 215 
 
 Experimental Section 
Pharmacophore hypothesis. Two 3D-pharmacophoric model were created using HypoGen module of 
Catalyst program [133, 134] according to the results obtained in the ATPase assay for twenty three 
noncompetitive and for nineteen competitive inhibitors both newly synthetized thioxanthonic derivatives 
and commercial drugs previously described  [42, 124]. For each molecule the number of conformers 
generated using the „best‟ functionality for each inhibitor was limited to a maximum number of 255 (with 
an energy range of 20 kJ.mol
-1
). Ten hypotheses were generated using these conformers for the twenty 
three or nineteen inhibitors and the % values of RLU related to ATPase activity. The feature groups 
selected were hydrogen bond (Hb)-donor and -acceptor, hydrophobic, aromatic, positive ionizable, and 
remaining default parameters. After assessing all ten hypotheses generated, the lowest energy-cost 
hypothesis was considered the best, because it possessed features representative of all the hypothesis. A 
good pharmacophore model should have a high correlation coefficient, lowest total cost and RMSD 
values, and the total cost should be close to the fixed cost and away from the null cost. The two 
pharmacophores are aligned by comparison analysis. The analysis uses the Catalyst Compare/fit 
algorithm to map and align two pharmacophores. Validation of the best pharmacophore for each activity 
was performed using an enrichment test with 1000 decoy molecules from National Cancer Institute (NCI) 
and eleven know P-gp inhibitors. These test molecules were fit by the FAST-fit algorithm to the 
Catalyst™ model and fitting values of decoys and known inhibitors were graphically analysed (not 
shown).  
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Abstract 
Our research group has been focusing in the discovery of potential antitumour small molecules based on 
the xanthone scaffold. However, a serious obstacle in the field of cancer therapy is the multidrug 
resistance (MDR) phenotype, most often caused by the overexpression of P-glycoprotein (P-gp). Another 
limitation to their development as drug candidates is the reduced information available about the 
bioavailability and pharmacokinetics of these compounds. We have previously identified four interesting 
compounds as inhibitors of tumor cell growth namely two dihydroxyxanthones (1-2), a xanthonolignoid 
(3) and a pyranoxanthone (4). Based on these considerations, it was our aim to: i) investigate their effect 
on the P-gp activity; and ii) estimate their intestinal absorption using Caco-2 cell monolayers as an 
intestinal model. 
According to a drug efflux cytometry assay, compounds 3 and 4 were found to increase the accumulation 
of Rh123 in K562Dox cells (from a leukaemia cell line which overexpresses P-gp), indicating that they 
may inhibit P-gp activity. On the other hand, compound 2 showed compatible effect with P-gp activation, 
decreasing the intracellular accumulation of rhodamine 123 (Rh123). In an attempt to understand the 
molecular mechanism involved in P-gp inhibition, a luminescence assay involving ATPase activity was 
performed and results indicated that both compounds 3 and 4 act by noncompetitive inhibition of P-gp. 
HPLC/DAD analysis from the in vitro permeation assay with Caco-2 cells monolayer showed that 
transport of xanthones 1-4 occurred in the absorptive direction (apparent permeability values, Papp, 
0.012-2.8 nm/s).  
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In conclusion, the behavior of compounds 3 and 4 as P-gp inhibitors and their high apparent permeability 
coefficients which are suggestive of potential oral bioavailability make them promising hit compounds to 
pursuit with further studies. 
 
Keywords: xanthones, antitumour, P-glycoprotein, permeability 
 
Introduction 
The xanthone structure is a very interesting scaffold for different groups in different positions leading 
to a large variety of pharmacological activities [1].
 
In our research group we have been particularly 
interested in xanthone derivatives with diverse substituents such as hydroxyl, lignoid, and prenyl as 
growth inhibitors of tumour cell lines [2-5] and as PKC modulators [6-8]. Although we can find several 
studies concerning the multiple biological activities of xanthones and their derivatives, there is little 
information available about their bioavailability and pharmacokinetics. The studies available concern 
mostly DMXAA, a xanthonic acetic acid derivative which has reached clinical trials [9].  
We were particularly interested in studying hit compounds inhibitors of tumour cell growth, such as 
simple oxygenated xanthones (1,2-dihydroxyxanthone (1) and 3,4-dihydroxyxanthone (2)), the 
xanthonolignoid (±)-trans-kielcorin C (3) and a prenylated derivative 12-hydroxy-4,4-dimethyl-3,4-
dihidropyrano[3,2-b]xanthone (4). Compounds 1-4 (Fig. 1) are particularly interesting regarding their 
demonstrated inhibitory effect against several human tumour cell lines, namely melanoma, breast 
adenocarcinoma [3, 4, 10], and leukaemia [2]. Previous studies by some of us suggested that compounds 
1-3 may act, at least in part, by interaction with protein kinase C (PKC), causing effects compatible not 
only with PKC activation (compound 1) [6] but also with PKC inhibition (compounds 2 and 3) [6, 7] and 
compound 4 was found to decreased cell proliferation, induced an S-phase cell cycle arrest, and increased 
the percentage of apoptotic cells which was confirmed by an appropriate response at the protein level 
(e.g. PARP cleavage) [2]. Additionally, compound 4 was found to enhance the anti-estrogenic effect of 4-
hydroxytamoxifen in a breast adenocarcinoma cell line (MCF-7 ER(+))[10]. 
 
 
Fig. 1. Representative scheme of the strategy followed on the investigation of xanthonic derivatives 1-4.  
 
Multidrug resistance (MDR) is a serious obstacle to cancer therapy. Indeed, although enormous 
progress has been made in the field of cancer therapy, only approximately 50 % of all cancers are 
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susceptible to chemotherapy and of these, more than 50 % rapidly develop drug resistance [11]. Most 
often, the MDR phenotype found is caused by the overexpression of P-glycoprotein (P-gp), a membrane-
bound efflux pump which transports a wide variety of anticancer agents out of the tumour cells [12]. 
From a pharmacological aspect, P-gp function may be modulated as a result of 
competitive/noncompetitive antagonism, interference with ATP binding/hydrolysis /coupling or by 
altering the drug/membrane interaction [13]. The mechanism of action ranges from direct binding to P-gp 
and depressing ATPase activity to inhibiting protein kinase C (PKC) [13]. Most chemosensitizers can be 
classified into several broadly defined groups such as calcium channel blockers, calmodulin antagonists, 
PKC inhibitors, steroids or hormonal analogs [14] and also flavonoids [15] and xanthones [16, 17]. 
Although the P-glycoprotein (P-gp) modulatory activity of this group of compounds is already 
documented for prenylated and lignoid derivatives [16], there is no information concerning xanthones 
which are known inhibitors of tumour cell lines. 
As a large portion of early pipeline dropouts occur due to toxicity, poor pharmacokinetic 
characteristics, and suboptimal absorption, distribution, metabolism and excretion (ADME) properties, 
increasing attention has been given to optimizing compounds earlier in the process [18]. The study of 
ADME and pharmacokinetics (PK) has developed into a relatively mature discipline in drug discovery, 
through the application of well-established in vitro and in vivo methodologies [19]. Moreover, anticancer 
drugs have to cross many layers of cells and the extracellular matrix in order to reach and enter the 
tumour cells, and elicit their pharmacological action. Therefore, it is essential to determine if the drug is 
able to be absorbed by the intestinal epithelium cells and particularly the enterocytes, in order to 
understand if oral administration will be possible [9]. 
Based on these considerations, we decided to investigate herein the effect of these xanthonic 
derivatives (1-4) in the accumulation of rhodamine 123 (Rh123) in a leukaemia cell line overexpressing 
P-gp, the K562Dox cell line. Additionally, the P-gp‟s ATP hydrolysis assay was also used, to distinguish 
between noncompetitive and competitive inhibitors of P-gp [20]. 
The Caco-2 cells represent a well-known and interesting in vitro model for enterocytes and have been 
used in several in vitro bioavailability assays to evaluate the intestinal absorption rate of a broad range of 
molecules and drugs. To investigate the intestinal absorption of compounds 1-4, we developed a 
quantitative method by HPLC-UV  [21], which allows the determination of the exact amount of 
compound that passes through the membrane of Caco-2 intestinal cells, translating the permeability of 
those cells to the compound that was being tested. The strategy followed in this work is schematized in 
Fig. 1. 
 
 
Material 
Compounds 
Verapamil and Rh123 were obtained from Sigma-Aldrich. The synthesis of compounds 1-4 was 
published elsewhere [2-4]. 
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Cell culture 
K562 (human chronic myelogenous leukaemia, erythroblastic), and K562-Dox (a kind gift of 
Professor J. P. Marie, France, who previously obtained these P-gp overexpressing cells from K562 cells) 
cell lines were routinely maintained in RPMI-1640 (with Hepes and Glutamax, Gibco), with 10 % fetal 
bovine serum (FBS, Gibco) and incubated in a humidified incubator at 37 ºC with 5 % CO2 in air. All 
experiments were performed with cells in exponential growth and repeated at least three times. K562-Dox 
cells were treated with 1 µM doxorubicin every two weeks and all experiments were performed at least 
four days after this administration and in doxorubicin-free medium. 
Human colon adenocarcinoma Caco-2 cells, obtained from the American Type Culture Collection, 
were cultured in high Dulbecco‟s Modified Eagle‟s Medium (DMEM) supplemented with 10% fetal 
bovine serum, 1% (v/v) non-essential amino-acids, 1% L-glutamine, 100 U/mL penicillin, and 100 μg/mL 
of streptomycin. All cells were grown to confluence at 37
o
C in a humidified atmosphere of 5% CO2-95% 
air and 90% relative humidity. The medium was replaced every two to three days. Cell stocks were 
cultured in flasks and passaged weekly using trypsin (0.25% w/v)-EDTA (0.2% w/v) solution. 
For permeability experiments, Caco-2 were seeded onto polyester Transwell® filters at a seeding 
density of 1.0 × 10
5
 cell/cm
2
 (4.2 x 10
5
 cell/well). Transepithelial electrical resistance (TEER) of the 
Caco-2 cell monolayers on the Transwell® insert filters was measured using an epithelial voltohmmeter 
(EVOM) and were cultured for 21–22 days before the initiation of an experiment. 
 
Drug Accumulation Assay 
K562 and K562Dox (5 x l0
6 
cells/mL) were incubated for 1 h at 37°C in the presence of 10 or 20µM 
of the test compounds, and with 1µM Rh123. Controls included K562Dox cells and K562 cells alone, as 
well as K562Dox in the presence of a known P-gp inhibitor verapamil (10 or 20 µM). After incubation 
with compounds, cells were washed twice, ressuspended in ice cold PBS and kept at 4ºC in the dark until 
analysis in the flow cytometer. At least 20 000 cells per sample were counted and analyzed by flow 
cytometry (Epics XL-MCL, Coulter). Cells shown in forward scatter and side scatter were electronically 
gated and acquired through the FL1 channel. The amount of fluorescence was plotted as a histogram of 
FL1 within the gate. Data acquisition was performed using WINMDI (version 2.9) to determine median 
fluorescence intensity values. For simple interpretation, the rate of accumulation was calculated as 
(MFIK562Dox+Drug - MFIK562Dox)/MFIK562Dox. Results represent the mean of at least three independent 
experiments. 
 
Determination of ATPase activity 
The ATPase activity of P-gp was determined using the luminescent ATP detection kit (P-gp-Glo 
Assay Kit, Promega, Madison, WI) according to the manufacturers‟ recommendation [22]. Test 
compounds at 200µM or sodium vanadate (Na3VO4) at 20µM (positive control, noncompetitive inhibitor) 
or verapamil at 200µM (negative control, competitive inhibitor) in buffer solution were incubated with 
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0.5 mg/mL P-gp and 5 mM MgATP at 37°C for exactly 40 min, and the remaining ATP was detected as a 
luciferase-generated luminescent signal after 20 min resting at room temperature. Basal P-gp ATPase 
activity was determined as the difference between the ATP hydrolysis in the presence or absence of 
Na3VO4. Results are presented as average of three independent experiments. Percentage of luminescence 
(%lum) was calculated in relation to non-treated control (NT) for easier interpretation, using the formula: 
%lum = (lumtest -lumNT) / lumNT  x 100. 
 
Cell permeability assay 
Briefly, the cell monolayers were washed three times at 37°C with Hank's Buffered Salt Solution 
(HBSS) at pH 7.4. The cell monolayers were incubated with this buffer for 1 h and the incubation 
medium was then aspirated. Afterward, the test compound (100μM) was added to one side of the 
monolayer while HBSS was placed on the receiver chamber and the amounts of compounds 
transepithelial transport were followed as a function of time. Transport studies were conducted in the 
absorptive direction [apical (AP)  basolateral (BL)]. Donor and receiver samples (100μL) were taken at 
time 15, 30, 60, and 120 minutes, for compounds 1-4. The integrity of the monolayer was monitored 
routinely over the experiment period by measuring TEER. TEER values were higher than 200 cm2 
throughout the permeation studies indicating the viability of Caco-2 cells during the study.  
All the samples were stored at 4ºC until analyzed. Afterward, the supernatant was analyzed by HPLC-
UV. Three independent experiments were performed. 
 
 
Calculations and statistics 
Permeability values were estimated by calculating Papp (cm/s) according to the following equation: 
Papp= S · (1/A · Co), where Co is the initial concentration in the donor chamber (100μM), A is the surface 
area of the monolayer (4.2cm
2
) and S is the slope (nmol/s) of appearance of the test compounds on the 
receiver side. The permeability ratio was determined according to: Papp APBL/ Papp BLAP, where 
Papp APBL and Papp BLAP are the APBL and BLAP permeability values. The mass balance, 
expressed as the recovery percentage (R%), was evaluated by the equation: R% = 100 · [C tf
R
 · V
R
 + Ctf
D
 · 
V
D
] / [Cti
D
 · V
D
] where Ctf
R
 and Ctf
D
 are the concentrations measured at the end of the assay in the 
receiver and donor chambers, respectively; Cti
D
 is the concentration in the donor chamber at ti (0 
minutes); V
R
 and V
D
 are the volumes of the receiver and donor chambers, respectively. 
Data was expressed as the mean ± SE and analyzed by the Student‟s t test. P-values below 0.05 
considered statistically significant. 
 
HPLC quantification method 
Methanol and acetonitrile were of HPLC grade from Merck. HPLC ultrapure water was generated by 
a Milli-Q system (Millipore, Bedford, MA, USA). The phosphate buffer solution used for the preparation 
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of standard solutions of compounds 1-4 was composed of 10mM potassium dihydrogen phosphate, 
adjusted to pH 7.4 with 10M potassium hydroxide solution. The phosphate buffer solution used for the 
development of the HPLC quantification method for compound 1 was composed of 10mM potassium 
dihydrogen phosphate, adjusted to pH 7.4 with 10M potassium hydroxide solution and then added with 
25mM TBA. The mobile phases were degassed for 15 min in an ultrasonic bath before use.  
Standard solutions were obtained by the dilution of 10mM stock solutions (in DMSO) with phosphate 
buffer to five different concentrations over the range of interest: 10, 25, 50, 75 and 100μM for compounds 
1-4. 
The chromatograph used was an 880 PU (Jasco, Japan) equipped with an 875-UV detector (Jasco, 
Japan), a Rheodyne 7125 injector and the CSW 1.7 integrator was the software employed. Analysis was 
performed at 25
o
C on a C-18 Nucleosil column (5 μm, 250x4.6 mm I.D.), from Macherey-Nagel (Düren, 
Germany). Quantifications of xanthone derivatives 1-4 were performed in isocratic work at a flow rate of 
1 mL/min with detection at 237nm for compounds 1, 2, and 3 and at 254nm for compound 4. The sample 
injection volume was 20μL. For compounds 1 and 4 separation was achieved with methanol in water 
(80:20), for compound 2 with methanol in water (70:30) and for compound 3 with methanol in water 
(85:15). The retention factor (k) was determined as [k = (tr-t0)/t0] where tr is the retention time of the 
analyte eluted. The column void time (t0) was considered to be equal to the peak of the solvent front and 
was taken from each particular run. 
 
Results and Discussion 
The determination of P-gp activity is possible by measuring the mean fluorescence intensity of cells 
treated concomitantly with Rh123, a known fluorescent P-gp substrate, and the potential P-gp inhibitor 
[23]. This is a simple and fast approach, although indirect. Compounds that enhance the intracellular 
retention of the probe (Rh123) are considered as P-gp inhibitors, because they interfere with the extrusion 
of the marker. On the other hand, compounds that decrease the retention of the probe (compared to 
control) are considered as P-gp activators [24]. 
The intracellular accumulation of this fluorescent probe was measured and its accumulation ratio 
was calculated for interpretation of the results. The results of the effect of compounds 1-4 on the 
accumulation ratio of Rh123 are presented in Fig. 2. 
Since the K562Dox cell line overexpresses P-gp, differences in the accumulation pattern between 
the several treatments can be related to modulation of this pump. According to the cytometry assay, 
verapamil (a known P-gp inhibitor) and compounds 3 (a xanthonolignoid) and 4 (a prenylated xanthone) 
were found to increase the accumulation of the P-gp substrate, Rh123. Therefore, they may be in fact 
blocking P-gp from pumping Rh123 to the extracellular medium. However, this assay does not give any 
indication about the possible mechanism of action of these potential P-gp inhibitors. These results are in 
accordance with the previously described for the non-cytotoxic flavonolignoids and prenylated 
xanthones/flavonoids structurally-related to xanthones 3 and 4, respectively [25]. On the other hand, 
dihydroxyxanthones 1 and 2 showed an effect compatible with P-gp activation, increasing the 
intracellular accumulation of Rh123. 
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Fig. 2. Accumulation ratio of Rh123 following 1h incubation of K562 or K562Dox cell lines with a 
positive control (verapamil, 10 or 20 M) or the compounds under study (10 or 20 M). Results are the 
average of three independent experiments. All values are statistically significant. P<0.001 when 
comparing results with componds to control (no drug in K562Dox, second entry in the Figure). 
 
To understand the molecular mechanism of P-gp inhibition, characterized by the very broad activity 
for the recognition of its substrates or inhibitors, an assay capable of measuring ATPase activity based on 
alterations of luminescence was performed [26]. Therefore, to elucidate if the accumulators of Rh123, 
compounds 3 and 4, were either substrates for transport by P-gp (competitive inhibitors), or P-gp activity 
inhibitors (noncompetitive inhibitors), their effect on the P-gp ATPase activity was investigated using 
human P-glycoprotein membranes (Fig. 3) [27]. Several controls were used: no treatment (NT), sodium 
orthovanadate treatment (Na3VO4) and verapamil treatment. Sodium orthovanadate, a noncompetitive 
inhibitor of the P-gp ATPase, serves as a control where no P-gp-dependent ATP consumption occurs. 
Verapamil is a substrate for transport by P-gp that stimulates P-gp ATPase activity (competitive 
inhibitor). 
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Fig. 3. P-gp ATPase assay. Results are % of RLU (Relative Light Unit) in relation to non-treated control 
(NT). NT luminescence is represented as zero for easier interpretation. Values of % of RLU superior to 
zero corresponds to noncompetitive P-gp inhibitors whereas values of % of luminescence inferior to zero 
corresponds to competitive inhibitors. Results are the mean of three independent experiments. Na3VO4 
and verapamil (VP) are used as controls. All values are statistically significant with p<0.01 when 
comparing to NT control. 
 
As shown in Fig. 3, verapamil causes a significant drop in the % of luminescence in relation to the 
non-treated samples (NT). Both compounds 3 and 4 seem to be acting by noncompetitive inhibition of P-
gp at the tested concentration, blocking the ATPase activity and thus increasing the percentage of 
luminescence. This behavior could be benefic for the pharmacokinetic profile of these compounds (3-4). 
To analyze the permeability of compounds, a method for quantifying compounds 1-4 was 
developed. The analysis was performed on RP-HPLC and was optimized for each compound (1-4) in the 
described experimental conditions. The conditions were considered optimized when baseline resolutions 
were obtained from unretained compounds and impurities and when retention factors were lower than 2 to 
obtain a higher throughput. Several proportions of mobile phase compositions were investigated in order 
to obtain satisfactory retention factors (Table 1).  
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Table 1 – Retention factors (k) of the investigated xanthonic derivatives (1-4) in optimised 
chromatographic conditions.
a
 
Mobile Phase  (nm) 
Retention 
Factor (k) 
Regression Analysis 
80:20 (MeOH:H2O), 1% CH3COOH 237 0.69 
y = 14.918x - 159.43 
R² = 0.9962 
70:30 (MeOH:H2O), 1% CH3COOH 237 0.39 
y = 16.13x - 56.675 
R² = 0.9979 
85:15 (MeOH:H2O), 1% CH3COOH 237 0.20 
y = 31.122x -230.02 
R² = 0.9993 
80:20 (MeOH:H2O), 1% CH3COOH 254 1.50 
y = 0.4245x - 10.36 
R² = 0.9999 
a
The values are the mean of three experiments. The column void time (t0) was considered to be equal to 
the peak of the solvent front and was taken from each particular run.  
 
The assay was validated with respect to linearity (Table 1) and range. Specificity, limits of 
quantification and detection, precision and accuracy were previously established for compounds 1-3 in a 
described method [28]. Linearity was evaluated in triplicates of at least five calibration standard solutions 
of the compounds 1-4. The terms were defined according to ICH guideline Q2(R1) [29] and to 
USPharmacopeia 24 [30]. A calibration curve was obtained for each xanthone (1-4) and linear regression 
analysis was carried out by plotting peak area (y) versus analyte concentration (x), where y was the 
response (peak area expressed in mV) and x the compound concentration (M). The calibration curves 
were constructed at five concentration levels (10, 25, 50, 75, and 100 M) using the linear-squares 
regression procedure. The peak area values obtained for three replicate analyses were averaged at each 
concentration. Linear relationships with regression coefficients of at least 0.9962 were found for all 
compounds over the concentration range. The RSD (relative standard deviation) values for the response 
factors of the three experiments were in the range of 0-15% and they were considered adequate for 
verifying the linearity of the regression. The calibration curves were further used to determine the 
concentration of the samples collected in the Caco-2 cells assay. 
The permeability of compounds 1-4 was evaluated by an in vitro assay using Caco-2 cells, a model 
commonly utilized during drug discovery and development as a predictive tool to estimate intestinal 
absorption [31]. In this model, permeability is tested across a differentiated monolayer of intestinal cells. 
Caco-2 cells are able to express several efflux transport proteins that may hamper a drug‟s absorption and 
these characteristics make the system particularly useful as a model for determining a drug candidate‟s 
absorption potential, studying the transport mechanism of drugs and elucidating their metabolism [32, 
33]. 
To evaluate the amount of xanthonic derivatives 1-4 that is transported through the membrane of 
intestinal cells, experiments were conducted across the Caco-2 cells in the absorptive direction and HPLC 
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analysis was carried out as a function of time by plotting analyte concentration (M) versus time 
(minutes). The cumulative amount of analogs permeated across the Caco-2 multilayers is shown in Fig. 4.  
 
 
Fig. 4. Data from Caco-2 absorption assay of compounds 1-4. 
 
The apparent permeability of the xanthones across Caco-2 multilayers is shown in Table 2. From the 
observation of the chromatograms obtained for compounds 1-4 (data not shown) it is possible to infer that 
no metabolization processes occurred (since the profile of those chromatograms was the same as the 
standard solutions chromatograms). 
 
Table 2 – Papp values for the four xanthones tested (compounds 1-4). 
 
Absorptive transport 1 2 3 4 
Papp (x10
-6
cm/s) 15.2 19.4 14.4 14.2 
LogPapp - 4.82 - 4.71 - 4.84 - 4.85 
Recovery (%) 40.7 53.6 164.7 29.4 
CLogP 2.84 2.83 3.02 4.09 
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These results indicate that compounds 1-4 present high apparent permeability coefficients (7.1x10
-5 
<Papp<9.7x10
-5
 cm/s) across Caco-2 cells, similar to DMXAA (>3x10
−5
 cm/s) in a Caco-2 model [34], and 
similar to that previously reported for many drugs that are highly absorbed [9]. A poor recovery (lower 
than 60%) was observed for compounds 1, 2, and 4 which could be due to non-specific binding to cell 
devices [31], or to retention of drugs inside the epithelial cells. The lag time and attainment of steady state 
indicated the presence of a uniform diffusion barrier offered by the Caco-2 cells. Of the four analogs 
studied, compound 2 showed higher permeability than the other analogs, across the Caco-2 multilayers. 
Additionally, the xanthones 1-4 present CLogP between 2 and 4, which suggests high permeability across 
the in vitro barriers [35]. As shown in Table 2, the in vitro permeability studies on xanthones 1-4 yielded 
a LogPapp between −4.71 and −4.85, thus they are expected to exhibit good distribution in vivo. If the 
flux of a drug substance is found to be unsaturable, equal in both the donor and receiver sides, pH 
independent, and causes no effect on the flux or on the TEER (as observed for compounds 1-4), it is an 
indication that the absorption mechanism of the drug is passive and transcellular. 
 
Conclusions 
For compounds 3 and 4, previously shown to have inhibitory effects on the growth of human tumour 
cell lines, the here shown inhibitory effect on P-gp is expected to be a favourable factor, possibly favoring 
the success of these hit compounds in the subsequent preclinical phase of drug development. 
Additionally, through the study of their permeability across the Caco-2 cells, we were able to 
conclude that all four xanthone derivatives presented high apparent permeability coefficients and 
suggested potential oral bioavailability.  
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Abstract 
 
For many pathologies, there is a crescent effort to design multiple ligands that interact with a 
wide variety of targets. 1-Aminated thioxanthone derivatives were synthesized and assayed for 
their in vitro dual activity as antitumor agents and P-glycoprotein (P-gp) inhibitors. The approach 
was based on molecular hybridization of a thioxanthone scaffold, present in known antitumor 
drugs, and an amine, described as an important pharmacophoric feature for P-gp inhibition. A 
rational approach using homology modeling and docking was used, to select the molecules to 
be synthesized by conventional or microwave-assisted Ullmann C-N cross-coupling reaction. 
 
 
 
(thio)Xanthone derivatives with dual activity: antitumor and p-glycoprotein inhibition 
268  
 
The obtained aminated thioxanthones were highly effective at inhibiting P-gp and/or causing 
growth inhibition in a chronic myelogenous leukemia cell line, K562. Six of the aminated 
thioxanthones had GI50 values in the K562 cell line below 10 µM and 1-{[2-
(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (37) had a GI50 concentration 
(1.90M) 6 fold lower than doxorubicin (11.89M) in the K562Dox cell line. The best P-gp 
inhibitor found was 1-[2-(1H-benzimidazol-2-yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one 
(45), which caused an accumulation rate of rhodamine-123 similar to that caused by verapamil 
in the K562Dox resistant cell line, and a decrease in ATP consumption by P-gp. At a 
concentration of 10 µM, compound 45 caused a decrease of 12.5 fold in the GI50 value of 
doxorubicin in the K562Dox cell line, being 2 fold more potent than verapamil. From the overall 
results, the aminated thioxanthones represent a new class of P-gp inhibitors with improved 
efficacy in sensitizing a resistant P-gp overexpressing cell line (K562Dox) to doxorubicin. 
 
Keywords: thioxanthones; P-glycoprotein; multidrug resistance; anticancer; dual ligands 
 
Abbreviations: ABC, ATP-binding cassette; ATP, adenosine-5’-triphosphate; BLAST, basic 
local alignment search tool; DNA, deoxyribonucleic acid; GI50, inhibition of cell growth (the 
concentration needed to reduce the growth of treated cells to half that of untreated cells); MDR, 
multidrug resistance; MFI, mean fluorescence intensity; MRP, multridrug resistance proteins; 
MRP-1, multidrug resistance protein 1; MW, molecular weight; NBD, nucleotide binding domain; 
P-gp, P-glycoprotein; Rh123, rhodamine-123; RLU, relative light unit; RMSD, Root-mean-
squared error displacement; SE, standard error; SRB, sulphorhodamine-B; TM, transmembrane 
(one -helix); TMD, transmembrane domain (six -helixes).   
 
1. Introduction 
 
Resistance to chemotherapy represents one of the major obstacles to cancer treatment. 
Multidrug resistance (MDR) can be broadly defined as a phenomenon by which tumor cells in 
vivo, and cultured cells in vitro, show simultaneous resistance to a variety of structurally and 
functionally dissimilar cytotoxic and xenobiotic compounds [1]. P-glycoprotein (P-gp), an ABC 
(ATP-binding cassette) super-family member [2, 3], is a membrane transporter that actively 
extrudes a set of structurally unrelated compounds, namely chemotherapeutic agents, out of the 
cells [4] conferring the MDR phenotype in cancer [5]. Despite promising in vitro results obtained 
for several generations of P-gp inhibitors, disappointing clinical trials demand for new drugs and 
strategies to reverse the P-gp-mediated MDR phenotype [6, 7]. 
Simultaneous modulation of multiple biological targets can be beneficial for treatment of 
diseases with complex ethiologies such as cancer [8, 9]. Recently, there has been a paradigm 
shift in drug design towards the development of multifunctional drugs, i.e. drugs that aim 
multiple targets [8, 9]. The benefits of this approach include improved compliance, efficacy and 
                                                
 
 
Annex v 
 
 269 
 
often reduced side effects in comparison with polypharmacy [8]. In addition, some 
multifunctional drugs may work better at normalizing the pathology than a single targeted 
compound. This strategy has already been used for the design of multifunctional agents for HIV 
[10] and several neurodegenerative diseases [11, 12]. Podophyllotoxin derivatives were recently 
described to fight simultaneously cancer and MDR [13]. Nevertheless, a structure-based design 
strategy to obtain antitumor agents which are concomitantly P-gp inhibitors has never been 
attempted before. The aim of this work was the design of P-gp inhibitors which would also 
behave as cancer cell growth inhibitors. 
Thioxanthones are S-heterocycles with a dibenzo--thiopyrone scaffold and they are an 
important class of molecules showing interesting biological properties, namely antitumor activity 
[14, 15]. Also, dibenzo--pirones (xanthones) have already been described as potential P-gp 
inhibitors, binding in the ATP-binding site [16]. Therefore, thioxanthones combine structural 
features that make them promising as dual ligands. 
The first thioxanthones described as potential antitumor agents were lucanthone (1) [17] and 
hycanthone (2) [18], used in therapeutics as antischistosomal agents (Fig. 1). However, 
mutagenicity [19],  probably resulting from the methylene moiety directly linked to C-4, was 
reported as a major drawback, leading to their withdraw [20]. Later, SR233377 (3) [15, 21] and 
SSR271425 (4) [14, 22, 23] (Fig. 1) were tested in clinical trials as antitumor agents but showed 
cardiotoxicity. In contrast, for the photoinitiators 2-isopropyl-9H-thioxanthen-9-one (ITX, 5) [24], 
and 1-chloro-4-propoxy-9H-thioxanthen-9-one (6), in vivo genotoxicity studies do not indicate a 
genotoxic potential, and compound 6 was considered not to be a dangerous substance 
according to GHS and to Directive 67/548/EEC [25]. Hence, to continue the search for new 
potential anticancer drugs with a thioxanthonic scaffold, we considered compound 6 to be a 
suitable chemical substrate and we introduced an amine side chain to pursuit a hybridization 
approach.  
In this work, computational studies, synthesis and subsequent investigation of cell growth 
inhibitory effects and P-gp modulation for a series of new thioxanthonic derivatives are 
described, as schematized in Fig. 2. A virtual library of molecules was built by merging a 
thioxanthonic scaffold with P-gp inhibitors’ pharmacophoric features, i.e., a planar system of 
rings (thioxanthonic scaffold) and a ionizable group such as an amine [26] (Fig. 2.I). Those 
thioxanthonic derivatives were docked into P-gp homology models (Fig. 2.II); the molecules with 
the best docking scores were then synthesised (Fig. 2.III) and their P-gp inhibition and cell 
growth inhibitory effects experimentally assessed using several techniques (Fig. 2.IV-2.VIII).  
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Fig. 1. First thioxanthones described as potential antitumor agents: lucanthone (1) and 
hycanthone (2), SR233377 (3) and SSR271425 (4); thioxanthones used safely as 
photoinitiators: 2-isopropyl-9H-thioxanthen-9-one (5) and 1-chloro-4-propoxy-9H-thioxanthen-9-
one (6). 
 
 
2. Matherial and Methods 
 
2.1. Preparation of a libray of virtual thioxanthones and known P-gp inhibitors/ligands 
 
About one thousand thioxanthones, 22 known P-gp inhibitors from the 1
st
, 2
nd
, and 3
rd
 
generation, thirty six flavonoids that are known to bind the P-gp ATP-binding site [27] 
(Supplementary data, Annex B), were drawn and minimized using AM1 semi-empirical method, 
with a gradient energy minimization method until the energy change between steps was lower 
than 0.01 kcal.mol
-1
 (Hyperchem, Hypercube, USA). The algorithm used was the Polak-Ribiere 
(conjugate gradient).  
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Fig. 2. Schematic representation of cheminformatics and laboratorial procedures. I)  Dual 
ligands design by merging a thioxanthonic scaffold with an amine. II) Docking studies. III) 
Synthesis. IV) Sulphorhodamine-B assay (SRB) for investigation of tumor cell growth inhibition 
in K562 and K562Dox cell lines. V) Trypan blue exclusion assay for investigation of cellular 
viability in a fibroblast cell line (MRC-5). VI) Rhodamine-123 cellular accumulation assay and 
VII) ATPase assay for P-gp inhibition screening. VIII) SRB assay in cells treated with a 
combination of doxorubicin and the test compound. 
 
 
2.2. Docking of virtual thioxanthones 
 
Virtual screening was carried out on a commodity PC running Linux Ubuntu 6.06. The software 
eHiTS from SimBioSys Inc [28, 29] was used for active site detection and docking. Docking was 
performed on P-gp models built using Sav1866 as template (Supplementary data, Annex A). No 
special preparation of the 3D structures was carried out because eHiTS automatically evaluates 
all of the possible protonation states for ligands and receptor. eHiTS ran using the residues at: i) 
the ATP-binding site on nucleotide-binding domains (NBD) and ii) the drug binding pocket on 
the interface of the TMD as clip files. The docking is performed, by default, within a 7Å margin 
around those residues. The input files of the molecules (virtually designed thioxanthones) were 
in mol format. The docking accuracy was set to 2, the number of docking poses was set to 5, 
and sdf was chosen as the output file format. Open Babel [30] was used to manipulate the 
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various file formats of ligands. PyMol from DeLano [31] and Chimera from UCSF [32] were used 
for visual inspection of results and graphical representations.  
 
2.3. Chemistry 
 
1-Chloro-4-propoxy-9H-thioxanthen-9-one (6) and amines (7-28) were purschased from Sigma-
Aldrich (Spain). The solvents used were products pro analysis or HPLC grade from Sigma-
Aldrich and Fluka. Microwave reactions were performed using a MicroSYNTH 1600 from 
Millestone (ThermoUnicam, Portugal) synthesizer in sealed reaction vessels (10 mL). 
Purifications of compounds were performed by flash chromatography using Merck silica gel 60 
(0.040-0.063 mm), liquid-liquid extraction (NMP:water and diethyl ether system) and preparative 
thin layer chromatography (TLC) using Merck silica gel 60 (GF254) plates. Reaction progression 
were controlled by TLC performed using silica plates HF254 (l=0.2 mm) (ethyl 
acetate:acetone:TEA 80:20:1 or 90:10:1). Compounds were visually detected on visible light, by 
absorbance at 254 and/or 365 nm. Melting points were obtained in a Köfler microscope. IR 
spectra were measured on an ATI Mattson Genesis series FTIR (software: WinFirst v.2.10) 
spectrophotometer in KBr microplates (cm
-1
). 
1
H and 
13
C NMR spectra were taken in CDCl3 or 
DMSO-d6 at room temperature, on Bruker Avance 300 instrument (300.13 MHz for 
1
H and 75.47 
MHz for 
13
C). Chemical shifts are expressed in (ppm) values relative to tetramethylsilane (TMS) 
as an internal reference (Supplementary data, Annex D). Elemental analysis results were 
obtained in the services of C.A.C.T.I., Vigo, Spain. The purity of each compound was 
determined by HPLC-DAD analysis. All tested compounds, whether synthesized or purchased, 
possessed a purity of at least 95%. The following compounds were synthesized and purified by 
the described procedures. 
 
2.4. HPLC Chromatographic Conditions 
 
The HPLC analysis was performed in a Finnigan Surveyor – Autosampler Plus and LC Pump 
Plus (Thermo Electron Corporation, United States), equipped with a diode array detector TSP 
UV6000LP, and using a C-18 column (5 m, 250 mm × 4.6 mm I.D.), from Macherey-Nagel 
(Deuren, Germany). XcaliburÒ 2.0 SUR 1 software (Thermo Electron Corporation) managed 
chromatographic data. Acetonitrile was of HPLC grade from Merck. HPLC ultrapure water was 
generated by a Milli-Q system (Millipore, Bedford, MA, USA). The mobile phases were 
degassed for 15 min in an ultrasonic bath before use. Is was used an isocratic elution of 
MeOH:H2O basified with TEA (1%) or acidified with CH3COOH (1%) at a constant flow rate of 
1.0 mL.min
-1
. 
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2.5. Synthesis 
 
2.5.1. General procedure for the synthesis of 1-aminated 4-propoxy-9H-thioxanthen-9-
ones (Procedure a) 
 
To a solution of 1-chloro-4-propoxy-9H-thioxanthen-9-one (6, 300 mg, 0.1 mmol) alone or with 
the amine (8, 7, 10, 13, 15, or 23; 0.2 mmol) in methanol (25 mL), Cu2O (2 mg) was added and 
the suspension was heated at 100 ºC for 48h.  
1-Methoxy-4-propoxy-9H-thioxanthen-9-one (30): 9% as yellow solid (procedure a); mp 115 
ºC (acet). IR (KBr) max: 3424, 3052, 2960, 2926, 2877, 2856, 1635, 1582, 1457, 1425, 1387, 
1289, 1256, 1092, 1065, 1032, 944, 865, 799, 741, 666, 585, 550, 463. 
1
H NMR (CDCl3, 300.12 
MHz) : 8.48 (1H, dd, J = 8.2 and 0.9 Hz, H-8), 7.59 (1H, ddd, J = 8.2, 5.2, and 2.3 Hz, H-6), 
7.55 (1H, dd, J = 8.4 and 1.3 Hz, H-5), 7.44 (1H, ddd, J = 8.2, 5.3 and 0.6 Hz, H-7), 7.10 (1H, d, 
J = 8.9 Hz, H-3), 6,89 (1H, d, J = 9.0 Hz, H-2), 4.10 (2H, t, J = 6.4 Hz, H-a), 3.99 (3H, s, H-1’), 
1.93 (2H, m, H-b), 1.14 (3H, t, J = 7.3 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.2 (C-9), 
156.2 (C-4), 147 (C-1), 136.0 (C-6), 133.8 (C-8a), 130.0 (C-4a), 131.5 (C-8), 129.5 (C-3), 126.2 
(C-9a), 125.8 (C-7), 120.2 (C-10a), 114.6 (C-5), 108.7 (C-2), 71.5 (C-a), 56.8 (C-1’), 22.6 (C-b), 
10.7 (C-c). Anal. Calc. for C17H16O3S (300.37): C, 67.98; H, 5.37; O, 15.98; S, 10.68. Found: C, 
68.13; H, 5.66;O, 15.45; S, 10.63. 
1-(Isobutylamino)-4-propoxy-9H-thioxanthen-9-one (31): 30% as an orange solid (procedure 
a); mp 100-103 ºC. IR (KBr) max: 3457, 3221, 2943, 2910, 2855, 1598, 1554, 1497, 1449, 1418, 
1373, 1279, 1255, 1234, 1210, 1150, 1117, 1056, 1007, 941, 779, 727, 661, 572. 
1
H NMR 
(CDCl3, 300.12 MHz)  : 8.54 (1H, d, J = 8.2 Hz, H-8), 7.71 (1H, m, H-6), 7.58 (2H, m, H-5 and 
H-2), 7.44 (1H, m, H-7), 7.16 (1H, m, H-3) 4.05 (2H, t, J = 6.4 Hz, H-a), 3.08 (2H, d, J = 6.8 Hz, 
H-a’), 1.90 (2H, m, H-b), 1.41 (2H, m, H-b’), 1.12 (9H, m, H-c’), 0.98 (3H, m, H-c). 
13
C NMR 
(CDCl3, 75.47 MHz) : 183.5 (C-9), 167.7 (C-4), 137.1 (C-1), 136.9 (C-6), 132.5 (C-8a), 130.9 
(C-4a), 129.5 (C-8), 129.2 (C-3), 128.8 (C-9a), 126.5 (C-7), 126.2 (C-10a), 126.1 (C-5), 126.0 
(C-2), 72.3 (C-a), 38.7 (C-a’), 28.5 (C-b’), 22.7 (C-b), 20.5 (C-c’), 10.8 (C-c). Anal. Calc. 
for C19H21NO3S (343.44): C, 66.45; H, 6.16; N, 4.08; O, 13.98; S, 9.34. Found: C, 66.45; H, 
6.16; N, 4.08; O, 13.98; S, 9.34. 
1-[(3-Hydroxypropyl)amino]-4-propoxy-9H-thioxanthen-9-one (32): 30% as red solid 
(procedure a); mp 125 ºC (acet). IR (KBr) max: 3426, 3261, 2925, 2857, 1614, 1567, 1511, 
1462, 1431, 1384, 1293, 1263, 1224, 1161, 1115, 1065, 867, 801, 747, 668, 565, 459. 
1
H NMR 
(CDCl3, 300.12 MHz) : 8.48 (1H, d, J = 8.1 Hz, H-8), 7.55 (2H, m, H-6 and H-5), 7.41 (1H, m, 
H-7), 7.11 (2H, m, H-3 and H-2), 4.02 (2H, t, J = 6,4, H-a), 3.88 (2H, t, J = 5.8 Hz, H-3’), 3.37 
(2H, t, J = 6.5 Hz, H-1’), 2.08 (2H, m, H-b’), 1.85 (2H, m, H-b), 1.54 (1H, s, 3’-OH), 1.08 (3H, m, 
H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.4 (C-9), 151.2 (C-4), 143.8 (C-1), 137.2 (C-6), 132.7 
(C-8a), 130.0 (C-4a), 129.5 (C-8), 127.4 (C-3), 126.6 (C-9a), 126.3 (C-7), 118.2 (C-10a), 113.1 
(C-5), 106.5 (C-2), 72.1 (C-a), 59.9 (C-3’), 41.0 (C-1’), 30.7 (C-2’), 22.6 (C-b), 10.6 (C-c). Anal. 
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Calc. for C19H21NO3S (343.44): C, 66.45; H, 6.16; N, 4.08; O, 13.98; S, 9.34. Found: C, 66.68; 
H, 6.42; N, 4.13; O, 14.62; S, 9.08. 
1-(Isopropylamino)-4-propoxy-9H-thioxanthen-9-one (34): 30% as an orange solid 
(procedure a); mp 95-98 ºC. IR (KBr) max: 3435, 2951, 2915, 2861, 1605, 1559, 1502, 1451, 
1422, 1374, 1287, 1242, 1220, 1060, 938, 775, 734, 668, 577. 
1
H NMR (CDCl3, 300.12 MHz) : 
8.54 (1H, d,  J = 8.1 Hz, H-8), 7.62 (2H, m, H-6 and H-5), 7.47 (1H, m, H-7), 7.17 (2H, m, H-3 
and H-2), 4.09 (2H, t, J = 6.0 Hz, H-a), 3.72 (1H, m, H-a’), 1.93 (2H, m, H-b), 1.35 (6H, m, H-b’), 
0.87 (1H, m, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.8 (C-9), 137.6 (C-4), 137.0 (C-1), 134.0 
(C-6), 133.7 (C-8a), 130.4 (C-4a), 129.8 (C-8), 128.3 (C-3), 127.7 (C-9a), 126.6 (C-7), 124.4 (C-
10a), 115.2 (C-5), 113.1 (C-2), 71.7 (C-a), 57.07 (C-a’), 29.7 (C-b’), 22.2 (C-b), 10.6 (C-c). Anal. 
Calc. for C19H21NO2S (327.44): C, 66.45; H, 6.16; N, 4.08; O, 13.98; S, 9.34. Found: C, 69.21; 
H, 6.99; N, 3.99; O, 9.91; S, 9.89. 
1-((2-(Diethylamino)ethyl)amino)-4-propoxy-9H-thioxanthen-9-one (37): 50% as an orange 
solid (procedure a); mp 66-69 ºC; IR (KBr) max: 3410, 2967, 2928, 2873, 2814, 1641, 1614, 
1567, 1504, 1435, 1386, 743. 
1
H NMR (DMSO, 300.13 MHz) : 12.60 (1H, brs), 8.45 (1H, d, J = 
6.0 Hz, H-8), 7.59 (2H, m, H-5 and H-6), 7.44 (1H, m, H-7), 7.22 (1H, d, J = 9.0 Hz, H-3), 6.95 
(1H, d, J = 9.0 Hz, H-2), 4.20 (2H, t, J = 6.5 Hz, H-a’), 4.05 (2H, t, J = 6.9 Hz, H-a), 3.97 (2H, t, J 
= 6.5 Hz, H-b’), 3.47 (2H, q, J = 6.9 Hz, H-c’), 1.91 (2H, q, J = 7.3 Hz, H-b), 1.45 (6H, t, J = 7.3 
Hz, H-d’), 1.12 (3H, t, J = 7.3 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.6 (C-9), 136.8 (C-
4), 131.7 (C-1), 130.0 (C-6), 129.7 (C-8a), 129.6 (C-4a), 129.1 (C-8), 126.5 (C-3), 126.0 (C-9a), 
125.9 (C-7), 119.8 (C-10a), 113.3 (C-5), 106.7 (C-2), 72.4 (C-a), 51.9 (C-b’), 47.2 (C-c’), 46.8 
(C-a’), 24.8 (C-b), 22.7 (C-d’), 10.7 (C-c). Anal. Calc. for C22H28N2O2S (384.53): C, 68.72; H, 
7.34; N, 7.29; O, 8.32; S, 8.34. Found: C, 68.29; H, 6.91; N, 7.05; O, 8.86; S, 8.88. 
1-{[4-(Aminomethyl)benzyl]amino}-4-propoxy-9H-thioxanthen-9-one (39): 9%  as orange 
solid; mp 102 ºC (acet). IR (KBr) max: 3421, 3358, 3287, 3248, 2948, 2913, 2851, 1643, 1601, 
1557, 1495, 1451, 1421, 1376, 1280, 1250, 1212, 1152, 1059, 1010, 947, 858, 789, 735, 557, 
526. 
1
H NMR (CDCl3, 300.12 MHz) : 8.43 (1H, d, J = 8.5 Hz; H-8), 7.47 (2H, m, H-6 and H-5), 
7.28 (5H, m, H-7, H-2’, H-3’, H-4’, H-5’), 6.98 (1H, d, J = 9.0 Hz, H-3), 6.38 (1H, d, J = 9.1 Hz, 
H-2), 4.36 (2H, s, H-a’), 3.91 (2H, t, J = 6.44 Hz, H-a), 2.32 (1H, s, -NH-), 1.79 (2H, st, J = 6.9 
Hz, H-b), 1.18 (2H, s, H-b’), 1.02 (3H, t, J = 7.3 Hz, H-c), 0.81 (2H, m, -NH2). 
13
C NMR (CDCl3, 
75.47 MHz) : 183.4 (C-9), 148.8 (C-4), 142.6 (C-1), 136.7 (C-6), 131.6 (C-8a), 129.4 (C-4a), 
129.0 (C-8), 128.6 (C-3), 128.0 (C-4’), 127.8 (C-2’, C-6’), 127.3 (C-9a), 127.2 (C-3’, C-5’), 125.9 
(C-7), 119.8 (C-10a), 112.0 (C-5), 106.9 (C-2), 72.4 (C-a), 47.0 (C-b’), 30.9 (C-a’), 22.8 (C-b), 
10.7 (C-c). Anal. Calc. for C24H24N2O2S (404.52): C, 71.26; H, 5.98; N, 6.93; O, 7.91; S, 7.93. 
Found: C, 71.65; H, 5.34; N, 6.39; O, 8.50; S, 8.11. 
 
2.5.2. General procedure for the synthesis of 1-aminated 4-propoxy-9H-thioxanthen-9-
ones (Procedure b) 
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To a solution of 1-chloro-4-propoxy-9H-thioxanthen-9-one (6, 300 mg, 0,1 mmol) and the 
appropriated amine (12 or 23; 0.2 mmol) in methanol (25 mL), Cu2O (2 mg) and K2CO3 (0.1 
mmol) was added and the suspension was heated at 100 ºC for 48h.  
1-{[(2S)-1-Hydroxy-3-methylbutan-2-yl]amino}-4-propoxy-9H-thioxanthen-9-one (36): 25%  
(procedure b) and 45% (procedure c) as a red solid; mp 96 ºC (acet). IR (KBr) max: 3451, 3418, 
2949, 2916, 2846, 1628, 1550, 1504, 1368, 1255, 1211, 1110, 1059, 874, 792, 735, 661, 605, 
572, 530, 502. 
1
H NMR (CDCl3, 300.12 MHz) : 8.45 (1H, dd, J = 8.1 and 1.0 Hz, H-8), 7.46 
(2H, m, H-6, H-5), 7.35 (1H, ddd, J = 8.0, 3.6, and 1.0 Hz, H-7), 7.04 (1H, d, J = 9.2 Hz, H-3), 
6.68 (1H, d, J = 9.2 Hz, H-2), 3.95 (2H, t, J = 6.5 Hz, H-a), 3.70 (2H, d, J = 6.6 Hz, H-a’’), 3.48 
(1H, q, J = 6.4 Hz, H-a’), 2.10 (1H, s, -OH), 1.98 (1H, m, H-b’), 1.81 (3H, st, J = 6,4 Hz, H-b), 
1.05 (3H, t, J = 7.4 Hz, H-c), 1.00 (3H, d, J = 6.8 Hz, H-b’-1), 0.95 (3H, d, J = 6.8 Hz, H-b’-2). 
13
C NMR (CDCl3, 75,47 MHz) : 183.6 (C-9), 149.6 (C-4), 142.6 (C-1), 136.7 (C-6), 131.9 (C-
8a), 130.0 (C-4a), 129.5 (C-8), 129.1 (C-3), 125.8 (C-9a), 125.7 (C-7), 120.0 (C-10a), 113.3 (C-
5), 107.7 (C-2), 72.5 (C-a), 63.3 (C-a’’), 60.9 (C-a’), 29.9 (C-b’), 22.8 (C-b), 19.4 (C-b’-1), 18.8 
(C-b’-2), 10.7 (C-c). Anal Calc. for C21H25NO3S (371.49): C, 67.89; H, 6.78; N, 3.77; O, 12.92; S, 
8.63. Found: C, 68.06; H, 5.76; N, 3.84; O, 13.74; S, 8.17. 
1-[(3,4-Dimethoxybenzyl)amino]-4-propoxy-9H-thioxanthen-9-one (47): 75% as yellow-
orange solid (procedure b); mp 160 ºC (acet). IR (KBr) max: 3536, 3454, 3422, 3367, 3272, 
3224, 2955, 2921, 2868, 1611, 1562, 1501, 1454, 1379, 1264, 1233, 1133, 1061, 961, 890, 
788, 746, 701, 665, 569, 538. 
1
H NMR (CDCl3, 300.12 MHz) : 8.51 (1H, dd, J = 8.0 and 0.8 Hz, 
H-8), 7.54 (2H, m, H-6, H-5), 7.41 (1H, ddd, J = 8.2, 3.5, and 0.9 Hz, H-7), 7.07 (1H, d, J = 9.0 
Hz, H-3), 6.96 (1H, d, J = 9.0 Hz, H-6’), 6.94 (1H, s, H-2’), 6.84 (1H, d, J = 8.0 Hz, H-5’), 6.48 
(1H, d, J = 9.1 Hz, H-2), 4.43 (2H, s, H-a’), 3.99 (2H, t, J = 6.4, H-a), 3.88 (3H, s, H-a’’), 3.87 
(3H, s, H-b’’), 1.87 (2H, st, J = 6.6, H-b), 1.11 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 
MHz) : 183.4 (C-9), 149.1 (C-4), 148.8 (C-3’), 148.0 (C-4’), 142.6 (C-1), 136.7 (C-1’), 131.5 (C-
6), 131.1 (C-8a), 130.0 (C-4a), 129.3 (C-8), 129.0 (C-3), 125.9 (C-9a), 125.8 (C-7), 119.8 (C-
10a), 119.2 (C-5), 113.0 (C-6’), 111.2 (C-2), 110.2 (C-5’), 106.7 (C-2’), 72.4 (C-a), 55.9 (C-b’’), 
55.8 (C-a’’), 47.2 (C-a’), 22.8 (C-b), 10.7 (C-c). Anal. Calc. for C25H25NO4S (435.53): C, 68.94; 
H, 5.79; N, 3.22; O, 14.69; S, 7.36. Found: C, 68.04; H, 5.99; N, 3.72; O, 14.30; S, 7.19. 
 
2.5.3. General procedure for the synthesis of 1-aminated 4-propoxy-9H-thioxanthen-9-
ones (Procedure c) 
 
To a solution of 1-chloro-4-propoxy-9H-thioxanthen-9-one (6, 300 mg, 0,1 mmol) and the 
appropriated amine (7, 9-14, 16-22, 24-28; 0.2 mmol) in NMP, or NMP:water 1:1 in the case of 
amine 11, 21 and 28 (10 mL), Cu2O (2 mg) and K2CO3 (27.5 mg, 0.2 mmol) was added and the 
suspension was irradiated at 400 W for 50 min under stirring. Final temperature range was 200-
205 ºC. 
1-(Piperidin-1-yl)-4-propoxy-9H-thioxanthen-9-one (33): 20% as orange solid (procedure c); 
mp 84 ºC (acet). IR (KBr) max: 3443, 3398, 2911, 2845, 2782, 2731, 1630, 1581, 1556, 1423, 
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1370, 1273, 1241, 1203, 1135, 1104, 1064, 956, 917, 843, 784, 739, 667, 640, 604, 560. 
1
H 
NMR (CDCl3, 300.12 MHz) : 8.43 (1H, dd, J = 8.0 and 1.0 Hz, H-8), 7.56 (2H, m, H-6, H-5), 
7.41 (1H, ddd, J = 7.5, 3.8, and 1.0 Hz, H-7), 7.05 (1H, d, J = 8.8 Hz, H-3), 6.94 (1H, d, J = 8.8 
Hz, H-2), 4.08 (2H, t, J = 6.5 Hz, H-a), 3.02 (3H, m, H-a’, H-e’), 1,93 (2H, st, J = 6.7 Hz, H-b), 
1.84 (4H, m, H-d’, H-b’), 1.62 (2H, m, H-c’), 1.14 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 
MHz) : 181.3 (C-9), 150.1 (C-4), 147.6 (C-1), 135.5 (C-6), 131.9 (C-8a), 131.1 (C-4a), 129.7 
(C-8), 129.4 (C-3), 125.8 (C-9a), 125.6 (C-7), 119.0 (C-10a), 115.8 (C-5), 114.9 (C-2), 71.5 (C-
a), 54.6 (C-a’, C-e’), 26.2 (C-b’, C-d’), 24.4 (C-c’), 22.7 (C-b), 10.7 (C-c). Anal. Calc. for 
C21H23NO2S (353.48): C, 71.36; H, 6.56; N, 3.96; O, 9.05; S, 9.07. Found: C, 71.87; H, 6.46; N, 
3.87; O, 8.22; S, 9.66. 
3-Hydroxy-2-[(9-oxo-4-propoxy-9H-thioxanthen-1-yl)amino]butanoic acid (35): 85% as 
orange solid (procedure c); mp 95 ºC (acet). IR (KBr) max: 3447, 2955, 2925, 2853, 1742, 1620, 
1567, 1507, 1461, 1434, 1380, 1266, 1224, 1158, 1104, 1069, 956, 795, 746, 721, 471, 439. 
1
H 
NMR (CDCl3, 300.12 MHz) : 10.15 (1H, s, J = 8,0 Hz, H-a’’), 8.42 (1H, d, J = 8.0 Hz, H-8), 7.76 
(1H, d, J = 7.9 Hz, H-5), 7.68 (1H, t, J = 7.9 Hz, H-6), 7.52 (1H, t, J = 7.8 Hz, H-7), 7.35 (1H, d, J 
= 9.1 Hz, H-3), 6.56 (1H, d, J = 9.1 Hz, H-2), 4.28 (1H, m, H-a’), 4.11 (1H, m, H-b’), 4.02 (2H, t, 
J = 6.3 Hz, H-a), 1.76 (2H, st, H-b), 1.23 (3H, d, J = 10.4 Hz, H-c’), 1.05 (3H, t, J = 7.3 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 182.1 (C-9), 173.0 (C-a’’), 148.5 (C-4), 142.0 (C-1), 135.7 (C-
6), 132.4 (C-8a), 129.4 (C-4a), 128.7 (C-8), 127.5 (C-3), 126.4 (C-9a), 126.3 (C-7), 120.4 (C-
10a), 112.1 (C-5), 107.5 (C-2), 71.6 (C-a), 66.7 (C-a’), 61.3 (C-b’), 22.4 (C-b), 20.9 (C-c’), 10.7 
(C-c). Anal. Calc. for C20H21NO5S (387.45): C, 62.00; H, 5.46; N, 3.62; O, 20.65; S, 8.28. Found: 
C, 62.23; H, 5.30; N, 3.34; O, 20.26; S, 8.20. 
1-(4-Acetylpiperazin-1-yl)-4-propoxy-9H-thioxanthen-9-one (38): 65% as orange solid 
(procedure c); mp 127 ºC (acet). IR (KBr) max: 3424, 2928, 1641, 1621, 1565, 1460, 1425, 
1380, 1281, 1248, 1060, 992, 963, 751. 
1
H NMR (CDCl3, 300.12 MHz) : 8.43 (1H, d, J = 7.62 
Hz, H-8), 7.57 (1H, ddd, J = 7.9, 5.4 and 1.5 Hz, H-6), 7.54 (1H, dd, J = 8.0 and 1.3 Hz, H-5), 
7.45 (1H, ddd, J = 8.2, 4.8 and 1.5 Hz, H-7), 7.06 (1H, d, J = 8.8 Hz, H-3), 6.96 (1H, d, J = 8.6 
Hz, H-2), 4.10 (2H, t, J = 6.4 Hz, H-a), 3.78 (4H, t, J = 4.9 Hz, H-b’, H-c’), 3.05 (4H, s, H-a’, H-
d’), 2.16 (3H, s, H-b’’), 1.93 (2H, st, J = 7.3 Hz, H-b), 1.14 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR 
(CDCl3, 75.47 MHz) : 180.9 (C-9), 169.1 (C-a’’), 148.9 (C-4), 148.3 (C-1), 135.5 (C-6), 131.5 
(C-8a), 131.4 (C-4a), 130.4 (C-8), 129.4 (C-3), 126.1 (C-9a), 125.8 (C-7), 123.0 (C-10a), 116.1 
(C-5), 114.2 (C-2), 71.3 (C-a), 53.9 (C-b’), 52.5 (C-c’), 46.7 (C-a’), 41.8 (C-d’), 22.6 (C-b), 22.8 
(C-b’’), 10.7 (C-c). Anal. Calc. for C22H24N2O3S (396.50): C, 66.64; H, 6.10; N, 7.07; O, 12.11; S, 
8.09. Found: C, 66.62; H, 6.15; N, 7.06; O, 12.15; S, 8.02. 
1-{[2-(Phenylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (40): 21% as red solid 
(procedure c); mp 128 ºC (acet). IR (KBr) max: 3648, 3531, 3508, 3455, 3419, 3360, 3253, 
2954, 2915, 2863, 2781, 1596, 1559, 1498, 1453, 1425, 1376, 1279, 1214, 1160, 1111, 1064, 
1016, 866, 735, 681, 606, 563, 430. 
1
H NMR (CDCl3, 300.12 MHz) : 8.51 (1H, d, J = 8.0 Hz, H-
8), 7.55 (2H, m, H-6, H-5), 7.42 (1H, ddd, J = 8.1, 4.0, and 1.0 Hz, H-7), 7.22 (2H, q, J = 8.2 Hz, 
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H-3’, H-5’), 7.13 (1H, d, J = 9.0 Hz, H-3), 6.74 (3H, q, J = 8.6, H-2’, H-4’, H-6’), 6.61 (1H, d, J = 
9.0 Hz, H-2), 4.01 (2H, t, J = 6.5 Hz, H-a), 3.54 (4H, s, H-a’, H-b’), 1.89 (2H, st, J = 7.1 Hz, H-b), 
1,12 (3H, t, J = 7.4 z, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.5 (C-9), 148.9 (C-4), 147.5 (C-
1’), 145.9 (C-1), 142.9 (C-6), 136.8 (C-3’, C-5’), 134.2 (C-8a), 132.0 (C-4a), 131.7 (C-8), 130.1 
(C-3), 129.8 (C-9a), 129.3 (C-7), 129.2 (C-10a), 125.9 (C-5), 118.0 (C-4’), 113.3 (C-2’, C-6’), 
106.6 (C-2), 72.6 (C-a), 43.1 (C-a’, C-b’), 22.9 (C-b), 10.7 (C-c). Anal. Calc. for C24H24N2O2S 
(404.52): C, 71.26; H, 5.98; N, 6.93; O, 7.91; S, 7.93. Found: C, 71.62; H, 5.64; N, 6.77; O, 
8.06; S, 7.14. 
N'-(9-Oxo-4-propoxy-9H-thioxanthen-1-yl)pyridine-4-carbohydrazide (41): 52% as orange 
solid (procedure c); mp 62 ºC (acet). IR (KBr) max: 3443, 3251, 2957, 2921, 2849, 1643, 1618, 
1579, 1460, 1432, 1380, 1296, 1257, 1088, 1063, 1021, 874, 800, 422. 
1
H NMR (CDCl3, 300.12 
MHz) :  8.57 (1H, d, J = 8.0 Hz, H-8), 8.28 (2H, d, J = 5.4 Hz, H-3’, H-5’), 8.09 (1H, s, -NHCO-), 
7.73 (2H, d, J = 5.9 Hz, H-2’, H-6’), 7.61 (2H, m, H-5, H-6), 7.46 (1H, ddd, J = 7.1, 4.1 and 0.7 
Hz, H-7), 7.10 (1H, d, J = 9.0 Hz, H-3), 6.91 (1H, d, J = 8.9 Hz, H-2), 4.12 (1H, s, -NHAr-), 4.05 
(2H, t, J = 6.4 Hz, H-a), 1.90 (2H, st, J = 7.2 Hz, H-b), 1.11 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR 
(CDCl3, 75.47 MHz) : 183.1 (C-9), 173.0 (C-a’), 152.4 (C-4), 146.9 (C-3’, C-5’), 143.1 (C-1’), 
140.1 (C-1), 138.6 (C-6), 136.5 (C-8a), 133.0 (C-4a), 132.1 (C-8), 130.1 (C-3), 129.6 (C-9a), 
126.3 (C-7), 125.9 (C-10a), 123.9 (C-5), 121.6 (C-2’, C-6’), 113.8 (C-2), 71.1 (C-a), 22.7 (C-b), 
10.7 (C-c). Anal. Calc. for C22H19N3O3S (405.47): C, 65.17; H, 4.72; N, 10.36; O, 11.84; S, 7.91. 
Found: C, 65.39; H, 4.64; N, 10.74; O, 11.80; S, 7.44. 
2-[(9-Oxo-4-propoxy-9H-thioxanthen-1-yl)amino]ethyl hydrogen sulfate (42): 9% as yellow-
orange solid (procedure c); mp 166 ºC (acet). IR (KBr) max: 3439, 3245, 3109, 2913, 2854, 
1736, 1624, 1532, 1441, 1301, 1245, 1110, 1046, 868, 806, 739, 622, 566, 494, 441. 
1
H NMR 
(CDCl3, 300.12 MHz) : 8.46 (1H, dd, J = 8.0 and 1.0, H-8), 7.61 (2H, m, H-6, H-5), 7.45 (1H, 
ddd, J = 8.1, 3.9, and 1.4, H-7), 7.32 (1H, d, J = 8.4 Hz, H-3), 7.10 (1H, d, J = 8.5 Hz, H-2), 4.66 
(2H, t, J = 7.9 Hz, H-b’), 4.15 (2H, t, J = 6.4 Hz, H-a), 4.05 (2H, t, J = 8.0 Hz, H-a’), 1.95 (2H, st, 
J = 6.4 Hz, H-b), 1.60 (1H, s, -S-OH), 1.16 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 
MHz) : 180.8 (C-9), 158.2 (C-4), 153.8 (C-1), 136.1 (C-6), 132.1 (C-8a), 131.2 (C-4a), 130.7 
(C-8), 130.4 (C-3), 129.6 (C-9a), 128.3 (C-7), 126.5 (10a), 126.0 (C-5), 122.5 (C-2), 62.8 (C-b’), 
62.8 (C-a), 48.8 (C-a’), 22.4 (C-b), 10.6 (C-c). Anal. Calc. for C18H19NO6S2 (409.48): C, 52.8; H, 
4.68; N, 3.42; O, 23.44; S, 15.66. Found: C, 52.30; H, 4.49; N, 3.50; O, 23.72; S, 15.39. 
1-(5-Amino-3,4-dihydroisoquinolin-2(1H)-yl)-4-propoxy-9H-thioxanthen-9-one (43): 26% as 
red solid (procedure c); mp 130 ºC (acet). IR (KBr) max: 3420, 3338, 2912, 1623, 1558, 1458, 
1426, 1370, 1284, 1250, 1218, 1154, 1104, 1048, 961, 929, 851, 799, 721, 536, 425, 403. 
1
H 
NMR (CDCl3, 300.12 MHz) : 8.36 (1H, dd, J = 8.4 and 0.9 Hz, H-8), 7.52 (1H, m, H-6), 7.48 
(1H, dd, J = 8.0 and 1.5 Hz, H-5), 7.35 (1H, ddd, J = 8.1, 3.7, and 0.9 Hz, H-7), 7.00 (2H, m, H-
3'', H-4''), 6.93 (1H, d, J = 7.7 Hz, H-3), 6.51 (2H, d, J = 7.9 Hz, H-2, H-2''), 4.26 (2H, s, H-1'), 
4.01 (2H, t, J = 6.5 Hz, H-a), 3.37 (2H, m, H-5'), 2.77 (2H, t, J = 2.9 Hz, H-4'), 1.85 (2H, st, J = 
6.5 Hz, H-b), 1.06 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.4 (C-9), 148.0 
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(C-1''), 144.2 (C-4), 135.7 (C-1), 131.6 (C-6), 131.3 (C-8a), 130.0 (C-4a), 129.4 (C-8), 126.3 (C-
3), 126.0 (C-9a), 125.7 (C-7), 122.5 (C-10a), 122.0 (C-2'), 120.0 (C-3''), 116.7 (C-2), 115.7 (C-
3'), 114.6 (C-4’’), 112.7 (C-2''), 71.4 (C-a), 54.1 (C-1'), 52.7 (C-5'), 24.3 (C-4'), 22.6 (C-b), 10.7 
(C-c). Anal. Calc. for C25H24N2O2S (416.54): C, 72.09; H, 5.81; N, 6.73; O, 7.68; S, 7.70. Found: 
C, 72.13; H, 5.93; N, 6.45; O, 7.45; S, 7.99. 
1-[(3,5-Dimethoxyphenyl)amino]-4-hydroxy-9H-thioxanthen-9-one (44): 28% as marron 
solid (procedure c); mp 127 ºC (acet). IR (KBr) max: 3713, 3444, 3419, 3335, 3248, 2951, 2921, 
2861, 1698, 1674, 1628, 1571, 1454, 1421, 1376, 1297, 1243, 1146, 1100, 1043, 949, 798, 
739, 633, 565, 458, 430. 
1
H NMR (CDCl3, 300.12 MHz) : 8.46 (1H, dd, J = 7.5 and 0.8 Hz, H-
8), 7.60 (2H, m, H-6, H-5), 7.48 (1H, ddd, J = 8.3, 3.2, and 1.0 Hz, H-7), 7.45 (1H, d, J = 8.7 Hz, 
H-3), 6.98 (1H, d, J = 8.7 Hz, H-2), 6.51 (2H, s, H-2’, H-6’), 6.21 (1H, s, H-4’), 4.10 (2H, t, J = 
6.4 Hz, H-a), 3.80 (6H, s, H-a’, H-b’), 1.94 (2H, st, J = 7.3 Hz, H-b), 1.15 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 180.4 (C-9), 161.5 (C-3’, C-5’), 152.5 (C-4), 144.6 (C-1’), 143.3 
(C-1), 131.9 (C-6), 130.9 (C-8a), 130.3 (C-4a), 129.5 (C-8), 129.2 (C-3), 126.6 (C-9a), 126.5 (C-
7), 126.0 (C-10a), 125.9 (C-5), 112.8 (C-2), 99.8 (C-2’, C-6’), 95.4 (C-4’), 71.2 (C-a), 55.4 (C-a’, 
C-b’), 22.8 (C-b), 10.7 (C-c). Anal. Calc. for C24H23NO4S (421.51): C, 68.39; H, 5.50; N, 3.32; O, 
15.18; S, 7.61. Found: C, 67.26; H, 4.40; N, 3.45; O, 16.52; S, 7.91. 
1-[2-(1H-Benzimidazol-2-yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one (45): 10% as 
orange redish solid (procedure c); mp 229 ºC (acet). IR (KBr) max: 3459, 3421, 3251, 2952, 
2920, 2861, 1646, 1605, 1563, 1503, 1429, 1383, 1265, 1223, 1158, 1096, 1062, 1020, 949, 
799, 736, 647, 538, 428. 
1
H NMR (CDCl3, 300.12 MHz) : 8.39 (1H, dd, J = 8.0 and 0.8 Hz, H-
8), 7.45 (4H, m, H-6, H-5, H-2’, H-5’), 7.31 (1H, ddd, J = 8.0, 4.6 and 1.1 Hz, H-7), 7.13 (2H, m, 
H-3’, H-4’), 6.98 (1H, d, J = 9.0 Hz, H-3), 6.53 (1H, d, J = 9.1, H-2), 3.93 (2H, t, J = 6.4 Hz, H-a), 
3.31 (2H, t, J = 7.1 Hz, H-a’), 2.31 (2H, t, J = 8.0 Hz, H-b’), 1.94 (2H, st, J = 6.2 Hz, H-b), 1.04 
(3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.3 (C-9), 175.0 (C-1’), 152.6 (C-4), 
148.5 (C-1), 142.7 (C-1’’, C-6’’), 136.7 (C-6), 131.6 (C-8a), 129.9 (C-4a), 129.3 (C-8), 128.9 (C-
3), 125.8 (C-9a), 125.8 (C-7), 122.1 (C-10a), 118.7 (C-3’’, C-4’’), 114.7 (C-5), 112.7 (C-2’’, C-
5’’), 106.6 (C-2), 72.3 (C-a), 49.4 (C-a’), 30.6 (C-b’), 22.8 (C-b), 10.6 (C-c). Anal. Calc. for 
C25H23N3O2S (429.53): C, 69.91; H, 5.40; N, 9.78; O, 7.45; S, 7.47. Found: C, 69.41; H, 5.41; N, 
9.32; O, 7.04; S, 7.60. 
1-{[2-(1,3-Benzodioxol-5-yl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (46): 24% as 
orange solid (procedure c); mp 142 ºC (acet). IR (KBr) max: 3529, 3450, 3288, 2957, 2924, 
2867, 1611, 1566, 1503, 1435, 1389, 1302, 1253, 1187, 1093, 1069, 1030, 923, 784, 733, 628, 
566, 486. 
1
H NMR (CDCl3, 300.12 MHz) : 8.51 (1H, dd, J = 8.2 and 0.7 Hz, H-8), 7.53 (2H, m, 
H-6, H-5), 7.42 (1H, ddd, J = 8.1, 3.6, and 1.0 Hz, H-7), 7.14 (1H, d, J = 9.0 Hz, H-3), 6.80 (3H, 
d, J = 8.8 Hz, H-2, H-5’, H-6’), 6.58 (1H, d, J = 8.9 Hz, H-2’), 5.94 (2H, s, H-c’), 4.03 (2H, t, J = 
6.6 Hz, H-a), 3.45 (2H, t, J = 7.7 Hz, H-a’), 2.99 (2H, t, J = 7.7 Hz, H-b’), 1.89 (2H, st, J = 7.4 
Hz, H-b), 1.12 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.3 (C-9), 147.7 (C-
3’), 146.0 (C-4’), 136.7 (C-4), 133.1 (C-1), 131.9 (C-6), 131.5 (C-8a), 130.2 (C-4a), 129.6 (C-8), 
129.1 (C-3), 127.7 (C-9a), 125.9 (C-7), 125.8 (C-1’), 124.0 (C-10a), 121.7 (C-5), 120.1 (C-6’), 
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109.1 (C-5’), 108.3 (C-2), 104.0 (C-2’), 100.8 (C-c’), 72.6 (C-a), 35.2 (C-a’), 29.7 (C-b’), 22.9 (C-
b), 10.7 (C-c). Anal. Calc. for C25H23NO4S (433.52): C, 69.26; H, 5.35; N, 3.23; O, 14.76; S, 
7.40. Found: C, 69.05; H, 5.49; N, 3.63; O, 14.59; S, 7.59. 
1-{[2-(4-Nitrophenyl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (48): 7% as a dark 
redish oil (procedure c). IR (KBr) max: 3447, 3422, 3338, 2921, 2852, 1673, 1633, 1576, 1553, 
1514, 1436, 1341, 1300, 1265, 1233, 1146, 1120, 1058. 
1
H NMR (CDCl3, 300.12 MHz)  : 8.13 
(1H, dd, J = 8.0 and 1.5 Hz, H-8), 8.00 (2H, d, J = 6.0 Hz, H-3’, H-5’), 7.87 (1H, ddd, J = 8.0, 
3.9, and 1.2 Hz, H-6), 7.74 (1H, dd, J = 8.0 and 1.9 Hz, H-5), 7.68 (1H, ddd, J = 8.0, 3.7, and 
1.3 Hz, H-7), 7.56 (1H, d, J = 8.9 Hz, H-3), 7.51 (2H, d, J = 6.0 Hz, H-2’, H-6’), 7.11 (2H, d, J = 
8.9 Hz, H-2), 4.10 (2H, t, J = 6.4 Hz, H-a), 2.10 (2H, t, J = 9.0 Hz, H-a’), 1.90 (2H, st, J = 6.5 Hz, 
H-b), 1.18 (2H, t, J = 9.0 Hz, H-b’), 1.06 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 
182.4 (C-9), 156.9 (C-4), 155.0 (C-4’), 140.7 (C-1), 138.1 (C-6), 136.9 (C-8a), 134.0 (C-4a), 
133.5 (C-8), 132.9 (C-3), 132.2 (C-1’), 130.3 (C-9a), 129.6 (C-7), 128.3 (C-10a), 126.8 (C-5), 
125.0 (C-2’, C-6’), 122.0 (C-3’, C-5’), 117.9 (C-2), 71.9 (C-a), 48.0 (C-a’), 29.6 (C-b’), 22.3 (C-b), 
10.5 (C-c). Anal. Calc. for C22H24N2O4S (434.52): C, 66.34; H, 5.10; N, 6.45; O, 14.73; S, 7.38. 
Found: C, 66.42; H, 5.54; N, 6.80; O, 14.14; S, 7.06. 
4-Hydroxy-1-{[(4-nitrobenzyl)oxy]amino}-4-propoxy-9H-thioxanthen-9-one (49): 13% as a 
red solid (procedure c); mp 81 ºC (acet). IR (KBr) max: 3423, 3321, 3053, 2918, 2856, 1715, 
1614, 1546, 1437, 1374, 1259, 1162, 1061, 947, 806, 741, 560, 478. 
1
H NMR (CDCl3, 300.12 
MHz) : 8.52 (1H, dd, J = 8.0 and 0.8 Hz, H-8), 7.72 (2H, d, J = 5.7 Hz, H-2’, H-6’), 7.53 (4H, m, 
H-6, H-5, H-3’, H-5’), 7.42 (1H, ddd, J = 8.2, 4.1, and 1.0 Hz, H-7), 7.04 (1H, d, J = 8.8 Hz, H-3), 
6.57 (1H, d, J = 8.8, H-2), 4.30 (2H, s, H-a’), 4.02 (2H, t, J = 6.5 Hz, H-a), 1.87 (2H, st, J = 6.5 
Hz, H-b), 1.13 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 175.1 (C-9), 155.4 (C-4), 
148.8 (C-4’), 147.7 (C-1), 147.2 (C-6), 145.9 (C-8a), 135.2 (C-4a), 131.7 (C-8), 126.7 (C-3), 
125.9 (C-1’), 124.5 (C-9a), 121.0 (C-7), 120.6 (C-10a), 118.1 (C-5), 117.4 (C-2’, C-6’), 115.7 (C-
3’, C-5’), 113.9 (C-2), 76.5 (C-a), 55.7 (C-a’), 20.7 (C-b), 11.8 (C-c). Anal. Calc. for C23H20N2O5S 
(436.48): C, 63.29; H, 4.62; N, 6.42; O, 18.33; S, 7.35. Found: C, 63.07; H, 4.57; N, 6.42; O, 
17.63; S, 7.96. 
1-[(4-Ethoxy-2-nitrophenyl)amino]-4-hydroxy-9H-thioxanthen-9-one (50): 47% as brown 
solid (procedure c); mp 96 ºC (acet). IR (KBr) max: 3467, 3343, 2926, 1558, 1504, 1456, 1411, 
1387, 1334, 1243,1216, 1155, 1059, 1040, 956, 813, 569, 495, 438. 
1
H NMR (CDCl3, 300.12 
MHz) : 8.60 (1H, d, J = 8.1 Hz, H-8), 7.63 (4H, m, H-5, H-6, H-3’, H-5’), 7.46 (1H, ddd, J = 8.5, 
4.3, and 0.9 Hz, H-7), 7.32 (1H, d, J = 8.9 Hz, H-3), 7.08 (1H, d, J = 9.3 Hz, H-6’), 7.06 (1H, d, J 
= 8.9 Hz, H-2), 4.11 (1H, q, J = 6.4 Hz, H-a’), 4.05 (2H, t, J = 7.2 Hz, H-a), 1.93 (2H, st, J = 7.2 
Hz, H-b), 1.43 (1H, t, J = 6.9 Hz, H-b’), 1.15 (3H, t, J = 7.4 Hz, H-c). 
13
C NMR (CDCl3, 75.47 
MHz) : 183.1 (C-9), 152.4 (C-4), 147.0 (C-4’), 142.5 (C-2’), 140.1 (C-1), 138.6 (C-1’), 136.5 (C-
6), 133.0 (C-8a), 132.1 (C-4a), 130.1 (C-8), 129.6 (C-3), 126.3 (C-9a), 126.0 (C-7), 123.0 (C-6’), 
121.6 (C-5’), 118.3 (C-10a), 115.8 (C-3’), 113.8 (C-5), 108.8 (C-2), 71.1 (C-a), 64.3 (C-5’), 22.7 
(C-b), 14.7 (C-6’), 10.7 (C-c). Anal. Calc. for C24H24N2O5S (452.52): C, 63.70; H, 5.35; N, 6.19; 
O, 17.68; S, 7.09. Found: C, 63.01; H, 5.16; N, 6.19; O, 17.73; S, 7.90. 
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1-[(3,4,5-Trimethoxyphenyl)amino]-4-propoxy-9H-thioxanthen-9-one (51): 53% as orange 
redish solid (procedure c); mp 145 ºC (acet). IR (KBr) max: 3532, 3415, 3331, 3252, 3009, 
2951, 2918, 1570, 1505, 1454, 1418, 1476, 1282, 1238, 1179, 1120, 1064, 1005, 948, 797, 
737, 623, 563, 432. 
1
H NMR (CDCl3, 300.12 MHz) : 8,52 (1H, d, J = 8.0 Hz, H-8), 7.58 (2H, m, 
H-6, H-5), 7,46 (1H, ddd, J = 8.3, 4.5, and 0.8 Hz, H-7), 7.16 (H-3, d, J = 9.1 Hz, H-3), 7.08 (1H, 
d, J = 9.1 Hz, H-2), 6.58 (2H, s, H-2’, H-6’), 4.06 (2H, t, J = 6.6 Hz, H-a), 3.85 (6H, s, H-a’’, H-
c’’), 3.77 (3H, s, H-b’’), 3,6 (1H, s, -NH-), 1.90 (2H, st, J = 6.8 Hz, H-b), 1.12 (3H, t, J = 7.3 Hz, 
H-c). 
13
C NMR (CDCl3, 75.47 MHz) : 183.7 (C-9), 153.8 (C-4), 145.8 (C-3’, C-5’), 144.1 (C-1), 
142.8 (C-1’), 137.2 (C-6), 134.5 (C-8a), 131.8 (C-4a), 130.0 (C-8), 129.2 (C-3), 126.0 (C-9a), 
125.9 (C-7), 109.9 (C-2), 100.6 (C-2’, C-6’), 72.3 (C-a), 61.0 (C-b’), 56.1 (C-a’, C-c’), 22.8 (C-b), 
10.7 (C-c). Anal. Calc. for C25H25NO5S (451.53): C, 66.50; H, 5.58; N, 3.10; O, 17.72; S, 7.10. 
Found: C, 65.94; H, 5.00; N, 3.76; O, 17.72; S, 6.87. 
1-[(2S,3R,4S,5R,6R)-2-(4-Aminophenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-
triol]-4-propoxy-9H-thioxanthen-9-one (52): 5% as brown redish solid (procedure c); mp > 
330 ºC (acet). IR (KBr) max: 3423, 2954, 2923, 1652, 1558, 1505, 1380, 1227, 1068, 1052, 880, 
823, 667, 542, 437, 421. 
1
H NMR (DMSO-d6, 300.12 MHz) : 8.39 (1H, d, J = 8.2 Hz, H-8), 7.49 
(1H, d, J = 8.2 Hz, H-6), 7.10 (1H, d, J = 8.4 Hz, H-5), 6.82 (1H, m, H-7), 6.74 (1H, d, J = 8.7 
Hz, H-3), 6.65 (2H, d, J = 8.8 Hz, H-3’, H-5’), 6.56 (2H, d, J = 9.0 Hz, H-2’, H-6’), 6.47 (1H, d, J 
= 8.7, H-2), 4.90 (4H, m, b’-f’-OH), 4.55 (7H, m, H-a’-f’), 2.66 (2H, t, J = 7.7 Hz, H-a), 2.23 (2H, 
m, H-b), 1.18 (3H, t, J = 6.4 Hz, H-c). 
13
C NMR (DMSO-d6, 75.47 MHz) : 183.4 (C-9), 148.8 (C-
4), 142.6 (C-4’), 136.7 (C-1), 131.6 (C-1’), 130.1 (C-6), 129.4 (C-8a), 129.2 (C-4a), 129.0 (C-8), 
128.6 (C-3), 128.3 (C-9a), 128.0 (C-7), 127.8 (C-10a), 127.2 (C-5), 125.9 (C-2’, C-6’), 118.6 (C-
3’, C-5’), 115.0 (C-2), 106.9 (C-a’), 72.4 (C-e’), 70.4 (C-c’), 66.0 (C-a), 47.0 (C-b’), 30.9 (C-d’) 
29.7 (C-f’), 22.9 (C-b), 10.7 (C-c). Anal. Calc. for C28H29NO8S (539.60): C, 62.32; H, 5.42; N, 
2.60; O, 23.72; S, 5.94. Found: C, 63.21; H, 5.30; N, 2.91; O, 23.61; S, 4.98. 
 
2.5.4. Synthesis of 1-chloro-4-hydroxy-9H-thioxanthen-9-one (53) 
 
A solution of 1-chloro-4-propoxy-9H-thioxanthen-9-one (6, 1.5 g, 5 mmol) in dry CH2Cl2 (12 mL) 
was cooled to – 70 ºC. BBr3 (10 mL) was added to the stiring solution. The reaction proceeded 
until room temperature was reached. Reaction was stopped by drop-wise adding of methanol. 
The reaction product was extracted with NaOH 5%, followed by acidification and extraction with 
ethyl acetate. Crystallization from ethyl acetate furnished compound 53 as a light yellow solid 
(1.49 g, 98%). mp 133 ºC (ethyl acetate). IR (KBr) max: 3064, 1767, 1642, 1577, 1460, 1425, 
1367, 1297, 1226, 1182, 1099, 1076, 1014, 896, 860, 825, 800, 738, 706, 558. 
1
H NMR (CDCl3, 
300.12 MHz) : 8.27 (1H, dd, J = 7.9 and 0.8 Hz, H-8), 7.81 (1H, ddd, J = 8.0, 5.2 and 0.9 Hz, 
H-5), 7.74 (1H, dd, J = 8.1 and 1.4 Hz, H-5), 7.67 (1H, ddd, J = 7.2, 5.4 and 1.3 Hz, H-7), 7.62 
(1H, dd, J = 8.0 and 1.4 Hz, H-2), 7.57 (1H, dd, J = 8.0 and 1.4 Hz, H-3), 2.46 (3H, s, COCH3). 
13
C NMR (CDCl3, 75.47 MHz) : 178.8 (C-9), 168.3 (COCH3), 144.2 (C-4), 133.3 (C-1), 133.0 
(C-6), 132.9 (C-8a), 132.0 (C-4a), 130.0 (C-8), 129.9 (C-3), 129.0 (C-9a), 127.4 (C-7), 126.5 (C-
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10a), 126.3 (C-5), 126.2 (C-2), 20.5 (COCH3). Anal. Calc. for C15H9ClO3S (304.75): C, 59.12; H, 
2.98; O, 15.75; S, 10.52. Found: C, 59.19; H, 3.00; O, 15.75; S, 10.62. 
 
2.5.5. Synthesis of 1-chloro-9-oxo-9H-thioxanthen-4-yl acetate (54) 
 
A mixture of compound 53 (100 mg, 0.3 mmol), acetic anhydride (10 mL), and pyridine (5 drops) 
was magnetically stirred at room temperature. After the reaction was finished, aqueous sodium 
bicarbonate 10% (10 mL) was added. The reaction mixture was poured onto 50 g of crushed 
ice. The solid obtained was filtered, washed with water and dried, furnishing compound 54 (69 
mg, 88%) as a yellow brownish solid; mp 194 ºC (acet); IR (KBr) max: 3255, 2927, 1703, 1628, 
1565, 1433, 1403, 1308, 1222, 1161, 1109, 1075, 1032, 876, 810, 740, 673, 633, 593, 496, 
439. 
1
H NMR (DMSO-d6, 300.12MHz) : 8.38 (1H, dd, J = 8.4 and 1.1 Hz, H-8), 7.65 (1H, ddd, J 
= 8.0, 6.0, and 1.3 Hz, H-6), 7.62 (1H, dd, J = 3.0 and 1.0 Hz, H-5), 7.47 (1H, ddd, J = 7.8, 5.7, 
and 0.9 Hz, H-7), 7.31 (1H, d, J = 8.5 Hz, H-3), 7.10 (1H, d, J = 8.7 Hz, H-2); 
13
C NMR (DMSO-
d6, 75.47 MHz)  : 179.8 (C-9), 162.3 (C-4), 151.3 (C-1), 135.2 (C-6), 131.5 (C-8a), 130.2 (C-
4a), 128.9 (C-8), 128.7 (C-3), 127.5 (C-9a), 125.8 (C-7), 125.6 (C-10a), 124.6 (C-5), 116.0 (C-
2). Anal. Calc. for C13H7ClO2S (262.71): C, 59.43; H, 2.69; O, 12.18; S, 12.21. Found: C, 59.34; 
H, 2.62; O, 12.26; S, 12.69. 
 
2.5.6. Amination of 4-hydroxy-9H-thioxanthen-9-one (54) 
 
To a solution of compound 54 (300 mg, 0.1 mmol) and amine 27 (0.2 mmol)  in NMP (10 mL), 
Cu2O (2 mg) was added and the suspension was irradiated at 400 W for 50 min, under stirring, 
and final temperature range was 200-205 ºC. 
4-Hydroxy-1-[(3,4,5-trimethoxyphenyl)amino]-9H-thioxanthen-9-one (55): 7% as red 
brownish powder; mp 155 ºC (acet). IR (KBr) max: 3447, 3395, 3181, 2911, 2844, 1706, 1578, 
1487, 1437, 1256, 1105, 1049, 1005, 858, 793, 726, 635, 591, 484. 
1
H NMR (DMSO-d6, 300.12 
MHz) : 8.44 (1H, d, J = 7.9 Hz, H-8), 7.82 (1H, m, H-6), 7.69 (3H, m, H-5, H-2’, H-6’), 7.56 (1H, 
m, H-7), 7.40 (1H, d, J = 9.2 Hz, H-3), 7.27 (1H, d, J = 9.1 Hz, H-2), 5.76 (1H, s, 4-OH), 3.78 
(6H, s, H-a’, H-c’), 3.65 (3H, s, H-b’). 
13
C NMR (CDCl3, 75.47 MHz) : 128.8 (C-9), 153.6 (C-3’, 
C-5’), 144.5 (C-4), 136.6 (C-1), 135.8 (C-1’), 133.7 (C-6), 132.8 (C-8a), 131.6 (C-4a), 129.2 (C-
8), 128.8 (C-3), 126.9 (C-9a), 126.8 (C-4’), 126.5 (C-7), 117.9 (C-10a), 113.4 (C-5), 110.5 (C-2), 
99.7 (C-2’, C-6’), 55.9 (C-b’), 54.9 (C-a’, C-c’). Anal. Calc. for C22H19NO5S (409.45): C, 64.53; H, 
4.68; N, 3.42; O, 19.54; S, 7.83. Found: C, 64.85; H, 4.62; N, 3.58; O, 19.78; S, 7.28. 
4-Hydroxy-9H-thioxanthen-9-one (56): 5% as yellow greenish powderv; mp 247 ºC (acet). IR 
(KBr) max: 3522, 3256, 2918, 1768, 1681, 1624, 1585, 1556, 1455, 1428, 1333, 1312, 1274, 
1174, 1144, 730, 682, 565, 442; 
1
H NMR (DMSO-d6, 300.12 MHz) : 8.45 (1H, dd, J = 8.0 and 
1.0 Hz, H-8), 7.99 (1H, d, J = 8.0 Hz, H-1), 7.89 (1H, d, J = 8.0 Hz, H-5), 7.78 (1H, ddd, J = 8.0, 
7.3 and 0.7 Hz, H-6), 7.58 (1H, J = 8.0, 7.2 and 0.7, H-7), 7.43 (1H, t, J = 8.0 Hz, H-3), 7.24 (1H, 
d, J = 7.7 Hz, H-2). 
13
C NMR (DMSO-d6, 75.47 MHz) : 179.1 (C-9), 152.7 (C-4), 136.8 (C-1), 
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132.8 (C-6), 130.1 (C-8a), 129.6 (C-4a), 128.9 (C-8), 128.1 (C-3) 127.2 (C-9a), 126.6 (C-7), 
125.0 (C-10a), 119.4 (C-5), 116.8 (C-2). Anal. Calc. for C13H8O2S (228.27): C, 68.4; H, 3.53; O, 
14.02; S, 14.05. Found: C, 67.29; H, 3.12; O, 14.50; S, 14.74. 
 
2.6. Biological activity 
 
2.6.1. Cell lines 
 
K562 (human chronic myelogenous leukemia, erythroblastic; ECACC, Europe Collection of Cell 
Cultures, UK), K562Dox (derived from K562 by doxorubicin stimulated overexpression of P-gp; 
kind gift from Prof. J.P. Marie, Paris, France), and MRC-5 (human lung fibroblasts which 
undergo between 60-70 doublings before senescence) cell lines were routinely maintained in 
RPMI-1640 (with Hepes and Glutamax, Gibco®, Invitrogen, Germany), with 10% or 5% fetal 
bovine serum (FBS, Gibco®, Invitrogen, Germany) and incubated in a humidified incubator at 
37 ºC with 5% CO2 in air. All experiments were performed with cells in exponential growth, with 
viabilities over 90% and repeated at least three times. K562Dox cells were maintained by 
treating them with 1.0 µM doxorubicin every two weeks in order to maintain the P
-gp overexpression, and all experiments were performed at least four days after this 
administration and in doxorubicin-free medium. 
 
2.6.2. Compounds 
 
SRB and rh123 were obtained from Sigma-Aldrich. Verapamil, quinidine and mibefradil (known 
P-gp inhibitors) were used as controls (Sigma Aldrich, Spain). 
 
2.6.3. Flow cytometry determination of rhodamine-123 accumulation 
 
K562 and K562Dox (5 × 10
6 
cells.mL
-1
) were incubated for 1 h at 37°C in the presence of 10 or 
20 µM of the test compounds, and with 1µM rh123. K562Dox and K562 cells alone as well as 
K562Dox cells in the presence of the known P-gp inhibitors verapamil, mibefradil, quinidine and 
hycanthone (2) [33] (10 and 20 µM) were used as controls. After the incubation time, cells were 
washed twice, re-suspended in ice cold PBS and kept at 4 °C in the dark until analysis in the 
flow cytometer. At least 20 000 cells per sample were counted and analyzed by flow cytometry 
(Epics XL-MCL, Beckman Coulter, USA). Cells shown in forward scatter and side scatter were 
electronically gated and acquired through the FL1 channel. The amount of fluorescence was 
plotted as a histogram of FL1 within the gate. Data acquisition was performed using WINMDI 
2.9 (TSRI, USA) to determine median fluorescence intensity values (MFI). For simple 
interpretation, the ratio of rh123 accumulation was calculated as (MFIK562Dox+Drug - 
MFIK562Dox)/MFIK562Dox. Results represent the average of at least three independent experiments. 
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2.6.4. Determination of ATPase activity 
 
The ATPase activity of P-gp was determined using the luminescent ATP detection kit (P-gp-Glo 
Assay Kit, Promega, Germany) according to the manufacturers’ recommendation [34]. Test 
compounds at 200 µM or sodium vanadate at 20 µM (positive control, noncompetitive inhibitor) 
or verapamil, mibefradil, and quinidine at 200 µM (positive controls, competitive inhibitors) in 
buffer solution were incubated with 0.5 mg.mL
-1
 P-gp and 5 mM MgATP at 37°C for exactly 40 
min, and the remaining ATP was detected after 20 min resting at room temperature, as a 
luciferase-generated luminescent signal. Results are presented as the average of three 
independent experiments. % Values of RLU (relative light unit) was calculated in relation to non-
treated control (NT). It was calculated using the following formula that fits the NT control to zero 
for easier interpretation: % RLU = (RLUtest -RLUNT) / RLUNT  x 100. 
 
2.6.5. Sulphorhodamine-B assay 
 
K562 and K562Dox cells were plated into 96-well tissue culture plates at 5×10
4
 cells.mL
-1
. After 
24 h, cells were treated with serial dilutions of the test compound. Following 48 h treatment, cell 
growth was assayed using the SRB assay. The GI50 values for the thioxanthonic derivatives 
(concentration resulting in 50% inhibition of cell growth) were calculated from the plotted results.  
The ability of the tested compounds to decrease doxorubicin GI50 was evaluated in K562 and 
K562Dox cells by SRB assay, as previously described [33]. K562 and K562Dox cells were 
plated into 96-well tissue culture plates at 5×10
4
 cells.mL
-1
. After 24 h, cells were treated with 
serial dilutions of doxorubicin in combination with 1 or 10 µM of the test compound. Following 48 
h treatment, cell growth was assayed using the SRB assay.  The GI50 values for doxorubicin 
(concentration resulting in 50% inhibition of cell growth) were calculated from the plotted results. 
The ratio of doxorubicin GI50 decrease was obtained by calculating the GI50 of doxorubicin alone 
/ GI50 of doxorubicin in the presence of the tested compound. 
 
2.6.6. Viable cell number by trypan blue exclusion assay 
 
Adherent MRC-5 cells were plated (210
5
 cells.mL
-1
 in 6-well plates). 24 h after plating, cells 
were treated with complete medium (blank), with the solvent of the compounds (DMSO, 
control), or with the following compounds: 30, 33, 37, 38, 41, 43, 45, and 48 in a concentration 
corresponding to their GI50 on K562 cell line. Viable cell number was assessed following 48 and 
72h of incubation with the compounds using the trypan blue exclusion assay (results not 
shown).  
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2.6.7. Statistical analysis 
 
Data was expressed as the mean ± SE and analysed by the Student’s t test. P-values below 
0.05 were considered statistically significant. 
 
 
3. Results 
 
3.1. Design and docking of thioxanthones 
 
Docking was performed using a dataset of approximately 1000 virtual new aminated 
thioxanthones (Table 1A) and two P-gp models constructed using the homologous Sav1866 
from S.aureus (Supplementary data, Annex A) as template. The designed molecules resulted 
from a merging strategy for dual ligands [8, 9] (represented in Fig. 2.I) between a thioxanthonic 
scaffold, associated to antitumor activity [15, 22, 23], with an 4-alkoxyl or 4-hydroxyl group; and 
an amine group at C-1, associated to P-gp inhibitory activity [26, 35]. The introduction of an 
amine side chain, namely an aminoalkylamino group, on the thioxanthonic nucleus seems to be 
also an important feature for the expression of cytotoxicity [36-38]. Thus, amine structures [39, 
40], such as the N,N-diethylethane-1,2-diamine, present in thioxanthones SR233377 (3) and 
SR271425 (4), and in several DNA intercalating agents, were also used in the design of 1-
aminated thioxanthonic derivative. Additionally, the presence of an amine in these derivatives 
allows the formation of salts, which improves compound water solubility [41].  
Computational filters were applied to the initial library of aminated thioxanthones, in order to 
select the molecules that complied with the Lipinski rules of five [42], and other features 
described as important for P-gp inhibition, such as logP value of at least 2.92 or higher [26, 35] 
(Table 1A). The molecules that respected these cutoffs were docked into the drug binding 
pocket formed by the interface between TMD1 and TMD2 and in the ATP-binding site located 
on the NBD of P-gp. Twenty three aminated thioxanthones with the best docking scores (on 
NBD or TMD) (Table 1B and C) and with a rapid synthetic protocol, were selected to be 
synthesized, starting from thioxanthone 6 and amines 7-28. These molecules were selected 
based on the following cut-offs: molecules with NBD docking scores lower than -3.0 kJ.mol
-1
, 
and/or with TMD docking score lower than -2.0 kJ.mol
-1
 (see examples of discarded molecules 
in Supplementary data, Annex C). 
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Table 1. (A) Scheme of the virtual screening protocol; best scoring virtually designed 
tioxanthones with (B) a 4-propoxyl or (C) a 4-hydroxyl substituent at C-4.  
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3.2. Synthesis 
 
Thioxanthones 31-52 (Scheme 1) were synthesized from 1-chloro-4-propoxy-9H-thioxanthen-9-
one (6) by nucleophilic aromatic substitution of the chloride on position C-1 by a primary or 
secondary amine (7-28). 
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Scheme 1. Copper-catalyzed nucleophilic aromatic substitution of thioxanthone. 
 
    
S
O
O
CH3
Cl
RH+
S
O
O
CH3
R
a, b or c
1
3
2
44a10a5
7
8 8a 9a
6
9
a
b
c
R= 7 - 29
30 - 52
     
30*: R= -OCH3 (29)  38: R= 14  46: R= 22 
31: R= 7  39: R= 15  47: R= 23 
32: R= 8  40: R= 16  48: R= 24 
33: R= 9  41: R= 17  49: R= 25 
34: R= 10  42: R= 18  50: R= 26 
35: R= 11  43: R= 19  51: R= 27 
36: R= 12  44: R= 20  52: R= 28 
37: R= 13  45: R= 21    
 
*obtained as a secondary product by reaction of 6 with methanol (procedure a) 
 
The synthesis of aminated thioxanthones was initially investigated by a classical copper 
mediated cross-coupling reaction, using amine in excess (two equivalents of amine, 7-28) and 
thioxanthone 6 as limitating reagent, Cu2O [43] in catalytic amounts (5% eq) at 100 ºC in a 
closed vessel for 1-2 days (Scheme 1, procedure a). However, the reaction was only successful 
for simple aliphatic amines (such as 8, with a yield of 30%). The nucleophilic substitution of 
thioxanthones with an electron donating group such as a propoxyl on C-4 is a very difficult 
reaction [44, 45] and the reported methods require harsh conditions [46]. The addition of K2CO3 
(Scheme 1, procedure b) provided a alkaline media and allowed the synthesis of 36 with a 25% 
yield and of 47 with a 75% yield. As microwave-promoted synthesis is an area of crescent 
interest in N-C cross-coupling reaction [47], the heating source was also modified (Fig. 2, 
procedure c) [48, 49]. Additionally, the solvent was changed to N-methyl-pirrolidone (NMP), an 
aprotic, alkaline solvent, more appropriate for microwave heating. In some cases, a mixture of 
NMP:water [50, 51] was used in order to improve the solubility of the alkaline catalyst and the 
amine, allowing the reaction to proceed (amines 11, 21, and 28). Under these conditions, the 
amination reaction worked not only for alkylamines (e.g. 12 and 13) but also for cyclic amines 
a) Cu2O, MeOH, 100 
ºC, 2 days; b) Cu2O, 
K2CO3, MeOH, 100 
ºC, 2 days; c) Cu2O, 
K2CO3, NMP, 
microwaves, 205 ºC, 
50 min 
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(e.g. 14 and 19) and aromatic amines (e.g. 20, 26, and 27) and allowed to obtain the desirable 
aminated thioxanthones (36, 37, 38, 43, 44, 50, and 51, respectively). 
To obtain compound 55, a dealkylation of 6 with boron bromide, BBr3 [52] followed by an 
acetylation was performed (Scheme 2). Reaction of compound 54 with 3,4,5-trimethoxyaniline 
(27) furnished directly the desirable 4-hydroxy-1-aminated derivative 55 along with compounds 
53 and 56 (Scheme 2). 
 
Scheme 2. Synthesis of compound 55. 
S
O
O
CH3
Cl
1) dry CH2Cl2, -70°C, BBr3
2) MeOH (drop-wise)
S
O
OH
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NH2
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O
CH3
O
CH3
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HN O
CH3
O
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S
O
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O
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S
O
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S
O
OH
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+ +
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5355
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88% 98%
7% 51% 5%
 
In summary, twenty-three new aminated thioxanthones predicted from the docking study to be 
potential P-gp modulating agents were synthesized in reasonable yields to perform biological 
assays. Other thioxanthonic derivatives obtained were also investigated in the biological assays 
(30, 53, 54, and 56). The structure elucidation (Supplementary data, Annex D) of the 
synthesized compounds was based on spectral data (IR, 
1
H NMR, 
13
C NMR, HMBC, and 
HSQC) and on elemental analysis. 
 
3.3. Flow cytometry rhodamine-123 assay 
 
An indirect way to analyse P-gp activity is by the evaluation of the mean fluorescence intensity 
(MFI) of cells exposed to rhodamine-123 (rh123), a know P-gp fluorescent substrate, together 
with the potential P-gp inhibitor [53-55]. Quantification of the relative fluorescence accumulation 
can be used as an indirect way to study the individual potency of inhibitors [56]. This flow 
cytometry method for P-gp functional evaluation has been used for decades [57, 58] and was 
chosen to initiate the present study. However, rh123 is a substrate not only for P-gp but also for 
MRP [59] and expression of both P-gp and MRP has been reported to occur in leukemic cells 
[60]. We have previously failed to detect MRP-1 by Western Blot in either K562 and K562Dox 
cell lines, whereas we confirmed that P-gp is expressed in K562Dox cell line but not in K562 cell 
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line [33]. The results from the effect of the test compounds 2, 6, 30-56 in the cellular 
accumulation of rh123 are shown in Fig. 3. 
 
Fig. 3. Relative accumulation ratios of rh123 after 1h of incubation in K562 or K562Dox cell 
lines. K562Dox alone (no drug) is represented as zero for easier interpretation. Accumulation 
ratio superior to zero correspond to rh123 accumulation superior to K562Dox, i.e., potential P-
gp inhibitors. Results are the mean ± SE of three independent experiments. Statistical 
significance was tested by paired t-test using the untreated K562Dox (second entry) as control. 
*** Indicates P < 0.001; ** indicates 0.001 < P ≤ 0.01; * indicates 0.01 < P ≤ 0.05; ns indicates 
not significant, i.e., P > 0.05 (n=3 independent experiments). 
 
After K562 cells were incubated with rh123, accumulation ratio increased when compared with 
K562Dox, as it was expected for a cell line which does not express P-gp (Fig. 3). Untreated 
K562Dox cells rh123 accumulation was considered residual (Fig. 3).  Verapamil, quinidine and 
mibefradil, known first-generation P-gp inhibitors [61], and hycanthone (2), were used in this 
study as controls. As expected, they caused a rh123 accumulation on K562Dox cells similar to 
the one observed on the sensitive cell line, K562 (Fig. 3). After K562Dox cells were incubated in 
the presence of the test compounds (2, 6, 30-56), the accumulation ratios varied. In the case of 
fifteen of the investigated compounds (compounds 30, 33, 35, 37, 38, 41-45, 48-51, and 55, 
Fig. 3), together with the controls (verapamil, quinidine, mibefradil and compound 2), an 
increase in the accumulation ratio of rh123 was observed, an effect compatible with P-gp 
inhibition. Particularly, 1-[2-(1H-benzimidazol-2-yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one 
(45), 1-(4-acetylpiperazin-1-yl)-4-propoxy-9H-thioxanthen-9-one (38) and 1-{[2-(4-
nitrophenyl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (48) showed an effect similar to that 
elicited by the known P-gp inhibitor, quinidine, and higher than the known thioxanthone 
hycanthone (2). A dose-dependent response was clearly observed for compound 48, whereas 
there was no clear evidence of a dose-dependent response for compounds 38 and 45. In 
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contrast, twelve derivatives (compounds 31, 32, 34, 36, 39, 40, 46, 47, 52-54, and 56, Fig. 4) 
showed a significant decrease in the accumulation ratio, an effect compatible with P-gp 
activation. Although the building block 6 had no effect on P-gp function (Fig. 3), the side product 
30 revealed an interesting rh123 accumulation rate. 
 
3.4. P-gp ATPase assay 
 
The rate of P-gp ATP hydrolysis allows to discriminate between compounds that increase the 
ATP consumption by P-gp (i.e., competitive inhibitors or substrates) and compounds that 
reduce the use of ATP either by acting directly on ATP-binding site or indirectly by blocking an 
allosteric site relevant for P-gp activity (i.e., noncompetitive inhibitors) [62, 63]. Therefore, to 
elucidate if the thioxanthonic derivatives that caused accumulation of rh123 were either 
competitive inhibitors (substrates for transport by P-gp), or P-gp noncompetitive inhibitors, 
effects on the ATPase activity of P-gp were measured using human P-gp membranes [33, 64]. 
The results for the fifteen potential P-gp inhibitors (compounds 30, 33, 35, 37, 38, 41-45, 48-51, 
and 55) along with the building block 6 and four controls (sodium orthovanadate, verapamil, 
mibefradil and quinidine) are shown in Fig. 4.  
 
Fig. 4. P-gp ATPase assay. Results are % of RLU (relative light unit) in relation to non-
treated (NT) control. NT control luminescence is represented as zero for easier interpretation. % 
Value of RLU superior to zero correspond to inhibitors of P-gp ATPase, i.e., noncompetitive P-
gp inhibitors. % Value of RLU inferior to zero correspond to substrates of P-gp, i.e., competitive 
P-gp inhibitors. Results are the mean ± SE of three independent experiments. Na3VO4, 
verapamil, mibefradil, and quinidine were used as controls. Statistical significance was tested by 
paired t-test using the NT-control as a negative control. *** Indicates P < 0.001; ** indicates 
0.001 < P ≤ 0.01; * indicates 0.01 < P ≤ 0.05; ns indicates not significant, i.e., P > 0.05 (n=3). 
 
Sodium orthovanadate is an inhibitor of P-gp ATPase activity [65] and as expected caused 
significant increase in % relative light unit (% RLU), whereas verapamil, mibefradil and quinidine 
are P-gp substrates and competitive inhibitors, showing decreased % RLU (Fig. 4). 
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Compounds 30, 33, 35, 38, 41, 42, 45, and 48-51 (Fig. 4) caused a significant increase in the % 
RLU in relation to the untreated (NT), i.e., they were found to be P-gp ATPase inhibitors 
(noncompetitive P-gp inhibitors). They may prevent ATP hydrolysis by targeting the P-gp ATP 
binding site directly [16, 66] or by binding to an allosteric residue [67, 68] which causes 
inhibition of P-gp function with resulting inhibition of ATPase activity. Compounds such as 37, 
43, 44, and 55 behave similarly to verapamil, mibefradil, and quinidine, i.e., they increased the 
hydrolysis of ATP through P-gp, indicating that they are competitive inhibitors of P-gp, possibly 
being themselves transported by the pump. In summary, from the fifteen compounds that had 
caused accumulation of rh123 in the cells, four are acting as competitive and eleven as 
noncompetitive inhibitors of P-gp (docking poses of two of the best P-gp inhibitors, 43 and 45, 
are described on Supplementary data, Annex E). Furthermore, there was a correlation between 
docking scores on NBD and experimental results for noncompetitive ATPase inhibitors, as well 
as between docking scores on TMD and experimental results for competitive ATPase inhibitors 
(Supplementary data, Annex F). 
 
3.5. Growth inhibition assay 
 
The cell growth inhibitory effect of twenty seven thioxanthones (30-56) was examined in the 
K562 and K562Dox cell lines by the sulphorhodamine-B assay (SRB) and results are presented 
in Table 2A and 2B, respectively. On K562 cell line, the GI50 values for twenty four of the 
compounds (30, 33-39, 41-56) were in the range 1.9–104.7 µM (Table 2A). Six compounds 
showed a GI50 < 10 µM (30, 33, 37, 41, 43, 55). The most potent cell growth inhibitor 
thioxanthone was 1-{[2-(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one  (37), with a 
GI50 of 1.9 µM. Eight of the thioxanthones that presented the best P-gp and cell growth inhibitory 
activity (30, 33, 37, 38, 41, 43, 45, and 48) were further investigated on the K562Dox cell line 
(Table 2B). As expected, the GI50 values in K562Dox cell line were generally higher than in the 
K562 cells.  Six of the compounds investigated on K562Dox cell line showed a GI50 value < 20 
µM (30, 33, 37, 41, 43, and 45), indicating that they might have both P-gp and cell growth 
inhibitory activity. Interestingly, compound 37, which is structurally similar to the known 
antitumor thioxanthones 1-4, was 9-fold more potent than doxorubicin in this cell line.  
The growth inhibitory effect of the thioxanthonic derivatives was also assayed on a nontumor 
cell line model, MRC-5. There was no significant decrease in viable cell number of cells treated 
with compounds 30, 33, 37, 38, 41, 43, 45, and 48, when compared to DMSO solvent control, 
48 and 72 h after treatment (results not shown). 
To investigate the ability of these newly designed dual inhibitors to reverse the MDR phenotype, 
a doxorubicin sensitization assay in the P-gp overexpressing cell line (K562Dox) was performed 
(Table 3A). To understand if the growth inhibitory effect on this cell line was due to their dual 
actions, a sensitization assay was also performed on K562 cell line (Table 3B). We 
hypothesized that if a compound was able to decrease doxorubicin GI50 in K562Dox, without 
decreasing doxorubicin GI50 in K562 cell line, then its effect should be mainly due to P-gp 
H2 
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inhibition. On the other hand, if a compound decreases doxorubicin GI50 on both K562 and 
K562Dox cell lines, then its effect should be due to both cell growth inhibitory activity and P-gp 
inhibition. Results of the SRB assay on cells treated with a combination of the thioxanthonic 
derivative (30, 33, 37, 38, 41, 43, 45, or 48) and doxorubicin are presented in Table 3. Two 
concentrations of the thioxanthonic derivatives were used, 1 and 10 µM, which are below the 
GI50 of the compounds tested alone. 
 
Table 2. Cytotoxic effects of thioxanthones 30-56 on sensitive K562 (A) and resistant 
K562Dox cells (B). 
A            B 
Compound GI50 (K562)  (µM) 
37 1.90 ± 0.15 
43 3.00 ± 0.48 
33 3.72 ± 1.47 
55 4.38 ± 0.44 
30 4.47 ± 1.93 
41 4.81 ± 4.21 
50 12.98 ± 0.36 
54 13.57 ± 2.96 
51 15.57 ± 3.15 
35 16.22 ± 0.48 
39 16.50 ± 3.06 
45 16.99 ± 2.33 
49 18.13 ± 4.35 
44 19.23 ± 0.98 
48 20.96 ± 2.08 
36 21.47 ± 2.61 
53 22.73 ± 0.64 
38 29.79 ± 3.02 
34 52.95 ± 1.47 
52 59.45 ± 2.77 
42 60.58 ± 2.01 
56 74.32 ± 7.16 
46 92.92 ± 3.33 
47 104.71 ± 7.29 
31 > 150    
32 > 150    
40 > 150    
Verapamil > 150     
Doxorubicin 0.06 ± 0.01 
Results are mean ± SE of at least three independent experiments, except for compounds with GI50 > 150 
µM (two independent experiments). 
* Values of K562Dox GI50 are statistically different (P < 0.05) from the K562 GI50 
ns
 Values of K562Dox GI50 are not statistically different (P > 0.05) from the K562 GI50 
Compound GI50 (K562Dox) (µM) 
37 1.95 
ns ± 0.34 
43 11.89* ± 1.17 
33 12.59* ± 0.69 
41 15.38* ± 0.53 
45 19.43ns ± 0.76 
30 19.60* ± 2.73 
38 37.31* ± 2.08 
48 41.56* ± 5.48 
Verapamil > 150     
Doxorubicin 11.62* ± 1.14 
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At 10 µM, verapamil caused a 5.9-fold decrease in doxorubicin GI50 on K562Dox cell line. At the 
same concentration, compound 45 decreased the doxorubicin GI50 by 12.6-fold, followed by 
compound 38 with a 8.9-fold decrease, and by compound 48 with a 7.5-fold decrease (Table 
3A). Compound 45 at 10 µM was approximately 2-fold more potent than verapamil, and 
compounds 38 and 48 were approximately 1.5-fold more potent than verapamil, probably due to 
a dual activity as P-gp and cell growth inhibitors, since these compounds also reduced 
doxorubicin GI50 in the sensitive K562 cell line (Fig. 3B).  
 
Table 3. Cytotoxic effects of doxorubicin in combination with newly synthesized thioxanthones 
(at 1 or 10 µM) on resistant K562Dox (A) and sensitive K562 cells (B). 
 
  (A) K562Dox (B) K562 
 
 
     
    GI50  
   µM 
Ratio of 
doxorubicin 
GI50 
decrease 
GI50 
nM 
Ratio of 
doxorubicin 
GI50 
decrease 
  Doxorubicin 11.62 ± 1.14  - 61.67 ± 1.27 - 
D
o
x
o
ru
b
ic
in
 +
 
10  
µM 
Verapamil 1.97 ± 0.03*** 5.90 55.76 ± 1.12* 1.11 
45 0.92 ± 0.16*** 12.6 15.89 ± 0.6*** 3.88 
38 1.30 ± 0.25*** 8.94 6.34 ± 0.02*** 9.73 
48 1.56 ± 0.16*** 7.45 9.65 ± 1.07*** 6.39 
1  
µM 
Verapamil 4.46 ± 0.21** 2.61 58.45 ± 1.17
ns
 1.05 
37 3.15 ± 0.32** 3.69 4.71 ± 0.40*** 13.09 
45 7.17 ± 0.20* 1.62 58.31 ± 0.9
ns
 1.06 
48 7.36 ± 0.16* 1.58 57.16 ± 1.80
ns
 1.08 
38 8.50 ± 0.33* 1.37 51.84 ± 0.52* 1.19 
41 9.60 ± 0.27* 1.21 49.11 ± 0.62** 1.26 
43 9.64 ± 0.21* 1.21 13.00 ± 0.88*** 4.74 
33 11.57 ± 0.37
ns
 1.00 16.37 ± 1.00*** 3.77 
30 11.70 ± 0.34
ns
 0.99 42.20 ± 1.45** 1.46 
The selected concentrations of test compounds are below the GI50 of the tested compounds on each cell 
line when tested alone. 
Statistical significance was tested by paired t-test using the doxorubicin alone GI50 of each cell line as the 
control. *** Indicates P < 0.001; ** indicates 0.001 < P ≤ 0.01; * indicates 0.01 < P ≤ 0.05. ns indicate not 
significant, i.e., P > 0.05 (n=3 independent experiments). 
The ratio of doxorubicin GI50 decrease was calculated as follows: GI50 of doxorubicin alone / GI50 of 
doxorubicin in the presence of the test compound. 
 
When compounds were tested at 1 µM, compounds 37, 45, 48, and 38 were the ones which 
had a greater effect in reducing the GI50 of doxorubicin in the K562Dox cell line. In contrast, in 
K562 cell line, compounds 45 and 48 at 1 µM did not cause any alteration in the GI50 of 
doxorubicin, suggesting that the sensitization effect of those two compounds seen in the 
K562Dox cell line is due to their P-gp inhibitory activity. On the other hand, compound 37 at 1 
µM caused a 13-fold decrease on doxorubicin GI50 on the K562 cell line (GI50 = 4.71 ± 0.40 nM), 
suggesting that the effects of compound 37 are not only due to P-gp inhibition but also and 
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mainly due to cell growth inhibition. Additionally, compound 38 at 1 µM caused a 1.2 fold-
reversal on this cell line, which implies that, besides the P-gp inhibitory effect of this compound, 
which seems predominant, a significant antileukemic effect is also observed. Compounds 30, 
33, and 43, sensitized K562 cells more than K562Dox cells to the effect of doxorubicin, 
suggesting that their effect is mostly on cell growth. 
  
4. Discussion  
The synthesis of 1-aminated thioxanthones was performed by Ullman cross-coupling, using 
conventional or microwave heating. Both methods yielded the desirable compounds. The 
presence of a base was favorable and increased the yields of reaction. After purification and 
structural elucidation, a rh123 accumulation assay was performed in order to select the 
thioxanthones which were interfering with the efflux of rh123 by P-gp (Fig.3). Noteworthy, the 
most potent compounds (potential P-gp inhibitors) present two nitrogen atoms (amine or nitro 
groups) separated by an alkyl (37 and 38), or alkylaryl chain (45 and 48).  
From the fifteen compounds that had caused accumulation of rh123 in the cells, four are acting 
as competitive inhibitors (increased P-gp ATPase activity compared to non treated control) 
(compounds 37, 43, 44, and 55) and eleven as noncompetitive inhibitors of P-gp (decreased P-
gp ATPase activity comparing to non treated control) (compounds 30, 33, 35, 38, 41, 42, 45, 
and 48-51). When comparing these results (Fig. 4) with the ones obtained on the rh123 
accumulation assay (Fig. 3), general agreement between the outcomes of the two assays could 
be observed. Indeed, most of the compounds with the highest accumulation ratio (>1.0) in the 
rh123 accumulation assay, such as 30, 38, 45, and 48 also showed a high activity in the 
ATPase assay. Nevertheless, compound 41, which presented a high % value of RLU in the 
ATPase assay, showed an accumulation ratio of rh123 <0.5. This discrepancy in the activity of 
some compounds measured by two assays is probably due to the fact that the rh123 
accumulation assay uses cells and the ATPase assay uses membrane fractions, and therefore, 
the latter does not suffer interferences by factors related to drug permeability [69, 70].  
Concerning the capacity of MDR reversal of P-gp overexpressing cell line K562Dox, compound 
45 at 10 µM was approximately 2-fold more potent than verapamil, and compounds 38 and 48 
were approximately 1.5-fold more potent than verapamil (Table 3A), probably due to a dual 
activity as P-gp and cell growth inhibitors, since these compounds also reduced doxorubicin 
GI50 in the sensitive K562 cell line (Table 3B). In spite of the lower rh123 accumulation on 
K562Dox in comparison to verapamil (Fig. 3), compounds 38 and 48 at 10µM succeed to 
sensitize resistant K562Dox cells due to its dual activity as P-gp and cell growth inhibitors.  
These results suggest that the dual effect of some 1-aminated thioxanthones have a 
sensitization effect to a traditional chemotherapeutical agent such as doxorubicin, which might 
be a valuable strategy to explore further in the design of efficient dual activity molecules.   
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5. Conclusion 
 
The rational merged scaffolds approach rendered a new class of dual activity agents (cell 
growth and P-gp inhibitors), aminoalkylthioxanthones. We identified 1-{[2-
(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (37) as a potent cell growth 
inhibitor. We also recognized 1-[2-(1H-benzimidazol-2-yl)ethanamine]-4-propoxy-9H-
thioxanthen-9-one (45) and 1-{[2-(4-nitrophenyl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one 
(48) as dual noncompetitive inhibitors of P-gp and inhibitors of cell growth, being more active 
than verapamil in sensitizing a P-gp overexpressing cell line to doxorubicin. 
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Supplementary Data 
 
Annex A. Development of P-gp homology models based on Sav1866 
UniprotKb (Protein knowledge database) [1] was used to locate human P-gp sequence (code 
P08183). The FASTA file was saved as .txt file and opened in Swiss-PdbViewer [2, 3] (SPDB, 
Swiss Institute of Bioinformatics). An initial Swiss Model search (Swiss Institute of 
Bioinformatics) [4-6] was used to identify possible template structures for homology modelling. 
At the time of modelling, the only suitable complete template structure isolated was the ADP-
bound S. aureus Sav1866 (2HYD.pdb) and the structure of Sav1866 in complex with AMP-PNP. 
These templates had the same BLAST score but the ADP-bound Sav1866 had a better 
resolution; so this was the template chosen. Both chains of Sav1866 (2HYDa.pdb and 
2HYDb.pdb) were aligned with the human P-gp sequence using Swiss PdbViewer. Each P-gp 
half-transporter was modelled separately using Swiss Model and a manual alignment was 
performed following the additional information presented by Swiss Model. Therefore, gaps were 
introduced into the sequence to allow the simultaneous alignment of all conserved regions. The 
alignment was submitted to Swiss Model server and the model 1 was created. The model was 
subjected to a semi-empirical AM1 energy minimisation using Hyperchem (Hypercube, USA) [7] 
until the energy gradient was inferior to 0.1 kcal.mol
-1
. The model 2 was created from model 1 
by manual rotation of TM4, TM5, TM10, and TM11, in order to place important binding residues 
to the inside-pocket. This new model was then minimized (Amber, Molecular Mechanics) and 
subjected to molecular dynamics (1 microsec, 298K, 1 fs timestep) using Hyperchem 
(Hypercube, USA) [7]. Model validation was done by single-point energy calculation and 
Ramachandran plot analysis. 
 
P-glycoprotein (P-gp) is an ATP binding cassette transporter formed by four domains: two 
transmembrane domains (TMD1 and TMD2, composed of six spanning -helixes TM1-6 and 
TM7-12, respectively), which contain the drug binding sites and define the translocation 
pathway across the membrane; and two cytoplasmic nucleotide binding domains (NBD1 and 
NBD2), which bind and hydrolise ATP, and this energy allows drug transport [8, 9] (Fig. A.1.A 
and B). The number and location of the drug binding sites remains unclear. Initially a large 
common binding site was assumed [10], but later a minimum of two binding sites was proposed 
to explain the complex behaviour of P-gp when cooperative, competitive, and noncompetitive 
interactions between MDR modulators were observed [11] which interacted in a positively 
cooperative manner [12, 13]. P-gp was the first multidrug transporter for which structural data 
was obtained, albeit at low-to-medium resolution [9, 14-16] which does not allow a structure-
based design approach for the discovery of potential P-gp inhibitors. The effort to find new P-gp 
modulators has been accelerated after the crystal structure of several ATPase structures and 
ABC cassette proteins became available. By the time this study was performed, there was no P-
gp 3D structure at adequate resolution to perform docking studies (a 3D structure obtained by 
crystallography of mouse P-gp was discovered later) [17] and only a high-resolution structure of 
a homologous bacterial multidrug ABC transporter, Sav1866, from Staphylococcus aureus, was 
available [18]. Sav1866 structure is consistent with the lower resolution structures [9, 14-16] and 
biochemical cross-linking data [19, 20] for P-gp. The organization and pseudo-symmetrical 
arrangement of TMD in the 8Å electron microscopy structure of P-gp correlates to the TMD 
structure of Sav1866, while the overall dimensions of the two transporters also correspond [21]. 
Biochemical evidence demonstrates that P-gp has the same domain inter-linking motif as 
Sav1866, where P-gp ICL4 (intracellular loop 4) in TMD2 interacts with residues in NBD1 [22], 
strengthening the argument that Sav1866 is a suitable template structure for P-gp modeling. 
Likewise, it is generally accepted that a sequence identity above 25% leads to reasonable 
homology models [23].  In fact, each of the Sav1866 chains presented an identity of 172 in 488 
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residues in relation to P-gp, after the alignment. The ADP-bound prokaryotic S.aureus Sav1866 
(2HYD.pdb) structure had the best BLAST score (3×10
-72
) and resolution (3.0 Å); thus, this was 
the template chosen for the construction of homology models using SwissModel [24].  Model 1 
(Fig. A.1.A and B) was obtained by alignment and AM1 minimization. The backbone root-mean-
squared error displacement (RMSD) between Sav1866 and the P-gp model 1 was 5.01 Å after 
fitting the backbone atoms. The quality of the entire P-gp model 1 was assessed on single point 
energy calculation (the final total energy of the model was -3327 kJ.mol
-1
), by comparison with 
Sav1866, and by analysis of Ramachandran plot (96.6%, i.e. 1117/1156 of all residues were in 
allowed regions).  
It is known that ligands bind at a common drug-binding pocket [10] that is formed by the 
interface between the TMD of both P-gp halves (TM 4-6 and 10-12) [25]. However, some 
residues that are considered important to form the drug binding pocket were located outside the 
interface between the two halves on model 1, namely S222 (TM4), I306 (TM5), I868, and G872 
(TM10), F942, and F945 (TM11). Therefore, TM4-5 and TMD10-11 were manually rotated in 
order to place those important residues to the inside-pocket (Fig. A.1.C). This new model was 
then minimized using molecular dynamics (MD). The final model obtained (model 2, Fig. A.1.C) 
was also used in docking studies, and validation of the model was performed by single-point 
energy calculation (-3033 kJ.mol
-1
) and Ramachandran plot (92.6%, i.e. 1072/1158 of all 
residues were in allowed regions). Further validation of the models by docking (using known P-
gp inhibitors), enrichment tests and correlation between experimental data and docking scores 
were also performed (Annex B). 
 
 
 
 
Fig. A.1. A) 3D 
representation of P-
gp model 1 (side 
view). B) TMD of P-
gp  model 1 (top 
view). C) P-gp model 
2; residues that were 
turned to the inside 
pocket by TMD 
rotation are 
represented in yellow. 
 
 
 
Annex B. Models Validation 
 
B.1. Docking of known P-gp inhibitors  
 
Virtual screening was carried out on a commodity PC running Linux Ubuntu 6.06. The 
software eHiTS from SimBioSys Inc [26, 27] was used for active site detection and docking. No 
special preparation of the 3D structures was carried out because eHiTS automatically evaluates 
all of the possible protonation states for ligands and receptor. eHiTS ran using the residues at: i) 
the ATP-binding site on nucleotide-binding domains (NBD) and ii) the drug binding pocket on 
the interface of the TMD as clip files. The docking is performed, by default, within a 7Å margin 
around those residues. The input files of the molecules (Table B.1 and B.2) were in mol format. 
The docking accuracy was set to 2, the number of docking poses was set to 5, and SDF was 
chosen as the output file format. Open Babel [28] was used to manipulate the various file 
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formats of ligands. PyMol from DeLano [29] and Chimera from UCSF [30] were used for visual 
inspection of results and graphical representations. 
The program eHits was used to dock a set of known inhibitors compounds to the P-gp 
homology models. eHits uses a systematic docking algorithm that takes a divide and conquer 
approach to the docking problem [26, 27, 31]. The docking efforts were divided into two areas: 
targeting the ATP binding site to block the ATP hydrolysis (NBD), an energy source of the 
efflux, and targeting directly the binding site (TMD) by designing the compound that would bind 
and compete with the chemotherapeutic agent for transportation [32]. NBD are highly conserved 
amongst ABC transporters, they are absolutely required as the mechanistic driving force for the 
function of P-gp and the presence of two NBD increase the number of potential sites for inhibitor 
binding [32]. On the other hand, the drug-binding sites formed by TMD are the classic targets of 
inhibitor design and possess a distinctive sequence amongst the other members of the ABC 
superfaily [32]. A wide range of known P-gp inhibitors from three generations (presumed to bind 
the TMD, Table B.1) and flavonoids (presumed to bind the NBD, Table B.2) were used in the 
docking studies for validations of the models.  
 
Table B.1. Scores for known P-gp inhibitors (model 1 and model 2) (kJ.mol
-1
) 
  TMD  
on model 1 
TMD  
on model 2 
F
ir
s
t 
G
e
n
e
ra
ti
o
n
 
Verapamil  [33, 34] 0.844 -2.82 
Quinidine  [35] -1.732 -1.815 
Tamoxifen  [36, 37] -0.519 -2.314 
Mibefradil  [38] -0.589 -- 
Erythromycin  [39] -2.996 -1.041 
Tetrandine  [40, 41] -2.38 2.598 
S
e
c
o
n
d
 
g
e
n
e
ra
ti
o
n
 Dexverapamil  [42, 43] -0.178 -2.927 
Dexniguldipine  [44, 45] -1.055 -2.338 
S9788  [46-48] -1.01 -2.412 
Sr33557  [49] -0.615 -4.564 
Biricodar  [50-52] -3.649 -4.332 
T
h
ir
d
 
g
e
n
e
ra
ti
o
n
 Ontogen  [53-55] -1.144 -2.121 
Elacridar  [56] -4.743 -3.439 
Laniquidar  [57] -3.308 -2.552 
Tariquidar  [58, 59] -1.132 -5.274 
Zosuquidar  [60-62] -0.595 -2.043 
 
The tested inhibitors are described as competitive inhibitors (first and second generation) by 
being themselves transported by P-gp, or noncompetitive inhibitors (third generation) by 
mechanism under investigation, presumed to bind preferentially on TMD residues evolved in 
allosteric regulation [63]. Docking results are represented on Table B.1. 
Flavonoids such as flavonols, flavones, isoflavones and chalcones  [23, 64-68] have been 
reported as MDR reversing agents by inhibiting the ATP-binding site of P-gp (located on the 
NBD) [12]. P-gp flavonoid-binding site is cytosolic and partly overlaps the ATP-binding site. So, 
docking studies of these molecules on P-gp NBD were performed, as it is well documented that 
they bind with different affinity grades to the ATP-binding sites on NBD (Table B.2). 
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Table B.2. Structures and scoring values of known flavonoids on both NBD (model 1) [23, 64, 
65] 
 Model 1 
 NBD 1 NBD 2 
2’,4’,6’-trihydroxy-4-(p-fluorophenyl)-chalcone [69] -3.915 -4.482 
2’,4’,6’-trihydroxy-4-(p-iodophenyl)-chalcone [69] -2.784 -4.284 
2’,4’,6’-trihydroxy-4-etoxychalcone [23] -2.627 -3.905 
2’,4’,6’-trihydroxy-4-butoxychalcone [23] -4.505 -5.109 
2’,4’,6’-trihydroxy-4-hexanoxychalcone [23] -4.366 -2.573 
2’,4’,6’-trihydroxy-4-octanoxychalcone [23] -2.008 -3.82 
2’,4’,6’-trihydroxy-4-dexyloxychalcone [23] -3.025 -2.551 
5,7-dihydroflavonoid (chrysin) [23] -2.753 -2.674 
7-benzyloxy-chrysin [70] -3.116 -3.458 
6-benzyl-chrysin [70] -3.392 -3.237 
8-benzyl-chrysin [70] -3.659 -3.404 
6,8-dibenzyl-chrysin [70] -4.123 -4.067 
6-prenyl-chrysin [70] -4.102 -2.763 
8-prenyl-chrysin [23] -4.06 -4.019 
6,8-diprenyl-chrysin [23] -4.817 -3.508 
6-geranyl-chrysin [23] -2.952 -2.727 
7-methoxychrysin [70] -2.909 -3.125 
7-methoxy-6-methyl-chrysin [70] -2.727 -3.457 
6-isopropyl-chrysin [23] -3.352 -4.241 
7-isopropoxy-chrysin [23] -2.415 -3.923 
6-isopropyl-7-isopropoxy-chrysin [23] -3.283 -4.492 
6,8-diisopropyl-7-isopropoxy-chrysin [23] -3.816 -3.667 
8-(1,1- dimethylallyl)-chrysin [71] -4.135 -2.282 
3,5,7-trihydroxyflavonoid 
(galangin) [23] 
-2.804 -2.799 
8-(1,1-dimethylallyl)-galangin [71] -2.962 -1.802 
8-prenylgalangin [71] -3.704 -4.007 
kaempferol [23] -3.037 -3.733 
taxifolin [72] -2.491 -3.555 
7,3’,4’-trimethoxiflavone [73] -2.677 -1.987 
silybin [72] -2.551 -3.415 
dehydrosilybin [72] -4.16 -4.169 
6-prenyldehydrosilybin [72] -3.628 -2.297 
8-prenyldehydrosylibin [72] -4.367 -3.392 
6-geranyldehydrosilybin [72] -4.309 0.882 
8-geranyldehydrosylibin [72] -2.8 -5.468 
 
 
B.2. Enrichment tests 
 
For docking validation, enhanced NCI Database Browser (http://129.43.27.140/ncidb2/) was 
used to obtain the three-dimensional (3D) structures of 1000 compounds in the interval Xa±σ, 
with a = molecular weight, number of hydrogen bond donors, number of hydrogen bond 
acceptors, number of heavy atoms or number of rotable bonds, with X=average for known P-gp 
inhibitors, and σ = standard deviation of a for known P-gp inhibitors. The compounds from the 
diversity set of the NCI database were employed as decoys presumed not to bind the protein 
target. The 3D conformations provided by the NCI were taken as initial 3D structures. 1000 
Molecules were docked in both P-gp models and scores were obtained. Enrichment plots for 
docking known ligands and decoy compounds (1000 putative non-ligands obtained from NCI 
database, as referred previously) into both models were traced and analysed.  
(thio)Xanthone derivatives with dual activity: antitumor and p-glycoprotein inhibition 
304  
 
A way of evaluating docking results is assessing how well annotated ligands, placed within a 
large database of other presumed nonbinding “decoy” molecules, are retrieved. Thus, the 
success of a docking screen is evaluated by its ability to rank a small number of known active 
compounds in the top scores when screening a database with a much higher number of decoy 
molecules [74]. The database’s decoys should share the physical properties of the annotated 
ligands (Table B.3), so that enrichment is not simply a separation of trivial physical features. But 
the decoys should be chemically distinct from the ligands because they are predicated as 
nonbinders [74]. The results from the enrichment tests are represented on Fig. B.1. 
 
Table B.3. Properties of known P-gp inhibitors used to create a list of “decoy” molecules 
  Molecular 
Weight 
Number 
of 
hidrogen 
donnor 
Number 
of 
hidrogen 
acceptors 
Heavy 
atoms 
Rotable 
bounds 
Verapamil 454.6 0 6 33 13 
Quinidine 324.4 1 4 24 4 
Tamoxifen 371.5 0 2 28 8 
Mibefradil 495.6 1 7 36 12 
Erythromycin  733.9 5 14 51 7 
Tetrandrine 622.7 0 8 46 4 
Dexniguldipine 609.7 1 8 45 11 
Dexverapamil 454.6 0 6 33 13 
S9788 505.6 3 9 37 12 
Sr33667 550.7 7 0 39 11 
Biricodar 603.7 0 9 44 16 
Ontogen 494.7 3 5 37 11 
Elacridar 563.6 2 7 42 8 
Laniquidar 584.7 0 7 44 8 
Tariquidar 640.7 2 8 48 11 
Zosuquidar 564.1 2 7 40 6 
Average (X) 535.925 1 6 39 9 
Standard Deviation (σ) 103.649 2 3 7 3 
X + σ 639.574 3 9 46 12 
X - σ 432.276 0 3 32 6 
 
The results investigated show a remarkable enrichment for docking results of the TMD from 
model 2 (Fig. B.1.A, squares) compared to those of the TMD from model 1 (Fig. B.1.B, 
diamonds). In fact, model 2 is able to perfectly distinguish the best molecules (left side of the 
graphic showing three molecules over the yy axis). So, TMD from model 2 was selected for 
docking studies using newly designed thioxanthones. On the other hand, model 1 is able to 
distinguish molecules that dock into the ATP-binding site as there is a significant displacement 
of the points in the graphic to the left (Fig. B.1.B), and, therefore, was also selected for docking 
studies using newly designed thioxanthones. 
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Fig. B.1. Enrichment tests for P-gp homology models. A) Enrichment results for TMD, model 1 
and 2 (using known P-gp inhibitors as ligands); the black line represents a situation where the 
model is not distinguishing between ligands and non-ligands; the grey line represents a model 
that distinguishes them almost completely. B) Enrichment results for ATP-binding site 1 and 2 
(NBD1 and 2 respectively) on model 1 (using flavonoids as ligands). 
 
B.3. Correlation between experimental data and docking scores 
 
A correlation between docking scores and experimental data was performed. Several 
experimental data was collected from the literature, namely Kd (dissociation constant) and IC50 
(the concentration of a drug that is required for 50% inhibition in vitro); those values were 
plotted against docking scores and quadratic correlation coefficient was determined.  
Experimentally measured values may correlate with calculated results, and increase the 
reliability of related results when only computational results are available [75]. Therefore, after 
the docking calculation, the correlation between experimental data and computational results 
was determined. The results obtained from our docking studies are supported by 
measurements of flavonoid Kd and known P-gp inhibitors IC50 experimentally obtained (Table 
B.4 and B.5). Although Kd and IC50 were obtained from different conditions and experiments, a 
correlation was possible to establish. Regression coefficients of r
2
 = 0.84 and r
2
 = 0.65 (ATP-
binding sites 1 and 2, model 1) and r
2
 = 0.78 (TMD, model 2) were obtained (Fig. B.2). Thus, 
the quadratic correlation coefficient was obtained with a minimum of five points, after the 
elimination of the molecules that originated worst scores and outliers. All r
2
 values were higher 
than 0.6, a threshold routinely accepted to establish the goodness of homology-based models 
used in computational studies [23]. This suggests the in ATP-binding site from model 1 and 
TMD from model 2 are robust and able to predict potential P-gp interactions.  
 
Table B.4. Best ATP-binding site score of flavonoids (model 1) versus Kd 
 score Kd LogKd 
2’,4’,6’-trihydroxy-4-(p-fluorophenyl)-chalcone [69] -3.177 0.180 -0.745 
2’,4’,6’-trihydroxy-4-(p-iodophenyl)-chalcone [69] -3.443 0.300 -0.523 
2’,4’,6’-trihydroxy-4-(p-bromophenyl)-chalcone [69] -3.760 0.030 -1.522 
2’,4’,6’-trihydroxy-4-etoxychalcone [23] -3.385 0.370 -0.432 
2’,4’,6’-trihydroxy-4-butoxychalcone [23] -2.228 1.400 0.146 
2’,4’,6’-trihydroxy-4-hexanoxychalcone [23] -4.235 0.340 -0.469 
2’,4’,6’-trihydroxy-4-octanoxychalcone* [23] -3.82 0.020 -1.699 
2’,4’,6’-trihydroxy-4-dexyloxychalcone* [23] -3.025 0.06 -1.222 
5,7-dihydroflavonoid or chrysin [23] -4.976 0.250 -0.602 
A B 
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7-benzyloxy-chrysin [70] -3.578 0.620 -0.208 
6-benzyl-chrysin [70] -- 0.570 -0.244 
8-benzyl-chrysin [70] -- 4.600 0.663 
6,8-dibenzyl-chrysin [70] -- 1.300 0.114 
6-prenyl-chrysin* [70] -4.702 0.015 -1.824 
8-prenyl-chrysin [23] -- 3.100 0.491 
6,8-diprenyl-chrysin [23] -3.889 6.300 0.799 
6-geranyl-chrysin [23] -3.356 1.300 0.114 
7-methoxychrysin [70] -4.139 0.210 -0.678 
7-methoxy-6-methyl-chrysin [70] -3.471 1.320 0.121 
6-isopropyl-chrysin [23] -2.381 0.280 -0.553 
7-isopropoxy-chrysin [23] -3.76 0.030 -1.523 
6-isopropyl-7-isopropoxy-chrysin [23] -4.14 0.341 -0.467 
6,8-diisopropyl-7-isopropoxy-chrysin [23] -4.313 0.990 -0.004 
8-(1,1-dimethylallyl)-chrysin* [71] -3.251 0.036 -1.444 
3,5,7-trihydroxyflavonoid or galangin [23] -3.798 0.068 -1.167 
8-(1,1-dimethylallyl)-galangin [71] -4.114 0.300 -0.523 
8-prenylgalangin [71] -2.986 0.280 -0.553 
kaempferol [23] -4.702 0.015 -1.824 
taxifolin* [72] -3.448 0.045 -1.347 
7,3’,4’-trimethoxiflavone [73] -- 0.025 -1.602 
silybin [72] -5.176 2.200 0.342 
dehydrosilybin [72] -1.659 2.100 0.322 
6-prenyldehydrosilybin [72] -3.025 0.06 -1.222 
8-prenyldehydrosylibin [72] -5.109 1.00 0 
6-geranyldehydrosilybin [72] -4.366 0.27 -0.569 
8-geranyldehydrosylibin [72] -3.82 0.02 -1.699 
Kd = dissociation constant 
*compounds represented on graphic A of Fig. B.2. 
 
Table B.5. IC50 values for the known P-gp inhibitors 
  Cell line IC50 (nM) Log IC50 Score 
Verapamil
7
 K562R 5000 3.70 -3.426 
Quinidine
8
 LLC-PK 46700 4.67 -1.815 
Erythromycin
9
 MDCR11-MDR1 100000 5.00 -1.041 
Tetrandrine
10
 KBV200 31.76 1.50 -2.38 
Mibefradil
11
 MDCR11-MDR1 1600 3.20 -0.234 
Dexniguldipine*
12
 HelaMDR1 8.2 0.91 -2.338 
Dexverapamil
13
 U118-Mg 8600 3.93 -2.82 
S9788
7
 K562 350 2.54 -4.998 
SR33667
14
 CHr B30 8.3 0.92 -0.615 
Biricodar*
15
 Several 550 2.74 -4.332 
Ontogen*
16
 MCF-7/ADR 38 1.58 -2.121 
Elacridar*
17
 U118-Mg 193 2.29 -4.743 
Laniquidar
18
 Human MDR cells 510 2.71 -2.552 
Tariquidar
17
 U118-Mg 223 2.35 -1.132 
Zosuquidar*
19
 patients with AML 1.77 0.25 -2.043 
  IC50= half maximal inhibitory concentration 
* compounds represented on graphic B of Fig. B.2 
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A       B 
   
Fig. B.2. Correlation between A) scores of flavonoids (ATP-binding site 1, model 1) and log(Kd), 
and between B) scores of known P-gp inhibitors (TMD model 2) and log(IC50). 
 
B.4.Visual inspection of the docking results and accordance with literature 
 
    An inspection of the docked conformations of known inhibitors was performed. Table B.6 
shows that flavonoids (Table B.2) bind in the ATP-bind sites (model 1), namely on Walker A 
and ABC signature sequence; known inhibitors (Table B.1) bind on the pocket formed by the 
TMD (model 2). Therefore, the interactions detected from the docking of known P-gp inhibitors 
are in accordance with the literature (Table B.6). 
 
Table B.6. (A) Residues involved in the binding of flavonoids in the ATP-binding sites on P-gp – 
model 1. (B) Residues involved in the binding of known P-gp inhibitors in the drug binding 
pocket within the TMD – model 2.  
      A                      B 
 NBD (model 1)* TMD (model 2)** 
 
 
  
 
Contacts (sequence) Contacts 
Residues -Tyr401 
-Ser403 
-Lys408 
-Cys431 (WalkerA) 
-Arg538 (ABC signature) 
-Asp562 
-Ala1067 
-Val1069 
-Trp232 
-Ile235 
-Leu236 
-Gln725 
A B 
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-Ser432 (WalkerA) 
-Ser434 (WalkerA) 
-Thr436 
-Val437 
-Met440 
-Asp446 
-Leu531 (ABC 
signature) 
-Ser532 (ABC 
signature) 
-Gln535 (ABC 
signature) 
-Gln537 (ABC 
signature) 
 
-Ser1071 (Walker A) 
-Ser1072 (Walker A) 
-Cys1074 (Walker A) 
-Gly1075 (Walker A) 
-Lys1076 (Walker A) 
-Ser1077 (Walker A) 
-Glu1159 
-Ser1160 
-Thr1174 
-Gln1175 (just before 
ABC signature) 
-Ser1117 (Q-loop) 
-Gln1118 (Q-loop) 
-Ile1230 
-Ala728 
-Arg832 
-Ile868 
-Ala871 
-Gly872 
-Glu875 
-Leu879 
-Phe983 
-Gln990 
 
*the image exemplifies the interaction pattern within the NBD using 2’,4’,6’-trihydroxy-4-
butoxychalcone as example for easier interpretation. 
** the image exemplifies the interaction pattern within the TMD using verapamil as example for 
easier interpretation. 
 
Annex C. Xanthones discarded by the docking virtual screening 
 
The molecules selected to be synthetized were based on the docking scores, logP values 
and MW. Molecules with MW inferior to 500 g.mol
-1
, 2.92<logP<5.00 and highly negative 
docking scores were selected for synthesis. Both thioxanthonic and xanthonic derivatives were 
used in the virtual screening. Therefore, molecules with NBD docking scores inferior to -3.0 
kJ.mol
-1
, or with TMD docking score inferior to -2.0 kJ.mol
-1
, were selected to be synthesized. 
Table C.1 shows examples of xanthonic derivatives that were discarded. 
 
Table C.1. Docking scores, MW, and LogP values of (thio)xanthonic derivatives not selected 
for further development. 
 
 
Docking 
scores on 
a) NBD 
b)TMD 
(kJ.mol
-1
) 
MW LogP 
Cutoffs not 
fullfilled 
O
O
O
O
N
H
OH
 
a) -2.647 
b) 1.315 
343.4 2.5 
Scores 
LogP 
O
O
O
O
NH
H
OH
 
a) -2.533 
b) 2.241 
363.3 3.8 Scores 
O
O
O
N
H
OH
 
a) -1.098 
b) -1.217 
389.4 4.2 Scores 
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O
OH O
O
NH
NH
 
a) -1.788 
b) -1.784 
390.4 3.6 Scores 
O
O
O
O
NH
H
NH
O
N
 
a) -2.178 
b) -1.096 
391.4 2.0 
Scores 
LogP 
O
O
O
O
NH
H
NH
NH2
 
a) no pose 
b) 0.098 
411.5 2.2 
Scores 
LogP 
O
OH
OO
N
O
O
 
a) no pose 
b) no pose 
 
435.5 4.3 Scores 
O
O
O
O
NH
H  
a) -1.844 
b) 2.79 
451.5 5.0 Scores 
O
O
O
O
NH
H
OO
 
a) -1.266 
b) 0.642 
461.5 5.0 Scores 
NH
OH
O
O
O
O
O
OH  
a) -2.346 
b) -1.044 
463.5 3.2 Scores 
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O
O
O
O
N
H
O
O
 
a) -1.563 
b) -0.954 
501.5 5.0 Scores 
O
O
O
O
O
OHN
N
O  
a) -2.415 
b) 0.132 
516.5 3.4 Scores and MW 
O
O
NH
S
O
F F
F
 
a)-4.761 
b) -0.955 
 
459.5 6.8 LogP 
O
O
NHO
O
S
 
a)-4.655 
b) -2.993 
 
587.7 8.9 MW and LogP 
N
CH3
OH
O
CH3
O
O
S
 
a)-4.13 
b) -1.613 
461.6 6.2 LogP 
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Annex D. Structure elucidation 
The structure elucidation of aminothioxanthone derivatives was established on the basis of IR 
or NMR techniques. 
As expected, the IR data of the aminated derivatives when compared to compound 6 puts in 
evidence the presence of a typical stretch band corresponding to the N-H bond (3410 cm
-1
), as 
well as, additional bands corresponding to the aliphatic chain of the amine and to other 
functional groups that appear in the spectrum of the amine indicating the presence of the 
desirable compound. 
The 
1
H NMR spectra of 1-aminated 4-propoxy-9H-thioxanthen-9-ones (31-52) exhibited 
characteristic signals as schematically shown (Fig. D.1). 
S
N
O
CH3
O
RH
2
3
5
6
7
8
a
b
c
7.11 - 6.47
      dd
7.45 - 6.74
     dd
7.74 - 7.10
     dd
7.87 - 7.45
      ddd
7.68 - 6.28
     ddd
8.60 - 8.13
      dd
4.15 - 2.66
       t
2.23 - 1.76
       st
1.43 - 1.02
       t
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Fig. D.1. Main 
1
H NMR signals in 4-propoxy-1-aminated-9H-thioxanthen-9-ones (31-52) 
 
The NMR profile relatively to the aromatic moieties was similar and with similar chemical 
shifts and coupling constants to the building block 6. These signals and the other spectral data, 
confirm the success of the coupling of the thioxanthone scaffold and the amine. 
When the proton chemical shifts for an aminated 4-propoxy-9H-thioxanthen-9-one are 
compared with those of 6, upfield shift for H-2 and H-3 signals were observed. These alterations 
in the 
1
H NMR spectra indicated that there was an efficient C-N coupling.  
In the 
13
C NMR spectra the resonances of and all of the other protonated carbons were 
assigned using HSQC experiments, which correlate directly bonded 
1
H and 
13
C chemical shifts. 
The main feature of the 
13
C NMR spectra of aminated thioxanthones (Fig. D.2) is that the 
introduction of amino substituent on C-1 caused a deshielding of the carbon directly linked. 
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Fig. D.2. Main 
13
C NMR signals in 4-propoxy-1-aminated-9H-thioxanthen-9-ones (31-52) 
 
In cases where one amine functional group was the only group present in the building block 
susceptible of nucleophilic aromatic substitution, the structure elucidation was straightforwards 
(e.g. 44 and 39). For compounds with both an alkyl and an aryl amine, or with both an amine 
and an alcohol group, HMBC was needed for elucidation. The position of the amine on C-1 was 
confirmed from the correlations observed in the HMBC spectra between H-2 of the thioxantone 
and the carbon directly linked to the amine group (C-1’), as exemplified for compounds 43 and 
36 (Fig. D.3). 
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                              36                                                                            43   
Fig. D.3. Main connectivities found in the HMBC of the aminated thioxanthones 36 and 43. 
 
As far as the 4-dealkyl derivatives are concerned (53 and 55), their structure was confirmed by 
comparison of both 
1
H NMR and 
13
C NMR spectra with the correspondent 4-propoxyl derivative 
(6 and 51, respectively). 
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Annex E. Docking poses of best in vitro P-gp inhibitors (compounds 43 and 45).  
A visual inspection of the noncompetitive inhibitor 45 on the ATP-binding site and on the TMD 
(as both sites can justify the aforementioned mechanism of action), and the competitive inhibitor 
43 on the TMD was performed. Fig. E.1.A reveals that compound 45 binds in the site that 
corresponds to the ATP-bind site (model 1). The residues involved in interaction with compound 
45 are, for example, Gly432 (from Walker A sequence) and Leu1176 (from ABC signature). We 
hypothesize that residues that integrate the Walker A sequence may be blocked by 
thioxanthones, and interaction with the phosphates of nucleotide di- and tri-phosphates will be 
blocked. Moreover, as molecules fit perfectly in the ATP-binding pocket, sterical crowding will 
not allow ATP molecules to enter into those sites. Analysing docking results, an interaction 
between compounds 45 and the allosteric residue Phe983 [76] on TMD was also hypothised 
(Fig. E.1.B). The binding of ligands to this residue may result in a loss of compound-stimulated 
ATPase activity [32]. Analysing the docking for the competitive inhibitor 43 on the TMD of model 
2 (Fig. E.1.C), residues from TM4 and TM10, described as forming the drug binding pocket [19], 
establish interactions with the thioxanthonic derivative.  
Further understanding of the potential location of the site of action of these molecules would 
require a systematic analysis of the ATPase profile [77, 78], using combinations of verapamil 
and other transporter substrates with the new P-gp modulators, or even alanine or cystein 
scanning mutagenesis [19, 79]. 
 
 
 
Fig. E.1. Prediction of the best docking 
pose of the noncompetitive P-gp 
inhibitor 45 on ATP-binding site of P-gp 
model 1 (A) and on TMD of P-gp 
model 2 (B). Prediction of the best 
docking pose of the competitive 
inhibitor 43 on TMD of model 2 (C). 
Red dashes: polar interactions; yellow 
dashes: other interactions.  
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Annex F. Correlation between in silico docking scores and in vitro ATPase activity 
In order to investigate if the models indeed allowed the prediction of P-gp inhibitors, a 
correlation between docking scores on TMD and on NBD, and competitive and noncompetitive 
inhibitors ATPase activity, respectively, was established (Fig. F.1). As far as the docking scores 
on the TMD are concerned, a r
2
 of 0.8213 was obtained for five competitive inhibitors (6, 37, 43, 
44, and 55), which contrasts with the r
2
 of 0.0754 of all datapoints (Fig. F.1.A). Concerning the 
NBD docking results, a r
2
 of 0.634 was obtained for six noncompetitive inhibitors (compounds 
30, 35, 42, 45, 48, and 50), in contrast with the r
2
 of 0.0342 of all datapoints (Fig. F.1.B). These 
results show that there is considerable correlation between docking scores on TMD and 
competitive inhibitors ATPase results, and between scores on NBD and noncompetitive P-gp 
inhibitors ATPase results. 
   
           
 
Fig. F.1. A) Docking scores on TMD versus logarithm of ATPase activity in RLU. 
Compounds 6, 30, 33, 35, 37, 38, 41-45, 48-51 and 55 are represented. Compounds 6, 37, 43, 
44, and 55 (competitive inhibitors) are highlighted in grey. B) Docking scores on NBD versus 
logarithm of ATPase activity in RLU. Compounds 6, 30, 33, 35, 37, 38, 41-45, 48-51 and 55 are 
represented. Compounds 30, 35, 42, 45, 48, and 50 (noncompetitive inhibitors) are highlighted 
in grey. 
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Antitumor activity of novel thioxanthonic derivatives mediating cell cycle arrest and 
apoptosis in human tumor cell lines 
 
The aim of this work was to investigate the antitumor activity of thioxanthones 1-27 (Table 1) 
on other tumor cell lines, melanoma, non-small lung cancer, and breast cancer, as well as the 
interference with levels of apoptosis and cell cycle profile. 
Table 1. Structure of thioxanthonic derivatives 1-27 
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Matherial 
 
Cell lines 
 
K562 (human chronic myelogenous leukemia, erythroblastic; ECACC, Europe Collection of 
Cell Cultures, UK), A375-C5 (human malignant melanoma; ECACC, Europe Collection of Cell 
Cultures, UK), MCF-7 (human breast cancer; ECACC, Europe Collection of Cell Cultures, UK), 
and NCI-H460 (large cell lung cancer; ECACC, Europe Collection of Cell Cultures, UK) cell lines 
were routinely maintained in RPMI-1640 (with Hepes and Glutamax, Gibco; Invitrogen, 
Darmstadt, Germany), with 10% fetal bovine serum (Gibco; Invitrogen, Darmstadt, Germany) 
and incubated in a humidified incubator at 37 ºC with 5% CO2 in air. All experiments were 
performed with cells in exponential growth, with viabilities over 90% and repeated at least three 
times. 
 
Methods 
 
Sulphorhodamine-B assay 
 
A375-C5, MCF-7, and NCI-H460 cells were plated into 96-well tissue culture plates. After 24 
h, cells were treated with serial dilutions of the test compound. Following 48 h treatment, cell 
growth was assayed using the SRB assay
1, 2
. The GI50 values for the thioxanthonic derivatives 
(concentration resulting in 50% inhibition of cell growth) were calculated from the plotted results.  
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Cell cycle analysis 
 
For the analysis of cell cycle phase distribution of DNA, K562 cells were treated with 
complete medium (blank), the solvent of the compounds (DMSO 0.2% v ⁄ v, control), or with 
compounds 1, 4, 8, 12, and 14 (GI50 concentration, Table 2, K562 column) and processed at 48 
h after incubation with the compounds. Cells were pelleted and fixed in 70% ethanol for 10 min 
at room temperature. After centrifugation, cells were stained for 30 min on ice in propidium 
iodide (40 μg ⁄ mL; Sigma Aldrich, Sintra, Portugal) and RNase in PBS (100 μg ⁄ mL; Sigma 
Aldrich, Sintra, Portugal). At least 50 000 cells per sample were counted and analyzed by flow 
cytometry (Epics XL-MCL; Beckman Coulter, Brea, CA, USA), and the percentage of cells in the 
G1, S, and G2 ⁄M phases of the cell cycle was determined using the FlowJo 7.2 software (Tree 
Star Inc., Ashland, OR, USA) after cell debris exclusion. 
 
Levels of apoptosis 
 
For the analysis of cell cycle phase distribution of DNA, K562 cells were treated as indicated 
earlier with complete medium (blank), the solvent of the compounds (DMSO 0.2% v ⁄ v, control), 
or with compounds 1, 4, 8, 12, and 14 (GI50 concentration, Table 2, K562 column) and 
processed at 48 h after incubation with the compounds. Cells were pelleted, resuspended in 
200 μl of binding buffer (0.01 M HEPES, pH 7.4; 0.14 M NaCl; 2.5 mM CaCl2; Annexin-V kit, 
Roche, Indianapolis, IN, USA) and incubated with 5 μl of FITC-conjugated Annexin-V
3
 for 10 
min. Then 10µl of propidium iodide is added, cells are incubated for 1-2 minutes and placed on 
ice until analysis.  
 
Statistical analysis 
 
Data was expressed as the mean ± SE and analyzed by the Student’s t test. P-values below 
0.05 considered statistically significant. 
 
Results 
 
The in vitro growth inhibitory activity of all the compounds (1-27) was evaluated using three 
solid human tumor cell lines, representing different tumor types, namely breast adenocarcinoma 
(MCF-7), melanoma (A375-C5), and non-small cell lung cancer (NCI-H460), after a continuous 
exposure of 48 h. The results are summarized on Table 2. 
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Table 2. GI50 of thioxanthonic derivatives 30-56 on A375-C5, MCF-7, and NCI-H460 cell lines. 
          
GI50 
(µM)           
  A375-C5     MCF-7     NCI-H460   
1 H 
 
  H 
 
  H 
 
  
2 H 
  
H 
 
  H 
 
  
3 H 
 
  H 
 
  H 
 
  
4 13.33 ± 0.33 15 ± 1 13.33 ± 0.67 
5 H 
 
  H 
 
  H 
 
  
6 73 ± 5.5 111 ± 11.72 73 ± 6.62 
7 33 ± 2.65 33 ± 2.31 27.33 ± 2.73 
8 8.5 
 
  10.6 
 
  8.8 
 
  
9 60.33 ± 1.85 92.67 ± 2.6 89.67 ± 2.4 
10 H 
 
  H 
 
  H 
 
  
11 81.67 ± 2.85 85 ± 1 58.33 ± 7.17 
12 27.33 ± 5.33 48 ± 3.05 38.67 ± 4.41 
13 H 
 
  H 
 
  H 
 
  
14 24.33 ± 3.28 34 ± 3.06 39.33 ± 6.44 
15 55 ± 1.53 65.67 ± 1.45 59.33 ± 7.88 
16 20 ± 2.08 28.33 ± 2.85 22.67 ± 2.52 
17 H 
 
  H 
 
  H 
 
  
18 H 
 
  H 
 
  H 
 
  
19 54.75 ± 9.42 70.75 ± 6.9 61.25 ± 4.12 
20 34 ± 4.04 34.33 ± 2.96 35 ± 5.2 
21 H 
 
  H 
 
  H ±   
22 H 
 
  H 
 
  H 
 
  
23 H 
 
  H 
 
  H 
 
  
24 15.33 ± 0.88 23.33 ± 1.45 21 ± 1.53 
25 8.23 ± 0.34 9.37 ± 0.18 8.7 ± 0.2 
26 34.33 ± 1.86 24.33 ± 2.85 23 ± 2.52 
27 34 ± 6.51 39 ± 3.61 28.67 ± 2.19 
 Results are expressed as means ± SE of at least three independent experiments performed in duplicate, 
except for values >150 µM where only two independent experiments were performed. 
 
assays performed 
only once (ongoing work). 
 
From the analysis of Table 2 it can be concluded that compound 8 and 25 have the lowest 
GI50 on the adherent cell lines (inferior to 10 µM).  Differences in the GI50 values in the three 
adherent cell lines and in the suspension cell line
4
 may be a result of the different target and/or 
mechanism of action of that compound. Targets involved in survival, apoptosis, cell cycle 
progression, or other mechanisms may be implied
5-7
.  
In order to evaluate if the increased levels of cell death or the decreased cellular proliferation 
was involved in the cell growth inhibition on K562 cell line, a flow cytometry evaluation of the 
number of alive/apoptotic cells and of the number of cells on each phase of the cell cycle was 
performed. Compounds 1, 4, 8, 12, and 14 were chosen as they were some of the most potent 
growth inhibitory agents on K562 cell line. Those compounds caused the cell cycle arrest at G1. 
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Compound 1 also causes a slight increase in the number of cells in S-phase. Compounds 1, 4, 
8, and 14 cause a decrease in the number of cells in G2/M-phase. Compound 8 seems to be 
the most promising thioxanthonic derivative affecting the cell cycle, causing an increase of 10% 
in the number of cells in G1-phase and a 15% decrease of the number of cells in G2/M-phase 
when comparing to the DMSO control (Figure 1). 
All the tested compounds caused a decrease in the % of alive cells. Compounds 1, 4, 8, 12 
and 14 and increase the % of cells in apoptosis. Once more, compound 8 seems to be the most 
promising as in causes a 20% increase in the number of apoptotic cells (Figure 2). 
 
Figure 1. Cell cycle analysis of K562 cells treated with compounds 1, 4, 8, 12, and 14. K562 
cells were cultured with the GI50 concentration of the compounds for 48 h. Untreated cells were 
used as control (blank). A DMSO treatment was also included (control). Cell cycle analysis was 
performed by flow cytometry following propidium iodide staining and a minimum of 50 000 cells 
were analyzed. Results were obtained with the FlowJo 7.2 software. Means ± SE were 
calculated from four independent experiments. Statistical significance was tested by paired t-
test using DMSO as a negative control. ***Indicates P < 0.001; **Indicates 0.001 < P < 0.01; 
*Indicates 0.01 < P < 0.05; ns indicates not significant, i.e., P > 0.05 (n = 4). 
Table 3. Level of apoptosis on K562 cells treated with compounds 1, 4, 8, 12, and 14.  
Treatment Viable Cells (%) Apoptotic Cells (%) 
Blank 95.7±1.0 3.9±0.4 
DMSO 92.9±1.3 6.5±0.8 
Compound 12 89.1±2.7 * 9.2±1.4 * 
Compound 1 86.4±2.6 ** 13.0±1.7 ** 
Compound 4 81.8±2.4 ** 16.8±2.2 ** 
Compound 14 81.7±1.0 ** 17.6±2.5 ** 
Compound 8 77.4±4.8 *** 22.1±2.6 *** 
K562 cells were cultured with the GI50 concentration of the compounds for 48 h.  
Untreated cells were used as control (blank). A DMSO treatment was also 
included.  
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Apoptosis analysis was performed by flow cytometry following FITC-conjugated 
Annexin-V and propidium iodide staining and a minimum of 50 000 cells were 
analyzed. Results were obtained with the FlowJo 7.2 software.  
Means ± SE were calculated from three independent experiments. Statistical 
significance was tested by paired t-test using DMSO as a negative control. 
***Indicates P < 0.001; **Indicates 0.001 < P < 0.01; *Indicates 0.01 < P < 0.05 (n 
= 3). 
 
Proteins of the cell cycle and apoptotic pathways are considered as valuable targets for the 
treatment of cancer. Several anticancer agents cause cell cycle arrest. Cell cycle arrest is one 
of the typical responses exhibited by proliferating eukaryotic cells when exposed to a variety of 
DNA binding agents, such as DNA alkylators, intercalators and topoisomerase inhibitors
8
.  To 
determine if the proliferation inhibition of xanthones 1, 4, 8, 12, and 14 in K562 involved the cell 
cycle arrest and/or apoptosis, the number of viable and apoptotic cells, as well as the cell cycle 
phase distribution of the treated cells were analysed by flow cytometry. It was verified that 
thioxantones 1, 4, 8, 12 and 14 were significantly inducing the level of apoptosis. As far as the 
cell cycle distribution is concerned, all the tested aminated thioxanthones (4, 8, 12, and 14) 
were causing a G1-phase cell cycle arrest, whereas only the non-aminated thioxanthone 
(compound 1) was also causing a slight accumulation of cells in S-phase. The G1 and S-phase 
arrest of K562 cells might arise from various degrees of DNA binding and damage induced by 
thioxanthones
9
. It is suggested that interaction with DNA, either by intercalation, or by some 
other non-covalent processes, may be the mechanism of action of aminated (thio)xanthonic 
derivatives
10
. The induction of apoptosis and cell cycle arrest has already been described for 
several xanthones
11-13
. However, further studies are needed to investigate how G1 and S phase 
arrest occurred.  
In conclusion, the growth inhibitory effect by the thioxanthonic derivatives seems to be 
related both to a cell cycle arrest and an increase in the levels of apoptosis. Moreover, 
appendance diversity with the introduction of amines was a successful strategy in the discovery 
of potent antitumoral thioxanthones. 
 
Conclusion 
Thioxanthonic derivatives exhibited cytotoxic effect on chronic myeloid leukemia, melanoma, 
non-small lung cancer and breast cancer cell lines, and cause cell cycle arrest and induction 
of apoptosis on a chronic myeloid leukemia cell line. The mechanistic link between these events 
remains to be determined. However, the present data point to the importance of thioxanthonic 
derivatives as potential hit candidates for the design of antitumor agents. 
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ABSTRACT - Purpose. Aminated thioxanthones have recently been described as dual activity agents: 
inhibitors of growth of leukemia cell lines and P-glycoprotein (P-gp) inhibitors. In order to evaluate the 
selectivity profile of thioxanthones as inhibitors of multidrug resistance (MDR), their interaction with 
other ABC transporters such as multidrug resistant proteins 1 (MRP1), 2 (MRP2) and 3 (MRP3) and 
breast cancer resistance protein (BCRP), which were found to have a strong correlation with multidrug 
resistance, was also evaluated. The interaction of thioxanthones with cytochrome P450 3A4, as well as 
the prediction of the binding poses and sites of metabolism, was also performed. Methods. An UIC2 
labelling was performed using P-gp overexpressing cells, K562Dox, incubated with the thioxanthonic 
derivatives, in order to confirm their P-gp inhibitory activity. A colorimetric ATPase assay using 
membrane vesicles from mammalian cells overexpressing a selected human ABC transporter protein (P-
gp, MRP1, MRP2, MRP3, or BCRP) was performed in order to identify the potential of some of the 
thioxanthonic derivatives to bind those transporters. A luciferin-based luminescence assay was executed 
with the aim of inspecting if some of the thioxanthonic derivatives were substrates/inhibitors of CYP3A4. 
Finanlly, a metabolization predication of thioxanthonic derivatives, and a docking pose prediction of 
those molecules on CYP3A4 binding site were performed. Results. Thioxanthones were able to interact 
not only with P-gp but also with MRP and BCRP transporters. Those compounds also interfere with 
CYP3A4 activity in vitro, in accordance with the in silico results. Conclusion. Thioxanthonic derivatives 
are multiple target compounds. A better characterization of the interactions of these compounds with 
classical resistance mechanisms may possibly identify improved treatment applications. 
 
Keywords: ABC-binding cassette, Breast cancer resistance protein, CYP3A4, Multidrug resistance 
proteins, P-glycoprotein. 
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INTRODUCTION 
Cancer is a major health concern worldwide and the emergence of cell populations resistant to 
multidrug-based chemotherapy constitutes a major obstacle to treatment (1). Multidrug resistance (MDR) 
involves cellular resistance to several structurally unrelated drugs, and one of the possible reasons is the 
overexpression of ABC transporters (2). These transporters pump the antitumor agents to the extracellular 
medium, removing them from the site of action,  and therefore the treatment becomes ineffective (3). The 
first ABC transporter whose overexpression was shown to confer a MDR phenotype was P-glycoprotein 
(P-gp), the product of the mdr1 (ABCB1) gene (4). P-gp transports neutral or positively charged 
hydrophobic substrates, and particularly anticancer drugs, consuming energy from ATP hydrolysis (1).  
Drug discovery in the last century was largely based on the concept “one molecule – one target – one 
disease”, but recently there has been a growing recognition that molecules that modulate multiple targets 
simultaneously can be beneficial for treating several diseases (5). According to this concept, we have 
previously shown that aminated thioxanthones may be dual activity agents capable of simultaneously 
inhibiting cell growth and P-gp function (compounds 1-8, Figure 1) (submitted for publication). These 
compounds resulted from the hybridization between a thioxanthonic scaffold (described for its antitumor 
activity) (6,7) and pharmacophoric features for P-gp inhibition (an amine group) (8). Overall results with 
a leukaemia cell line resistant (P-gp overexpressing) to doxorubicin, show that aminated thioxanthones 
can be characterized as a new class of P-gp inhibitors with improved efficacy when compared to 
verapamil, a known P-gp inhibitor (submitted publication). 
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 Figure 1. Thioxanthonic derivatives 1-8 described as dual P-gp and cell growth inhibitors (submitted 
for publication): 1-[2-(1H-benzimidazol-2-yl)ethanamine]-4-propoxy-9H-thioxanthen-9-one (1), 1-(5-
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amino-3,4-dihydroisoquinolin-2(1H)-yl)-4-propoxy-9H-thioxanthen-9-one (2), 1-{[2-
(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (3), 1-(piperidin-1-yl)-4-propoxy-9H-
thioxanthen-9-one (4), 1-methoxy-4-propoxy-9H-thioxanthen-9-one (5), 1-(4-acetylpiperazin-1-yl)-4-
propoxy-9H-thioxanthen-9-one (6), N'-(9-oxo-4-propoxy-9H-thioxanthen-1-yl)pyridine-4-carbohydrazide 
(7) and 1-{[2-(4-nitrophenyl)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one (8). 
 
However, before proceeding to in vivo studies or to a new round of synthesis, the evaluation of the 
interaction with other drug transporters, or metabolizing enzymes, is necessary. In fact, as data regarding 
the role of P-gp in drug resistance accumulated, it became clear that other transporters could confer 
resistance to cytotoxic agents. The multidrug-resistance associated transporters MRP1 (ABCC1), MRP2 
(ABCC2) and MRP3 (ABCC3), and the breast cancer associated protein BCRP (ABCG2) are also 
examples of transporters implicated in MDR (9). Indeed, an issue that affects all the generations of P-gp 
inhibitors concerns their multiple action towards ABC transporters. Even the most recent and potent P-gp 
inhibitors such as tariquidar (10) (P-gp and BCRP inhibitor) and CBT-1 (11) (P-gp and MRP1) modulate 
more than one ABC transporter, and both have entered clinical trials. It is not surprising to find 
compounds which are inhibitors of multiple ABC transporters, since these proteins share structural and 
functional similarity (12). Since the clinical MDR appears to be related to the overexpression of several 
transporters, compounds that inhibit multiple ABC transporters could possibly be preferable to the use of 
a combination of specific modulators, as they would reduce cumulative toxicities and drug–drug 
interaction (13-15).  
One of the main issues regarding second generation P-gp inhibitors was the pharmacokinetic 
interactions due to overlapping substrate specificity between P-gp and cytochrome P450, which required 
an increase in the dose of the cytotoxic drug in order to achieve therapeutic efficacy (16).  
The novelty of this work resides in the investigation of several potential targets of newly synthesized 
thioxanthonic derivatives. The aim was to better characterize the P-gp inhibitory activity of thioxanthones 
and to further explore the potential of interaction with other ABC transporters and with CYP3A4, as the 
selectivity profile of these compounds may help clarifying their possible clinical usefulness. Finally, a 
computational prediction of the docking poses of thioxanthones on CYP3A4 as well as of the most 
probable sites of metabolization was also performed. 
 
METHODS 
 
Chemicals 
 
UIC2 kit was purchased from Millipore (Madrid, Spain). The BCRP-HAM-ATPase kit, defBCRPHAM-
ATPase control kit, MDR1-ATPase kit, defMDR1 control Kit, MRP1, MRP2 and MRP3 ATPase kits and 
defMRP control kit were purchased from SOLVO Biotechnology (Budapest, Hungary). P450-Glo kit and 
NADPH regeneration system were purchased from Promega (Madison, USA).  D-Luciferin and CYP3A4 
membranes were purchased from Sigma Aldrich (St. Louis, USA).  Synthesis of compounds 1-8 was 
performed according to the described procedure (submitted publication).  
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UIC2 shift assay 
This assay was performed as previously described (17) with minor modifications (UIC2 Shift assay, 
Millipore, Madrid, Spain). K562Dox cells were washed with PBS and re-suspended in UIC2 binding 
buffer (PBS + 1% BSA). Approximately 1 × 10
6
 cells in 800 µL binding buffer were pre-warmed at 37ºC 
for 10 min, incubated with the compounds 1-8 (final concentration 200 μM) or Na3VO4 (final 
concentration of 20 μM; control, noncompetitive inhibitor), verapamil, quinidine, and mibefradil (final 
concentration of 200 μM; control, competitive inhibitors) at 37ºC for 30 min, and the monoclonal 
antibody UIC2 was added (final concentration 12.5 μg.mL-1). After 30 min at 37ºC, 800 µL of ice-cold 
UIC2 buffer was added to stop the reaction. Cell samples were washed with cold buffer twice, re-
suspended in 500 µL ice-cold UIC2 buffer and goat anti-mouse IgG2a-phycoerithrin (PE) was added (final 
concentration of 5 μg.mL-1). After 45 min at 4ºC in the dark, samples were washed twice using UIC2 ice-
cold buffer, and finally re-suspended in 250 µL ice-cold UIC2 binding buffer containing propidium 
iodide (final concentration of 40 µg.mL
-1
). Cellular suspension was analyzed using a flow cytometer 
(Epics XL-MCL, Beckman Coulter, USA) and FL2 and FL3 channels were used for indirect UIC2 
staining and dead cells exclusion by propidium iodide, respectively. At least 5000-10000 events were 
collected. Normal mouse IgG2a served as a negative control. Results are presented as the average of at 
least three independent experiments. Fluorescence intensity ratio (FL2-ratio) was calculated in relation to 
the DMSO solvent control (cells treated with DMSO and medium only, and incubated with primary and 
secondary antibodies as described). It was calculated using the following formula that fits the DMSO 
control to zero for easier interpretation: rFI= (FItest –FIdmso) / FIdmso. 
 
ATPase activity assays  
ATPase activity was measured according to described procedure (18). The predeasy MDR1-ATPase kit, 
BCRP-HAM-ATPase kit, MRP1, MRP2 and MRP3 ATPase kit (SOLVO Biotechnology, Budapest, 
Hungary) were used for the determination of the effect of compounds 1 and 2 in the MDR1, BCRP, 
MRP1, MRP2 and MRP3 ATPase activities, respectively, according to the manufacturer‟s instructions. In 
brief, membrane vesicles in TMEP solution (50 mM Tris, 50 mM mannitol, 2 mM EGTA, 8 μg.mL-1 
aprotinin, 10 μg.mL-1 leupeptin, 50 μg.mL-1 PMSF, 2 mM DTT, pH 7.0) were incubated at a 
concentration of 20 μg per well with an assay mix (40 mM 3-morpholinopropanesulfonic acid with (MRP 
assays) or without GSH (the remaining assays)), 5 mM ATP and four concentrations of test compounds 1 
and 2 (1.6, 8.0, 40.0, 200.0 μM). Two protocols were user: (a) incubation with or without 1.2 mM 
Na3VO4 (activation study), or (b) incubation with 200.0 μM of a known substrate (verapamil for MDR1 
assay, NEM-GS for MRP1 assay, sulfasalazine for MRP2 and BCRP assay, and benzbromarone for 
MRP3 assay) and with or without 1.2 mM sodium orthovanadate (inhibition study), for 10 min at 37°C. 
Controls without treatment and with a control inhibitor at 40.0 μM (cyclosporine A for MDR1 and MRP3 
assay, benzbromarone for MRP1 and MRP2, and Hoechst 33342 for BCRP assay) were also used. 
Reaction was stopped by addition of a developer solution (ethanol 95%) to each well, followed by 
addition of a blocker solution (4 mM sodium azide) and additional 30 min incubation at 37ºC. Optical 
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density (OD) was read at 630nm. The amount of phosphate (Pi) liberated by the transporter is 
proportional to the activity of the transporter. The activity of the transporters is measured as the vanadate 
sensitive portion of the total ATPase activity in order to eliminated background ATPase activity (19). The 
amount of liberated Pi was quantified based on the calibration line established with Pi standards (0, 4, 8 
nmol per well). Results are presented as % of control (% of the non-treated control). The IC50 
concentrations were calculated from the inhibition studies. Similar assays were also performed using the 
predeasy defMDR1, defBCRPHAM and defMRP ATPase control kits, using the protocols (a) of the 
manufacturer.  
 
CYP3A4 interaction assay 
Eight thioxanthonic derivatives (1-8) were screened for interference with CYP3A4 using the CY3A4 
P450-Glo assay (Promega, Madison, USA) following the manufacturer‟s instructions. In brief, 
recombinant CYP3A4, 1 pmol/well (Sigma Aldrich, St. Louis, USA), was pre-incubated for 10 min at 
37ºC, with 50 μM luciferin-6‟-benzyl ether (luciferin-BE) and 200 μM of each thioxanthone. The reaction 
was initiated upon the addition of 25.0 µL of the NADPH regenerating solution (1.3 mM NADP
+
, 3.3 
mM glucose-6-phosphate; 4U/ml glucose-6-phosphate dehydrogenase; Promega, Madison, USA). 
Following 30 min incubation at 37ºC, 50.0 µL of the detection reagent containing a recombinant, stable 
luciferase (Promega, Madison, USA) was added. The resulting luminescence was measured 20 min after 
revelation. Controls without compound or with a known CYP3A4 inhibitor, ketoconazole (200 μM), were 
also used.  
The IC50 value (concentration that inhibits the transport of a known substrate by 50%)  of compounds 
1 and 2 were determined with the same protocol but testing eight concentrations of 1 and 2 from 2 nM to 
200 μM (0.002, 0.013, 0.064, 0.32, 1.6, 8.0, 20, and 200 μM). The IC50 value was calculated after scaling 
the data to 100% activity. 
 
Modeling of compounds 1 and 2 metabolism 
All calculations were performed on a commodity PC Microsoft Windows 7 with an Intel(R) Core(TM) i5 
processor. Compounds 1-8 were drawn and minimized using AM1 semi-empirical method (Hyperchem 
v8.07, Hypercube, USA) (20).  
Compounds 1 and 2 were submitted to the program MetaSite v3.0.4 (MolDiscovery, Middlesex, 
United Kingdom) (21) that is a fully automated procedure that considers structural complementarity 
between the enzyme active site and the ligand and comes up with the most optimal orientation. Both the 
protein active site and the ligand are represented by selected distance-based descriptors using molecular 
interaction fields computed in GRID. The site of metabolism prediction was performed for CYP3A4. The 
sites of metabolism (SOM) or “hot spots” were plotted according to their scores. The site of metabolism 
is described by a probability index that is a product of similarity between ligand and protein. In this study, 
the top six averaged rankings with the reactivity component enabled were considered. SOM was used to 
calculate the atoms that contribute the most to orienting the site of metabolism towards the heme group.  
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Furthermore, compounds 1-8, ketoconazole (known CYP3A4 inhibitor) (22) and propofol (compound 
not metabolized by CYP3A but by CYP2B6) (23) were docked into CYP3A4 (pdb code: 2V0M; human 
CYP3A4 with crystallographic ketoconazol) by means of Autodock Vina embedded in PyRx.v3.2 
software (24) (Molecular Graphics Lab, La Jolla, CA, USA). Exhaustiveness of eight was used, and the 
box size used was 20 × 20 × 20 Å, centered around the crystallographic ligand coordinates. 
 
Statistical analysis 
 
Data was expressed as the mean ± SE of at least three independent experiments, except in the case of 
vanadate-sensitive ATPase activity (mean of two experiments only) and analyzed by the Student‟s t test. 
P-values below 0.05 were considered statistically significant when data was analysed for statistical 
meaningfulness (student‟s t test). 
 
RESULTS 
 
UIC2 shift assay 
 
In order to confirm the previously found direct interaction of thioxanthones 1-8 with P-gp (submitted for 
publication), a UIC2 shift assay was performed (Figure 2). Therefore, two competitive inhibitors (2 and 
3) and six noncompetitive inhibitors (1, 4-8) were selected from our previous work to perform the UIC2 
shift assay. This assay uses the monoclonal antibody (mAb) UIC2, a conformation-sensitive antibody 
which preferentially binds to an external epitope of P-gp that is in the process of substrate transportation 
(25,26). UIC2 is also unique among the mAbs directed against P-gp because it blocks drug pumping 
efficiently, probably by trapping P-gp in a certain conformational state of its enzymatic cycle (26). Based 
on this conformation-sensitive competition assay, it is possible to distinguish between compounds that are 
being transported (substrates or competitive inhibitors) from compounds that block P-gp transportation 
cycle (noncompetitive inhibitors) (27). Figure 2 shows that mibefradil, verapamil, and quinidine, all P-gp 
substrates used as controls, increased UIC2 labelling of K562Dox cells, as expected. The blocking of the 
ATP site by sodium vanadate decreased UIC2 labelling, also as expected. Compounds 1, 4, 6-8 had UIC2 
binding reactivity inferior to the DMSO control, whereas compound 2 had UIC2 binding reactivity 
superior to the DMSO control (Figure 2). 
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Figure 2. Effect of eight thioxanthonic derivatives on mAb UIC2 binding reactivity to P-gp, presented 
as a FL2-ratio. Normal IgG2a was used as negative control (data not shown). The control luminescence 
(DMSO) is represented as zero for easier interpretation. FL2-ratio inferior to zero corresponds to 
inhibitors of P-gp transportation cycle, i.e., noncompetitive P-gp inhibitors.  FL2-ratio superior to zero 
correspond to compounds that stimulate P-gp transportation cycle, i.e., substrates of P-gp or competitive 
P-gp inhibitors. Results are the mean ± SE of at least three independent experiments. Na3VO4, verapamil, 
mibefradil, and quinidine were used as controls. Statistical significance was tested by paired t-test using 
DMSO as control. *** indicates P < 0.001; ** indicates 0.001 < P ≤ 0.01; * indicates 0.01 < P ≤ 0.05. ns 
indicate not significant, i.e., P > 0.05 (n=4). 
 
ATPase assay 
As our previous data has shown that compound 1 and 2 were the most potent P-gp noncompetitive and 
competitive inhibitors, respectively (submitted for publication), they were further investigated with 
ATPase screening assays for various ABC transporters (including P-gp), which are based on purified 
membrane vesicles from mammalian cells overexpressing a selected human ABC transporter protein. The 
transport function of ABC transporters is tightly coupled to its ATPase activity, as ATP binding and 
hydrolysis drive the transport process (28). Substrates transported by P-gp, therefore, can be detected by 
the hydrolysis of ATP and the production of the inorganic phosphate (Pi) detected by a colorimetric 
reaction (29). The assay is composed of two different tests: an activation and an inhibition test. The 
activation and inhibition tests are complementary assays. The assay is a modification of the method of 
Sarkadi et al (30). In the activation test, the transported substrates increase baseline vanadate sensitive 
ATPase activity, whether inhibitors decrease the baseline vanadate sensitive ATPase activity. A 
stimulation detected in the activation assay indicates that the compound is a substrate of the transporter 
being studied. In the inhibition test, which is carried out in the presence of a known substrate (which 
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varies according to the ABC transporter under study), inhibitors inhibit the maximal vanadate sensitive 
ATPase activity (31). Interactions detected in the inhibition test indicate interactions of the test 
compounds with the transporter. The obtained results are graphically represented in Figures 3 and 4, and 
the IC50 values are indicated in Table 1. Compounds 1 and 2 did not affect levels of Pi liberation on 
membranes lacking P-gp, BCRP, or MRP (results not shown).  
 
Figure 3. Vanadate-sensitive ATPase activity (plotted as % of nontreated control in nmol Pi.mg 
protein
-1
.min
-1
) of P-gp (A), BCRP (B), MRP1 (C), MRP2 (D) and MRP3 (E) membrane preparations in 
the presence of compound 1 alone (activation assay) or in combination with a substrate (inhibition assay) 
at different concentrations (1.6, 8.0, 40.0, 200.0 μM). The results represent the average of two 
independent experiments performed in duplicate. IC50 values are represented with the broken line. 
 
Figure 4. Vanadate-sensitive ATPase activity (plotted as % of nontreated control)  in nmol Pi.mg 
protein
-1
.min
-1
) of P-gp (A), BCRP (B), MRP1 (C), MRP2 (D) and MRP3 (E) membrane preparations in 
the presence of compound 2 alone (activation assay) or in combination a substrate (inhibition assay) at 
different concentrations (1.6, 8.0, 40.0, 200.0 μM). The results represent the average of two independent 
experiments performed in duplicate. IC50 values are represented with the broken line. 
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Table 1. ATPase inhibitory effect of compounds 1 and 2 in the presence of known substrates of 
several ABC transporters. 
IC50 (μM) P-gp BCRP MRP1 MRP2 MRP3 
Compound 1 20 20 25 > 200 200 
Compound 2 20 2 4 145 13 
Results represent the average of two independent experiment performed as duplicates. 
 
 
CYP3A4 interaction assay 
Luciferin-BE is used as a CYP3A4 substrate that is converted by the enzyme to luciferin product, 
which in turn reacts with luciferase to produce an amount of light proportional to CYP activity (32). 
Changes in the luminescence signals from samples treated with test compound as compared to untreated 
control samples represent modulation of CYP3A4 activity by the test compound (33). Figure 5 shows that 
the eight thioxanthonic derivatives (1-8) interfere with CYP3A4 activity (inhibitors or substrates) as they 
were able to decrease the levels of luciferin-associated luminescence when tested at concentrations of 200 
µM.  
 
Figure 5. CYP3A4 inhibition assay. % of RLU in relation to the nontreated (NT) control was used to 
assay the potential od the thioxanthonic derivatives for interaction with CYP3A4. Reactions were 
performed using 1pmol recombinant CYP3A4 in 10 min reactions at 37ºC with 2 µM of luciferine-BE as 
substrate, in combination with 200 μM of a positive control (a known CYP3A4 inhibitor, ketoconazole) 
or 200 μM of the test thioxanthonic derivatives 1-8. Values are means ± SE of three independent 
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experiments. Statistical significance was tested by paired t-test using the non-treated cells (NT) as control. 
*** indicates P < 0.001 (n=3). 
 
In order to calculate the CYP3A4 IC50 of our best P-gp inhibitors, the same luciferin luminescence-
based assay was used to test several concentrations of compounds 1 and 2 (Figure 6). It was found that 
these compounds presented IC50 values for CYP3A4 inhibition of approximately 1-2 μM (Figure 6). The 
CYP3A4 inhibition is low for compounds 1 and 2 at concentrations below 0.01 μM, but is almost total for 
concentrations close to 100 μM. 
 
Figure 6. CYP3A4 inhibition assay. % of RLU in relation to the nontreated (NT) control was used to 
analyse the potential of compound 1 (A) and compound 2 (B) to inhibit CYP3A4. Reactions were 
performed using 1pmol recombinant CYP3A4 in 10 min reactions at 37ºC with 2 µM of luciferin-BE as 
substrate, in combination with concentrations from 0.002 to 200 µM of the test thioxanthonic derivatives. 
CYP3A4 IC50 values are represented with the broken line. Values are means ± SE of three independent 
experiments. 
 
Modeling of compounds 1 and 2 metabolism 
In view of these results, in silico analysis of the potential metabolization sites on the thioxanthonic 
derivatives 1 and 2 was performed. The site of metabolism and the molecular contribution to the exposure 
of a reactive atom to the heme moiety (activity contribution plot) were determined by MetaSite (34). The 
program has been described as being able to predict the most probable site of metabolism within the top 
three predictions in 80% of the cases in structurally diverse compounds (21). MetaSite predicted that the 
methyl groups directly linked to the amine at C-1 in compounds 1 and 2 were the top ranked sites of 
   Annex vii 
 
 341 
 
metabolism by CYP3A4 (Figure 7, dark red arrows). Other possible sites of metabolization are also 
depicted in Figure 7 (light red arrows). 
 
Figure 7. Sites of metabolism and contribution:  the groups in compound 1 (A) and 2 (B) that most 
likely will be metabolized by CYP3A4 are marked with a dark red arrows; the darker the color the higher 
is the probability of metabolism to occur. The atom in compound 1 (A) and 2 (B) with the highest 
molecular contribution to the exposure of the metabolic “hot spot” (blue circle) to the heme moiety of 
CYP3A4 is marked with a yellow arrow.  
 
In order to further predict the binding affinity of compounds 1 and 2 to CYP3A4 catalytic site, a 
docking study using Autodock Vina was performed on those compounds, ketoconazole, a known 
CYP3A4 inhibitor (35), and propofol, that does not interact with CYP3A4 (23). The structure of the 
CYP3A4–ketoconazole is available at 3.8 Å resolution (36,37). As expected, ketoconazole shows high 
affinity to CYP3A4 catalytic site, as predicted by the highly negative docking score (Table 2). Besides, 
the docked ketoconazole and the crystallographic ketoconazole are almost perfectly superimposed, with a 
RMSD of 0.14 Å. The negative control, propofol, as expected, had the worst docking score. Compounds 
1-8 had docking scores from -7.4 to -10.2 kJ.mol
-1
, values similar to the ketoconazole control (Table 2).  
 
DISCUSSION 
 
Although thioxanthones have been extensively studied for its P-gp modulation activity (submitted for 
publication), there is lack of comprehending information regarding their interaction with other ABC 
transporters.  This study represents the first investigation of the potential of thioxanthonic derivatives to 
interact with MRP1, MRP2, MRP3, and BCRP, and with CYP3A4. 
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Table 2. (A) Docking scores obtained for test compounds 1-8, and controls (ketoconazole and 
propofol); (B) scores from compounds 1 and 2 docking poses in accordance with Metasite prediction. 
                        
 
 
Concerning the UIC2 labelling assay, compounds 1, 4, 6-8 significantly decreased UIC2 reactivity, a 
result similar to the one produced by orthovanadate, behaving as noncompetitive inhibitors. On the other 
hand, compound 2 significantly increased UIC2 reactivity in the same order of magnitude as verapamil 
 Score (kJ.mol
-1
) 
A 
Top rank pose 
B 
Predicted by 
Metasite* 
Ketoconazole -10.8  
Compound 1 -9.0 -8.7* 
Compound 2 -9.2 -8.3* 
Compound 3 -7.6  
Compound 4 -8.5  
Compound 5 -7.4  
Compound 6 -10.2  
Compound 7 -8.5  
Compound 8 -9.1  
Propofol -5.8  
inhibitor of CYP3A4 
not metabolized by CYP3A4 
*poses represented in Figure 8 
Figure 8. Representation of the crystallographic 
ligand ketoconazole (grey) and best docking pose of 
the same compound (orange) (A) in CYP3A4 
binding pocket. Docking conformations of 
compound 1 (yellow) (B) and 2 (magenta) (C) in 
accordance with metabolization prediction. Heme 
group is represented as spheres. Hydrogen bonds are 
represented in yellow dashes. Other noncovalent 
bonds are omitted for simplification. 
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and quinidine, behaving as competitive inhibitors. These results are in accordance with the ones obtained 
by the luminescence-based ATPase assay (submitted for publication), confirming our previous data.  
Results regarding the effect of compound 1 on P-gp ATPase activity confirmed that compound 1 is 
not transported by P-gp (Figure 3A, activation study) as it does not interfere with the basal P-gp ATPase 
activity. Additionally, compound 1 was found to inhibit verapamil transport (Figure 3A, inhibition study) 
in a concentration dependent manner up to 40 µM, reaching a “plateau” after that concentration. The IC50 
value for the inhibition of P-gp by compound 1 is close to 20 μM (Table 1). Regarding the BCRP ATPase 
assay, compounds 1 has shown not to be substrate for BCRP (Figure 3B, activation assay) as the levels of 
Pi detected are close to the baseline. Also, compound 1 was able to inhibit the efflux of sulfasalazine 
(Figure 3B, inhibition assay) in a concentration dependent manner, with an IC50 value of 20 μM. In 
addition, compound 1 was shown to be transported by MRP1 at low concentrations, but at increasing 
concentrations (> 10 μM), the levels of transport decreased (Figure 3C, activation assay). Compound 1 
also inhibits the transport of a known MRP1 substrate, NEM-GS, particularly at concentrations above 8 
μM and in a concentration-dependant manner (Figure 3C, inhibition assay), presenting an IC50 of 25 μM. 
Compound 1 is a weak substrate (Figure 3D, activation assay) and a weak inhibitor of sulfasalazine 
transport by MRP2 (Figure 3D, inhibition study). Compound 1 is a weak MPR3 substrate at 
concentrations below 40 μM (Figure 3E, activation study). Compound 1 inhibits benzbromarone transport 
by MRP3, which only becomes more evident at concentrations above 40 μM (Figure 3E, inhibition 
assay), with the IC50 being reached only at 200 μM. Hence, compound 1 is not a substrate (or is a very low 
affinity substrate) for P-gp, BCRP, and MRP2, but it is a substrate for MRP3 and mainly for MRP1 (as 
shown by values above zero in the activation studies of Figures 3C and 3E). Besides, the decreasing 
curves in the inhibition studies (values below 100 %) reveal that compound 1 interferes with the transport 
of these known ABC transporters substrates (Figure 3, inhibition studies). 
The results from the effect of compound 2 on P-gp ATPase activity confirmed that compound 2 is 
transported by P-gp at concentrations above 10 μM (Figure 4A, activation study) and also revealed that 
compound 2 inhibits verapamil transport at concentrations above 8 μM, in a concentration dependent 
manner  (Figure 4A, inhibition study). The IC50 value for the inhibition of P-gp by compounds 2 is close 
to 20 μM (Table 1). Regarding the BCRP ATPase assay, compounds 2 has shown not to be a substrate for 
BCRP (Figure 4B, activation assay) as the levels of Pi detected are close to the baseline. In addition, 
compound 2 was able to inhibit the efflux of sulfasalazine (Figure 4B, inhibition assay), up to 
concentrations of approximately 10 μM, revealing an IC50 value of 2 μM. Compound 2 is actively 
transported by MRP1 at low concentrations (~1 μM), but the levels of transport decrease with increasing 
concentrations of these compound (Figure 4C, activation study). Indeed, data shows that compound 2 
stimulated ATPase activity at low concentrations (<50 μM), but at higher concentrations (>50 μM) 
ATPase stimulation was found to be decreased. Compound 2 strongly inhibits the transport of N-
ethylmaleimide glutathione (NEM-GS) (Figure 4C, inhibition study), with an IC50 of 4 μM. In addition, 
compound 2 is a weak MRP2 substrate (Figure 4D, activation assay), and decreases the level of Pi release 
to values inferior to the baseline, suggesting that it blocks MRP2 basal ATPase activity at concentrations 
above 100 μM. Compound 2 inhibits the transport of sulfasalazine by MRP2 (Figure 4D, inhibition 
study), reaching the IC50 at 145 μM. Finally, compound 2 is transported by MRP3; however, the ATPase 
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activity decreases in a concentration-dependent manner until complete loss of ATPase function becomes 
evident at concentrations above 100 μM (Figure 4E, activation study). Compound 2 inhibits MRP3 
mediated transport of benzbromarone in a concentration dependent manner (Figure 4E, inhibition study), 
with a IC50 of 13 μM.  
From the overall ATPase results, the IC50 of compounds 1 and 2 to inhibit P-gp is approximately 20 
μM (for a P-gp specific substrate). However, compound 1 is also a potent BCPR and MRP1 inhibitor, 
with IC50 values of 20 and 25 μM, respectively. Compound 2 is a strong inhibitor of BCRP, MRP1, and 
MRP3, with IC50 values of 2, 4, and 13 μM, respectively. 
ABC transporters are co-localized in protective tissues throughout the human body, with important 
roles in restricting the intestinal absorption of foreign compounds and mediating the secretion of drugs 
and metabolites to bile (38). As a consequence, inhibition of P-gp, BCRP, and MRP1, MRP2 and MRP3 
can lead to serious adverse effects, for example through the accumulation of toxic xenobiotics (39). 
Nonetheless, MRP1 and MRP3 are localized preferentially in basolateral membranes. P-gp, BCRP and 
MRP2 are localized in apical membranes. Thus, the efflux direction will be different for those pumps. For 
example, in an enterocyte, P-gp, BCRP, and MRP2 extrude substrates to the intestinal lumen, whether 
MRP1 and 3 pump their substrates to the systemic circulation (40,41). Besides, even if these transporters 
are partially blocked, other intestinal transporters such as peptide transporter 1 (PEPT1), organic anion 
transporters (OAT), organic cation transporters (OCT), as well as other members of the ABC family, are 
available for transport across the membrane (42). Therefore, as far as MDR reversal is concerned, these 
thioxanthonic derivatives could possibly be further studied for treating cancer cells that express the ABC 
transporters (43). These would only be possibly by a careful analysis of the phenotype of the cancer cells 
of each patient, using for example PET radiotracers (44). 
As the overlapping substrate specificity between P-gp and CYP3A4 is a common concern, namely 
concerning hydrophobic chemotherapeutic agents (45), the thioxanthonic derivatives 1-8 were screened 
for CYP3A4 interaction (Figure 5). CYP3A4 is the most prominent CYP in humans, comprising about 30 
and 70% of total CYP in liver and intestine, respectively (46), and is responsible for phase I metabolism 
of 50% of drugs administered to humans (46). CYP3A4 has a very broad substrate specificity, and it may 
deactivate several anticancer drugs within the tumor cells (47). 
The initial screen for CYP3A4 activity modulation demonstrated that all the thioxanthones inhibit the 
metabolization of BE-luciferin by CYP3A4, reducing the production of a luciferin product that generates 
light when compared to the untreated control (Figure 5). Thioxanthones 1-8 inhibit CYP3A4 in the same 
order of range as a known CYP3A4 inhibitor, ketoconazole (22), at the tested concentration (200 μM). 
Compound 1 was the compound with lower CYP3A4 inhibition ability, followed by compounds 2 and 3. 
Although thioxanthones are able to inhibit several ABC transporters, their further development to clinical 
MDR modulators could fail due to their dose-limiting effects (48,49). Indeed, at 1-2 μM concentration 
(Figure 6), compounds 1 and 2 exhibit strong potency for binding CYP3A4, and activities comparable to 
ketoconazole in binding that enzyme (50). Thus, the competition between cytotoxic agents and these P-gp 
modulators for cytochrome P450 3A4 activity requires monitoring of pharmacokinetic interactions (51). It 
has been previously reported that (thio)xanthonic derivatives can be substrates or inhibitors of multiple 
P450 isoforms (52). Therefore, the interference of compounds 1 and 2 with CYP3A4 determined 
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experimentally using the P450-Glo kit may result from a blockage of CYP3A4 catalytic site or a 
metabolization. However, this distinction would require further experiments, such as the analysis of the 
metabolite profile on incubation with CYP3A4 or with human liver microsomes (several CYPs) (53). 
The metabolism prediction software MetaSite predicted that aliphatic carbon atoms directly linked to 
the nitrogen or two bonds away (compounds 1 and 2), the alkyl amine (compound 1) or aryl primary 
amine (compound 2), and the sulphur from the thioxanthonic ring (compounds 1 and 2) as the most 
probable sites of metabolism (Figure 7). Other sites of metabolization would be the carbons from the 
propoxy side chain (Figure 7). It may be hypothesized that the alkyl amine will probably suffer an N-
dealkylation or N-oxigenation. The aryl amine will probably suffer an anilinic hydroxylation and the 
aliphatic carbons an aliphatic hydroxylation. The sulphur will probably be oxidized to an sulfoxide or 
sulfone (54). 
Concerning the docking results on CYP3A4, the ketoconazole molecule has its imidazole nitrogen 
bound to the heme iron group (Figure 8A). The ketoconazole keto group is located in a polar pocket lined 
by the side chains of Arg372, Arg106, and Glu374. It has also been described that the side chain of 
Ser119 is important for the establishment of hydrogen bonds with some binding conformations of 
ketoconazole (37). Both compounds 1 and 2 are predicted to be bound in the same binding pocket as 
ketoconazole and with similar docking scores (Table 2). As ketoconazole, compound 1 also establishes 
hydrogen bounds with residue Ser119 (Figure 8B), and residue Ile301. This interactions put the “hot 
spot”, the aliphatic carbon of the alkylarylamine, 3.0 Å from the ferryl group, in accordance with the 
predicted site of metabolization for compounds 1 (Figure 7A and 8B). To get a more metabolic stable 
compound, one could, for example, modify the carbonyl group from the thioxanthone. On the other hand, 
compound 2 has its aniline group facing the heme group of CYP3A4 (Figure 8C). This is in accordance 
with the prediction which pointed the tetrahydroisoquinolinamine as the main target of metabolism 
(Figure 7B).  Again, the carbon from thioxanthonic carbonyl on compound 2 binds noncovalently to 
Ser119. 
Although the use of computational methods as predictive tools for likelihood of interference with 
CYP3A4 are not conclusive, the study demonstrated that they could be useful in both predicting, 
explaining observed data obtained from the in vitro experiments, and could also guide further molecular 
modifications.  
 
CONCLUSION 
 
Thioxanthone 1 was found to be a multiple inhibitor of P-gp, BCRP and MRP1. Thioxanthone 2 is a 
multiple inhibitor of P-gp, BCRP, MRP1 and MRP3. Therefore, they could be further tested as potential 
MDR reversal agents in tumor cell lines that overexpress those transporters. Further in vivo work should 
be performed in order to assess the toxicity of these thioxanthones. Special attention should be taken in 
order to avoid prejudicial pharmacokinetic interactions, which may lead to increased accumulation and 
toxicity of the chemotherapy agent, if it is metabolized by CYP3A4. Therefore, future direction of this 
work will focus on the pharmacokinetic interaction between thioxanthones and anticancer agents. 
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Supporting information 1 
 
  
Flavone 
 
Code 
Substituent 
3 5 6 7 8 2' 4' 
Fla4 OH OH Prenyl OH H H H 
Fla7 OH OH H OH DMA H OCH3 
Fla8 OH OH H OH H H F 
Fla9 OH OH H OH H Cl Cl 
Fla10 OH OH H OH H H I 
Fla12 OH OH H OH H H C8H17 
Fla13 OCH3 OH H OCH3 DMA H H 
Fla14 OCH3 OH H OH H H H 
Fla17 H OH H OH H H H 
Fla18 H OH CH3 OH H H H 
Fla19 H OH H OCH3 H H H 
Fla26 H OH iPr O-iPr H H H 
Fla30 H OH Bn OH Bn H H 
Fla37 H OH H OH Geranyl H H 
 
 
Dehydrosylibin 
 
Code 
Substituent 
6 8 
Dhs1 H H 
Dhs3 H Prenyl 
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Chalcone 
 
Code 
Substituent 
3 4 2’ 4’ 5’ 6’ 
Cal1 H H OH OH H OH 
Cal6 H Br OH OH H OH 
Cal11 H C6H11 OH OH H OH 
Cal12 H C8H17 OH OH H OH 
Cal14 H C14H29 OH OH H OH 
Cal15 OH OH OH OH Prenyl OH 
Cal17 H OC10H21 OH OH H OH 
Cal18 H OC2H5 OH OH H OH 
Cal19 H OC6H13 OH OH H OH 
Cal20 H OC4H9 OH OH H OH 
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OH
O
O
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O
O
O
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O
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O OH
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OH
O
OH
 
15 8 3    
1-Methoxy-4-
propoxy-9H-
thioxanthen-9-
one 
O
O
O
S
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amino]-4-
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